0001493152-23-040121.txt : 20231109 0001493152-23-040121.hdr.sgml : 20231109 20231109171959 ACCESSION NUMBER: 0001493152-23-040121 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231109 DATE AS OF CHANGE: 20231109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oncocyte Corp CENTRAL INDEX KEY: 0001642380 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 271041563 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37648 FILM NUMBER: 231393813 BUSINESS ADDRESS: STREET 1: 15 CUSHING CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-409-7600 MAIL ADDRESS: STREET 1: 15 CUSHING CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: OncoCyte Corp DATE OF NAME CHANGE: 20200213 FORMER COMPANY: FORMER CONFORMED NAME: Oncocyte Corp DATE OF NAME CHANGE: 20200205 FORMER COMPANY: FORMER CONFORMED NAME: OncoCyte Corp DATE OF NAME CHANGE: 20150513 10-Q 1 form10-q.htm
false Q3 --12-31 0001642380 http://oncocyte.com/20230930#MachineryAndEquipmentNetAndConstructionInProgress http://oncocyte.com/20230930#MachineryAndEquipmentNetAndConstructionInProgress 0001642380 2023-01-01 2023-09-30 0001642380 2023-11-02 0001642380 2023-09-30 0001642380 2022-12-31 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember 2023-09-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember 2022-12-31 0001642380 2023-07-01 2023-09-30 0001642380 2022-07-01 2022-09-30 0001642380 2022-01-01 2022-09-30 0001642380 us-gaap:PreferredStockMember OCX:SeriesARedeemableConvertiblePreferredStockMember 2023-06-30 0001642380 us-gaap:CommonStockMember 2023-06-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001642380 us-gaap:RetainedEarningsMember 2023-06-30 0001642380 2023-06-30 0001642380 us-gaap:PreferredStockMember OCX:SeriesARedeemableConvertiblePreferredStockMember 2022-06-30 0001642380 us-gaap:CommonStockMember 2022-06-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001642380 us-gaap:RetainedEarningsMember 2022-06-30 0001642380 2022-06-30 0001642380 us-gaap:PreferredStockMember OCX:SeriesARedeemableConvertiblePreferredStockMember 2022-12-31 0001642380 us-gaap:CommonStockMember 2022-12-31 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001642380 us-gaap:RetainedEarningsMember 2022-12-31 0001642380 us-gaap:PreferredStockMember OCX:SeriesARedeemableConvertiblePreferredStockMember 2021-12-31 0001642380 us-gaap:CommonStockMember 2021-12-31 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001642380 us-gaap:RetainedEarningsMember 2021-12-31 0001642380 2021-12-31 0001642380 us-gaap:PreferredStockMember OCX:SeriesARedeemableConvertiblePreferredStockMember 2023-07-01 2023-09-30 0001642380 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001642380 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001642380 us-gaap:PreferredStockMember OCX:SeriesARedeemableConvertiblePreferredStockMember 2022-07-01 2022-09-30 0001642380 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001642380 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001642380 us-gaap:PreferredStockMember OCX:SeriesARedeemableConvertiblePreferredStockMember 2023-01-01 2023-09-30 0001642380 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001642380 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001642380 us-gaap:PreferredStockMember OCX:SeriesARedeemableConvertiblePreferredStockMember 2022-01-01 2022-09-30 0001642380 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0001642380 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001642380 us-gaap:PreferredStockMember OCX:SeriesARedeemableConvertiblePreferredStockMember 2023-09-30 0001642380 us-gaap:CommonStockMember 2023-09-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001642380 us-gaap:RetainedEarningsMember 2023-09-30 0001642380 us-gaap:PreferredStockMember OCX:SeriesARedeemableConvertiblePreferredStockMember 2022-09-30 0001642380 us-gaap:CommonStockMember 2022-09-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001642380 us-gaap:RetainedEarningsMember 2022-09-30 0001642380 2022-09-30 0001642380 OCX:RazorGenomicsIncMember 2021-02-23 0001642380 OCX:RazorStockPurchaseAgreementMember OCX:DragonScientificLLCMember 2022-12-15 2022-12-15 0001642380 OCX:RazorStockPurchaseAgreementMember OCX:DragonScientificLLCMember 2022-12-15 0001642380 OCX:RazorStockPurchaseAgreementMember OCX:RazorMember us-gaap:CommonStockMember OCX:DragonMember 2023-02-16 0001642380 OCX:RazorStockPurchaseAgreementMember us-gaap:CommonStockMember 2023-02-15 2023-02-16 0001642380 OCX:RazorStockPurchaseAgreementMember OCX:RazorMember 2023-02-16 0001642380 OCX:AtTheMarketSalesAgreementMember OCX:BTIGLLCMember 2021-06-10 2021-06-11 0001642380 OCX:BTIGLLCMember 2021-07-01 2023-09-30 0001642380 OCX:BTIGLLCMember 2023-09-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember OCX:SecuritiesPurchaseAgreementMember 2022-04-12 2022-04-13 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember OCX:SecuritiesPurchaseAgreementMember 2022-04-13 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember OCX:UnderwritingAgreementMember OCX:UnderwriterMember 2022-04-12 2022-04-12 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember OCX:UnderwritingAgreementMember OCX:UnderwriterMember 2022-04-12 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember OCX:UnderwritingAgreementMember OCX:UnderwriterMember srt:MinimumMember 2022-04-12 0001642380 2022-01-01 2022-12-31 0001642380 OCX:RegisteredDirectOfferingMember OCX:BoardMembersMember srt:MaximumMember 2023-04-03 2023-04-03 0001642380 OCX:RegisteredDirectOfferingMember OCX:BoardMembersMember 2023-04-03 0001642380 OCX:RegisteredDirectOfferingMember OCX:OtherInvestorsMember 2023-04-03 0001642380 2023-04-01 2023-04-12 0001642380 2023-07-23 2023-07-24 0001642380 2023-07-24 0001642380 OCX:LineageAndAgeXMember 2023-09-30 0001642380 OCX:LineageAndAgeXMember 2022-12-31 0001642380 us-gaap:MachineryAndEquipmentMember srt:MinimumMember 2023-09-30 0001642380 us-gaap:MachineryAndEquipmentMember srt:MaximumMember 2023-09-30 0001642380 us-gaap:EquipmentMember srt:MinimumMember 2023-09-30 0001642380 us-gaap:EquipmentMember srt:MaximumMember 2023-09-30 0001642380 OCX:PharmaServicesMember 2023-01-01 2023-09-30 0001642380 OCX:PharmaServicesMember 2022-01-01 2022-12-31 0001642380 OCX:MedicareAndMedicareAdvantageMember 2023-09-30 0001642380 OCX:MedicareAndMedicareAdvantageMember 2022-12-31 0001642380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCustomersOneMember 2023-01-01 2023-09-30 0001642380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCustomersTwoMember 2023-01-01 2023-09-30 0001642380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCustomersOneMember 2022-01-01 2022-12-31 0001642380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCustomersTwoMember 2022-01-01 2022-12-31 0001642380 OCX:MarketableEquitySecuritiesMember 2023-09-30 0001642380 us-gaap:FairValueInputsLevel1Member OCX:MarketableEquitySecuritiesMember 2023-09-30 0001642380 us-gaap:FairValueInputsLevel2Member OCX:MarketableEquitySecuritiesMember 2023-09-30 0001642380 us-gaap:FairValueInputsLevel3Member OCX:MarketableEquitySecuritiesMember 2023-09-30 0001642380 us-gaap:FairValueInputsLevel1Member 2023-09-30 0001642380 us-gaap:FairValueInputsLevel2Member 2023-09-30 0001642380 us-gaap:FairValueInputsLevel3Member 2023-09-30 0001642380 OCX:ContingentConsiderationLiabilitiesMember 2023-09-30 0001642380 us-gaap:FairValueInputsLevel1Member OCX:ContingentConsiderationLiabilitiesMember 2023-09-30 0001642380 us-gaap:FairValueInputsLevel2Member OCX:ContingentConsiderationLiabilitiesMember 2023-09-30 0001642380 us-gaap:FairValueInputsLevel3Member OCX:ContingentConsiderationLiabilitiesMember 2023-09-30 0001642380 OCX:MarketableEquitySecuritiesMember 2022-12-31 0001642380 us-gaap:FairValueInputsLevel1Member OCX:MarketableEquitySecuritiesMember 2022-12-31 0001642380 us-gaap:FairValueInputsLevel2Member OCX:MarketableEquitySecuritiesMember 2022-12-31 0001642380 us-gaap:FairValueInputsLevel3Member OCX:MarketableEquitySecuritiesMember 2022-12-31 0001642380 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001642380 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001642380 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001642380 OCX:ContingentConsiderationLiabilitiesMember 2022-12-31 0001642380 us-gaap:FairValueInputsLevel1Member OCX:ContingentConsiderationLiabilitiesMember 2022-12-31 0001642380 us-gaap:FairValueInputsLevel2Member OCX:ContingentConsiderationLiabilitiesMember 2022-12-31 0001642380 us-gaap:FairValueInputsLevel3Member OCX:ContingentConsiderationLiabilitiesMember 2022-12-31 0001642380 OCX:PharmaServicesMember 2023-07-01 2023-09-30 0001642380 OCX:PharmaServicesMember 2022-07-01 2022-09-30 0001642380 OCX:PharmaServicesMember 2023-01-01 2023-09-30 0001642380 OCX:PharmaServicesMember 2022-01-01 2022-09-30 0001642380 OCX:LaboratoryDevelopedTestServicesMember 2023-07-01 2023-09-30 0001642380 OCX:LaboratoryDevelopedTestServicesMember 2022-07-01 2022-09-30 0001642380 OCX:LaboratoryDevelopedTestServicesMember 2023-01-01 2023-09-30 0001642380 OCX:LaboratoryDevelopedTestServicesMember 2022-01-01 2022-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember OCX:PharmaServicesMember 2023-07-01 2023-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember OCX:PharmaServicesMember 2022-07-01 2022-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember OCX:PharmaServicesMember 2023-01-01 2023-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember OCX:PharmaServicesMember 2022-01-01 2022-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember OCX:LaboratoryDevelopedTestServicesMember 2023-07-01 2023-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember OCX:LaboratoryDevelopedTestServicesMember 2022-07-01 2022-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember OCX:LaboratoryDevelopedTestServicesMember 2023-01-01 2023-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember OCX:LaboratoryDevelopedTestServicesMember 2022-01-01 2022-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCompanyAMember 2023-07-01 2023-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCompanyAMember 2022-07-01 2022-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCompanyAMember 2023-01-01 2023-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCompanyAMember 2022-01-01 2022-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCompanyBMember 2023-07-01 2023-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCompanyBMember 2022-07-01 2022-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCompanyBMember 2023-01-01 2023-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCompanyBMember 2022-01-01 2022-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCompanyCMember 2023-07-01 2023-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCompanyCMember 2022-07-01 2022-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCompanyCMember 2023-01-01 2023-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCompanyCMember 2022-01-01 2022-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCompanyDMember 2023-07-01 2023-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCompanyDMember 2022-07-01 2022-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCompanyDMember 2023-01-01 2023-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember OCX:PharmaServicesCompanyDMember 2022-01-01 2022-09-30 0001642380 country:US us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 country:US us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0001642380 country:US us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 country:US us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0001642380 OCX:OutsideUnitedStatesPharmaServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 OCX:OutsideUnitedStatesPharmaServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0001642380 OCX:OutsideUnitedStatesPharmaServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 OCX:OutsideUnitedStatesPharmaServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0001642380 OCX:UnitedStatesLaboratoryDevelopedTestServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 OCX:UnitedStatesLaboratoryDevelopedTestServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0001642380 OCX:UnitedStatesLaboratoryDevelopedTestServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 OCX:UnitedStatesLaboratoryDevelopedTestServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0001642380 us-gaap:StockOptionMember 2023-07-01 2023-09-30 0001642380 us-gaap:StockOptionMember 2022-07-01 2022-09-30 0001642380 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001642380 us-gaap:StockOptionMember 2022-01-01 2022-09-30 0001642380 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001642380 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0001642380 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001642380 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001642380 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001642380 us-gaap:WarrantMember 2022-07-01 2022-09-30 0001642380 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001642380 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember 2023-07-01 2023-09-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember 2022-07-01 2022-09-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember 2023-01-01 2023-09-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember 2022-01-01 2022-09-30 0001642380 OCX:InsightMergerMember 2023-01-01 2023-09-30 0001642380 OCX:ChronixMergerMember 2023-01-01 2023-09-30 0001642380 OCX:MilestoneOneMember 2023-09-30 0001642380 OCX:MilestoneTwoMember 2023-09-30 0001642380 OCX:MilestoneThreeMember 2023-09-30 0001642380 OCX:RoyaltyOneMember 2023-09-30 0001642380 OCX:RoyaltyTwoMember 2023-09-30 0001642380 OCX:InsightMergerMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-01-01 2023-09-30 0001642380 srt:MaximumMember OCX:MergerAgreementMember OCX:ChronixBiomedicalIncMember 2021-04-14 2021-04-15 0001642380 OCX:MergerAgreementMember OCX:ChronixEquityMember 2023-02-07 2023-02-08 0001642380 OCX:MergerAgreementMember OCX:ChronixMilestoneMember 2023-02-07 2023-02-08 0001642380 OCX:ChronixMember 2023-01-01 2023-09-30 0001642380 OCX:ChronixMergerMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-01-01 2023-09-30 0001642380 OCX:ChronixBiomedicalIncMember 2023-09-30 0001642380 us-gaap:FairValueInputsLevel3Member OCX:InsightMergerMember 2021-12-31 0001642380 us-gaap:FairValueInputsLevel3Member OCX:InsightMergerMember 2022-01-01 2022-09-30 0001642380 us-gaap:FairValueInputsLevel3Member OCX:InsightMergerMember 2022-09-30 0001642380 us-gaap:FairValueInputsLevel3Member OCX:InsightMergerMember 2022-12-31 0001642380 us-gaap:FairValueInputsLevel3Member OCX:InsightMergerMember 2023-01-01 2023-09-30 0001642380 us-gaap:FairValueInputsLevel3Member OCX:InsightMergerMember 2023-09-30 0001642380 us-gaap:FairValueInputsLevel3Member OCX:ChronixMergerMember 2021-12-31 0001642380 us-gaap:FairValueInputsLevel3Member OCX:ChronixMergerMember 2022-01-01 2022-09-30 0001642380 us-gaap:FairValueInputsLevel3Member OCX:ChronixMergerMember 2022-09-30 0001642380 us-gaap:FairValueInputsLevel3Member OCX:ChronixMergerMember 2022-12-31 0001642380 us-gaap:FairValueInputsLevel3Member OCX:ChronixMergerMember 2023-01-01 2023-09-30 0001642380 us-gaap:FairValueInputsLevel3Member OCX:ChronixMergerMember 2023-09-30 0001642380 OCX:MPEEMValuationApproachMember 2023-01-01 2023-03-31 0001642380 OCX:DetermaIOMember 2023-01-01 2023-09-30 0001642380 OCX:DetermaIOMember 2022-01-01 2022-12-31 0001642380 OCX:DetermaCNIAndVitaGraftMember 2023-01-01 2023-09-30 0001642380 OCX:DetermaCNIAndVitaGraftMember 2022-01-01 2022-12-31 0001642380 us-gaap:CustomerRelationshipsMember 2023-09-30 0001642380 us-gaap:CustomerRelationshipsMember 2022-12-31 0001642380 OCX:AmendedLoanAgreementMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-10-17 0001642380 OCX:AmendedLoanAgreementMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-10-16 2019-10-17 0001642380 OCX:AmendedLoanAgreementMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-10-17 0001642380 OCX:AmendedLoanAgreementMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-09-30 0001642380 OCX:AmendedLoanAgreementMember 2019-10-17 0001642380 OCX:LoanDeferralAgreementMember 2020-04-01 2020-04-02 0001642380 OCX:BankWarrantMember OCX:AmendedLoanAgreementMember 2019-10-31 0001642380 us-gaap:WarrantMember 2017-12-31 0001642380 us-gaap:WarrantMember 2017-03-23 0001642380 OCX:BankWarrantMember OCX:AmendedLoanAgreementMember 2019-10-17 0001642380 OCX:BankWarrantMember OCX:AmendedLoanAgreementMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-10-16 2019-10-17 0001642380 OCX:OfficeLeaseAgreementMember 2019-12-23 0001642380 OCX:OfficeLeaseAgreementMember 2019-12-22 2019-12-23 0001642380 OCX:MonthlyRentMember OCX:OfficeLeaseAgreementMember 2019-12-22 2019-12-23 0001642380 OCX:FirstTenCalendarMember OCX:OfficeLeaseAgreementMember 2019-12-22 2019-12-23 0001642380 OCX:LandlordMember OCX:OfficeLeaseAgreementMember 2023-01-01 2023-09-30 0001642380 OCX:OfficeLeaseAgreementMember 2023-08-08 0001642380 OCX:MonthlyRentMember OCX:OfficeLeaseAgreementMember 2023-01-01 2023-09-30 0001642380 OCX:OfficeLeaseAgreementMember 2023-09-30 0001642380 OCX:LeaseAgreementMember 2021-08-27 0001642380 OCX:LaboratoryEquipmentMember 2023-09-30 0001642380 OCX:ExecutiveOfficersMember 2023-01-01 2023-09-30 0001642380 OCX:OperatingAndFinancingLeasesMember 2023-09-30 0001642380 OCX:OperatingAndFinancingLeasesMember 2022-12-31 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember OCX:SecuritiesPurchaseAgreementMember OCX:InvestorsMember 2022-04-12 2022-04-13 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember OCX:SecuritiesPurchaseAgreementMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2022-04-12 2022-04-13 0001642380 us-gaap:SeriesAPreferredStockMember OCX:OncocyteCorpMember 2023-01-01 2023-09-30 0001642380 2022-07-14 2022-07-15 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember 2022-04-13 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember OCX:InterestMember 2022-04-13 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember OCX:OncocyteCorpMember 2022-04-13 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember OCX:SecurityMember 2022-04-13 0001642380 OCX:RegisteredDirectOfferingMember us-gaap:SeriesAPreferredStockMember 2023-04-04 2023-04-05 0001642380 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-09-30 0001642380 us-gaap:OverAllotmentOptionMember OCX:AprilTwoThousandTwentyTwoWarrantsMember 2022-04-12 2022-04-13 0001642380 us-gaap:IPOMember OCX:AprilTwoThousandTwentyTwoWarrantsMember 2022-04-13 0001642380 us-gaap:IPOMember us-gaap:CommonStockMember 2022-04-13 0001642380 us-gaap:IPOMember us-gaap:WarrantMember 2022-04-13 0001642380 OCX:UnderwritingAgreementMember OCX:AprilTwoThousandTwentyTwoWarrantsMember 2022-04-12 2022-04-13 0001642380 OCX:UnderwritingAgreementMember us-gaap:WarrantMember 2022-04-13 0001642380 OCX:UnderwritingAgreementMember us-gaap:CommonStockMember 2022-04-13 0001642380 OCX:UnderwritingAgreementMember 2022-04-13 0001642380 us-gaap:CommonStockMember 2022-04-13 0001642380 OCX:UnderwritingAgreementMember 2022-04-12 2022-04-13 0001642380 us-gaap:OverAllotmentOptionMember 2022-04-12 2022-04-13 0001642380 us-gaap:OverAllotmentOptionMember 2022-04-18 2022-04-19 0001642380 OCX:RegisteredDirectOfferingMember srt:MaximumMember 2023-04-03 2023-04-03 0001642380 us-gaap:CommonStockMember OCX:SecuritiesPurchaseAgreementMember 2023-04-03 2023-04-03 0001642380 OCX:RegisteredDirectOfferingMember 2023-04-03 2023-04-03 0001642380 OCX:RegisteredDirectOfferingMember us-gaap:SeriesBPreferredStockMember 2023-04-03 2023-04-03 0001642380 srt:MinimumMember 2023-09-30 0001642380 srt:MaximumMember 2023-09-30 0001642380 OCX:TwoThousandTenStockOptionPlanMember 2023-09-30 0001642380 OCX:TwoThousandEighteenIncentivePlanMember 2023-09-30 0001642380 OCX:MonteCarloValuationTechniqueMember 2022-01-01 2022-12-31 0001642380 OCX:PerformanceBasedOptionsMember 2022-01-01 2022-12-31 0001642380 us-gaap:PerformanceSharesMember OCX:ExecutiveOfficersAndEmployeesMember 2022-05-01 2022-05-31 0001642380 OCX:MarketBasedAwardsMember OCX:ExecutiveOfficersAndEmployeesMember 2022-05-01 2022-05-31 0001642380 OCX:VitaGraftMember 2022-05-01 2022-05-31 0001642380 OCX:DetermalOMember 2022-05-01 2022-05-31 0001642380 2022-05-01 2022-05-31 0001642380 OCX:MarketBasedAwardsMember 2023-01-01 2023-09-30 0001642380 us-gaap:PerformanceSharesMember OCX:ExecutiveOfficersAndEmployeesMember 2022-07-01 2022-07-31 0001642380 OCX:VitaGraftMember 2022-07-01 2022-07-31 0001642380 OCX:DetermalOMember 2022-07-01 2022-07-31 0001642380 2022-07-01 2022-07-31 0001642380 us-gaap:PerformanceSharesMember 2022-01-01 2022-12-31 0001642380 OCX:DetermaCNIMember 2022-12-14 2022-12-16 0001642380 OCX:PerformanceBasedOptionsMember 2023-08-01 2023-08-31 0001642380 OCX:MonteCarloValuationTechniqueMember 2023-01-01 2023-09-30 0001642380 OCX:MonteCarloValuationTechniqueMember srt:MinimumMember 2023-01-01 2023-09-30 0001642380 OCX:MonteCarloValuationTechniqueMember srt:MaximumMember 2023-01-01 2023-09-30 0001642380 OCX:PerformanceBasedOptionsMember 2023-01-01 2023-09-30 0001642380 2023-08-01 2023-08-31 0001642380 OCX:TwoThousandTenPlanActivityMember 2023-01-01 2023-09-30 0001642380 OCX:TwoThousandTenPlanActivityMember 2022-12-31 0001642380 OCX:TwoThousandTenPlanActivityMember 2023-09-30 0001642380 OCX:TwoThousandEighteenPalnActivityMember 2022-12-31 0001642380 OCX:TwoThousandEighteenPalnActivityMember 2023-01-01 2023-09-30 0001642380 OCX:TwoThousandEighteenPalnActivityMember 2023-09-30 0001642380 OCX:EmployeeAndNonEmployeeMember 2023-01-01 2023-09-30 0001642380 us-gaap:EmployeeStockOptionMember OCX:CostOfRevenuesMember 2023-07-01 2023-09-30 0001642380 us-gaap:EmployeeStockOptionMember OCX:CostOfRevenuesMember 2022-07-01 2022-09-30 0001642380 us-gaap:EmployeeStockOptionMember OCX:CostOfRevenuesMember 2023-01-01 2023-09-30 0001642380 us-gaap:EmployeeStockOptionMember OCX:CostOfRevenuesMember 2022-01-01 2022-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2023-07-01 2023-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2022-07-01 2022-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2022-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0001642380 OCX:SecuritiesPurchaseAgreementMember us-gaap:SeriesAPreferredStockMember OCX:BroadwoodCapitalLPMember 2022-04-12 2022-04-12 0001642380 OCX:SecuritiesPurchaseAgreementMember us-gaap:SeriesAPreferredStockMember OCX:BroadwoodCapitalLPMember 2022-04-13 2022-04-13 0001642380 OCX:UnderwrittenOfferingMember us-gaap:CommonStockMember OCX:BroadwoodCapitalLPMember 2022-04-12 2022-04-13 0001642380 OCX:UnderwrittenOfferingMember OCX:BroadwoodCapitalLPMember 2022-04-13 0001642380 OCX:UnderwrittenOfferingMember OCX:PuraVidaInvestmentsLLCMember srt:MaximumMember 2022-04-13 0001642380 OCX:UnderwrittenOfferingMember OCX:UnderwritersMember OCX:BroadwoodCapitalLPMember 2022-04-13 0001642380 OCX:UnderwrittenOfferingMember us-gaap:CommonStockMember OCX:PuraVidaInvestmentsLLCMember 2022-04-12 2022-04-13 0001642380 OCX:UnderwrittenOfferingMember OCX:PuraVidaInvestmentsLLCMember 2022-04-13 0001642380 OCX:UnderwrittenOfferingMember OCX:BroadwoodCapitalLPMember srt:MaximumMember 2022-04-12 2022-04-13 0001642380 OCX:UnderwrittenOfferingMember OCX:PuraVidaInvestmentsLLCMember OCX:UnderwritersMember 2022-04-12 2022-04-13 0001642380 OCX:UnderwrittenOfferingMember us-gaap:CommonStockMember OCX:HalleSpecialSituationsFundLLCMember 2022-04-12 2022-04-13 0001642380 OCX:UnderwrittenOfferingMember OCX:HalleSpecialSituationsFundLLCMember 2022-04-13 0001642380 OCX:UnderwrittenOfferingMember OCX:HalleSpecialSituationsFundLLCMember srt:MaximumMember 2022-04-13 0001642380 OCX:UnderwrittenOfferingMember OCX:HalleSpecialSituationsFundLLCMember OCX:UnderwritersMember 2022-04-12 2022-04-13 0001642380 us-gaap:CommonStockMember OCX:SecuritiesPurchaseAgreementMember OCX:BroadwoodPartnersLPMember 2023-04-03 2023-04-03 0001642380 us-gaap:CommonStockMember OCX:SecuritiesPurchaseAgreementMember OCX:PuraVidaMember 2023-04-03 2023-04-03 0001642380 us-gaap:CommonStockMember OCX:SecuritiesPurchaseAgreementMember OCX:AVMMember 2023-04-03 2023-04-03 0001642380 us-gaap:CommonStockMember OCX:SecuritiesPurchaseAgreementMember OCX:ArnoMember 2023-04-03 2023-04-03 0001642380 us-gaap:CommonStockMember OCX:SecuritiesPurchaseAgreementMember OCX:MrGutfreundMember 2023-04-03 2023-04-03 0001642380 us-gaap:SeriesAPreferredStockMember 2023-04-05 2023-04-05 0001642380 OCX:ArnoMember 2023-01-01 2023-09-30 0001642380 OCX:LifeTechnologiesCorporationMember 2023-01-01 2023-09-30 0001642380 OCX:RazorStockPurchaseAgreementMember us-gaap:CommonStockMember OCX:DragonMember 2022-12-14 2022-12-15 0001642380 OCX:RazorStockPurchaseAgreementMember us-gaap:CommonStockMember OCX:RazorMember OCX:DragonMember 2022-12-15 0001642380 OCX:RazorStockPurchaseAgreementMember us-gaap:CommonStockMember OCX:RazorMember 2023-02-16 2023-02-16 0001642380 OCX:RazorStockPurchaseAgreementMember us-gaap:CommonStockMember OCX:RazorMember 2023-02-16 0001642380 OCX:RazorStockPurchaseAgreementMember us-gaap:CommonStockMember OCX:RazorMember 2023-02-16 2023-02-16 0001642380 OCX:RazorStockPurchaseAgreementMember us-gaap:CommonStockMember OCX:RazorMember 2023-01-01 2023-03-31 0001642380 OCX:RazorStockPurchaseAgreementMember us-gaap:CommonStockMember OCX:RazorMember 2022-01-01 2022-12-31 0001642380 us-gaap:DiscontinuedOperationsHeldforsaleMember 2023-01-01 2023-09-30 0001642380 us-gaap:DiscontinuedOperationsHeldforsaleMember 2023-09-30 0001642380 us-gaap:DiscontinuedOperationsHeldforsaleMember 2022-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares utr:sqft OCX:Number iso4217:EUR xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2023

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___________ to __________

 

Commission file number 1-37648

 

Oncocyte Corporation

(Exact name of registrant as specified in its charter)

 

California   27-1041563
(State or other jurisdiction   (I.R.S. Employer
of incorporation or organization)   Identification No.)

 

15 Cushing

Irvine, California 92618

(Address of principal executive offices) (Zip Code)

 

(949) 409-7600

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, no par value   OCX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer Smaller reporting company
  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

 

The number of shares of common stock outstanding as of November 2, 2023 was 8,260,762.

 

 

 

 

 

 

ONCOCYTE CORPORATION

TABLE OF CONTENTS

 

For the quarterly period ended September 30, 2023

 

  Page
CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS 3
   
PART 1—FINANCIAL INFORMATION 4
   
Item 1. Financial Statements 4
CONDENSED CONSOLIDATED BALANCE SHEETS 4
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 5
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS 6
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY 7
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 9
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 10
   
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 43
   
Item 3. Quantitative and Qualitative Disclosures about Market Risk 50
   
Item 4. Controls and Procedures 50
   
PART II - OTHER INFORMATION 51
   
Item 1. Legal Proceedings 51
   
Item 1A. Risk Factors 51
   
Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 52
   
Item 3. Default Upon Senior Securities 52
   
Item 4. Mine Safety Disclosures 52
   
Item 5. Other Information 52
   
Item 6. Exhibits 53
   
SIGNATURES 54

 

2

 

 

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

 

This Report on Form 10-Q (“Report”) contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Report are forward-looking statements. In some cases, you can identify forward-looking statements by words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these words or other comparable terminology.

 

Any forward-looking statements in this Report reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those discussed in this Report under Item 1 of the Notes to Consolidated Financial Statements, under Risk Factors in this Report and those Risk Factors in Part I, Item 1A of our most recent Annual Report on Form 10-K as filed with the Securities and Exchange Commission (“SEC”). Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

 

The forward-looking statements in this Report also include, among other things, statements about:

 

  the timing and potential achievement of future milestones;
  the timing and our ability to obtain and maintain coverage and reimbursements from the Centers for Medicare and Medicaid Services and other third-party payers;
  our plans to pursue research and development of diagnostic tests;
  the potential commercialization of our diagnostic tests currently in development;
  the timing and success of future clinical trials and the period during which the results of the clinical trials will become available;
  the potential receipt of revenue from future sales of our diagnostic tests or diagnostic tests in development;
  our assumptions regarding obtaining reimbursement and reimbursement rates;
  our estimates regarding future orders of tests and our ability to perform a projected number of tests;
  our estimates and assumptions around patient populations, market size and price points for reimbursement for our diagnostic tests;
  our estimates regarding future revenues and operating expenses, and future capital requirements;
  our intellectual property position;
  the impact of government laws and regulations; and
  our competitive position.

 

Unless the context otherwise requires, all references to “Oncocyte,” the “Company,” “we,” “us,” “our,” or similar words refer to Oncocyte Corporation, together with our consolidated subsidiaries.

 

The description or discussion, in Report, of any contract or agreement is a summary only and is qualified in all respects by reference to the full text of the applicable contract or agreement.

 

DetermaIO™, DetermaCNI™, and VitaGraft™ are trademarks of Oncocyte Corporation, regardless of whether the “” symbol accompanies the use of or reference to the applicable trademark in this Report.

 

3

 

 

PART 1—FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

ONCOCYTE CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

 

   September 30, 2023   December 31, 2022 
   (Unaudited)     
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents  $13,783   $19,993 
Accounts receivable, net of allowance for credit losses of $178 and $154, respectively   1,882    2,012 
Marketable equity securities   441    433 
Prepaid expenses and other current assets   672    977 
Assets held for sale   139    - 
Current assets of discontinuing operations   -    2,121 
Total current assets   16,917    25,536 
           
NONCURRENT ASSETS          
Right-of-use and financing lease assets, net   1,757    2,088 
Machinery and equipment, net, and construction in progress   4,076    8,763 
Intangible assets, net   56,617    61,633 
Restricted cash   1,700    1,700 
Other noncurrent assets   520    371 
TOTAL ASSETS  $81,587   $100,091 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
CURRENT LIABILITIES          
Accounts payable  $1,136   $1,253 
Accrued compensation   1,722    1,771 
Accrued royalties   1,116    2,022 
Accrued expenses and other current liabilities   826    1,817 
Accrued severance from acquisition   2,314    2,314 
Accrued liabilities from acquisition   109    109 
Right-of-use and financing lease liabilities, current   720    815 
Current liabilities of discontinuing operations   90    2,005 
Total current liabilities   8,033    12,106 
           
NONCURRENT LIABILITIES          
Right-of-use and financing lease liabilities, noncurrent   2,354    2,729 
Contingent consideration liabilities   28,715    45,662 
          
TOTAL LIABILITIES   39,102    60,497 
           
Commitments and contingencies   -     -  
           
Series A Redeemable Convertible Preferred Stock, no par value; stated value $1,000 per share; 5 and 6 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively; aggregate liquidation preference of $5,217 and $6,091 as of September 30, 2023 and December 31, 2022, respectively   4,923    5,302 
           
SHAREHOLDERS’ EQUITY          
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding   -    - 
Common stock, no par value, 230,000 shares authorized; 8,261 and 5,932 shares issued and outstanding at
September 30, 2023 and December 31, 2022, respectively
   309,995    294,929 
Accumulated other comprehensive income   32    39 
Accumulated deficit   (272,465)   (260,676)
Total shareholders’ equity   37,562    34,292 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY  $81,587   $100,091 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4

 

 

ONCOCYTE CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

 

                 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
                 
Net revenue  $429   $67   $1,189   $684 
                     
Cost of revenues   159    314    593    602 
Cost of revenues – amortization of acquired intangibles   22    22    66    73 
Gross profit   248    (269)   530    9 
                     
Operating expenses:                    
Research and development   2,185    1,472    6,747    5,923 
Sales and marketing   713    405    2,213    798 
General and administrative   2,487    5,702    9,430    16,794 
Change in fair value of contingent consideration   (435)   (6,142)   (16,947)   (17,157)
Impairment losses   1,811    -    6,761    - 
Loss on disposal and held for sale assets   -    -    1,283    - 
Total operating expenses   6,761    1,437    9,487    6,358 
                     
Loss from operations   (6,513)   (1,706)   (8,957)   (6,349)
                     
Other income (expenses):                    
Interest income (expense), net   117    (14)   108    (65)
Unrealized (loss) gain on marketable equity securities   (89)   (160)   8    (485)
Other (expenses) income, net   (4)   62    (22)   304 
Total other income (expenses)   24    (112)   94    (246)
                     
Loss from continuing operations   (6,489)   (1,818)   (8,863)   (6,595)
                     
Loss from discontinuing operations   -    (7,515)   (2,926)   (21,329)
                     
Net loss  $(6,489)  $(9,333)  $(11,789)  $(27,924)
                     

Less: dividends and accretion of Series A redeemable convertible preferred stock

   (198)   (294)   (739)   (294)
                     
Net loss attributable to common stockholders  $(6,687)  $(9,627)  $(12,528)  $(28,218)
                     
Net loss from continuing operations per share: basic and diluted  $(0.79)  $(0.31)  $(1.19)  $(1.22)
Net loss from discontinuing operations per share: basic and diluted  $-   $(1.27)  $(0.39)  $(3.94)
Net loss attributable to common stockholders per share: basic and diluted  $(0.81)  $(1.62)  $(1.68)  $(5.22)
                     
Weighted average shares outstanding: basic and diluted   8,256    5,931    7,446    5,408 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5

 

 

ONCOCYTE CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands)

 

                 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
                 
Net loss  $(6,489)  $(9,333)  $(11,789)  $(27,924)
Foreign currency translation adjustments   (9)   (12)   (7)   (18)
Comprehensive loss  $(6,498)  $(9,345)  $(11,796)  $(27,942)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

6

 

 

ONCOCYTE CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(In thousands)

 

   Shares   Amount   Shares   Amount   Income  

Deficit

  

Equity

 
   Three Months Ended September 30, 2023 
   Series A Redeemable Convertible Preferred Stock   Common Stock  

Accumulated Other

Comprehensive

   Accumulated  

Total

Shareholders’

 
   Shares   Amount   Shares   Amount   Income  

Deficit

  

Equity

 
Balance at June 30, 2023   5   $4,725    8,250   $309,535   $41   $(265,976)  $43,600 
Net Loss   -    -    -    -    -    (6,489)   (6,489)
Foreign currency translation adjustment   -    -    -    -    (9)   -    (9)
Stock-based compensation   -    -    -    608    -    -    608 
Vesting of bonus awards   -    -    -    14    -    -    14 
Shares issued upon vesting of RSU   -    -    2    -    -    -    - 
Shares issued for consultant services   -    -    9    36    -    -    36 
Accretion of Series A convertible preferred stock to redemption value   -    198    -    (198)   -    -    (198)
Balance at September 30, 2023   5   $4,923    8,261   $309,995   $32   $(272,465)  $37,562 

 

 

   Three Months Ended September 30, 2022 
   Series A Redeemable Convertible Preferred Stock   Common Stock  

Accumulated Other

Comprehensive

   Accumulated  

Total

Shareholders’

 
   Shares   Amount   Shares   Amount   Income  

Deficit

  

Equity

 
Balance at June 30, 2022   6   $4,854    5,930   $289,649   $31   $(206,437)  $83,243 
Net Loss   -    -    -    -    -    (9,333)   (9,333)
Foreign currency translation adjustment   -    -    -    -    (12)   -    (12)
Stock-based compensation   -    -    -    3,181    -    -    3,181 
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes   -    -    1    -    -    -    - 
Accretion of Series A convertible preferred stock to redemption value   -    222    -    (294)   -    72    (222)
Balance at September 30, 2022   6   $5,076   $5,931   $292,536   $19   $(215,698)  $76,857 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

7

 

 

ONCOCYTE CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(In thousands)

 

   Nine Months Ended September 30, 2023 
   Series A Redeemable Convertible Preferred Stock   Common Stock  

Accumulated Other

Comprehensive

   Accumulated  

Total

Shareholders’

 
   Shares   Amount   Shares   Amount   Income  

Deficit

  

Equity

 
Balance at December 31, 2022   6   $5,302    5,932   $294,929   $39   $(260,676)  $34,292 
Net Loss   -    -    -    -    -    (11,789)   (11,789)
Foreign currency translation adjustment   -    -    -    -    (7)   -    (7)
Stock-based compensation   -    -    -    2,276    -    -    2,276 
Vesting of bonus awards   -    -    -    72    -    -    72 
Sale of common shares, net of financing costs   -    -    2,275    13,421    -    -    13,421 
Deemed dividend on Series A redeemable convertible preferred stock   -    -    -    (118)   -    -    (118)
Shares issued upon vesting of RSU   -    -    45    -    -    -    - 
Shares issued for consultant services   -    -    9    36    -    -    36 
Redemption of Series A redeemable convertible preferred stock   (1)   (1,000)   -    -    -    -    - 
Accretion of Series A convertible preferred stock to redemption value   -    621    -    (621)   -    -    (621)
Balance at September 30, 2023   5   $4,923    8,261   $309,995   $32   $(272,465)  $37,562 

 

   Nine Months Ended September 30, 2022 
   Series A Redeemable Convertible Preferred Stock   Common Stock  

Accumulated Other

Comprehensive

   Accumulated  

Total

Shareholders’

 
   Shares   Amount   Shares   Amount   Income  

Deficit

  

Equity

 
Balance at December 31, 2021   -   $-    4,612   $252,954   $37   $(187,774)  $65,217 
Net Loss   -    -    -    -    -    (27,924)   (27,924)
Foreign currency translation adjustment   -    -    -    -    (18)   -    (18)
Stock-based compensation   -    -    -    7,423    -    -    7,423 
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes   -    -    5    -    -    -    - 
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts   -    -    1,314    32,453    -    -    32,453 
Issuance of Series A redeemable convertible preferred stock, net of financing costs   6    4,782    -    -    -    -    - 
Accretion of Series A convertible preferred stock to redemption value   -    294    -    (294)   -    -    (294)
Balance at September 30, 2022   6   $5,076    5,931   $292,536   $19   $(215,698)  $76,857 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

8

 

 

ONCOCYTE CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

         
   Nine Months Ended 
   September 30, 
   2023   2022 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(11,789)  $(27,924)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization expense   1,289    1,062 
Amortization of intangible assets   66    2,880 
Stock-based compensation   2,276    7,423 
Equity compensation for bonus awards and consulting services   108    - 
Unrealized (gain) loss on marketable equity securities   (8)   485 
Amortization of debt issuance costs   -    12 
Change in fair value of contingent consideration   (16,947)   (17,157)
Change in fair value of Series A redeemable convertible preferred stock second tranche obligation   -    (352)
Impairment losses   6,761    - 
Loss on disposal of discontinued operations   1,659    - 
Loss on disposal and held for sale assets   1,283    - 
           
Changes in operating assets and liabilities:          
Accounts receivable   130    (553)
Prepaid expenses and other assets   784    (745)
Accounts payable and accrued liabilities   (4,193)   422 
Accrued severance and liabilities from Chronix Biomedical acquisition   -    (1,317)
Lease assets and liabilities   (43)   (156)
Assets held for sale   (139)   - 
Net cash used in operating activities   (18,763)   (35,920)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Proceeds from sale of equipment   354    - 
Construction in progress and purchases of furniture and equipment   (17)   (3,538)
Cash sold in discontinued operations (Note 13)   (1,510)   - 
Net cash used in investing activities   (1,173)   (3,538)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from sale of common shares   13,848    32,812 
Financing costs to issue common shares   (427)   (389)
Proceeds from sale of redeemable convertible Series A preferred shares   -    4,875 
Redemption of redeemable convertible Series A preferred shares   (1,118)   - 
Financing costs to issue redeemable convertible Series A preferred shares   -    (93)
Proceeds from sale of common shares under at-the-market transactions   -    31 
Financing costs for at-the-market sales   -    (1)
Repayment of loan payable   -    (1,325)
Repayment of financing lease obligations   (87)   (4)
Net cash provided by financing activities   12,216    35,906 
           
NET CHANGE IN CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH   (7,720)   (3,552)
           
CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH, BEGINNING   23,203    37,305 
CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH, ENDING  $15,483   $33,753 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION          
Cash paid for interest  $-   $24 
           
SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES          
Construction in progress, machinery and equipment purchases included in accounts payable and accrued liabilities  $215   $1,032 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

9

 

 

ONCOCYTE CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

1. Organization, Description of the Business and Liquidity

 

Oncocyte Corporation (“Oncocyte,” the “Company,” “we” or “us”), incorporated in 2009 in the state of California, is a precision diagnostics company focused on developing and commercializing proprietary tests in three areas: VitaGraft is a blood-based solid organ transplantation monitoring test, DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients.

 

Oncocyte’s first product for commercial release was a proprietary treatment stratification test called DetermaRx that identifies which patients with early-stage non-small cell lung cancer may benefit from chemotherapy, resulting in a significantly higher, five-year survival rate. Beginning in September 2019 through February 23, 2021, Oncocyte held a 25% equity interest in Razor Genomics, Inc. (“Razor”), a privately held company, that had developed and licensed to Oncocyte the lung cancer treatment stratification laboratory test that Oncocyte was commercializing as DetermaRx. On February 24, 2021, Oncocyte completed the purchase of all the remaining issued and outstanding shares of common stock of Razor. As a result of the purchase of the Razor common stock, Oncocyte became the sole shareholder of Razor.

 

On December 15, 2022, the Company, entered into a Stock Purchase Agreement (the “Razor Stock Purchase Agreement”) with Dragon Scientific, LLC, a Delaware limited liability company (“Dragon”) and Razor. Pursuant to the Razor Stock Purchase Agreement, Oncocyte agreed to sell to Dragon, 3,188,181 shares of common stock of Razor, which constitutes approximately 70% of the issued and outstanding equity interests of Razor on a fully-diluted basis, and transfer to Razor all of the assets and liabilities related to DetermaRx (the “Razor Sale Transaction”).

 

Certain amounts in prior periods have been reclassified to reflect the impact of the discontinued operations treatment of Razor in order to conform to the current period presentation. As a result of the divestiture of Razor, the Company has retrospectively revised the consolidated statements of operations for the periods ended September 30, 2022, to reflect the operations and cash flows of Razor as discontinued operations and the related assets and liabilities disposed. See Note 13 for additional information.

 

On February 16, 2023, Oncocyte completed the Razor Sale Transaction (the “Razor Closing”). In connection with the Razor Closing, Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx. While no monetary consideration was received for the sale of 70% of the equity interests of Razor, the transaction allowed the Company to eliminate all development and commercialization costs with respect to DetermaRx. Following the Razor Closing, Oncocyte continues to own 1,366,364 shares of common stock of Razor, which constitutes approximately 30% of the issued and outstanding equity interests of Razor on a fully-diluted basis.

 

Liquidity and Going Concern

 

Oncocyte has incurred operating losses and negative cash flows since inception and had an accumulated deficit of $272.5 million as of September 30, 2023. Oncocyte expects to continue to incur operating losses and negative cash flows for the foreseeable future. Since its formation, Oncocyte has financed its operations primarily through the sale of shares of its common stock, convertible preferred stock and warrants to acquire common stock.

 

As of September 30, 2023, Oncocyte had $13.8 million of cash and cash equivalents. In addition, Oncocyte held shares of Lineage Cell Therapeutics, Inc. (“Lineage”) and AgeX Therapeutics, Inc. (“AgeX”) common stock as marketable equity securities with a combined fair market value of $441,000.

 

On June 11, 2021, Oncocyte entered into an at-the-market sales agreement with BTIG, LLC as sales agent and/or principal (the “Agent” or “BTIG”) pursuant to which Oncocyte may sell up to an aggregate of $50,000,000 of shares of Oncocyte common stock from time to time through the Agent (the “ATM Offering”).

 

10

 

 

Between July 1, 2021 and September 30, 2023, Oncocyte sold 56,167 shares of common stock at an average offering price of $111.60 per share, for gross proceeds of approximately $6.27 million through the ATM Offering. The most recent sale of common stock through the ATM Offering took place in January 2022. Oncocyte will need to raise additional capital to finance its operations, including the development and commercialization of its cancer diagnostic and other tests, until such time as it is able to generate sufficient revenues from the commercialization of one or more of its laboratory tests and other tests, and performing Pharma Services to cover its operating expenses.

 

On April 13, 2022, Oncocyte entered into a securities purchase agreement (the “Securities Purchase Agreement”) with institutional accredited investors (the “Investors”), including Broadwood Partners, L.P. (“Broadwood”), Oncocyte’s largest shareholder, in a registered direct offering of 11,765 shares of Series A Convertible Preferred Stock (the “Series A Preferred Stock”), which are convertible into a total of 384,477 shares of common stock, at a conversion price of $30.60 (the “Series A Preferred Stock Offering”).

 

Further, on April 13, 2022, Oncocyte entered into an underwriting agreement (the “Underwriting Agreement”) with BTIG, LLC, as representative of the underwriters named therein (the “Underwriters”), pursuant to which Oncocyte issued and sold to the Underwriters an aggregate of 1,313,320 shares of common stock, and 1,313,320 warrants to purchase up to 656,660 shares of common stock (“April 2022 Warrants”) (the “Underwritten Offering”). See Notes 8 and 11 for additional information about the Series A Preferred Stock Offering and Underwritten Offering.

 

In August 2022, the Company initiated a workforce reduction plan to strategically realign its operations and implement cost reduction programs to prioritize near term revenue generators and to manage and preserve cash. In connection with the reduction, the Company eliminated 14 positions, implemented tighter expense controls, and ceased non-core activities. Further, on December 16, 2022, Oncocyte initiated an additional reduction in work force involving over 40% of its full-time employees. The transition began on December 16, 2022 and was completed in February 2023. As of December 31, 2022, the Company incurred an aggregate of $1.9 million related to employee severance and benefits costs in connection with its reductions in force during fiscal year 2022.

 

On April 3, 2023, Oncocyte entered into an agreement with certain members of the Company’s board of directors, and several institutional and accredited investors, including Broadwood, the Company’s largest shareholder, relating to their purchase of an aggregate of up to 2,278,121 shares of its common stock at an offering price of $7.08 per share to board members and $6.03 per share to the other investors participating in the offering (the “April 2023 Offering”). See Notes 8 and 11 for additional information about the April 2023 Offering.

 

On April 12, 2023, Oncocyte announced a reduction in force involving approximately 20% of its workforce (the “April 2023 Reduction”), which management believes will extend Oncocyte’s cash runway into 2024. In connection with the April 2023 Reduction, we incurred approximately $300,000 related to employee severance and benefits costs during the second quarter of 2023.

 

As of September 30, 2023, Oncocyte is completing clinical development and planning commercialization of DetermaIO, although DetermaIO is currently available for biopharma diagnostic development and research use only as a companion test in immunotherapy drug development to select patients for clinical trials; and the clinical launch of VitaGraft. While Oncocyte plans to primarily market its laboratory tests in the United States through its own sales force, it is also beginning to make marketing arrangements with distributors in other countries. In order to reduce capital needs and to expedite the commercialization of any new laboratory tests that may become available for clinical use, Oncocyte may also pursue marketing arrangements with other diagnostic companies through which Oncocyte might receive licensing fees and royalty on sales, or through which it might form a joint venture to market its tests and share in net revenues, in the United States or abroad.

 

In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, we evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements included in this Report are issued. This evaluation initially does not take into consideration the potential mitigating effect of our plans that have not been fully implemented as of the date the consolidated financial statements included in this Report are issued. When substantial doubt exists under this methodology, we evaluate whether the mitigating effect of our plans sufficiently alleviates substantial doubt about our ability to continue as a going concern. The mitigating effect of our plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that such financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about our ability to continue as a going concern within one year after the date that such financial statements are issued. In performing this analysis, we excluded certain elements of our operating plan that cannot be considered probable.

 

11

 

 

Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that the consolidated financial statements are issued. Management intends to complete additional equity financings while maintaining reduced spending levels. However, due to several factors, including those outside management’s control, there can be no assurance that we will be able to complete additional equity financings. If we are unable to complete additional financings, management’s plans include further reducing or delaying operating expenses. We have concluded the likelihood that our plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

 

In addition to general economic and capital market trends and conditions, Oncocyte’s ability to raise sufficient additional capital to finance its operations from time to time will depend on a number of factors specific to Oncocyte’s operations such as operating revenues and expenses, progress in development of, or in obtaining reimbursement coverage from Medicare for DetermaIO and other future laboratory tests that Oncocyte may develop or acquire.

 

The unavailability or inadequacy of financing or revenues to meet future capital needs could force Oncocyte to modify, curtail, delay, or suspend some or all aspects of planned operations. Sales of additional equity securities could result in the dilution of the interests of its shareholders. Oncocyte cannot assure that adequate financing will be available on favorable terms, if at all.

 

2. Summary of Significant Accounting Policies

 

Accounting Principles

 

The consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (“GAAP”).

 

Reclassifications

 

Certain prior period amounts in the consolidated financial statements and notes to consolidated financial statements have been reclassified to conform to the current period presentation. These changes had no impact on the previously reported consolidated financial condition, results of operations or cash flows.

 

Basis of Presentation

 

The unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance with GAAP for financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations, certain information and footnote disclosures normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance sheet as of December 31, 2022 was derived from the audited consolidated financial statements at that date. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in Oncocyte’s Annual Report on Form 10-K for the year ended December 31, 2022. The accompanying unaudited condensed consolidated financial statements, in the opinion of management, include all adjustments of a normal recurring nature necessary for a fair presentation of Oncocyte’s financial condition and results of operations. The consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

 

12

 

 

On July 24, 2023, the Company implemented a 1-for-20 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230 million shares.

 

Principles of Consolidation

 

On January 31, 2020, with the acquisition of Insight Genetics, Inc. (“Insight”) through a merger with a newly incorporated wholly-owned subsidiary of Oncocyte (the “Insight Merger”) under the terms of an Agreement and Plan of Merger (the “Insight Merger Agreement”), Insight became a wholly-owned subsidiary of Oncocyte, and on that date Oncocyte began consolidating Insight’s operations and results with Oncocyte’s operations and results (see Note 3).

 

On April 15, 2021, with the acquisition of Chronix Biomedical, Inc. (“Chronix”) pursuant to an Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021 (as amended and restated, the “Chronix Merger Agreement”), by and among Oncocyte, CNI Monitor Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Oncocyte (“Merger Sub”), Chronix became a wholly-owned subsidiary of Oncocyte (the “Chronix Merger”), and on that date Oncocyte began consolidating Chronix’s operations and results with Oncocyte’s operations and results (see Note 3).

 

We have reflected the operations of Razor as discontinued operations for all periods presented. See Note 13 for further information. Amounts and disclosures throughout these Notes to consolidated financial statements relate solely to continuing operations and exclude all discontinued operations. Discontinued operations comprise activities that were disposed of or discontinued at the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting purposes and represent a strategic business shift having a major effect on the Company’s operations and financial results according to ASC Topic 205, Presentation of Financial Statements.

 

All material intercompany accounts and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and contingent assets and liabilities, at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including, but not limited to, valuation methods used, assumptions requiring the use of judgment to prepare financial projections, timing of potential commercialization of acquired in-process intangible assets, applicable discount rates, probabilities of the likelihood of multiple outcomes of certain events related to contingent consideration, comparable companies or transactions, determination of fair value of the assets acquired and liabilities assumed including those relating to contingent consideration, assumptions related to going concern assessments, allocation of direct and indirect expenses, useful lives associated with long-lived intangible assets, key assumptions in operating and financing leases including incremental borrowing rates, loss contingencies, valuation allowances related to deferred income taxes, allowances for credit losses, and assumptions used to value debt and stock-based awards and other equity instruments. Actual results may differ materially from those estimates.

 

Similarly, Oncocyte assessed certain accounting matters that generally require consideration of forecasted financial information. The accounting matters assessed included, but were not limited to, Oncocyte’s equity investments, the carrying value of goodwill, going concern assessment, acquired in-process intangible assets and other long-lived assets. Those assessments as well as other estimates referenced above were made in the context of information reasonably available to Oncocyte.

 

13

 

 

Segments

 

Oncocyte’s executive management team, as a group, represents the entity’s chief operating decision makers. To date, Oncocyte’s executive management team has viewed Oncocyte’s operations as one segment that includes the research, development and commercialization of diagnostic tests, including molecular diagnostic services to pharmaceutical customers. As a result, the financial information disclosed materially represents all of the financial information related to Oncocyte’s sole operating segment.

 

Fair Value Measurements, Business Combinations and Contingent Consideration Liabilities

 

Oncocyte accounts for business combinations in accordance with ASC 805, which requires the purchase consideration transferred to be measured at fair value on the acquisition date in accordance with ASC 820, Fair Value Measurement. ASC 820 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:

 

Level 1 – Quoted prices in active markets for identical assets and liabilities.

 

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

When a part of the purchase consideration consists of shares of Oncocyte common stock, Oncocyte calculates the purchase price attributable to those shares, a Level 1 security, by determining the fair value of those shares as of the acquisition date based on prices quoted on the principal national securities exchange on which the shares traded. Oncocyte recognizes estimated fair values of the tangible assets and identifiable intangible assets acquired, including in-process research and development, and liabilities assumed, including any contingent consideration, as of the acquisition date. Goodwill is recognized as any amount of the fair value of the tangible and identifiable intangible assets acquired and liabilities assumed in excess of the consideration transferred. ASC 805 precludes the recognition of an assembled workforce as an asset, effectively subsuming any assembled workforce value into goodwill.

 

In determining fair value, Oncocyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, Oncocyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for money market funds and marketable equity securities held by Oncocyte described below. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.

 

Certain of Oncocyte’s asset and business acquisitions involve the potential for future payment of consideration to third-parties and former selling shareholders in amounts determined as a percentage of future net revenues generated, or upon attainment of revenue milestones, from Pharma Services or laboratory tests, as applicable, or annual minimum royalties to certain licensors, as provided in the applicable agreements. The fair value of such liabilities is determined using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows. These obligations are referred to as contingent consideration, which are carried at fair value based on Level 3 inputs.

 

14

 

 

ASC 805 requires that contingent consideration be estimated and recorded at fair value as of the acquisition date as part of the total consideration transferred. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings, such as “earn-out” provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of certain revenues generated.

 

The fair value of contingent consideration after the acquisition date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in the consolidated statements of operations. Changes in key assumptions can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that Oncocyte records in its consolidated financial statements. See Note 3 for a full discussion of these liabilities and additional Level 3 fair value disclosures.

 

The following tables present the Company’s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy:

 

   As of September 30, 2023 
   Fair value   Level 1   Level 2   Level 3 
   (In thousands) 
Assets:                    
Marketable equity securities  $441   $441   $-   $- 
Total  $441   $441   $-   $- 
                     
Liabilities:                    
Contingent consideration liabilities (Note 3)  $28,715   $-   $-   $28,715 
Total  $28,715   $-   $-   $28,715 

 

   As of December 31, 2022 
   Fair value   Level 1   Level 2   Level 3 
   (In thousands) 
Assets:                    
Marketable equity securities  $433   $433   $-   $- 
Total  $433   $433   $-   $- 
                     
Liabilities:                    
Contingent consideration liabilities (Note 3)  $45,662   $-   $-   $45,662 
Total  $45,662   $-   $-   $45,662 

 

The carrying amounts of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.

 

In accordance with GAAP, from time to time, the Company measures certain assets at fair value on a nonrecurring basis. The Company reviews the carrying value of goodwill, intangibles, including in-process research and development (“IPR&D”) (see Note 5), and other long-lived assets for indications of impairment at least annually. Refer to related discussions of impairments below.

 

Cash, Cash Equivalents and Restricted Cash

 

Oncocyte considers all highly liquid securities with original maturities of three months or less when purchased to be cash equivalents. For the periods presented, Oncocyte’s cash equivalents are comprised of investments in AAA rated money market funds that invest in first-tier only securities, which primarily include domestic commercial paper and securities issued or guaranteed by the U.S. government or its agencies. Restricted cash relates to a bank letter of credit required under our office lease arrangement, refer to Note 7 for additional information.

 

15

 

 

Marketable Equity Securities

 

Oncocyte accounts for the shares of Lineage and AgeX common stock it holds as marketable equity securities in accordance with ASC 320-10-25, Investments – Debt and Equity Securities, as amended, as the shares have a readily determinable fair value quoted on the NYSE American and are held principally to meet future working capital purposes, as necessary. The securities are measured at fair value, with related gains and losses in the value of such securities recorded in the consolidated statements of operations in other income or expense, and are reported as current assets on the consolidated balance sheets based on the closing trading price of the security as of the date being presented.

 

As of September 30, 2023 and December 31, 2022, Oncocyte held 353,264 and 35,326 shares of common stock of Lineage and AgeX, respectively, as marketable equity securities, which had a combined fair market value of $441,000 and $433,000, respectively.

 

Investments in Capital Stock of Privately Held Companies

 

Oncocyte evaluates whether investments held in common stock of other companies require consolidation of the company under, first, the variable interest entity (“VIE”) model, and then under the voting interest model in accordance with accounting guidance for consolidations under ASC 810-10. If consolidation of the entity is not required under either the VIE model or the voting interest model, Oncocyte determines whether the equity method of accounting should be applied in accordance with ASC 323, Investments – Equity Method and Joint Ventures. The equity method applies to investments in common stock or in-substance common stock if Oncocyte exercises significant influence over, but does not control, the entity, where significant influence is typically represented by ownership of 20% or more, but less than majority ownership, of the voting interests of a company.

 

Oncocyte initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment balance based on Oncocyte’s pro rata share of earnings or losses from the investment.

 

From February 24, 2021, the date of Oncocyte’s acquisition of the remaining interests in Razor, through February 16, 2023 the date of its disposition, Razor entity’s financial statements were consolidated with Oncocyte. See Note 13 for additional information related to the discontinued operations of Razor.

 

Assets Held for Sale

 

Assets and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management, having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified as held for sale in the consolidated balance sheet. Assets classified as held for sale are reported at the lower of their carrying value or fair value less costs to sell. Depreciation and amortization of assets ceases upon designation as held for sale.

 

During the nine months ended September 30, 2023, the Company entered into various agreements to sell laboratory equipment. As a result, the Company classified the equipment as held for sale as current assets, in the consolidated balance sheet, as all the criteria of ASC subtopic 360-10, Property, Plant, and Equipment (“ASC 360-10”) have been met and the transactions were qualified as assets held for sale. The equipment was written down to its fair value, less cost to sell, the remainder of which was $139,000 as of September 30, 2023. As a result of these transactions, the Company recorded an impairment loss of $1.3 million on held for sale assets, in the consolidated statement of operations.

 

16

 

 

Machinery and Equipment, Net, and Construction in Progress

 

Machinery and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of 3 to 10 years. For equipment purchased under financing leases, Oncocyte depreciates the equipment based on the shorter of the useful life of the equipment or the term of the lease, ranging from 3 to 5 years, depending on the nature and classification of the financing lease. Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in Oncocyte’s results of operations.

 

Construction in progress, comprised primarily of leasehold improvements under construction, is not depreciated until the underlying asset is placed into service.

 

Goodwill and Intangible Assets

 

In accordance with ASC 350, Intangibles – Goodwill and Other, IPR&D projects acquired in a business combination that are not complete as of the acquisition date are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Oncocyte considers various factors and risks for potential impairment of IPR&D assets, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays or inability to obtain local determination coverage (“LCD”) from the Centers for Medicare and Medicaid Services (“CMS”) for Medicare reimbursement for a diagnostic test, the inability to bring a diagnostic test to market and the introduction or advancement of competitors’ diagnostic tests could result in partial or full impairment of the related intangible assets. Consequently, the eventual realized value of the IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. During the period between completion or abandonment, the IPR&D assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if Oncocyte becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts (see Note 5).

 

Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill, similar to IPR&D, is not amortized but is tested for impairment at least annually, or if circumstances indicate its value may no longer be recoverable. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors affecting Oncocyte’s business. Based on the qualitative assessment, if it is determined that the fair value of goodwill is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. Oncocyte continues to operate in one segment and considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at the enterprise level.

 

Oncocyte does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&D discussed in Notes 3 and 5. As of September 30, 2023, goodwill has been fully impaired and acquired IPR&D has been partially impaired.

 

Long-Lived Intangible Assets

 

Long-lived intangible assets, consisting primarily of acquired customer relationships, are stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful life of 5 years (see Note 5).

 

17

 

 

Impairment of Long-Lived Assets

 

Oncocyte assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. Oncocyte’s long-lived assets consist primarily of intangible assets, right-of-use assets for operating leases, customer relationships, and machinery and equipment. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. See Note 4 for additional information with respect to the impairment of leasehold improvements. See “Assets held for sale” above for additional impairment disclosures.

 

Leases

 

Oncocyte accounts for leases in accordance with ASC 842, Leases. Oncocyte determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. Under the available practical expedients for the adoption of ASC 842, Oncocyte accounts for the lease and non-lease components as a single lease component. Oncocyte recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheet. ROU assets represent the right to use an underlying asset during the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most leases do not provide an implicit rate, Oncocyte uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Oncocyte uses the implicit rate when it is readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that Oncocyte will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Operating leases include our office leases and are also included as right-of-use assets in machinery and equipment, and ROU lease liabilities, current and long-term, in the consolidated balance sheets. Financing leases are included in machinery and equipment, and in financing lease liabilities, current and long-term, in the consolidated balance sheets. Oncocyte discloses the amortization of our ROU assets and operating lease payments as a net amount in the consolidated statements of cash flows. Based on the available practical expedients under the standard, Oncocyte elected not to capitalize leases that have terms of twelve months or less.

 

During prior years, Oncocyte entered into various operating leases and an embedded operating lease in accordance with ASC 842 as discussed in Note 7. Oncocyte’s accounting for financing leases remained substantially unchanged.

 

Revenue Recognition

 

Pursuant to ASC 606, revenues are recognized when control of services performed is transferred to customers, in an amount that reflects the consideration Oncocyte expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes:

 

(i) identifying the contract with a customer,

(ii) identifying the performance obligations in the contract,

(iii) determining the transaction price,

(iv) allocating the transaction price to the performance obligations, and

(v) recognizing revenue when, or as, an entity satisfies a performance obligation.

 

Oncocyte determines transaction prices based on the amount of consideration we expect to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. The Company considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.

 

18

 

 

The following table presents consolidated revenues by service:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
   (In thousands) 
Pharma Services  $423   $67   $1,137   $684 
Laboratory developed test services   6    -    52    - 
Total  $429   $67   $1,189   $684 

 

Pharma Services Revenue

 

Revenues recognized include Pharma Services performed by Oncocyte’s Insight and Chronix subsidiaries for its pharmaceutical customers, including testing for biomarker discovery, assay design and development, clinical trial support, and a broad spectrum of biomarker tests. These Pharma Services are generally performed under individual scope of work (“SOW”) arrangements or license agreements (together with SOW the “Pharma Services Agreements”) with specific deliverables defined by the customer. Pharma Services are performed on a (i) time and materials basis or (ii) per test completed basis. Upon completion of the service to the customer in accordance with a Pharma Services Agreement, Oncocyte has the right to bill the customer for the agreed upon price (either on a per test or per deliverable basis) and recognizes Pharma Service revenue at that time. Insight identifies each sale of its Pharma Service offering as a single performance obligation. Chronix identifies the processing of test samples as a separate performance obligation (considered a series) within license agreements with customers.

 

Completion of the service and satisfaction of the performance obligation is typically evidenced by access to the report or test made available to the customer or any other form or applicable manner of delivery defined in the Pharma Services Agreements. However, for certain SOWs under which work is performed pursuant to the customer’s highly customized specifications, Oncocyte has the enforceable right to bill the customer for work completed, rather than upon completion of the SOW. For those SOWs, Oncocyte recognizes revenue over a period during which the work is performed using a formula that accounts for expended efforts, generally measured in labor hours, as a percentage of total estimated efforts for the completion of the SOW. As performance obligations are satisfied under the Pharma Services Agreements, any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed to the customer as of the date of Oncocyte’s consolidated financial statements are recorded as contract assets and are included in prepaids and other current assets as of the financial statement date. Amounts recorded in contract assets are reclassified to accounts receivable in Oncocyte’s consolidated balance sheets when the customer is invoiced according to the billing schedule in the contract.

 

As of September 30, 2023 and December 31, 2022, Oncocyte had accounts receivable from Pharma Services customers of $557,000 and $257,000, respectively.

 

Allowance for Credit Losses

 

Oncocyte establishes an allowance for credit losses based on the evaluation of the collectability of its Pharma Services accounts receivables after considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer’s ability to pay, such as a bankruptcy filing or deterioration in the customer’s operating results or financial position, reasonable and supportable forecast that affect the collectability of the reported amount, and historical experience. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. Oncocyte continuously monitors collections and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts, if any, based upon its historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are written off against the credit loss reserve accounts. As of September 30, 2023 and December 31, 2022, we had no allowance for credit losses related to Pharma Services.

 

19

 

 

Laboratory Developed Test Services

 

Prior to the Razor Sale Transaction, Oncocyte generated revenue from performing DetermaRx tests on clinical samples through orders received from physicians, hospitals, and other healthcare providers. In determining whether all the revenue recognition criteria (i) through (v) above are met with respect to DetermaRx tests, each test result is considered a single performance obligation and is generally considered complete when the test result is delivered or made available to the prescribing physician electronically, and, as such, there are no shipping or handling fees incurred by Oncocyte or billed to customers. Although Oncocyte has billed a list price for all tests ordered and completed for all payer types, Oncocyte considers constraints on the variable consideration when recognizing revenue for DetermaRx. Because DetermaRx is a novel test and there are no current reimbursement arrangements with third-party payers other than Medicare, the transaction price represents variable consideration. Application of the constraint for variable consideration is an area that requires significant judgment. For all payers other than Medicare, Oncocyte must consider the novelty of the test, the uncertainty of receiving payment, or being subject to claims for a refund, from payers with whom it does not have a sufficient payment collection history or contractual reimbursement agreements. Accordingly, for those payers, Oncocyte has recognized revenue upon payment because it has had insufficient history to reliably estimate payment patterns or has had contractual reimbursement arrangements, or both, in place.

 

As of September 30, 2023 and December 31, 2022, Oncocyte had accounts receivable of $1.5 million and $1.9 million, respectively, from Medicare and Medicare Advantage covered DetermaRx tests.

 

Allowance for Credit Losses

 

We maintain an allowance for credit losses related to laboratory developed test services at an amount we estimate to be sufficient to provide adequate protection against losses resulting from extending credit to our customers. We base this allowance, in the aggregate, on historical collection experience, age of receivables and general economic conditions. Our bad debt write-offs have not been significant and have been within management expectations. As of September 30, 2023 and December 31, 2022, we had an allowance for credit losses of $178,000 and $154,000, respectively, related to laboratory developed test services.

 

Licensing Revenue

 

Revenues recognized include licensing revenue derived from agreements with customers for exclusive rights to market Oncocyte’s proprietary testing technology. Under the agreements, Oncocyte grants exclusive rights to certain trademarks and technology of Oncocyte for the purpose of marketing Oncocyte’s tests within a defined geographic territory. A license agreement may specify milestone deliverables or performance obligations, for which Oncocyte recognizes revenue when its licensee confirms the completion of Oncocyte’s performance obligation. A licensing agreement may also include ongoing sales support from Oncocyte and typically includes non-refundable licensing fees and per-test Pharma Services revenues discussed above, for which Oncocyte treats the licensing of the technology, trademarks, and ongoing support as a single performance obligation satisfied by the passage of time over the term of the agreement.

 

Disaggregation of Revenues and Concentrations of Credit Risk

 

The following table presents the percentage of consolidated revenues by service:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
Pharma Services   99%   100%   96%   100%
Laboratory developed test services   1%   0%   4%   0%
Total   100%   100%   100%   100%

 

20

 

 

The following table presents the percentage of consolidated revenues generated by unaffiliated customers, based on the respective periods presented, that individually represented greater than ten percent of consolidated revenues:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
Pharma services - Company A   57%   28%   42%   60%
Pharma services - Company B   41%   22%   34%   11%
Pharma services - Company C    -*    22%   -*    -* 
Pharma services - Company D   -*    19%   -*    -* 

 

* Less than 10%

 

The following table presents the percentage of consolidated revenues attributable to geographical locations:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
United States – Pharma Services   42%   76%   54%   74%
Outside of the United States – Pharma Services   57%   24%   41%   26%
United States – Laboratory developed test services   1%   0%   4%   0%
Total   100%   100%   100%   100%

 

Financial instruments that potentially subject the Company to concentrations of credit risk are cash equivalents and accounts receivable. The Company places its cash equivalents primarily in highly rated money market funds. Cash and cash equivalents are also invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. The Company has not experienced any significant losses on its deposits of cash and cash equivalents.

 

Two Pharma Services customers individually represented approximately 54% and 45% of accounts receivable at September 30, 2023. Two Pharma Services customers individually represented approximately 59% and 30% of accounts receivable at December 31, 2022.

 

Cost of Revenues

 

Cost of revenues generally consists of cost of materials, direct labor including benefits, bonus and stock-based compensation, equipment and infrastructure expenses, clinical sample related costs associated with performing DetermaRx tests and Pharma Services, providing deliverables according to our licensing agreements, license fees due to third parties, and amortization of acquired intangible assets such as the customer relationship intangible assets. Infrastructure expenses include depreciation of laboratory equipment, allocated rent costs, leasehold improvements, and allocated information technology costs for operations at Oncocyte’s CLIA laboratories in California and Tennessee. Costs associated with generating the revenues are recorded as the tests or services are performed regardless of whether revenue was recognized. Royalties or revenue share payments for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expenses at the time the related revenues are recognized.

 

Research and Development Expenses

 

Research and development expenses are comprised of costs incurred to develop technology, which include salaries and benefits (including stock-based compensation), laboratory expenses (including reagents and supplies used in research and development laboratory work), infrastructure expenses (including allocated facility occupancy costs), and contract services and other outside costs. Indirect research and development expenses are allocated primarily based on headcount, as applicable, and include rent and utilities, common area maintenance, telecommunications, property taxes, and insurance. Research and development costs are expensed as incurred.

 

21

 

 

Sales and Marketing Expenses

 

Sales and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade show expenses, branding and positioning expenses, and consulting fees. Sales and marketing expenses also include indirect expenses for applicable overhead allocated based on headcount, and include allocated costs for rent and utilities, common area maintenance, telecommunications, property taxes, and insurance.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of compensation and related benefits (including stock-based compensation) for executive and corporate personnel, professional and consulting fees, rent and utilities, common area maintenance, telecommunications, property taxes, and insurance.

 

Stock-Based Compensation

 

Oncocyte recognizes compensation expense related to employee option grants and restricted stock grants in accordance with the Financial Accounting Standards Board (“FASB”) ASC 718, Compensation – Stock Compensation (“ASC 718”).

 

Oncocyte estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value over the requisite service period. For stock-based awards that vest only upon the attainment of one or more performance goals set by Oncocyte at the time of the grant (sometimes referred to as milestone vesting), compensation cost is recognized if and when Oncocyte determines that it is probable that the performance condition or conditions will be, or have been, achieved. Oncocyte uses the Black-Scholes option pricing model for estimating the fair value of options granted under Oncocyte’s equity plans. The fair value of each restricted stock unit (“RSU”) or award is determined based on the value of the common stock granted or sold. Oncocyte has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period. Forfeitures are accounted for as they occur. Refer to Note 9 for additional information.

 

The Black-Scholes option pricing model requires Oncocyte to make certain assumptions including the expected option term, the expected volatility, the risk-free interest rate and the dividend yield. The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. Oncocyte estimates the expected term of options granted based on its own experience. Oncocyte estimates the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of peer companies, for a period equal to the expected term of the options. The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of Oncocyte’s stock options. The dividend yield assumption is based on Oncocyte’s history and expectation of dividend payouts. Oncocyte has never declared or paid any cash dividends on its common stock, and Oncocyte does not anticipate paying any cash dividends in the foreseeable future.

 

All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as income tax benefit or expense, respectively, in the statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction. Because Oncocyte has a full valuation allowance for all periods presented (see Note 10), there was no impact to Oncocyte statements of operations for any excess tax benefits or deficiencies, as any excess benefit or deficiency would be offset by the change in the valuation allowance.

 

Accounting for Warrants

 

Oncocyte determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate Oncocyte to settle the warrants or the underlying shares by paying cash or other assets or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480, Oncocyte assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. This liability classification guidance also applies to financial instruments that may require cash or other form of settlement for transactions outside of the company’s control and, in which the form of consideration to the warrant holder may not be the same as to all other shareholders in connection with the transaction. However, if a transaction is not within the company’s control but the holder of the financial instrument can solely receive the same type or form of consideration as is being offered to all the shareholders in the transaction, then equity classification of the financial instrument is not precluded, if all other applicable equity classification criteria are met.

 

22

 

 

After all relevant assessments, Oncocyte concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. Based on the above guidance and, among other factors, the fact that our warrants cannot be cash settled under any circumstance but require share settlement, all of our outstanding warrants meet the equity classification criteria and have been classified as equity. Refer to Notes 6 and 8 for details about our outstanding warrants.

 

Net Loss Per Common Share

 

Basic loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of shares of common stock outstanding during the year. Diluted loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method or the if-converted method, or the two-class method for participating securities, whichever is more dilutive. Potential common shares are excluded from the computation if their effect is antidilutive.

 

All common stock equivalents are antidilutive because Oncocyte reported a net loss for all periods presented. The following table presents the calculation of basic and diluted loss per share of common stock:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
   (In thousands, except per share data) 
Numerator:                    
Net loss attributable to Oncocyte Corporation  $(6,489)  $(9,333)  $(11,789)  $(27,924)
Accretion of Series A redeemable convertible preferred stock   (198)   (294)   (621)   (294)
Deemed dividend on Series A redeemable convertible preferred stock   -    -    (118)   - 
Net loss attributable to common stockholders - basic and diluted  $(6,687)  $(9,627)  $(12,528)  $(28,218)
                     
Denominator:                    
Weighted average shares used in computing net loss per share attributable to common stockholders - basic and diluted   8,256    5,931    7,446    5,408 
                     
Basic and diluted net loss per common share  $(0.81)  $(1.62)  $(1.68)  $(5.22)
                     
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share:                    
Stock options   501    717    501    717 
RSUs   5    29    5    29 
Warrants   820    820    820    820 
Series A redeemable convertible preferred stock   5    4    5    4 
Total   1,331    1,570    1,331    1,570 

 

23

 

 

Recent Accounting Pronouncements

 

In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Previously, U.S. GAAP required entities to write down credit losses only when losses are probable and loss reversals are not permitted. The Company adopted this ASU in the first quarter of 2023. Adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.

 

In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, to provide specific guidance to eliminate diversity in practice on how to recognize and measure acquired contract assets and contract liabilities from revenue contracts from customers in a business combination consistent with revenue contracts with customers not acquired in an acquisition. The amendments in this update provide that the acquirer should consider the terms of the acquired contracts, such as timing of payment, identify each performance obligation in the contracts, and allocate the total transaction price to each identified performance obligation on a relative standalone selling price basis as of contract inception (that is, the date the acquiree entered into the contracts) or contract modification to determine what should be recorded at the acquisition date. The Company adopted this ASU in the first quarter of 2023. Adoption of this standard did not have an impact on the Company’s consolidated financial statements and related disclosures.

 

3. Business Combinations

 

Acquisition of Insight Genetics, Inc.

 

On January 31, 2020 (the “Insight Merger Date”), Oncocyte completed its acquisition of Insight pursuant to the Insight Merger Agreement.

 

Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings, such as “earn-out” provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of revenues generated from DetermaIO and Insight Pharma Services over their respective useful life. Accordingly, Oncocyte determined there are two types of contingent consideration in connection with the Insight Merger, the Milestone Contingent Consideration and the Royalty Contingent Consideration discussed below, which are collectively referred to as the “Contingent Consideration”.

 

There are three milestones comprising the Milestone Contingent Consideration, collectively referred to as the Milestones, in connection with the Insight Merger which Oncocyte valued and recorded as part of Contingent Consideration as of the Insight Merger Date (see table below), which consist of (i) a payment for clinical trial completion and related data publication (“Milestone 1”), (ii) a payment for an affirmative final local coverage determination from CMS for a specified lung cancer test (“Milestone 2”), and (iii) a payment for achieving specified CMS reimbursement milestones (“Milestone 3”). If achieved, any respective Milestone will be paid at the contractual value shown below, with the payment made either in cash or in shares of Oncocyte common stock as determined by Oncocyte. There can be no assurance that any of the Milestones will be achieved.

 

24

 

 

The following table shows the Insight Merger Date contractual payment amounts, as applicable, and the corresponding fair value of each respective Contingent Consideration liability:

 

   Contractual   Fair Value on the 
   Value   Merger Date 
   (In thousands) 
Milestone 1  $1,500   $1,340 
Milestone 2   3,000    1,830 
Milestone 3 (a)   1,500    770 
Royalty 1 (b)   See(b)    5,980 
Royalty 2 (b)   See(b)    1,210 
Total  $6,000   $11,130 

 

(a) Indicates the maximum payable if the Milestone is achieved.
   
(b) As defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration.

 

The fair value of the Contingent Consideration after the Insight Merger Date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in Oncocyte’s consolidated statements of operations. Durning 2023, based on Oncocyte’s reassessment of significant assumptions, there was a decrease of approximately $3.1 million to the fair value of the Contingent Consideration primarily attributable to revised estimates of the timing of the possible future payouts and, accordingly, this decrease was recorded as change in fair value of contingent consideration in the consolidated statement of operations for the nine months ended September 30, 2023.

 

Oncocyte uses a discounted cash flow valuation technique to determine the fair value of its Level 3 contingent consideration liabilities. The significant unobservable inputs used in Insight’s contingent consideration valuation on September 30, 2023, included: (i) a discount period, based on the expected milestone payment dates, ranging from 0.5 years to 1.5 years, (ii) a discount rate of 15.2% to 15.4%, and (iii) a management probability estimate of 15% to 50%.

 

The following tables reflect the activity for the Insight Contingent Consideration measured at fair value using Level 3 inputs:

 

   Fair Value 
   (In thousands) 
Balance at December 31, 2021  $7,060 
Change in estimated fair value   420 
Balance at September 30, 2022  $7,480 
      
Balance at December 31, 2022  $5,370 
Change in estimated fair value   (3,080)
Balance at September 30, 2023  $2,290 

 

Contingent consideration is not deductible for tax purposes, even if paid; therefore, no deferred tax assets related to the Contingent Consideration were recorded.

 

Acquisition of Chronix Biomedical, Inc.

 

On April 15, 2021 (the “Chronix Merger Date”), Oncocyte completed its acquisition of Chronix pursuant the Chronix Merger Agreement.

 

As additional consideration for holders of certain classes and series of Chronix capital stock, the Chronix Merger Agreement originally required Oncocyte to pay “Chronix Contingent Consideration” consisting of (i) “Chronix Milestone Payments” of up to $14 million in any combination of cash or Oncocyte common stock if certain milestones specified in the Chronix Merger Agreement are achieved, (ii) “Royalty Payments” of up to 15% of net collections for sales of specified tests and products during the five-to-ten year earnout periods, and (iii) “Transplant Sale Payments” of up to 75% of net collections from the sale or license to a third party of Chronix’s patents for use in transplantation medicine during a seven-year earnout period.

 

25

 

 

On February 8, 2023, the Company and equity holder representative entered into Amendment No. 1 to the Merger Agreement (the “Chronix Amendment”), pursuant to which the parties agreed that (i) Chronix’s equity holders will be paid earnout consideration of 10% of net collections for sales of specified tests and products, until the expiration of intellectual property related to such tests and products, (ii) Chronix’s equity holders will be paid 5% of the gross proceeds received from any sale of all or substantially all of the rights, titles, and interests in and to Chronix’s patents for use in transplantation medicine to such third party, and (iii) the Chronix Milestone Payments, 15% Royalty Payments and Transplant Sale Payment obligations were eliminated.

 

The fair value of the Chronix Contingent Consideration after the Chronix Merger Date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in Oncocyte’s consolidated statements of operations. During 2023, based on Oncocyte’s reassessment of significant assumptions, there was a decrease of approximately $13.9 million to the fair value of the Contingent Consideration primarily attributable to revised estimates of the timing of the possible future payouts and, accordingly, this decrease was recorded as a change in fair value of contingent consideration in the consolidated statement of operations for the nine months ended September 30, 2023.

 

Oncocyte uses a discounted cash flow valuation technique to determine the fair value of its Level 3 contingent consideration liabilities. The significant unobservable inputs used in Chronix’s contingent consideration valuation on September 30, 2023, included: (i) a discount period, based on the related patent expiration dates, ranging from 0.4 years to 12.2 years, (ii) a discount rate of 15.5% to 16.4%, and (iii) a payout percentage of 10% based on the earnout provision.

 

The following tables reflect the activity for the Chronix Contingent Consideration measured at fair value using Level 3 inputs:

 

   Fair Value 
   (In thousands) 
Balance at December 31, 2021  $69,621 
Change in estimated fair value   (17,577)
Balance at September 30, 2022  $52,044 
      
Balance at December 31, 2022  $40,292 
Change in estimated fair value   (13,867)
Balance at September 30, 2023  $26,425 

 

Goodwill was calculated as the difference between the acquisition date fair value of the Aggregate Chronix Merger Consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill also included the $2.2 million of net deferred tax liabilities recorded principally related to the VitaGraft discussed above. Oncocyte recognized approximately $9.5 million of goodwill related to the Chronix acquisition. None of the goodwill recognized is expected to be deductible for income tax purposes. During 2022, the Company identified circumstances that could indicate a potential impairment and after a valuation of the Company’s assets and liabilities was performed, management concluded that goodwill was impaired as of December 31, 2022 (see Note 2).

 

4. Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress

 

Right-of-use and financing lease assets, machinery and equipment, net, and construction in progress were as follows:

 

   September 30, 2023   December 31, 2022 
   (In thousands) 
Right-of-use assets  $4,036   $3,499 
Machinery and equipment   6,908    9,408 
Accumulated depreciation and amortization   (5,819)   (4,196)
Right-of-use assets and machinery and equipment, net   5,125    8,711 
Construction in progress   708    2,140 
Right-of-use and financing lease assets, machinery and equipment, net, and construction in progress  $5,833   $10,851 

 

26

 

 

Fixed asset depreciation and amortization expense amounted to $404,000 and $391,000 for the three months ended September 30, 2023 and 2022, respectively, and $1.3 million and $1.1 million for the nine months ended September 30, 2023 and 2022, respectively.

 

During the third quarter of 2023, in connection with a new sublease arrangement (see Note 7), the Company identified circumstances that indicated a potential impairment of certain leasehold improvements (included in construction in progress) and after a valuation was performed, management concluded that such leasehold improvements were impaired. Accordingly, the Company recorded an impairment of approximately $1.8 million.

 

5. Intangible Assets, Net

 

As part of the Insight and Chronix acquisitions completed on January 31, 2020, and April 15, 2021, respectively, the Company has acquired IPR&D and customer relationships.

 

During the first quarter of 2023, due to changes in management and the economic condition of the Company, management shifted the Company’s business strategy to direct efforts on fewer studies and to transition from tests that are laboratory developed tests to research use only sales. Due to the change in strategy, the Company’s long range plan forecasts were updated and anticipated future benefits derived from the Company’s assets. The change in strategy represent a significant indicator for change in value of the Company’s long-lived assets. The original IPR&D balance was reassessed based on the updated long range plan, using the multi-period excess earnings method (“MPEEM”) approach, the results of the valuation noted that the carrying value of the DetermaIO related IPR&D intangible assets was greater than the fair market value, whereas the CNI and VitaGraft related IPR&D intangible assets carrying value was lower than the fair market value. Accordingly, the Company recorded an impairment of approximately $5.0 million.

 

The MPEEM valuation approach is a discounted cash flow valuation technique and was used to determine the Level 3 fair value of Insight’s IPR&D discussed above. The significant unobservable inputs used on March 31, 2023, included: (i) a discount period of 20.0 years, based on the expected life of patent, (ii) a royalty rate of 0.3%, (iii) a contributory asset rate of return of 30.0%, and (iv) a weighted average cost of capital rate of 30.0%. As market conditions change, the Company will re-evaluate assumptions used in the determination of fair value for IPR&D and is uncertain to the extent of the volatility in the unobservable inputs in the foreseeable future. Refer to Note 2, “Goodwill and Intangible Assets” for additional IPR&D information.

 

Intangible assets, net, consisted of the following:

 

   September 30, 2023   December 31, 2022 
   (In thousands) 
Intangible assets:          
Acquired IPR&D - DetermaIOTM (1)  $9,700   $14,650 
Acquired IPR&D - DetermaCNI™ and VitaGraft™ (2)   46,800    46,800 
           
Intangible assets subject to amortization:          
Acquired intangible assets - customer relationship   440    440 
Total intangible assets   56,940    61,890 
Accumulated amortization - customer relationship(3)   (323)   (257)
Intangible assets, net  $56,617   $61,633 

 

(1) See Note 3 for information on the Insight Merger.
(2) See Note 3 for information on the Chronix Merger.
(3) Amortization of intangible assets is included in “Cost of revenues – amortization of acquired intangibles” on the consolidated statements of operations because the intangible assets pertain directly to the revenues generated from the acquired intangibles.

 

Intangible asset amortization expense amounted to $22,000 and $976,000 for the three months ended September 30, 2023 and 2022, respectively, and $66,000 and $2.9 million for the nine months ended September 30, 2023 and 2022, respectively.

 

27

 

 

Future amortization expense of intangible assets subject to amortization is expected to be the following:

 

   Amortization 
   (In thousands) 
Year ending December 31,     
2023  $22 
2024   88 
2025   7 
Total  $117 

 

6. Loan Payable to Silicon Valley Bank

 

Amended Loan Agreement

 

On October 17, 2019, Oncocyte entered into a First Amendment to Loan and Security Agreement (the “Amended Loan Agreement”) with Silicon Valley Bank (“the Bank”) pursuant to which Oncocyte obtained a new $3 million secured credit facility (“Tranche 1”), a portion of which was used to repay the remaining balance of approximately $400,000 on outstanding loans from the Bank, plus a final payment of $116,000, under the February 21, 2017 Loan Agreement. The credit line under the Amended Loan Agreement may be increased by an additional $2 million (“Tranche 2”) if Oncocyte obtains at least $20 million of additional equity capital, as was the case with the original Loan Agreement, and a positive final coverage determination is received from CMS for DetermaRx at a specified minimum price point per test (the “Tranche 2 Milestone”), and Oncocyte is not in default under the Amended Loan Agreement. As of September 30, 2023, Oncocyte had satisfied the Tranche 2 Milestone and was eligible to borrow the $2 million Tranche 2 funds. However, Oncocyte has not yet borrowed any funds under Tranche 2.

 

Payments of interest only on the principal balance were due monthly from the draw date through March 31, 2020, followed by 24 monthly payments of principal and interest, but the Bank has agreed to a deferral of principal payments, as discussed below. The outstanding principal balance of the loan will bear interest at a stated floating annual interest equal to the greater of (a) the prime rate or (b) 5% per annum. During August 2022, period in which the loan was paid off, the published prime rate was 5.5% per annum.

 

On April 2, 2020, as part of the Bank’s COVID-19 pandemic relief program, Oncocyte and the Bank entered into a Loan Deferral Agreement (“Loan Deferral”) with respect to the Amended Loan Agreement. Under the Loan Deferral Agreement, the Bank agreed to (i) extend the scheduled maturity date of the Amended Loan Agreement from March 31, 2022 to September 30, 2022, and (ii) deferred the principal payments by an additional 6 months whereby payments of interest only on the Bank loan principal balance will be due monthly from May 1, 2020 through October 1, 2020, followed by 23 monthly payments of principal and interest beginning on November 1, 2020, all provided at no additional fees to Oncocyte. No other terms of the Amended Loan Agreement were changed or modified. The Loan Deferral was accounted for as a modification of debt in accordance with ASC 470-50, Debt – Modifications and Extinguishments, thus there was no gain or loss recognized on the transaction.

 

At maturity of the loan, Oncocyte agreed to pay the Bank an additional final payment fee of $200,000, which was recorded as a deferred financing charge in October 2019 and is being amortized to interest expense over the term of the loan using the effective interest method. Since August 2022, there is no remaining unamortized deferred financing cost and the full principal balance of the loan in addition to the final payment fee have been paid off.

 

Bank Warrants

 

In 2017, in connection with the Loan Agreement, Oncocyte issued common stock purchase warrants to the Bank (the “2017 Bank Warrants”) entitling the Bank to purchase shares of Oncocyte common stock in tranches related to the loan tranches under the Loan Agreement. In conjunction with the availability of the loan, the Bank was issued warrants to purchase 412 shares of Oncocyte common stock at an exercise price of $97.00 per share, through February 21, 2027. On March 23, 2017, the Bank was issued warrants to purchase an additional 366 shares at an exercise price of $109.20 per share, through March 23, 2027. The Bank may elect to exercise the 2017 Bank Warrants on a “cashless exercise” basis and receive a number of shares determined by multiplying the number of shares for which the applicable tranche is being exercised by (A) the excess of the fair market value of the common stock over the applicable exercise price, divided by (B) the fair market value of the common stock. The fair market value of the common stock will be the last closing or sale price on a national securities exchange, inter-dealer quotation system, or over-the-counter market. These warrants meet the equity classification criteria and have been classified as equity, refer to Note 2 “Accounting for Warrants” for additional information.

 

28

 

 

On October 17, 2019, in conjunction with Tranche 1 becoming available under the Amended Loan Agreement, Oncocyte issued a common stock purchase warrant to the Bank (the “2019 Bank Warrant”) entitling the Bank to purchase 4,928 shares of Oncocyte common stock at the initial “Warrant Price” of $33.80 per share through October 17, 2029. The number of shares of common stock issuable upon the exercise of the 2019 Bank Warrant will increase on the date of each draw, if any, on Tranche 2. The number of additional shares of common stock issuable upon the exercise of the 2019 Bank Warrant will be equal to 0.02% of Oncocyte’s fully diluted equity outstanding for each $1 million draw under Tranche 2. The Warrant Price for Tranche 2 warrant shares will be determined upon each draw of Tranche 2 funds and will be closing price of Oncocyte common stock on the date immediately before the applicable date on which Oncocyte borrows funds under Tranche 2. The Bank may elect to exercise the 2019 Bank Warrant on a “cashless exercise” basis and receive a number of shares determined by multiplying the number of shares for which the 2019 Bank Warrant is being exercised by (A) the excess of the fair market value of the common stock over the applicable Warrant Price, divided by (B) the fair market value of the common stock. The fair market value of the common stock will be last closing or sale price on a national securities exchange, interdealer quotation system, or over-the-counter market. These warrants meet the equity classification criteria and have been classified as equity, refer to Note 2 “Accounting for Warrants” for additional information. As of September 30, 2023, Oncocyte has not borrowed any funds under Tranche 2.

 

7. Commitments and Contingencies

 

Office and Facilities Leases

 

Irvine Office Lease

 

On December 23, 2019, Oncocyte and Cushing Ventures, LLC (“Landlord”) entered into an Office Lease Agreement (the “Irvine Lease”) of a building containing approximately 26,800 square feet of rentable space located at 15 Cushing in Irvine, California (the “Premises”) that serves as Oncocyte’s principal executive and administrative offices.

 

The Irvine Lease has an initial term of 89 calendar months (the “Term”), which commenced on June 1, 2020 (the “Commencement Date”). Oncocyte has an option to extend the Term for a period of five years (the “Extended Term”).

 

Oncocyte agreed to pay base monthly rent in the amount of $61,640 during the first 12 months of the Term. Base monthly rent increases annually, over the base monthly rent then in effect, by 3.5%. Oncocyte was entitled to an abatement of 50% of the base monthly rent during the first ten calendar months of the Term. If the Irvine Lease is terminated based on the occurrence of an “event of default,” Oncocyte will be obligated to pay the abated rent to the lessor.

 

If Oncocyte exercises its option to extend the Term, the initial base monthly rent during the Extended Term will be the greater of the base monthly rent in effect during the last year of the Term or the prevailing market rate. The prevailing market rate will be determined based on annual rental rates per square foot for comparable space in the area where the Premises are located. If Oncocyte does not agree with the prevailing market rate proposed by the lessor, the rate may be determined through an appraisal process. The base monthly rent during the Extended Term shall be subject to the same annual rent adjustment as applicable for base monthly rent during the Term.

 

In addition to base monthly rent, Oncocyte agreed to pay in monthly installments (a) all costs and expenses, other than certain excluded expenses, incurred by the lessor in each calendar year in connection with operating, maintaining, repairing (including replacements if repairs are not feasible or would not be effective) and managing the Premises and the building in which the Premises are located (“Expenses”), and (b) all real estate taxes and assessments on the Premises and the building in which the Premises are located, all personal property taxes for property that is owned by lessor and used in connection with the operation, maintenance and repair of the Premises, and costs and fees incurred in connection with seeking reductions in such tax liabilities (“Taxes”). Subject to certain exceptions, Expenses shall not be increased by more than 4% annually on a cumulative, compounded basis.

 

29

 

 

Oncocyte was entitled to an abatement of its obligations to pay Expenses and Taxes while constructing improvements to the Premises constituting “Tenant’s Work” under the Irvine Lease prior to the Commencement Date, except that Oncocyte was obligated to pay 43.7% of Expenses and Taxes during the period prior to the Commencement Date for its use of the second floor of the Premises, which was already built out as office space.

 

The lessor provided Oncocyte with a “Tenant Improvement Allowance” in the amount of $1.3 million to pay for the plan, design, permitting, and construction of the improvements constituting Tenant’s Work. The lessor retained 1.5% of the Tenant Improvement Allowance as an administrative fee as provided in the Irvine Lease. As of June 2021, the lessor had provided $1.3 million of the total Tenant Improvement Allowance, which is being amortized over the Term.

 

Oncocyte has provided the lessor with a security deposit in the amount of $150,000 and a letter of credit in the amount of $1.7 million. The lessor may apply the security deposit, in whole or in part, for the payment of rent and any other amount that Oncocyte is or becomes obligated to pay under the Irvine Lease but fails to pay when due and beyond any cure period. The lessor may draw on the letter of credit from time to time to pay any amount that is unpaid and due, or if the original issuing bank notifies the lessor that the letter of credit will not be renewed or extended for the period required under the Irvine Lease and Oncocyte fails to timely provide a replacement letter of credit, or an event of default under the Irvine Lease occurs and continues beyond the applicable cure period, or if certain insolvency or bankruptcy or insolvency with respect to Oncocyte occur. Oncocyte is required to restore any portion of the security deposit that is applied by the lessor to payments due under the Irvine Lease, and Oncocyte is required to restore the amount available under the letter of credit to the required amount if any portion of the letter of credit is drawn by the lessor. The Irvine Lease provides that commencing on the 34th month of the Term, (a) the amount of the letter of credit that Oncocyte is required to maintain shall be reduced on a monthly basis, in equal installments, to amortize the required amount to zero at the end of the Term, and (b) Oncocyte has the right to cancel the letter of credit at any time if it meets certain market capitalization and balance sheets thresholds; provided, in each case, that Oncocyte is not in then default under the Irvine Lease beyond any applicable notice and cure period and the lessor has not determined that an event exists that would lead to an event of default.

 

To obtain the letter of credit, Oncocyte has provided the issuing bank with a restricted cash deposit that the bank will hold to cover its obligation to pay any draws on the letter of credit by the lessor. The restricted cash may not be used for any other purpose, accordingly, Oncocyte has reflected $1.7 million as restricted cash in the accompanying consolidated balance sheets.

 

Irvine Office Sublease

 

On August 8, 2023, Oncocyte and Induce Biologics USA, Inc. (“Subtenant”) entered into a Sublease Agreement (the “Sublease Agreement”), which subsequently became effective as of September 14, 2023, upon the execution and delivery by the Company, Subtenant, and Landlord, of that certain Landlord’s Consent to Sublease dated September 12, 2023 (the “Consent Agreement”), under which Landlord consented to the Sublease Agreement, on the terms and subject to the conditions set forth therein. The Sublease Agreement is subject and subordinate to the Irvine Lease.

 

Under the Sublease Agreement, the Company agreed to initially sublet to Subtenant a portion of the Premises consisting of approximately 13,400 square feet of rentable space for a term (the “Initial Period”) commencing on the date that is 120 days after the effective date of the Consent Agreement (the “Commencement Date”) and ending on the date that is 18 months following the Commencement Date or such earlier date as Subtenant may elect upon the exercise of its one-time option to accelerate such date upon 90 days prior written notice to the Company (the date on which the Initial Period ends, the “Expansion Date”). On the Expansion Date, the portion of the Premises that is subleased to Subtenant under the Sublease Agreement will automatically increase to include the remaining portion of the Premises, which consists of approximately 13,400 square feet of additional rentable space for a term (the “Expansion Period”) beginning on the Expansion Date through the expiration of the Irvine Lease on October 31, 2027, unless earlier terminated.

 

30

 

 

The Sublease Agreement provides that, from and after the Commencement Date, Subtenant will pay to the Company monthly base rent in the following amounts: (i) $36,850.00 for rental periods beginning on the Commencement Date and ending on or before December 31, 2024 (subject to adjustment in the event that Subtenant exercises its option to accelerate the Expansion Date, such that the Expansion Period begins prior to December 31, 2024); (ii) $37,955.50 for rental periods beginning on or after January 1, 2025 and ending on or before June 20, 2025 (subject to adjustment in the event that Subtenant exercises its option to accelerate the Expansion Date, such that the Expansion Period begins prior to June 20, 2025); (iii) $75,844.00 for rental periods beginning on or after July 1, 2025 and ending on or before December 31, 2025; (iv) $78,188.33 for rental periods beginning on or after January 1, 2026 and ending on or before December 31, 2026; and (v) $80,533.98 for rental periods beginning on or after January 1, 2027 and ending on or before October 31, 2027.

 

Following the Commencement Date, Subtenant will be responsible for the payment of Additional Rent, including Expenses and Taxes (as each such term is defined in the Irvine Lease), provided that, with respect to the Initial Period, Subtenant will be responsible for only 50% of the Expenses and Taxes due. In addition, Subtenant will pay the Company a security deposit in the amount of $101,987.38 in connection with the transactions contemplated by the Sublease Agreement.

 

The Sublease Agreement contains customary provisions with respect to, among other things, Subtenant’s obligation to comply with the Irvine Lease and applicable laws, the payment of utilities and similar services utilized by Subtenant with respect its use of the Premises, the indemnification of the Company by Subtenant, and the right of the Company to terminate the Sublease Agreement in its entirety and retake the Premises if Subtenant fails to remedy certain defaults of its obligations under the Sublease Agreement within specified time periods.

 

Nashville Office Lease

 

On August 27, 2021, Oncocyte entered into a lease agreement to add an additional suite to its Nashville office space, containing approximately 1,928 square feet of rentable space located at 2 International Plaza, Suite 103, Nashville TN. The term of the lease commenced on October 1, 2021 and extends through April 9, 2024 and will serve as additional office space for Insight’s operations.

 

Embedded Operating Lease

 

On December 31, 2019, in connection with Oncocyte’s purchase of 25% of the outstanding equity of Razor, Oncocyte entered into a Laboratory Services Agreement with Razor and Encore Clinical, Inc. (“Encore”), a former stockholder of Razor (the “Laboratory Agreement”). Under the Laboratory Agreement (which expired on September 29, 2021), Oncocyte assumed all of Razor’s Laboratory Agreement payment obligations. Although Oncocyte is not a party to any lease agreement with Razor or Encore, under the terms of the Laboratory Agreement, Oncocyte received the landlord’s consent for the use of the laboratory at Razor’s Brisbane, California location (the “Brisbane Facility”) under the terms of a sublease to which Encore is the sublessee. The sublease expired on March 31, 2023 (the “Brisbane Lease”). The laboratory fee payments to Encore include both laboratory services and the use of the Brisbane Facility. Under the provisions of the Laboratory Agreement, if Oncocyte terminates the Laboratory Agreement prior to the expiration of the Brisbane Lease, Oncocyte shall assume the costs related to the subletting or early termination of the Brisbane Lease. The Laboratory Agreement terminated on March 31, 2023. Oncocyte determined that the Laboratory Agreement contains an embedded operating lease for the Brisbane Facility and Oncocyte allocated the aggregate payments to this lease component for purposes of calculating the net present value of the right-of-use asset and liability as of the inception of the Laboratory Agreement in accordance with ASC 842, as shown in the table below.

 

Our office leases are operating leases under ASC 842 and are included in the tables below. The tables below provide the amounts recorded in connection with the application of ASC 842 for Oncocyte’s operating and financing leases (see Note 2 for additional policy information).

 

31

 

 

Financing Lease

 

As of September 30, 2023, Oncocyte has one financing lease remaining through December 2023 for certain laboratory equipment with aggregate remaining payments of approximately $30,000 shown in the table below. Oncocyte’s lease obligations are collateralized by the equipment financed under the lease schedule.

 

Operating and Financing Leases

 

The following table presents supplemental balance sheet information related to operating and financing leases:

 

   September 30, 2023   December 31, 2022 
   (In thousands) 
Operating lease          
Right-of-use assets, net  $1,748   $2,088 
           
Right-of-use lease liabilities, current  $653   $698 
Right-of-use lease liabilities, noncurrent   2,252    2,730 
Total operating lease liabilities  $2,905   $3,428 
           
Financing lease          
Machinery and equipment  $537   $537 
Accumulated depreciation   (528)   (446)
Machinery and equipment, net  $9   $91 
           
Current liabilities  $30   $117 
Noncurrent liabilities   -    - 
Total financing lease liabilities  $30   $117 
           
Weighted average remaining lease term          
Operating lease   3.9 years    4.5 years 
Financing lease   0.3 years    1.0 years 
           
Weighted average discount rate          
Operating lease   11.29%   11.24%
Financing lease   11.55%   11.55%

 

Future minimum lease commitments are as follows:

 

   Operating   Financing 
   Leases   Leases 
   (In thousands) 
Year Ending December 31,          
2023  $255   $31 
2024   903    - 
2025   869    - 
2026   899    - 
2027   695    - 
Total minimum lease payments   3,621    31 
Less amounts representing interest   (716)   (1)
Present value of net minimum lease payments  $2,905   $30 

 

The following table presents supplemental cash flow information related to operating and financing leases:

 

   2023   2022 
   Nine Months Ended 
   September 30,  
   2023   2022 
   (In thousands) 
Cash paid for amounts included in the measurement of financing lease liabilities:          
Operating cash flows from operating leases  $793   $854 
Operating cash flows from financing leases  $7   $77 
Financing cash flows from financing leases  $86   $4 

 

32

 

 

Litigation – General

 

Oncocyte may be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and other matters. When Oncocyte is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, Oncocyte will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, Oncocyte discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material.

 

Tax Filings

 

Oncocyte tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes Oncocyte has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could be significantly different than the amounts recorded in the consolidated financial statements.

 

Employment Contracts

 

Oncocyte has entered into employment and severance benefit contracts with certain executive officers. Under the provisions of the contracts, Oncocyte may be required to incur severance obligations for matters relating to changes in control, as defined, and certain terminations of executives. As of September 30, 2023, Oncocyte accrued approximately $2.7 million in severance obligations for certain executive officers, in accordance with the severance benefit provisions of their respective employment and severance benefit agreements, primarily related to Oncocyte’s acquisition of Chronix in 2021.

 

Indemnification

 

In the normal course of business, Oncocyte may provide indemnification of varying scope under Oncocyte’s agreements with other companies or consultants, typically Oncocyte’s clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, Oncocyte will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with the use or testing of Oncocyte’s diagnostic tests. Indemnification provisions could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to Oncocyte’s diagnostic tests. Oncocyte’s office and laboratory facility leases also will generally contain indemnification obligations, including obligations for indemnification of the lessor for environmental law matters and injuries to persons or property of others, arising from Oncocyte’s use or occupancy of the leased property. The term of these indemnification agreements will generally continue in effect after the termination or expiration of the particular research, development, services, lease, or license agreement to which they relate. The Razor Stock Purchase Agreement also contains provisions under which Oncocyte has agreed to indemnify Razor and Encore from losses and expenses resulting from breaches or inaccuracy of Oncocyte’s representations and warranties and breaches or nonfulfillment of Oncocyte’s covenants, agreements, and obligations under the Razor Stock Purchase Agreement. Oncocyte periodically enters into underwriting and securities sales agreements with broker-dealers in connection with the offer and sale of Oncocyte securities. The terms of those underwriting and securities sales agreements include indemnification provisions pursuant to which Oncocyte agrees to indemnify the broker-dealers from certain liabilities, including liabilities arising under the Securities Act, in connection with the offer and sale of Oncocyte securities. The potential future payments Oncocyte could be required to make under these indemnification agreements will generally not be subject to any specified maximum amounts. Historically, Oncocyte has not been subject to any claims or demands for indemnification. Oncocyte also maintains various liability insurance policies that limit Oncocyte’s financial exposure. As a result, Oncocyte management believes that the fair value of these indemnification agreements is minimal. Accordingly, Oncocyte has not recorded any liabilities for these agreements as of September 30, 2023 and December 31, 2022.

 

33

 

 

8. Shareholders’ Equity

 

Series A Redeemable Convertible Preferred Stock

 

On April 13, 2022, the Company entered into the Securities Purchase Agreement with the Investors in a registered direct offering of 11,765 shares of the Company’s Series A Preferred Stock, which shares of Series A Preferred Stock are convertible into a total of 384,477 shares of common stock, at a conversion price of $30.60. The purchase price of each share of Series A Preferred Stock was $850, which included an original issue discount to the stated value of $1,000 per share. The rights, preferences and privileges of the Series A Preferred Stock are set forth in the Company’s Certificate of Determination, which the Company filed with the Secretary of State of the State of California. The Securities Purchase Agreement provides that the closing of the Series A Preferred Stock Offering will occur, subject to the satisfaction of certain closing conditions, in two equal tranches of $5,000,000 each for aggregate gross proceeds from both closings of $10,000,000. The first closing occurred on June 1, 2022, and Oncocyte received net proceeds of approximately $4.9 million from the Series A Preferred Stock issued from the first tranche. The second closing would occur, subject to the satisfaction of certain closing conditions (including but not limited to a requirement that the Company has not received, in the 12 months preceding the second closing, a notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the listing and maintenance and listing requirements of Nasdaq), on the earlier of (a) the second trading day following the date that Oncocyte receives notice from an Investor to accelerate the second closing and (b) a date selected by Oncocyte on or after October 8, 2022 and on or prior to March 8, 2023. On August 9, 2022, Oncocyte received a letter from Nasdaq indicating that the Company no longer met the minimum bid price requirement of the Nasdaq continued listing requirements. Accordingly, the second closing did not occur and no additional proceeds were received under the Securities Purchase Agreement. On August 8, 2023, the Company received a letter from Nasdaq indicating that the Company had regained compliance with the minimum bid price requirement of the Nasdaq continued listing requirements.

 

The Series A Preferred Stock is convertible into shares of the Company’s common stock at any time at the holder’s option. The conversion price will be subject to customary anti-dilution adjustments for matters such as stock splits, stock dividends and other distributions on our common stock, and recapitalizations. A holder is prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of our common stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership limitation solely as to itself up to 19.99% of the number of shares of our common stock outstanding immediately after giving effect to the conversion, provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect to the issuance of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer apply to the holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval). On July 15, 2022, the Company received such shareholder approval to remove the beneficial ownership limitation with respect to the Series A Preferred Stock held by Broadwood. The Company may force the conversion of up to one-third of the shares of Series A Preferred Stock originally issued, subject to customary equity conditions, if the daily volume weighted average price of our common stock for 20 out of 30 trading days exceeds 140% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or exceeds 20,000 shares of our common stock. The Company may only effect one forced conversion during any 30-trading day period.

 

In the event of the Company’s liquidation, dissolution, or winding up, holders of Series A Preferred Stock will receive a payment equal to the stated value of the Series A Preferred Stock plus accrued but unpaid dividends and any other amounts that may have become payable on the Series A Preferred Stock due to any failure or delay that may have occurred in issuing shares of common stock upon conversion of a portion of the Series A Preferred Stock, before any distribution or payment to the holders of common stock or any of our other junior equity.

 

34

 

 

Shares of Series A Preferred Stock generally have no voting rights, except as required by law and except that the consent of holders of a majority of the outstanding Series A Preferred Stock will be required to amend any provision of our certificate of incorporation that would have a materially adverse effect on the rights of the holders of the Series A Preferred Stock. Additionally, as long as any shares of Series A Preferred Stock remain outstanding, unless the holders of at least 51% of the then outstanding shares of Series A Preferred Stock shall have otherwise given prior written consent, we, on a consolidated basis with our subsidiaries, are not permitted to (1) have less than $8 million of unrestricted, unencumbered cash on hand (“Cash Minimum Requirement”); (2) other than certain permitted indebtedness, incur indebtedness to the extent that our aggregate indebtedness exceeds $15 million; (3) enter into any agreement (including any indenture, credit agreement or other debt instrument) that by its terms prohibits, prevents, or otherwise limits our ability to pay dividends on, or redeem, the Series A Preferred Stock in accordance with the terms of the Certificate of Determination; or (4) authorize or issue any class or series of preferred stock or other capital stock of the Company that ranks senior or pari passu with the Series A Preferred Stock.

 

Shares of Series A Preferred Stock are entitled to receive cumulative dividends at a rate per share (as a percentage of stated value) of 6% per annum, payable quarterly in cash or, at our option, by accreting such dividends to the stated value.

 

The Company is required to redeem, for cash, the shares of Series A Preferred Stock on the earlier to occur of (1) April 8, 2024, (2) the commencement of certain a voluntary or involuntary bankruptcy, receivership, or similar proceedings against the Company or its assets, (3) a Change of Control Transaction (as defined herein) and (4) at the election and upon notice of 51% in interest of the holders, if the Company fails to meet the Cash Minimum Requirement. A “Change of Control Transaction” means the occurrence of any of (a) an acquisition by an individual or legal entity or “group” (as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective control (whether through legal or beneficial ownership of capital stock of the Company, by contract or otherwise) of in excess of 50% of the voting securities of the Company (other than by means of conversion of Series A Preferred Stock), (b) the Company merges into or consolidates with any other person, or any person merges into or consolidates with the Company and, after giving effect to such transaction, the stockholders of the Company immediately prior to such transaction own less than 50% of the aggregate voting power of the Company or the successor entity of such transaction, or (c) the Company sells or transfers all or substantially all of its assets to another person. Additionally, the Company has the right to redeem the Series A Preferred Stock for cash upon 30 days prior notice to the holders; provided if the Company undertakes a capital raise in connection with such redemption, the Investors will have the right to participate in such financing. On April 5, 2023, the Company redeemed 1,064 shares of the Series A Preferred Stock for approximately $1.1 million.

 

The issuance and sale of the Series A Preferred Stock was completed pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-256650), filed with the SEC on May 28, 2021 and declared effective by the SEC on June 8, 2021, and an accompanying prospectus dated June 8, 2021 as supplemented by a prospectus supplement dated April 13, 2022.

 

The Series A Preferred Stock dividend for all issued and outstanding shares is set at 6% per annum per share. As of September 30, 2023, the Company elected to accrete dividends of $399,000, net of the April 2023 redemption, with respect to shares of Series A Preferred Stock.

 

As of September 30, 2023 and December 31, 2022, Oncocyte had 4,818 and 5,882, shares issued and outstanding, respectively. The future right or obligation associated with the Series A Preferred Stock to be issued in the second closing was written off in the prior year since the second closing was not completed.

 

Common Stock

 

As of September 30, 2023 and December 31, 2022, Oncocyte has 230,000,000 shares of common stock, no-par value, authorized. As of September 30, 2023 and December 31, 2022, Oncocyte had 8,260,762 and 5,932,191 shares of common stock issued and outstanding, respectively.

 

Underwritten Offering

 

On April 13, 2022, Oncocyte entered into the Underwriting Agreement with the Underwriters, pursuant to which the Company agreed to issue and sell to the Underwriters an aggregate of 1,313,320 shares of common stock and 1,313,320 April 2022 Warrants to purchase up to 656,660 shares of common stock. Each share of common stock and the accompanying April 2022 Warrant was sold at a combined offering price of $26.65, representing an offering price of $26.45 per share of common stock and $0.20 per accompanying April 2022 Warrant, before underwriting discounts and commissions.

 

35

 

 

Under the terms of the Underwriting Agreement, the Company also granted to the Underwriters an over-allotment option, exercisable in whole or in part at any time for a period of 30 days from the date of the Underwriting Agreement, to purchase up to an additional 196,998 shares of common stock and 196,998 April 2022 Warrants to purchase 98,499 shares of common stock to cover over-allotments, if any. The over-allotment option may be exercised separately for shares of common stock at a price to the underwriters of $24.85 per share, and April 2022 Warrants at a price of $0.20 per April 2022 Warrant. On April 14, 2022, the Underwriters exercised their option to purchase the 196,998 April 2022 Warrants pursuant to the over-allotment option but did not exercise their option to purchase the additional 196,998 shares of common stock.

 

The Company received net proceeds of approximately $32.8 million from the Underwritten Offering, which includes the April 2022 Warrants sold upon the exercise of the Underwriters’ overallotment option. The Underwritten Offering closed on April 19, 2022. Refer to Note 11 for additional information.

 

The Underwritten Offering was made pursuant to the Company’s effective “shelf” registration statement on Form S-3 (Registration No. 333-256650) filed with the SEC Commission on May 28, 2021 and declared effective by the SEC on June 8, 2021, and an accompanying prospectus dated June 8, 2021 as supplemented by a prospectus supplement dated April 13, 2022.

 

April 2023 Offering

 

On April 3, 2023, Oncocyte entered into an agreement with certain members of the Company’s board of directors, and several institutional and accredited investors, including Broadwood, the Company’s largest shareholder, and certain members of the Company’s board of directors (and certain of their affiliated parties), relating to their purchase of an aggregate of up to 2,278,121 shares of its common stock at an offering price of $7.08 per share to board members and $6.03 per share to the other investors participating in the April 2023 Offering. The April 2023 Offering was intended to be priced at-the-market for purposes of complying with applicable Nasdaq Listing Rules. The Company issued an aggregate of 2,274,709 shares of common stock from this offering, as further discussed in Note 11. The aggregate gross proceeds from the offering were approximately $13.9 million. The Company used approximately $1.1 million of the net proceeds to immediately redeem an aggregate of 1,064 shares of its Series A Preferred Stock and may thereafter elect to redeem additional shares.

 

Common Stock Purchase Warrants

 

As of September 30, 2023, Oncocyte had an aggregate of 819,767 common stock purchase warrants issued and outstanding with exercise prices ranging from $30.60 to $109.20 per warrant. The warrants will expire on various dates ranging from February 2024 to October 2029. Certain warrants have “cashless exercise” provisions meaning that the value of a portion of warrant shares may be used to pay the exercise price rather than payment in cash, which may be exercised under any circumstances in the case of the 2017 Bank Warrants and 2019 Bank Warrants (see Note 6) or, in the case of certain other warrants, only if a registration statement for the warrants and underlying shares of common stock is not effective under the Securities Act or a prospectus in the registration statement is not available for the issuance of shares upon the exercise of the warrants. All of the outstanding warrants meet the equity classification criteria and have been classified as equity, refer to Note 2 for additional information.

 

9. Stock-Based Compensation

 

Equity Incentive Plans

 

Oncocyte had a 2010 Stock Option Plan (the “2010 Plan”) under which 260,000 shares of common stock were authorized for the grant of stock options or the sale of restricted stock. On August 27, 2018, Oncocyte shareholders approved a new Equity Incentive Plan (the “2018 Incentive Plan”) to replace the 2010 Plan. In adopting the 2018 Incentive Plan, Oncocyte terminated the 2010 Plan and will not grant any additional stock options or sell any stock under restricted stock purchase agreements under the 2010 Plan; however, stock options issued under the 2010 Plan will continue in effect in accordance with their terms and the terms of the 2010 Plan until the exercise or expiration of the individual options.

 

36

 

 

As of September 30, 2023, 1,050,000 shares of common stock were reserved under the 2018 Incentive Plan for the grant of stock options or the sale of restricted stock or for the settlement of RSUs. Oncocyte may also grant stock appreciation rights under the 2018 Incentive Plan. As of September 30, 2023, 387,000 shares are available for grant under the 2018 Incentive Plan.

 

2022 Equity Awards

 

During the year ended December 31, 2022, the Company awarded executive share-based payment awards under the 2018 Plan to certain executive officers and employees with time-based, market-based and performance-based vesting conditions (“2022 equity awards”).

 

The fair value of the RSU 2022 equity awards with performance-based vesting condition was estimated using the Black-Scholes option-pricing model assuming that performance goals will be achieved. If such performance conditions are not met, no compensation cost is recognized and any recognized compensation cost is reversed. The probability of 2022 equity awards performance-based vesting conditions will be evaluated each reporting period and the Company will true-up the amount of cumulative cost recognized for the 2022 performance-based awards at each reporting period based on the most up-to-date probability estimates. The Company will recognize the compensation expense for 2022 performance-based awards expected to vest on a straight-line basis over the respective service period for each separately vesting tranche.

 

The fair value of the RSU 2022 equity awards with market-based and time-based vesting conditions were estimated using the Monte Carlo simulation model. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated period to achievement of the performance and market conditions, which are subject to the achievement of the market-based goals established by the Company and the continued employment of the participant. These awards vest only to the extent that the market-based conditions are satisfied as specified in the vesting conditions. Unlike the performance-based awards, the grant date fair value and associated compensation cost of the market-based awards reflect the probability of the market condition being achieved, and the Company will recognize this compensation cost regardless of the actual achievement of the market condition. Assumptions utilized in connection with the Monte Carlo valuation technique included: estimated risk-free interest rate of 2.0 percent; term of 2.8 years; expected volatility of 100 percent; and expected dividend yield of 0 percent. The risk-free interest rate was determined based on the yields available on U.S. Treasury zero-coupon issues. The expected stock price volatility was determined using historical volatility. The expected dividend yield was based on expectations regarding dividend payments. The total grant date fair value of the market-based awards was $117,625.

 

2022 Modifications

 

In May 2022, the Company approved amendments to vesting conditions of 61,875 performance-based and 12,500 market-based awards of certain executive officers and employees. The performance-based awards were modified such that the stock awards will be eligible to vest as follows: (i) 50% will vest on December 31, 2023 if the Company achieves LCD reimbursement for VitaGraft (formerly TheraSure Transplant Monitor) for one organ no later than December 31, 2022 and (ii) 50% will vest on December 31, 2023 if DetermaIO or DetermaCNI (formerly TheraSure - CNI Monitor) submission for LCD is completed no later than December 31, 2022. Additional performance-based RSU awards were modified to be eligible to vest upon the achievement by the Company of average market capitalization minimum, target, and maximum goals of (i) $300 million; (ii) $400 million; and (iii) $500 million, respectively, during the period beginning on January 1, 2022 and ending on December 31, 2024. The market-based RSU awards were modified such that the awards will be eligible to vest upon the achievement of product commercial launch minimum, target, and maximum goals as follows: (i) one laboratory test product in the US; (ii) two laboratory test products in US, and (iii) three laboratory test products in the US, respectively.

 

In accordance with ASC 718, the Company calculated the fair value of the market-based awards on the date of modification, noting an increase in the fair value of approximately $58,500, with the incremental increase in fair value representing additional stock-based compensation expense. The following assumptions were used in calculating the fair value of the market-based options on the date of modification: estimated risk-free interest rate of 2.72 percent, term of 2.6 years, expected volatility of 95.0 percent and expected dividend yield of 0 percent.

 

37

 

 

In July 2022, the Company approved amendments to vesting conditions of 23,750 performance-based awards of certain executive officers and employees. Certain performance-based awards were modified such that the stock awards will be eligible to vest as follows: (i) fifty percent (50%) of the options will vest on December 31, 2023 (the “Vesting Date”), subject to Continuous Service through the Vesting Date, if local coverage determination is issued and priced for VitaGraft (Transplant) with respect to one organ no later than December 31, 2022; and (ii) fifty percent (50%) of the options will vest on the Vesting Date, subject to Continuous Service through the Vesting Date, if the Company submits a local coverage determination request for DetermaIO or DetermaCNI no later than December 31, 2022. Additional performance-based stock awards were modified to be eligible to vest upon the achievement of performance minimum, target, and maximum goals of (i) 90% of revenue goal; (ii) 100% of revenue goal; and (iii) exceed revenue goal by up to 150%, respectively, during fiscal year 2022. These same awards contained budget performance goals which were modified to be eligible to vest upon the achievement of performance minimum, target, and maximum goals of (i) complete fiscal year 2022 with sufficient cash to continue operations for 12 months; (ii) complete fiscal year 2022 with sufficient cash to continue operations for 15 months; and (iii) complete fiscal year 2022 with sufficient cash to continue operations for 16 months, respectively.

 

As of December 31, 2022, 50% of the performance-based were forfeited since the Company did not achieve LCD reimbursement for VitaGraft. The remaining 50% is eligible to vest on December 31, 2023, since the Company completed the LCD submission for DetermaCNI on December 16, 2022.

 

During the year ended December 31, 2022, the Company accelerated the vesting of certain equity awards in accordance with the 2018 Incentive Plan after the departure of officers of the Company and the adoption of the workforce reduction plan. Due to the acceleration of such awards all associated unrecognized compensation was accelerated and recognized in full.

 

2010 Plan Activity

 

A summary of Oncocyte’s 2010 Plan activity and related information follows:

 

   Shares   Number   Weighted 
   Available   of Options   Average 
Options  for Grant   Outstanding   Exercise Price 
   (In thousands, except weighted average exercise price) 
Balance at December 31, 2022   -    30   $80.78 
Exercised   -    -   $- 
Cancelled   -    (20)  $- 
Balance at September 30, 2023   -    10   $73.22 
Exercisable at September 30, 2023        10   $73.22 

 

2018 Plan Activity

 

A summary of Oncocyte’s 2018 Incentive Plan activity and related information follows:

 

  

Shares

Available

for Grant

  

Number

of Options

Outstanding

  

Number

of RSUs

Outstanding

  

Weighted

Average

Exercise Price

 
   (In thousands, except weighted average exercise price) 
Balance at December 31, 2022   442    428    22   $59.23 
RSUs vested   -    -    (14)  $- 
RSUs granted   (9)   -    5   $- 
Options granted   (298)   298    -   $5.96 
Options forfeited/expired   235    (235)   -   $- 
RSUs forfeited/expired   2    -    (1)  $- 
Performance RSUs forfeited/expired   15    -    (7)  $- 
Balance at September 30, 2023   387    491    5   $27.31 
Options exercisable at September 30, 2023        140        $98.80 

 

38

 

 

During the nine months ended September 30, 2023, the Company granted 178,000 employee and non-employee stock option awards. The assumptions used to calculate the Black-Scholes grant date fair value of such awards were as follows:

 

   Nine Months Ended 
   September 30, 
   2023   2022 
Expected life (in years)   6.25    5.98 
Risk-free interest rates   3.76%   2.29%
Volatility   105.99%   106.85%
Dividend yield   0%   0%

 

In August 2023, the Company awarded 120,000 stock option grants with market-based and time-based vesting conditions to certain executives. The fair value of such awards was estimated using the Monte Carlo simulation model. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated period to achievement of the performance and market conditions, which are subject to the achievement of the market-based goals established by the Company and the continued employment of the executives through December 31, 2025. These awards vest only to the extent that the market-based conditions are satisfied as specified in the vesting conditions. The grant date fair value and associated compensation cost of the market-based awards reflect the probability of the market condition being achieved, and the Company will recognize this compensation cost regardless of the actual achievement of the market condition. Assumptions utilized in connection with the Monte Carlo valuation technique included: estimated risk-free interest rate of 4.81 percent; term of 6.19 years; expected volatility of 91.0 percent; and expected dividend yield of 0 percent. The risk-free interest rate was determined based on the yields available on U.S. Treasury zero-coupon issues. The expected stock price volatility was determined using historical volatility. The expected dividend yield was based on expectations regarding dividend payments. Based on the market-based conditions, the grant date fair values of these awards ranged from $1.09 to $1.74, amounting to a total fair value of approximately $156,000.

 

Oncocyte recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
   (In thousands) 
Cost of revenues  $(2)  $94   $10   $239 
Research and development   294    521    931    1,416 
Sales and marketing   64    942    216    1,681 
General and administrative   252    1,624    1,119    4,087 
Total  $608   $3,181   $2,276   $7,423 

 

In August 2023, the Company issued 9,091 restricted stock awards in connection with a consulting service arrangement for a total fair value of $36,000.

 

The determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If Oncocyte had made different assumptions, its stock-based compensation expense and net loss for the three and nine months ended September 30, 2023, and 2022 may have been significantly different. Refer to Note 2 for additional information.

 

Oncocyte does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when a disqualified disposition has occurred.

 

10. Income Taxes

 

The provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270, Income Taxes, Interim Reporting. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where Oncocyte conducts business.

 

39

 

 

Oncocyte did not record any provision or benefit for income taxes for the nine months ended September 30, 2023 and 2022, as Oncocyte had a full valuation allowance for the periods presented.

 

A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. Oncocyte established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carry-forwards and other deferred tax assets.

 

11. Related Party Transactions

 

Financing Transactions

 

On April 13, 2022, Oncocyte entered into the Securities Purchase Agreement with the Investors, including Broadwood and John Peter Gutfreund, a former director of Oncocyte, for the Series A Preferred Stock Offering. Each of Broadwood and Mr. Gutfreund has a direct material interest in the Series A Preferred Stock Offering and agreed to purchase 5,882.35 and 1,176.48 shares, respectively, in the Series A Preferred Stock Offering and on the same terms as other investors. Additionally, Halle Capital Management, L.P. received $85,000 from the Company as reimbursement for its legal fees and expenses. Mr. Gutfreund is the Managing Partner of Halle Capital Management, L.P. See Note 8 for additional information about the Series A Preferred Stock Offering.

 

Further, on April 13, 2022, Oncocyte entered into the Underwriting Agreement with the Underwriters for the Underwritten Offering. Pursuant to the Underwritten Offering, Broadwood acquired from us (i) 261,032 shares of common stock, and (ii) 300,187 April 2022 Warrants to purchase up to 150,093 shares of common stock at an exercise price of $30.60 per share. However, the total number of shares of common stock that Broadwood purchased in the Underwritten Offering was 300,187, of which 39,154 existing shares were acquired by the underwriters in the open market and re-sold to Broadwood. Pura Vida acquired from us (i) 249,204 shares of common stock, and (ii) 286,585 April 2022 Warrants to purchase up to 143,292 shares of common stock. However, the total number of shares of common stock that Pura Vida purchased in the Underwritten Offering was 286,585, of which 37,380 existing shares were acquired by the underwriters in the open market and re-sold to Pura Vida. Halle Special Situations Fund LLC purchased from us (i) 309,976 shares of common stock, and (ii) 356,472 2022 Warrants to purchase up to 178,236 shares of common stock. Mr. Gutfreund is the investment manager and a control person of Halle Capital Partners GP LLC, the managing member of Halle Special Situations Fund LLC. However, the total number of shares of common stock that Halle Special Situations Fund LLC purchased in the Underwritten was 356,472, of which 46,496 existing shares were acquired by the underwriters in the open market and re-sold to Halle Special Situations Fund LLC. See Note 8 for additional information about the Underwritten Offering.

 

On April 3, 2023, Oncocyte entered into a securities purchase agreement (the “2023 Securities Purchase Agreement”) with certain investors, including Broadwood, Pura Vida and entities affiliated with AWM, and certain individuals, including our Chairman Andrew Arno and former director John Peter Gutfreund (and certain of their affiliated parties), which provides for the sale and issuance by the Company of an aggregate of 2,274,709 shares of common stock at an offering price of: (i) $6.03 to investors who are not considered to be “insiders” of the Company pursuant to Nasdaq Listing Rules (“Insiders”), which amount reflects the average closing price of the Common Stock on Nasdaq during the five trading day period immediately prior to pricing, and (ii) $7.08 to Insiders, which amount reflects the final closing price of the Common Stock on Nasdaq on the last trading day immediately prior to pricing (the “2023 Registered Direct Offering”). Broadwood purchased 1,341,381 shares of common stock for $8,093,361.84, Pura Vida purchased 33,150 shares of common stock for $200,013.84 and entities affiliated with AVM purchased 472,354 shares of common stock for $2,849,999.92. Mr. Arno and his affiliated parties purchased 21,162 shares of common stock for $150,000.51, and Mr. Gutfreund and his affiliated parties purchased 85,250 for $604,252.00.

 

On April 5, 2023, Oncocyte redeemed all of the 588.23529 shares of Series A Preferred Stock held by Mr. Gutfreund for $618,672.34. Mr. Gutfreund is no longer a related party as of June 23, 2023.

 

40

 

 

Company Employee

 

The Company previously employed the son of Andrew Arno, Chairman of the Board as its Senior Manager, Investor Relations, Corporate Planning & Development. The total compensation paid by the Company to Mr. Arno’s son since January 1, 2022 is approximately $200,000. Mr. Arno’s son is no longer an employee of the Company as of July 28, 2023.

 

12. Co-Development Agreement with Life Technologies Corporation

 

On January 13, 2022, Oncocyte entered into a Collaboration Agreement (the “LTC Agreement”) with Life Technologies Corporation, a Delaware corporation and subsidiary of Thermo Fisher Scientific (“LTC” and together with Oncocyte, the “Parties” or individually, a “Party”), in order to partner in the development and collaborate in the commercialization of Thermo Fisher Scientific’s existing Oncomine Comprehensive Assay Plus and Oncocyte’s DetermaIO assay for use with LTC’s Ion TorrentTM GenexusTM Integrated Sequencer and LTC’s Ion TorrentTM GenexusTM Purification System (“Genexus system”) in order to obtain in vitro diagnostic regulatory approval. On February 7, 2023, Oncocyte entered into a Termination Agreement with LTC, pursuant to which the parties terminated the LTC Agreement. As of the termination date, Oncocyte was responsible for reimbursing LTC for $749,000 of certain development costs under the terms of the LTC Agreement, which have been fully paid.

 

13. Discontinued Operations of Razor

 

On December 15, 2022, the Company entered into the Razor Stock Purchase Agreement with Dragon and Razor. Pursuant to the Razor Stock Purchase Agreement, Oncocyte agreed to sell, and Dragon agreed to purchase, 3,188,181 shares of common stock of Razor, which constitutes approximately 70% of the issued and outstanding equity interests of Razor on a fully-diluted basis. On February 16, 2023, Oncocyte completed the Razor Sale Transaction. In connection with the Razor Closing, Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx. While no monetary consideration was received for the sale of 70% of the equity interests of Razor, the transaction allows the Company to eliminate all development and commercialization costs with respect to DetermaRx. Following the Razor Closing, Oncocyte continues to own 1,366,364 shares of common stock of Razor, which constitutes approximately 30% of the issued and outstanding equity interests of Razor on a fully-diluted basis.

 

In addition to the transfer of 70% of the equity interests of Razor, the Razor Stock Purchase Agreement provided that Dragon would purchase furniture, fixtures, and equipment from the Company for a cash consideration of $115,660. Upon the Razor Closing, the Company deconsolidated the assets and liabilities of Razor as control of Razor has transferred to Dragon.

 

The Company recorded the final adjustment related to the disposal, including final working capital adjustments, and recognized a loss of $1.3 million during the first quarter of 2023. Including the impairment losses we recognized as of December 31, 2022 related to this transaction, we recorded an overall loss of $27.2 million. The operating results for Razor have been recorded in discontinued operations of the accompanying consolidated statements of operations for all periods presented, and we have reclassified their assets and liabilities as discontinued operations in the accompanying balance sheets. We have retrospectively adjusted the amounts reported for the period ended September 30, 2022, in the following table to give effect to such reporting of discontinued operations. For the period ended September 30, 2023, discontinued operations reflect operating results of Razor up to the closing of the sale.

 

The Company’s consolidated balance sheets and consolidated statements of operations report discontinued operations separate from continuing operations. Our consolidated statements of comprehensive loss, statements of shareholders’ equity and statements of cash flows combined continuing and discontinued operations. A summary of financial information related to the Company’s discontinued operations is as follows.

 

41

 

 

The following table represents the results of the discontinued operations of Razor:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
   (In thousands) 
Net revenue  $-   $950   $421   $3,824 
                     
Cost of revenues   -    1,855    507    5,854 
Research and development   -    2,949    702    9,200 
Sales and marketing   -    3,600    498    9,966 
General and administrative   -    61    329    133 
Loss from impairment of held for sale assets   -    -    1,311    - 
Net loss from discontinued operations  $-   $(7,515)  $(2,926)  $(21,329)

 

The following table represents the carrying amounts of the assets and liabilities of the discontinued operations of Razor:

 

   September 30,   December 31, 
   2023   2022 
   (In thousands) 
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents  $-   $1,510 
Prepaid expenses and other current assets   -    346 
Machinery and equipment, net, and construction in progress   -    211 
Intangible assets, net   -    25,920 
Impairment of held for sale assets   -    (25,866)
TOTAL ASSETS  $-   $2,121 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Accounts payable  $90   $492 
Accrued compensation   -    248 
Accrued expenses and other current liabilities   -    1,265 
Total current liabilities   90    2,005 
           
TOTAL LIABILITIES  $90   $2,005 

 

The following table summarizes cash used related to the discontinued operations of Razor:

 

   2023   2022 
   Nine Months Ended 
   September 30, 
   2023   2022 
   (In thousands) 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net cash used in operating activities  $(4,357)  $(15,744)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Net cash used in investing activities  $-   $(96)

 

 

42

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The matters addressed in this Item 2 that are not historical information constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, including statements about any of the following: any projections of earnings, revenue, cash, effective tax rate, use of net operating losses, or any other financial items; the plans, strategies and objectives of management for future operations or prospects for achieving such plans, and any statements of assumptions underlying any of the foregoing. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements. While Oncocyte may elect to update forward-looking statements in the future, it specifically disclaims any obligation to do so, even if the Oncocyte estimates change and readers should not rely on those forward-looking statements as representing Oncocyte views as of any date subsequent to the date of the filing of this Report. Although we believe that the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risks and Oncocyte can give no assurances that its expectations will prove to be correct. Actual results could differ materially from those described in this report because of numerous factors, many of which are beyond the control of Oncocyte. A number of important factors could cause the results of the company to differ materially from those indicated by such forward-looking statements, including those detailed under the heading “Risk Factors” in our Form 10-K for the year ended December 31, 2022, and our other reports filed with the SEC from time to time.

 

The following discussion should be read in conjunction with Oncocyte’s consolidated financial statements and the related notes provided under “Item 1- Financial Statements” above.

 

Recent Developments

 

Reverse Stock Split

 

At a special meeting of our shareholders, held on July 24, 2023, our shareholders approved a proposal granting the Company’s board of directors the authority to exercise its discretion to amend the Articles of Incorporation of the Company, as currently in effect, to effect a reverse stock split of the outstanding shares of the Company’s common stock at any time within one year after the date such shareholder approval was obtained at the special meeting and at any of certain specified reverse split ratios that were approved by the shareholders of the Company in connection therewith. On July 24, 2023, our board of directors approved the reverse stock split at a ratio of 1-for-20, and on that date, we filed a Certificate of Amendment of Articles of Incorporation with the Secretary State of the State of California to effect the reverse stock split.

 

Unless otherwise noted, all share and per share amounts set forth in this Report have been adjusted to reflect the impact of the reverse stock split.

 

Irvine Office Sublease Agreement

 

On August 8, 2023, Oncocyte and Subtenant entered into the Sublease Agreement, which subsequently became effective as of September 14, 2023, upon the execution and delivery by the Company, Subtenant, and Landlord, of the Consent Agreement, under which Landlord consented to the Sublease Agreement, on the terms and subject to the conditions set forth therein. The Sublease Agreement is subject and subordinate to the Irvine Lease. For additional information about the Sublease Agreement, see Note 7 to our consolidated financial statements included elsewhere in this Report.

 

43

 

 

Results of Operations

 

Summary Results of Operations

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30,  
   2023   2022   $ Change   % Change   2023   2022   $ Change   % Change 
   (In thousands, except percentage change values) 
Net revenue  $429   $67   $362    540%  $1,189   $684   $505    74%
Cost of revenues   159    314    (155)   -49%   593    602    (9)   -1%
Cost of revenues – amortization of acquired intangibles   22    22    -    0%   66    73    (7)   -10%
Research and development   2,185    1,472    713    48%   6,747    5,923    824    14%
Sales and marketing   713    405    308    76%   2,213    798    1,415    177%
General and administrative   2,487    5,702    (3,215)   -56%   9,430    16,794    (7,364)   -44%
Change in fair value of contingent consideration   (435)   (6,142)   5,707    -93%   (16,947)   (17,157)   210    -1%
Impairment losses   1,811    -    1,811    -    6,761    -    6,761    100%
Loss on disposal and held for sale assets   -    -    -    -    1,283    -    1,283    100%
Loss from operations   (6,513)   (1,706)   (4,807)   282%   (8,957)   (6,349)   (2,608)   41%
Total other income (expenses)   24    (112)   136    -121%   94    (246)   340    -138%
Loss from continuing operations   (6,489)   (1,818)   (4,671)   257%   (8,863)   (6,595)   (2,268)   34%
Loss from discontinuing operations   -    (7,515)   7,515    -100%   (2,926)   (21,329)   18,403    -86%
Net loss  $(6,489)  $(9,333)  $2,844    -30%  $(11,789)  $(27,924)  $16,135    -58%

 

Results of Operations – Three Months Ended September 30, 2023 Compared with the Three Months Ended September 30, 2022

 

Revenues increased to $429,000 for the three months ended September 30, 2023, as compared to $67,000 in the comparable prior year, due to increased revenues in Pharma Services.

 

Loss from continuing operations was $6.5 million for the three months ended September 30, 2023, and $1.8 million for the three months ended September 30, 2022. The net change was comprised primarily of the changes in operating expenses and other income and expenses from continuing operations as follows:

 

Pharma Services revenue increased by $356,000 due to an increased number of contracts performed during the period.
   
Cost of revenues decreased by $155,000, primarily related to labor and allocated overhead associated with performing our Pharma Services.
   
Cost of revenues - amortization of acquired intangibles remained at $22,000, and relates to noncash amortization of acquired intangible assets such as our customer relationship intangible assets acquired as part of the Insight merger.
   
Research and development expenses increased by $713,000, as the Company continues development of DetermaIO, VitaGraft (formerly TheraSure Transplant Monitor), and DetermaCNI (formerly TheraSure - CNI Monitor). See below for additional details.
   
Sales and marketing expenses increased by $308,000, primarily attributable to continued ramp in sales and marketing activities related to the transplant business, as well as support the commercialization efforts within oncology. See below for additional details.
   
General and administrative expenses decreased by $3.2 million, primarily due to decreased stock-based compensation and personnel expenses. See below for additional details.
   
Change in fair value of contingent consideration decreased by $5.7 million, from a gain of $6.1 million to a gain of $435,000, due to changes in discount rates and revised estimates on the timing of possible future payouts. Change is driven in part by the Chronix Amendment which amended the earnout considerations eliminated the Chronix Milestone Payments, 15% Royalty Payments and Sale Payment obligations (see Note 3 to our consolidated financial statements included elsewhere in this Report). See below for additional details.

 

44

 

 

Impairment loss increased due to a 2023 asset impairment charge of $1.8 million related to leasehold improvements (see Note 4 to our consolidated financial statements included elsewhere in this Report).
   
Total other income (expense) increased by $136,000, from an expense of $112,000 in the three months ended September 30, 2022 to an income of $24,000 in the three months ended September 30, 2023, primarily due to interest income and the change in unrealized gain/loss on marketable equity securities. See below for additional details.

 

Results of Operations – Nine Months Ended September 30, 2023 Compared with the Nine months ended September 30, 2022

 

Revenues increased to $1.2 million for the nine months ended September 30, 2023, as compared to $684,000 in the comparable prior year, due to increased revenues in Pharma Services.

 

Loss from continuing operations was $8.9 million for the nine months ended September 30, 2023, and $6.6 million for the nine months ended September 30, 2022. The net change was comprised primarily of the changes in operating expenses and other income and expenses from continuing operations as follows:

 

Pharma Services revenue increased by $453,000 due to an increased number of contracts performed during the period.
   
Cost of revenues decreased by $9,000, primarily related to labor and allocated overhead associated with performing our Pharma Services.
   
Cost of revenues - amortization of acquired intangibles decreased by $7,000, and relates to noncash amortization of acquired intangible assets such as our customer relationship intangible assets acquired as part of the Insight merger.
   
Research and development expenses increased by $824,000, as the Company continues development of DetermaIO, VitaGraft (formerly TheraSure Transplant Monitor), and DetermaCNI (formerly TheraSure - CNI Monitor). See below for additional details.
   
Sales and marketing expenses increased by $1.4 million, primarily attributable to continued ramp in sales and marketing activities related to the transplant business, as well as support the commercialization efforts within oncology. See below for additional details.
   
General and administrative expenses decreased by $7.4 million, primarily due to decreased stock-based compensation and personnel expenses. See below for additional details.
   
Change in fair value of contingent consideration decreased by $210,000, from a gain of $17.2 million to a gain of $16.9 million, due to changes in discount rates and revised estimates on the timing of possible future payouts. Change driven in part by the Chronix Amendment which amended the earnout considerations eliminated the Chronix Milestone Payments, 15% Royalty Payments and Sale Payment obligations (see Note 3 to our consolidated financial statements included elsewhere in this Report). See below for additional details.
   
Impairment losses relate to two 2023 assets impairment charges, including $5.0 million to intangible assets (see Note 5 to our consolidated financial statements included elsewhere in this Report) and $1.8 million to leasehold improvements (see Note 4).
   
Total other income (expense) increased by $340,000, from an expense of $246,000 in the nine months ended September 30, 2022, to an income of $94,000 in the nine months ended September 30, 2023, primarily due to interest income and the change in unrealized gain/loss on marketable equity securities. See below for additional details.

 

45

 

 

Revenues

 

The following table shows our service revenues:

 

   Three Months Ended   Nine Months Ended 
   September 30,    September 30,  
   2023   2022   $ Change   % Change   2023   2022   $ Change   % Change 
   (In thousands, except percentage change values) 
Pharma Services  $423   $67   $356    531%  $1,137   $684   $453    66%
Laboratory developed test services   6    -    6    100%   52    -    52    100%
Total  $429   $67   $362    540%  $1,189   $684   $505    74%

 

Pharma Services are generally performed on a time and materials basis. Upon our completion of the service to the customer in accordance with the contract, we have the right to bill the customer for the agreed upon price (either on a per test or per deliverable basis) and recognize the Pharma Services revenue at that time, on an accrual basis. Pharma Services revenues are generated under discrete agreements for particular customer projects that generally expire with the completion or termination of the customer’s project. Accordingly, different customers may account for greater or lesser portions of Pharma Services during different accounting periods, and Pharma Services revenues may exhibit a larger variance from accounting period to accounting period than other revenues such as DetermaRx testing revenues. Refer to Note 2 to our consolidated financial statements included elsewhere in this Report for additional revenue information.

 

Laboratory developed test services generally relate to payments received from sales prior to the Razor Sale Transaction (see Note 13 to our consolidated financial statements included elsewhere in this Report). Oncocyte generated revenue from performing DetermaRx tests on clinical samples through orders received from physicians, hospitals, and other healthcare providers. For all payers other than Medicare, Oncocyte must consider the novelty of the test, the uncertainty of receiving payment, or being subject to claims for a refund, from payers with whom it does not have a sufficient payment collection history or contractual reimbursement agreements. Accordingly, for those payers, Oncocyte has recognized revenue upon payment. Refer to Note 2 to our consolidated financial statements included elsewhere in this Report for additional revenue information.

 

Cost of Revenues

 

Cost of revenues generally consists of cost of materials; direct labor including payroll, payroll taxes, bonus, benefit and stock-based compensation; equipment and infrastructure expenses; clinical sample costs associated with performing Pharma Services; and amortization of acquired intangible assets. Infrastructure expenses include depreciation of laboratory equipment; allocated rent costs; and leasehold improvements. Cost of revenues for Pharma Services varies depending on the nature, timing, and scope of customer projects.

 

Research and Development Expenses

 

A summary of the main drivers of the change in research and development expenses is as follows:

 

   Three Months Ended    Nine Months Ended  
   September 30,    September 30,  
   2023   2022   $ Change   % Change   2023   2022   $ Change   % Change 
   (In thousands, except percentage change values) 
Personnel-related expenses  $886   $719   $167    23%  $2,813   $2,438   $375    15%
Depreciation   321    82    239    291%   1,036    229    807    352%
Share-based compensation   294    208    86    41%   926    589    337    57%
Laboratory supplies and expenses   380    304    76    25%   955    1,019    (64)   -6%
Facilities and insurance   217    66    151    229%   529    281    248    88%
Professional fees, legal, and outside services   91    195    (104)   -53%   259    1,162    (903)   -78%
Severance   (7)   -    (7)   -100%   152    -    152    100%
Other   8    57    (49)   -86%   49    182    (133)   -73%
Clinical trials   (5)   (159)   154    -97%   28    23    5    22%
Total  $2,185   $1,472   $713    48%  $6,747   $5,923   $824    14%
% of Net Revenue   509%   2197%        -1688%   567%   866%        -298%

 

46

 

 

We expect to continue to incur a significant amount of research and development expenses during the foreseeable future. As of September 30, 2023, we will continue development of DetermaIO and VitaGraft. Our future research and development efforts and expenses will also depend on the amount of capital that we are able to raise to finance those activities and whether we acquire rights to any new diagnostic tests. A portion of our costs for leasing and operating our CLIA laboratories in California and Tennessee, and in Germany with Chronix, will also be included in research and development expenses to the extent allocated to the development of our diagnostic tests.

 

We may commence clinical trials of DetermaIO if we develop that diagnostic test to the point where we determine that its use as a clinical diagnostic appears to be feasible.

 

Sales and Marketing Expenses

 

A summary of the main drivers of the change in sales and marketing expenses is as follows:

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30,  
   2023   2022   $ Change   % Change   2023   2022   $ Change   % Change 
   (In thousands, except percentage change values) 
Personnel-related expenses  $486   $289   $197    68%  $1,494   $477   $1,017    213%
Share-based compensation   64    39    25    64%   203    68    135    199%
Facilities and insurance   58    15    43    287%   174    24    150    625%
Professional fees, legal, and outside services   28    59    (31)   -53%   140    219    (79)   -36%
Marketing & Advertising   44    -    44    100%   107    -    107    100%
Other   33    3    30    1000%   95    10    85    850%
Total  $713   $405   $308    76%  $2,213   $798   $1,415    177%
% of Net Revenue   166%   604%        -438%   186%   117%        69%

 

We expect to continue to incur sales and marketing expenses during the foreseeable future as we complete product development and begin commercialization efforts for DetermaIO as a clinical test. Sales and marketing expenses will also increase if we successfully develop and begin commercializing DetermaCNI, and VitaGraft, or if we acquire and commercialize other diagnostic tests. Our commercialization efforts and expenses will also depend on the amount of capital that we are able to raise to finance commercialization of our tests. Our future expenditures on sales and marketing will also depend on the amount of revenue that those efforts are likely to generate. Because physicians are more likely to prescribe a test for their patients if the cost is covered by Medicare or health insurance, demand for our diagnostic and other tests and our expenditures on sales and marketing are likely to increase if our diagnostic or other tests qualify for reimbursement by Medicare or private health insurance companies.

 

General and Administrative Expenses

 

A summary of the main drivers of the change in general and administrative expenses is as follows:

 

   Three Months Ended   Nine Months Ended 
   September 30,    September 30,  
   2023   2022   $ Change   % Change   2023   2022   $ Change   % Change 
   (In thousands, except percentage change values) 
Personnel-related expenses and board fees  $756   $1,939   $(1,183)   -61%  $2,846   $6,496   $(3,650)   -56%
Professional fees, legal, and outside services   774    642    132    21%   2,720    2,883    (163)   -6%
Facilities and insurance   572    676    (104)   -15%   1,791    2,015    (224)   -11%
Share-based compensation   252    1,624    (1,372)   -84%   1,119    4,087    (2,968)   -73%
Severance   17    558    (541)   -97%   498    682    (184)   -27%
Other   116    263    (147)   -56%   456    631    (175)   -28%
Total  $2,487   $5,702   $(3,215)   -56%  $9,430   $16,794   $(7,364)   -44%
% of Net Revenue   580%   8510%        -7931%   793%   2455%        -1662%

 

Change in Fair Value of Contingent Consideration

 

We will pay contingent consideration if various payment milestones are triggered under the merger agreements through which we acquired Insight and Chronix. See Note 3 to our consolidated financial statements included elsewhere in this Report. Changes in the fair value of the contingent consideration will be based on our reassessment of the key assumptions underlying the determination of this liability as changes in circumstances and conditions occur from the Insight and Chronix acquisition dates to the reporting period being presented, with the subsequent changes in fair value recorded as part of our consolidated loss from operations for that period. See above change explanations for additional information.

 

47

 

 

Other Income and Expenses

 

Total other income (expenses) is primarily comprised of interest income and expense, and unrealized gains and losses on Lineage and AgeX marketable equity securities we hold (see Note 2 to our consolidated financial statements included elsewhere in this Report). Interest income is earned from money market funds we hold for capital preservation. In the prior year, interest expense was incurred under our loan payable to the Silicon Valley Bank, and under financing lease obligations. Interest income (expense), net, reflects the interest income earned from money market accounts in excess of interest expense incurred on our loans and financing obligations.

 

Income Taxes

 

Oncocyte did not record any provision or benefit for income taxes for the nine months ended September 30, 2023 and September 30, 2022, as Oncocyte had a full valuation allowance for the periods presented (see Note 10 to the consolidated financial statements included elsewhere in this Report).

 

A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. We established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from our net operating loss carry-forwards and other deferred tax assets.

 

Liquidity and Capital Resources

 

Our foreseeable material cash requirements as of September 30, 2023, are recognized as liabilities or generally are otherwise described in Note 7, “Commitments and Contingencies,” to the consolidated financial statements included elsewhere in this Report. Cash requirements are generally derived from our operating and investing activities including expenditures for working capital, human capital, business development, investments in intellectual property, and business combinations. Our office lease obligations, net of sublease payments, and certain contingent obligations are further described in Note 3, “Business Combinations,” related to contingent consideration, and Note 7. Historically, we have not entered into any off-balance sheet arrangements.

 

Since formation, we have financed our operations primarily through the sale of our common stock, preferred stock and warrants. We have incurred operating losses and negative cash flows since inception and had an accumulated deficit of $272.5 million at September 30, 2023. We expect to continue to incur operating losses and negative cash flows for the near future. Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that the financial statements are issued.

 

At September 30, 2023, we had $13.8 million of cash and cash equivalents, and held shares of Lineage and AgeX common stock as marketable equity securities valued at $441,000. In 2022, we raised approximately $30,000 in net cash proceeds through sales of shares of our common stock through the ATM Offering. On June 1, 2022, Oncocyte received net proceeds of approximately $4.9 million from the Series A Preferred Stock issued from the first tranche of the Series A Preferred Stock Offering. On April 19, 2022, Oncocyte received net proceeds of approximately $32.8 million from the Underwritten Offering of 1,313,320 shares of common stock and 1,313,320 shares of April 2022 Warrants to purchase up to 656,660 shares of common stock.

 

On April 3, 2023, the Company entered into an agreement with certain members of the Company’s board of directors, and several institutional and accredited investors, including Broadwood Capital, L.P., the Company’s largest shareholder, relating to their purchase of an aggregate of up to 2,278,121 shares of its common stock at an offering price of $7.08 per share to board members and $6.03 per share to the other investors participating in the offering. The offering was intended to be priced ‘at-the market’ for purposes of complying with applicable Nasdaq Listing Rules. The aggregate gross proceeds from the offering were approximately $13.9 million before deducting offering expenses payable by the Company. The Company used approximately $1.1 million of the net proceeds to immediately redeem an aggregate of 1,064 shares of its Series A Convertible Preferred Stock and may thereafter elect to redeem additional shares. See Notes 1 and 8 to the consolidated financial statements included elsewhere in this Report for additional information about the Company’s going concern discussion and equity offerings.

 

48

 

 

We expect that our operating expenses will remain flat as we continue to manage our available cash. Although we intend to market our diagnostic tests in the United States through our own sales force, we are also beginning to make marketing arrangements with distributors in other countries. We may also explore a range of other commercialization options in order to enter overseas markets and to reduce our capital needs and expenditures, and the risks associated the timelines and uncertainty for attaining the Medicare reimbursement approvals that will be essential for the successful commercialization of additional cancer diagnostic tests. Those alternative arrangements could include marketing arrangements with other diagnostic companies through which we might receive a licensing fee and royalty on sales, or through which we might form a joint venture to market one or more tests and share in net revenues, in the United States or abroad.

 

In addition to sales and marketing expenses, we will incur expenses from leasing and improving our offices and laboratory facilities in Nashville, Tennessee. During the third quarter of 2023, we entered into a sublease arrangement for our main office (see “Irvine Office Sublease Agreement” discussion above).

 

We may need to meet significant cash payment or stock obligations to former Insight and Chronix shareholders in connection with our acquisition of those companies, as disclosed in Note 3 to the consolidated financial statements included elsewhere in this Report. To meet the future cash payment obligations, we may have to utilize cash on hand that would otherwise be available to us for other business and operational purposes, which could cause us to delay or reduce activities in the development and commercialization of our cancer tests.

 

We will need to continue to raise additional capital to finance our operations, including the development and commercialization of our diagnostic tests, and making payments that may become due under our obligations to former Chronix shareholders and former Insight shareholders, until such time as we are able to generate sufficient revenues to cover our operating expenses. Delays in the development of DetermaIO, or obtaining reimbursement coverage from Medicare for that diagnostic test and for the other diagnostic tests that we may develop or acquire, could prevent us from raising sufficient additional capital to finance the completion of development and commercial launch of those tests. Investors may be reluctant to provide us with capital until our tests are approved for reimbursement by Medicare or reimbursement by private healthcare insurers or healthcare providers, or until we begin generating significant amounts of revenue from performing those tests. The unavailability or inadequacy of financing or revenues to meet future capital needs could force us to modify, curtail, delay, or suspend some or all aspects of our planned operations. Sales of additional equity securities could result in the dilution of the interests of our shareholders. We cannot assure that adequate financing will be available on favorable terms, if at all.

 

Cash Used in Operations

 

During the nine months ended September 30, 2023, our total research and development expenses from continuing operations were $6.7 million, our sales and marketing expenses were $2.2 million, and our general and administrative expenses were $9.4 million. We also incurred $659,000 in cost of revenues, including $66,000 amortization of intangible expenses, in the first nine months of 2023. Net loss for the nine months ended September 30, 2023 amounted to $11.8 million and net cash used in operating activities amounted to $18.8 million. Our cash used in operating activities during the nine months ended September 30, 2023 does not include the following noncash items: $2.3 million in stock-based compensation; $16.9 million gain from change in fair value of contingent consideration; $6.8 million loss from asset impairments; $1.7 million loss related to discontinued operations; $1.3 million loss on disposal and held for sale assets; $1.4 million in depreciation and amortization expenses; $108,000 in other equity compensation expenses, and $8,000 in unrealized gain on marketable equity securities. Changes in operating assets and liabilities were approximately $3.5 million as an additional use of cash.

 

Cash Used in Investing Activities

 

During the nine months ended September 30, 2023, net cash used in investing activities was $1.2 million, attributable to cash sold in discontinued operations, partially offset by proceeds from the sale of equipment.

 

49

 

 

Cash Provided by Financing Activities

 

During the nine months ended September 30, 2023, net cash provided by financing activities was $12.2 million, attributable to the $13.4 million of net cash proceeds from the sale of shares of common stock, offset by redemption of Series A Preferred Stock of $1.1 million and repayments of financing lease obligations of $87,000.

 

Critical Accounting Estimates

 

This Management’s Discussion and Analysis of Financial Condition and Results of Operations discusses and analyzes data in our consolidated financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles. Preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual conditions may differ from our assumptions and actual results may differ from our estimates.

 

An accounting policy is deemed critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate are reasonably likely to occur, that could materially impact the financial statements. Management believes that there have been no significant changes during the nine months ended September 30, 2023 to the matters that we disclosed as our critical accounting estimates in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2022. Refer to additional discussion of “Significant Accounting Policies” in Note 2 to our consolidated financial statements included elsewhere in this Report.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Under SEC rules and regulations, as a smaller reporting company, we are not required to provide the information required by this item.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

It is management’s responsibility to establish and maintain adequate internal control over all financial reporting pursuant to Rule 13a-15 under the Securities Exchange Act of 1934 (“Exchange Act”). Our management, including our principal executive officer and principal financial officer, have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Following this review and evaluation, the principal executive officer and principal financial officer determined that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and (ii) is accumulated and communicated to management, including our principal executive officer, and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

 

Changes in Internal Controls

 

There were no changes in our internal control over financial reporting that occurred during the period covered by this Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

50

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

From time to time, we may be involved in routine litigation incidental to the conduct of our business. We are not presently involved in any material litigation or proceedings, and to our knowledge no such litigation or proceedings are contemplated.

 

Item 1A. Risk Factors

 

Our business, financial condition, results of operations and future growth prospects are subject to various risks, including those described in Item 1A “Risk Factors” of our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on April 12, 2023, which we encourage you to review. Other than as noted below, there have been no material changes from the risk factors disclosed in our most recent Annual Report on Form 10-K.

 

Our recently implemented reverse stock split may decrease the liquidity of our common stock and result in higher transaction costs.

 

The liquidity of our common stock may be negatively impacted by our implementation of a 1-for-20 reverse stock split on July 24, 2023, given the significantly reduced number of shares that are now issued and outstanding after the reverse stock split, and because our stock price did not increase commensurate with the ratio of the reverse stock split. In addition, as a result of our reverse stock split, we now have a greater number of shareholders who own “odd lots” of fewer than 100 shares of our common stock. Brokerage commission and other costs of transactions for the sale of odd lots are generally higher than the costs of transactions of more than 100 shares of common stock. Accordingly, a reverse stock split may not achieve the desired results of increasing marketability and liquidity of our common stock.

 

The effective increase in the authorized number of shares of our common stock as a result of our reverse stock split could have anti-takeover implications and result in further dilution to our existing shareholders.

 

In connection with the recent implementation of the reverse stock split, we maintained the total number of authorized shares of our common stock. The combination of a reverse stock split of our issued and outstanding shares, and maintaining the number of our authorized shares, has significantly increased our authorized shares relative to our issued and outstanding shares. This effective increase in the number of authorized shares will allow us to sell additional shares of our common stock (or securities convertible or exchangeable for our common stock), which would result in further dilution of our current shareholders. In addition, the effective increase in the number of authorized shares could, under certain circumstances, have anti-takeover implications. For example, the additional shares of common stock that have become available for issuance could be used by us to oppose a hostile takeover attempt or to delay or prevent changes in control or our management. Although our reverse stock split was prompted by business and financial considerations and not by the threat of any hostile takeover attempt, shareholders should be aware that our reverse stock split could facilitate future efforts by us to deter or prevent changes in control, including transactions in which our shareholders might otherwise receive a premium for their shares over then-current market prices.

 

There is substantial doubt about our ability to continue as a going concern and management’s plans to alleviate this condition may be unsuccessful. We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our operations.

 

Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that the financial statements are issued. See Part I, Item 2 “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Liquidity and Capital Resources” of this Report for a discussion of our cash position. Accordingly, we intend to complete additional equity financings and reduce spending in the remainder of fiscal 2023 and in 2024. However, due to several factors, including those outside management’s control, there can be no assurance that we will be able to complete additional equity financings. If we are unable to complete additional financings, management’s plans include further reducing or delaying operating expenses. We have concluded the likelihood that our plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements.

 

51

 

 

Our fundraising efforts to raise additional funding may divert our management from their day-to-day activities, which may adversely affect our ability to conduct operations. In addition, we cannot guarantee that financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute all of our shareholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire assets and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable, which may result in terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.

 

In addition to general economic and capital market trends and conditions, Oncocyte’s ability to raise sufficient additional capital to finance its operations from time to time will depend on a number of factors specific to Oncocyte’s operations such as operating revenues and expenses, progress in development of, or in obtaining reimbursement coverage from Medicare for DetermaIO and other future laboratory tests that Oncocyte may develop or acquire.

 

If we are unable to obtain funding on a timely basis, or if revenues from collaboration arrangements or financing sources are less than we have projected, we may be required to further revise our business plan and strategy, which may result in us significantly curtailing, delaying or discontinuing portions or all of our operations, or may result in our being unable to expand our operations or otherwise capitalize on our business opportunities. As a result, our business, financial condition and results of operations could be materially affected.

 

Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities

 

On August 23, 2023 we issued to PCG Advisory, Inc. 9,091 shares of our common stock (the “PCG Shares”). The PCG Shares were issued without registration under the Securities Act in reliance on the exemption from registration under Section 4(a)(2).

 

Item 3. Default Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

52

 

 


Item 6. Exhibits

 

Exhibit Numbers   Exhibit Description
3.1   Articles of Incorporation with all amendments (Incorporated by reference to Oncocyte Corporation’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on July 14, 2021)
     
3.2   Certificate of Determination of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (Incorporated by reference to Oncocyte Corporation’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 13, 2022)
     
3.3   Certificate of Amendment of Articles of Incorporation of Oncocyte Corporation, as filed with the Secretary of State of the State of California on July 24, 2023 (Incorporated by reference to Oncocyte Corporation’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 24, 2023)
     
3.4   Second Amended and Restated By-Laws (Incorporated by reference to Oncocyte Corporation’s Quarterly Report on Form 8-K filed with the Securities and Exchange Commission on November 9, 2022)
     
10.1†   Amendment to 2018 Equity Incentive Plan (Incorporated by reference to Oncocyte Corporation’s Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on July 10, 2023)
     
10.2†   Amendment to Amended and Restated Employment Agreement, dated July 13, 2023, by and between Oncocyte Corporation and Joshua Riggs (Incorporated by reference to Oncocyte Corporation’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 14, 2023)
     
10.3*   Sublease Agreement, dated August 8, 2023, by and between Oncocyte Corporation and Induce Biologics USA, Inc.
     
31.1*   Certification of Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2022
     
31.2*   Certification of Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2022
     
32.1**   Certifications of Principal Executive Officer and Principal Financial Officer, pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2022
     
101*   Interactive Data Files. The following financial statements from the Company’s Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2023 and 2022, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Comprehensive Loss, (iv) Consolidated Statements of Shareholders’ Equity, (v) Consolidated Statements of Cash Flows and (vi) Notes to Consolidated Financial Statements, tagged as blocks of text and including detailed tags.
     
104*   Cover Page Interactive Data File (formatted in iXBRL and included in Exhibit 101)

 

* Filed herewith.

 

** This certification is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the registrant specifically incorporates it by reference.

 

† The referenced exhibit is a management contract, compensatory plan or arrangement.

 

53

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  ONCOCYTE CORPORATION
   
Date: November 9, 2023 /s/ Joshua Riggs
  Joshua Riggs
 

President and Chief Executive Officer

(Principal Executive Officer)

   
Date: November 9, 2023 /s/ James Liu
  James Liu
 

Controller, Principal Accounting Officer and interim Principal Financial Officer

(Principal Financial Officer)

 

54

EX-10.3 2 ex10-3.htm

 

Exhibit 10.3

 

SUBLEASE AGREEMENT

 

This SUBLEASE AGREEMENT (this “Sublease”), dated as of the 8th day of August, 2023, is made and entered into by and between ONCOCYTE CORPORATION, a California corporation (“Sublessor”), and INDUCE BIOLOGICS USA, INC., a Michigan corporation (“Sublessee”).

 

BASIC LEASE DEFINITIONS

 

NAME OF SUBLESSOR:   Oncocyte Corporation
     
SUBLESSOR’S ADDRESS(ES):   15 Cushing
    Irvine, California 92618
     
NAME OF SUBLESSEE:   Induce Biologics USA, Inc.
     
SUBLESSEE’S ADDRESS(ES):   Prior to the Commencement Date:
     
    1646 West Snow Ave., Suite 188
    Tampa, FL 33606
     
    After the Commencement Date:
     
    To the Sublet Premises
     
UNDERLYING LANDLORD:   Cushing Ventures, LLC
     
UNDERLYING LEASE:   That certain Office Lease Agreement dated as of December 23, 2019, by and between Underlying Landlord, as landlord, and Sublessor, as tenant
     
SUBLET PREMISES:   The entire ground floor of the Building which comprises a portion of the Premises in the Underlying Lease, consisting of approximately 13,400 rentable square feet, as mutually agreed by Sublessor and Sublessee for purposes of this Sublease, without any representation by Sublessor whatsoever as to the actual square feet contained in the Sublet Premises or the Building or any portions thereof; provided, however, that, upon the date which is eighteen (18) months following the Commencement Date hereof (or an earlier date as provided in Paragraph 1 below) (the “Premises Expansion Date”), the Sublet Premises shall automatically be increased to include the second (2nd) floor of the Building, at which time the Sublet Premises shall comprise the entirety of the Building. See Paragraph 1 hereinbelow.
     
BUILDING:   15 Cushing
    Irvine, California 92618

 

1

 

 

COMMENCEMENT DATE:   The later of (a) January 1, 2024, or (b) that date which is 120 days following the Underlying Landlord’s written consent with respect to this Sublease.
     
EXPIRATION DATE:   October 31, 2027
     
TERM:   The period commencing on the Commencement Date and ending on the Expiration Date.
     
PERMITTED USES:   General laboratory, office and storage uses as and to the extent set forth and permitted in the Underlying Lease.
     
BASE RENT:   Commencing on the Commencement Date, each month of the Term, Sublessee shall pay Base Rent to Sublessor as follows:

 

Lease Dates  Square Footage  Base Rent PSF   Monthly Base Rent 
            
1/1/24 – 12/31/24  13,400  $2.75   $36,850.00 
1/1/25 – 6/30/25  13,400  $2.83   $37,955.50 
7/1/25 – 12/31/25  26,800  $2.83   $75,844.00 
1/1/26 – 12/31/26  26,800  $2.92   $78,188.33 
1/1/27 – 10/31/27  26,800  $3.00   $80,533.98 

 

ADDITIONAL RENT:   From and after the Commencement Date, Sublessee shall be responsible for Additional Rent (including, but not limited to, Expenses and Taxes) pursuant to Section 3 of the Underlying Lease; provided, however, that for the period of the Term prior to the Premises Expansion Date, Sublessee shall be responsible for only fifty percent (50%) of the Expenses and Taxes due during such period. From and after the Premises Expansion Date, Sublessee shall be responsible for 100% of the Additional Rent (including Expenses and Taxes) due for the remainder of the Term. See Paragraphs 3 and 5 hereinbelow.

 

SECURITY DEPOSIT:   $101,987.38

 

BROKERS:  Jones Lang Lasalle represents Sublessor and Lee & Associates represents Sublessee.

 

2

 

 

W I T N E S S E T H:

 

WHEREAS, Sublessor is the tenant of the Premises in the Building, and Sublessee is desirous of subletting the Premises as more particularly described in the Underlying Lease and this Sublease (the “Sublet Premises”) from Sublessor upon the terms and conditions hereinafter set forth:

 

NOW, THEREFORE, in consideration of the rental payments to be made hereunder by Sublessee to Sublessor and the mutual terms, covenants, conditions, provisions and agreements hereinafter set forth, Sublessor does hereby sublet to Sublessee and Sublessee does hereby take and hire from Sublessor, the Sublet Premises.

 

This Sublease shall be expressly subject and subordinate to all of the terms, covenants, conditions, provisions and agreements contained in the Underlying Lease. A true copy of the Underlying Lease, has been delivered to, and reviewed by, Sublessee and is annexed hereto and made a part hereof as Exhibit A. The provisions of the Underlying Lease are specifically incorporated herein by reference except that all references therein to “Landlord” shall mean Sublessor, all references therein to “Tenant” shall mean Sublessee, all references to “Premises” shall mean Sublet Premises, and all references to “this Lease” shall mean this Sublease. If any provisions of this Sublease shall conflict with any provision of the Underlying Lease, then, as between Sublessor and Sublessee the provisions of this Sublease shall control, provided, however, that if such construction of terms would cause Sublessor to be in default under the terms of the Underlying Lease, then such inconsistency shall be resolved in favor of the Underlying Lease.

 

1.Sublet Premises.

 

In consideration of Sublessee’s obligation to pay Rent as herein provided and in consideration of the other terms, covenants, and conditions hereof, Sublessor leases to Sublessee, and Sublessee leases from Sublessor, the Sublet Premises (as the same may be adjusted during the Term hereof), to have and to hold for the Term, subject to the terms, covenants and conditions of this Sublease. As appurtenant thereto, the “Sublet Premises” shall include all rights and easements on, over and through the Building, including all entrances and exits to the public streets, for vehicular and pedestrian access, ingress and egress to and from the Sublet Premises. The parties hereto hereby acknowledge and agree that the “Sublet Premises” additionally include both the back-up generator located on-site and the shipping container presently located in the parking area servicing the Building; provided, however, that for the period beginning on the Commencement Date and continuing through the Premises Expansion Date, Sublessor shall have the exclusive right to use the shipping container for storage purposes and Sublessee hereby acknowledges that such exclusive use by Sublessor for such period does not materially interfere with Sublessee’s use of the Sublet Premises nor does such exclusive use by Sublessor constitute any manner of constructive eviction of Sublessee’s possessory rights provided by this Sublease.

 

Notwithstanding the foregoing, including in the definition of “Sublet Premises” set forth in the Basic Lease Definitions hereinabove, Sublessee shall have the one (1) time option to move forward the Premises Expansion Date to a date which is earlier than the date which is eighteen (18) months following the Commencement Date hereof. In any case, any such notice from Sublessee to move forward the Premises Expansion Date must be received by Sublessor no less than ninety (90) days prior to Premises Expansion Date. In the event, Sublessee effectively exercises the right to advance the Premises Expansion Date, the Base Rent schedule set forth above, and all amounts due from Sublessee to Sublessor as provided pursuant to this Sublease, shall be adjusted to reflect that Sublessee shall be occupying the entire Building, and by and from the effectiveness thereof, the definition of “Sublet Premises” shall include the entire 26,800 rentable square feet of the Building.

 

3

 

 

2.Term; Early Entry.

 

The Term of this Sublease shall be for the Term as defined in the Basic Lease Definitions hereinabove, unless sooner terminated in accordance herewith. Tenant and its contractors, subcontractors and agents shall be permitted to enter into the Sublet Premises from and after the later of (a) October 1, 2023, or (b) the date which is thirty (30) days following receipt of the consent of Underlying Landlord to this Sublease, for the purpose of (i) renovating existing laboratory space through the installation of clean rooms, laboratory equipment, and a steam autoclave, and (ii) installing furniture, trade fixtures, telephones, computers, photocopy equipment, and other business equipment, including, without limitation, low voltage cable, telephone and/or data equipment. Such early entry will not advance the Commencement Date but shall be subject to all of the terms and conditions of this Sublease except for Tenant’s obligation to pay Base Rent pursuant to Paragraph 3 of this Sublease. If Tenant does enter the Sublet Premises prior to the Commencement Date, Landlord shall not be responsible for, and Tenant is required to obtain, insurance covering, any loss, including theft, damage or destruction to any work or material installed or stored by Tenant or any contractor or individual involved in the completion of such installation or other work, or for any injury to Tenant or Tenant’s employees, agents, contractors, licensees, directors, officers, partners, trustees, visitors or invitees or to any other person. Landlord shall have the right to post the appropriate notices of non-responsibility and to require Tenant to provide Landlord with evidence that Tenant has fulfilled its obligation to provide insurance pursuant to this Sublease.

 

3.Base Rent.

 

Sublessee shall pay to Sublessor, each month during the Term, without notice or demand, and without any set-off, counterclaim, abatement or deduction whatsoever, Base Rent in equal monthly installments, on the first day of each and every calendar month during the Term, in lawful money of the United States of America, by check made payable to Sublessor, except the first full monthly installment of Base Rent shall be paid upon execution of this Sublease. All Base Rent, Additional Rent and other sums and charges due to Sublessor under this Sublease shall be paid by Sublessee at the office of Sublessor set forth above, or at such other place as Sublessor may designate, without any notice, setoff or deduction whatsoever. If the Term commences on a day other than the first day of a calendar month or terminates on a day other than the last day of a calendar month, monthly Base Rent and Additional Rent for the applicable month shall be prorated based on the number of days in such calendar month. Sublessee’s obligation to make such payments accruing during the Term hereof shall survive the Expiration Date or sooner termination of this Sublease.

 

In addition to Base Rent and Additional Rent required to be paid hereunder, Sublessee agrees to pay all invoices rendered by Underlying Landlord or Sublessor for charges incurred by Sublessor for services and materials or utilities supplied to the Sublet Premises that are requested by Sublessee or that are attributable to Sublessee’s particular manner of use (for example, Sublessee shall pay the prevailing rate for after-hours HVAC requested by or used by Sublessee) (the “Special Costs”). In the event of non-payment of Additional Rent and/or Special Costs, Sublessor shall have all the rights and remedies provided for herein or the Underlying Lease in case of non-payment of Base Rent (or its equivalent term) in the Underlying Lease.

 

If Sublessee shall fail to duly and timely pay any installment of Base Rent or Additional Rent and/or Special Costs, Sublessee shall also pay to Sublessor a late charge(s) and interest charges due and payable from Sublessor to Underlying Landlord pursuant to the Underlying Lease, or, if no such charges are specified in the Underlying Lease, Sublessee shall pay to Sublessor a late charge of five percent (5%) of such overdue amount and interest shall accrue on said overdue amount at the rate of twelve percent (12%) per annum (or such maximum rate allowable by law) from the date such payment was due until same is paid, such interest and/or late charge to be payable as Additional Rent hereunder. The payment of such late charge and interest shall be in addition to all other rights and remedies available to Sublessor in the case of non-payment of all such amounts hereunder.

 

4.Utilities.

 

Sublessee shall pay, prior to the date which is five (5) calendar days following Sublessor’s delivery of a monthly invoice therefor, all charges or assessments for water, sewer, gas, heat, electricity, garbage disposal, trash disposal, and all other utilities and services utilized by Sublessee with respect to Sublessee’s use of the Building (the “Utilities”); provided, however, that for the period of the Term prior to the Premises Expansion Date, Sublessee shall be responsible for an amount equal to eighty percent (80%) of the Utilities invoiced to Sublessee by Sublessor during such period. For purposes of clarity, Sublessee acknowledges and agrees that from and after the Premises Expansion Date, Sublessee shall be responsible for 100% of the Utilities due for the remainder of the Term. Upon the reasonable request of Sublessee, Sublessor shall use commercially reasonable efforts to provide Sublessee with any individual invoice or other supporting documentation with respect to any monthly invoice for Utilities which Sublessor delivers to Sublessee pursuant to this Paragraph 4, if any, provided that any such documents or materials are within Sublessor’s possession and control. For the avoidance of doubt, telephone and janitorial services are expressly excluded from the definition of Utilities, and Sublessee, at its sole cost and expenses, shall be responsible for obtaining any such telephone and/or janitorial services as needed for Sublessee’s use of the Building.

 

4

 

 

5.Additional Rent.

 

Sublessee shall pay to Sublessor, as Additional Rent, (a) all Special Costs, and (b) all charges, payments, fees, costs and sums (i) required to be paid by Sublessor as Additional Rent pursuant to the Underlying Lease (subject to adjustment as expressly provided herein), (ii) required to be paid by Sublessee under this Sublease, including, without limitation, any sums in connection with Sublessee’s repair and/or maintenance obligations hereunder, and (iii) attributable to Sublessee’s negligence, willful misconduct or a breach of the terms of this Sublease. The Additional Rent payable by Sublessee shall be paid to Sublessor in the manner and five (5) days before each such date as Sublessor shall be required to pay its corresponding share of such Additional Rent pursuant to the Underlying Lease. A copy of any bill or statement actually received by Sublessor from the Underlying Landlord in respect of which Sublessee shall, pursuant to the terms of this paragraph, be required to pay Additional Rent, shall be delivered by Sublessor to Sublessee.

 

6.Compliance with Underlying Lease and Laws.

 

Sublessee covenants and agrees to observe and perform all of the terms, covenants, conditions, provisions and agreements to be performed by Sublessor, as tenant pursuant to the Underlying Lease, and further covenants and agrees not to do or suffer or permit anything to be done which would result in a default under or cause the Underlying Lease to be terminated. Notwithstanding the foregoing, all grace periods specified in the Underlying Lease shall, for purposes of determining compliance by Sublessee with the provisions hereof, be each reduced by two (2) days. In relation to Sublessee performing the obligations of Sublessor, as tenant pursuant to the Underlying Lease, said obligations shall be those of Sublessor in relation to the Sublet Premises.

 

Sublessee shall use the Sublet Premises only for the Permitted Uses. Sublessee shall use and occupy the Sublet Premises in a manner consistent with the terms of the Underlying Lease, and in compliance with all governmental laws, rules and regulations (“Laws”) applicable to the Sublet Premises. Sublessee, at its expense, shall procure and at all times maintain and comply with the terms and conditions of all licenses and permits required for the lawful conduct of the Permitted Uses in the Sublet Premises. Sublessor agrees that Sublessee shall be entitled to receive all services and repairs to be provided by Underlying Landlord to Sublessor under the Underlying Lease provided Sublessor shall not be responsible or liable for Underlying Landlord’s failure to perform any such services or repairs.

 

5

 

 

7.Non-Liability, Indemnity.

 

Except and to the extent caused by or due to the willful acts or gross negligence of Sublessor, or its agents, contractors, servants, licensees and employees, Sublessee shall and hereby does indemnify, defend and hold Sublessor harmless from and against any and all actions, claims, demands, damages, liabilities and expenses (including, without limitation, reasonable attorneys’ fees and disbursements) asserted against, imposed upon or incurred by Sublessor by reason of (a) any violation caused, suffered or permitted by Sublessee, its agents, contractors, servants, sublessees, licensees, employees or invitees, of any of the terms, covenants, conditions, provisions or agreements of the Underlying Lease, (b) any damage or injury to persons or property occurring upon or in connection with the use or occupancy of the Sublet Premises, (c) the use or maintenance of the Sublet Premises or any business therein or any work or thing whatsoever done, or any condition created in or about the Sublet Premises during the Term (or any time prior to the Commencement Date that Sublessee may have been given access to the Sublet Premises), (d) any negligent or otherwise wrongful act or omission of Sublessee or any of its agents, contractors, servants, sublessees, licensees, employees or invitees, (e) any failure of Sublessee to perform or comply with all of the provisions of this Sublease hereof that are applicable to Sublessee, and (f) any obligation Sublessor may have to indemnity Underlying Landlord pursuant to the Underlying Lease, to the extent related to the Sublet Premises during the Term or Sublessee’s occupancy of the Sublet Premises. For the avoidance of doubt, the foregoing indemnity shall apply only with respect to such actions, claims, demands, damages, liabilities or expenses relating to the Sublet Premises during the Term (or Sublessee’s earlier occupancy thereof). Neither Sublessor nor any agent, contractor, servant, licensee, employee or invitee of Sublessor shall be liable to Sublessee for any death of or injury or damage to Sublessee or any other person or for any damage to or loss (by theft or otherwise) of any property of Sublessee or any other person, except to the extent caused by or due to the willful acts or gross negligence of Sublessor, or its agents, contractors, servants, sublessees, licensees or employees. In case any action or proceeding be brought against Sublessor or any agent, contractor, servant, licensee, employee or invitee of Sublessor by reason of any of the foregoing, Sublessee, upon notice from Sublessor, shall defend such action or proceeding by counsel chosen by Sublessee. Sublessee or its counsel shall keep Sublessor fully apprised at all times of the status of such defense and shall not settle same without the written consent of Sublessor, not to be unreasonably withheld, delayed or conditioned.

 

Sublessor shall and hereby does indemnify, defend and hold Sublessee harmless from and against any and all actions, claims, demands, damages, liabilities and expenses (including, without limitation, reasonable attorneys’ fees and disbursements) asserted against, imposed upon or incurred by Sublessee by reason of the gross negligence or willful misconduct of Sublessor in or about the Sublet Premises during the Term.

 

8.Performance by Underlying Landlord.

 

Sublessor does not assume any obligation to perform the terms, covenants, conditions, obligations, provisions and agreements contained in the Underlying Lease on the part of Underlying Landlord to be performed, including, without limitation, the provision of utilities or services to the Sublet Premises. The representations of Underlying Landlord are not the representations of Sublessor. In the event Underlying Landlord shall fail to perform any of the terms, covenants, conditions, provisions and agreements contained in the Underlying Lease on its part to be performed, Sublessor shall be under no obligation or liability whatsoever to Sublessee, except as otherwise set forth in this Sublease. Sublessor shall cooperate with Sublessee, at no cost to Sublessor, in seeking to obtain the performance of Underlying Landlord under the Underlying Lease. Subject to the following sentence, Sublessee shall not be allowed any abatement or diminution of Base Rent or Additional Rent under this Sublease because of or due to Underlying Landlord’s failure to perform any of its obligations under the Underlying Lease.

 

If Underlying Landlord shall default in any of its obligations with respect to the Sublet Premises, or there shall exist a bona fide dispute with Underlying Landlord under the terms, covenants, conditions, provisions and agreements of this Sublease and/or the Underlying Lease and Sublessee notifies Sublessor in writing that Sublessee has previously notified Underlying Landlord of such dispute and that such default or notice has been disregarded or not reasonably satisfactorily acted upon, then Sublessor shall notify Underlying Landlord of such default or dispute in its name on Sublessee’s behalf. Sublessee shall be entitled to participate with Sublessor in the enforcement of Sublessor’s rights against Underlying Landlord, but Sublessor shall have no obligation to bring any action or proceeding nor to take any steps to enforce Sublessor’s rights against Underlying Landlord.

 

6

 

 

9.Maintenance Obligations.

 

Sublessee shall assume the responsibility for and pay for all maintenance, repairs and replacements during the term of this Sublease, to the extent that such maintenance, repairs or replacements are required to be performed by Sublessor as tenant under the Underlying Lease and then only to the extent applicable to the Sublet Premises.

 

10.Alterations.

 

Sublessee shall not make any alterations, additions or improvements to the Sublet Premises without first obtaining the written consent of the Underlying Landlord and Sublessor. Sublessor’s consent shall not be unreasonably withheld if the written consent of the Underlying Landlord is first obtained, as well as a written waiver from Underlying Landlord of any restoration obligation of Sublessor pursuant to the Underlying Lease. Simultaneously with the submission of documents to the Underlying Landlord, Sublessee shall send copies of all such documents regarding alterations to Sublessor. Sublessee shall pay all costs and expenses relating to any changes, alterations, additions or improvements and shall cause same to be completed in accordance with law and the terms, covenants, conditions, provisions and agreements of the Underlying Lease. Sublessee hereby agrees to indemnify, defend and hold Sublessor harmless from any and all loss, cost, and expense (including, without limitation, reasonable attorneys’ fees) incurred by Sublessor as a result of Sublessee’s failure to comply with the aforesaid terms, covenants, conditions, provisions or agreements.

 

11.Initial Condition of Sublet Premises; Underlying Lease.

 

Sublessee represents that it has inspected the Sublet Premises and agrees to take the same in its present “As-Is, Where-Is” condition, and Sublessee acknowledges that no representations with respect to the condition of the Sublet Premises have been made by Sublessor or anyone on Sublessor’s behalf. Sublessor has no obligation to perform any work, supply any materials, incur any expense or make any alterations or improvements to prepare the Sublet Premises for Sublessee’s occupancy. Sublessee’s occupancy of any part of the Sublet Premises shall be conclusive evidence, as against Sublessee, that Sublessee has accepted possession of the Sublet Premises in its then current condition. Any work required by Sublessee to prepare the Sublet Premises for its occupancy shall be made by Sublessee, at Sublessee’s sole cost and expense, and shall be subject to all of the terms, covenants, conditions, provisions and agreements set forth in the Underlying Lease.

 

12.Assignment and Subletting.

 

Sublessee shall not assign this Sublease or sublet the Sublet Premises or otherwise transfer, mortgage or encumber this Sublease, the Sublet Premises or any part thereof or permit the use or occupancy thereof without first complying with the provisions of the Underlying Lease and obtaining Sublessor’s consent thereto. Any transfer of more than twenty-five percent (25%) of the stock, partnership interests or membership interests, as the case may be, of Sublessee shall be deemed an assignment requiring Sublessor’s consent thereto. Sublessor’s consent shall not be unreasonably withheld, delayed or conditioned if the written consent of the Underlying Landlord is first obtained and said assignment or subletting of the entire Sublet Premises is to one (1) assignee or sublessee for its undivided occupancy for the remainder of the Term of this Sublease. Sublessor shall not be required to consent to any such assignment or further subletting if Sublessee is then in default under this Sublease or if such further subletting or assignment would cause Sublessor to be in default under the Underlying Lease. No such consent shall relieve Sublessee from the obligation to seek consent to a further subletting or assignment, and Sublessor may withhold its consent to each further subletting or assignment in its sole and absolute discretion. Copies of all documentation required by the Underlying Lease shall be delivered simultaneously to Sublessor, together with Sublessee’s request for any such consent. If Underlying Landlord and Sublessor shall give their consent to any assignment of this Sublease or any sub-sublease, Sublessee shall, in consideration therefor, pay to Sublessor, as additional rent:

 

(i) In the case of an assignment, an amount equal to 50% of all sums and other consideration paid to Sublessee by the assignee for or by reason of such assignment, after deduction of the commercially reasonable and customary costs incurred by Sublessee in effectuating such assignment including reasonable attorneys’ fees, advertising costs, rent concessions, construction costs and brokerage commissions, in each case based upon bills, receipts or other evidence of such costs reasonably satisfactory to Sublessor (collectively, “Transfer Expenses”).

 

7

 

 

(ii) In the case of a sub-sublease, 50% of any rents, additional rents or other consideration payable under the sub-sublease or otherwise to Sublessee by the sub-subtenant which are in excess of the fixed annual rent and additional rent accruing during the term of this Sublease in respect of the sub-subleased space (at the rate per square foot payable by Sublessee hereunder) pursuant to the terms hereof, after deduction of Transfer Expenses incurred by Sublessee in connection with such sub-sublease, amortized over the term of the sub- sublease.

 

The sums payable under this paragraph shall be paid to Sublessor as and when received by the Sublessee.

 

If this Sublease be assigned, or if the Sublet Premises or any portion thereof be underlet or occupied by anybody other than Sublessee, Sublessor may, in the event of an uncured, monetary default by Sublessee, collect rent from the assignee, undertenant or occupant, and apply the net amount collected to the Rent herein reserved, but no such assignment, underletting, occupancy or collection shall be deemed a waiver of this covenant, or the acceptance of the assignee, undertenant or occupant as tenant, or a release of Sublessee from the further performance by Sublessee of the covenants on the part of Sublessee herein contained, and Sublessee shall be and remain liable under all of the terms, covenants, conditions, provisions and agreements hereof.

 

If Sublessee shall at any time request the consent of Sublessor to any proposed assignment of this Sublease or sub-subletting of all or any portion of the Sublet Premises, Sublessee shall pay on demand: (i) the reasonable costs and expenses incurred by Sublessor and Underlying Landlord, including, without limitation, architect, engineer and reasonable attorneys’ fees and disbursements; and (ii) an administrative fee of $1,000.00 for review and/or preparation of documents in connection with any proposed or actual assignment of this Sublease or subletting of the Sublet Premises or any part thereof.

 

13.Insurance.

 

During the Term, Sublessee, at its sole cost and expense, shall provide and maintain commercial liability insurance, property damage insurance, and any other insurance required to be carried by Sublessor under the Underlying Lease, all in conformity with the provisions of the Underlying Lease which shall include, without limitation, coverage of replacement value of any and all existing leasehold improvements, regardless of whether such improvements were or are installed by Underlying Landlord, Sublessor or Sublessee. Sublessee shall cause Sublessor and Underlying Landlord to be included as additional insureds in said policy or policies which shall contain provisions, if and to the extent available, that it or they will not be cancellable except upon at least thirty (30) days’ prior notice to all insureds, and that the act or omission of one insured will not invalidate the policy as to the other insureds. Sublessee shall furnish to Sublessor a certificate of insurance confirming that all such insurance is in effect at or before the Commencement Date and, on request, at reasonable intervals thereafter.

 

Nothing contained in this Sublease shall relieve Sublessee from liability that may exist as a result of damage from fire or other casualty, but each party shall look first to any insurance in its favor before making any claim against the other party for recovery for loss or damage resulting from fire or other casualty. To the extent that such insurance is in force and collectible and to the extent permitted by law, Sublessor and Sublessee each hereby releases and waives all right of recovery against the other or anyone claiming through or under the other by way of subrogation or otherwise. The foregoing release and waiver shall be in force only if the insurance policies of Sublessor and Sublessee provide that such release or waiver does not invalidate the insurance. Each party agrees to use reasonable efforts to include in its applicable insurance policies such a provision. If the inclusion of said provision would involve an additional expense, either party, at its expense, may require such provision to be inserted in the other’s policy.

 

8

 

 

Sublessee hereby releases Underlying Landlord or anyone claiming through or under Underlying Landlord by way of subrogation or otherwise to the extent that Sublessor released Underlying Landlord or Underlying Landlord was relieved of liability or responsibility pursuant to the provisions of the Underlying Lease, and Sublessee will cause its insurance carriers to include any clauses or endorsements in favor of Underlying Landlord which Sublessor is required to provide pursuant to the provisions of the Underlying Lease.

 

14.Default.

 

The occurrence of any of the following events shall constitute a default by Sublessee of Sublessee’s obligations under this Sublease: (i) Sublessee’s failure to pay any installment of Rent (including, Base Rent or Additional Rent due hereunder) or other monies when due and payable under this Sublease, which failure continues for five (5) days after receipt of written notice from Sublessor thereof; provided, however, and notwithstanding the foregoing, Sublessor will not be required to provide more than two (2) such notices of Sublessor’s failure to pay any installment of Rent in any twelve (12)-month period, such that it shall, after such second (2nd) notice in such period, be deemed a default if such failure to pay an installment of Rent continues for more than five (5) days after such payment is due, without the giving of any further notice being required; or (ii) Sublessee’s failure to perform any of the other terms, covenants or conditions of this Sublease or the Underlying Lease to be performed by Sublessee, which failure continues for thirty (30) days after Sublessee’s receipt of written notice from Landlord, or if the nature of such failure to perform is such that it cannot reasonably be cured in thirty (30) days, Sublessee’s failure to commence action to cure the failure within the initial thirty (30) day period and thereafter to prosecute the cure diligently to completion.

 

In the event Sublessee defaults in the performance of any of the terms, covenants, conditions, provisions and agreements of this Sublease or of the Underlying Lease, and such default continues beyond any and all applicable notice and cure periods, Sublessor shall be entitled to exercise any and all of the rights and remedies to which Sublessor is entitled by law and also any and all of the rights and remedies specifically provided to or for the benefit of Underlying Landlord in the Underlying Lease, which rights and remedies are hereby incorporated herein and made a part hereof with the same force and effect as if herein specifically set forth in full, and that wherever in the Underlying Lease rights and remedies are given to Underlying Landlord, the same shall be deemed to apply to Sublessor. Sublessee agrees Sublessee shall look solely to Sublessor’s right, title and interest in the property comprising the Building, including any income therefrom, for the satisfaction of any judgment (or other judicial process) or collection of any obligation from Sublessor, and no other assets of Sublessor, its members, shareholders or partners shall be subject to levy, execution or other procedures for the satisfaction of Sublessee’s remedies, if any.

 

15.Sublease Consent.

 

This Sublease shall become effective only if the written consent hereto of Underlying Landlord is first obtained. If such written consent is not obtained, then this Sublease shall be void and of no force or effect and Sublessor shall return to Sublessee the first month’s rent and the security deposit, and thereupon neither party shall have any further obligation to the other. Upon execution and delivery of this Sublease by Sublessor and Sublessee and receipt of the first month’s rent and security deposit, Sublessor shall promptly request the consent of Underlying Landlord to this Sublease. Sublessee agrees to provide such information in connection with such request as Underlying Landlord shall reasonably request. If the foregoing consent is not obtained within the time period provided to Underlying Landlord pursuant to the Underlying Lease, then this Sublease shall be deemed cancelled, null and void. Sublessee acknowledges and agrees that Underlying Landlord shall retain and be afforded any and all rights granted specifically to Underlying Landlord by the Underlying Lease with respect to a requested subletting of the Premises, and that any potential interest of Sublessee to occupy the Sublet Premises shall remain subject and subordinate to the rights of Underlying Landlord related thereto.

 

9

 

 

16.Attornment.

 

If the Underlying Lease and Sublessor’s leasehold interest in the Sublet Premises shall be terminated, other than as a result of a casualty or condemnation or sale in lieu thereof, Sublessee shall, if so requested in writing by Underlying Landlord, attorn to Underlying Landlord and shall, during the term of this Sublease, perform all of the terms, covenants, conditions, provisions and agreements of this Sublease on the part of Sublessee to be performed. In the event of any such attornment, Underlying Landlord shall not be: (i) liable for any act or omission or default of any prior sublessor (including, without limitation, Sublessor); (ii) subject to any offsets or defenses which Sublessee might have against any prior sublessor (including, without limitation, Sublessor); (iii) bound by any Base Rent or Additional Rent which Sublessee might have paid for more than the current month to any prior sublessor (including, without limitation, Sublessor); or (iv) bound by any amendment or modification of this Sublease made without Underlying Landlord’s written consent. The foregoing shall be self-operative without the necessity of the execution of any further instruments, but Sublessee agrees, upon the demand of Underlying Landlord, to execute, acknowledge and deliver any reasonable instrument or instruments confirming such attornment.

 

17.Notices.

 

Any notice to be given under this Sublease shall be in writing and shall be sent by registered or certified mail, return receipt requested, or by nationally-recognized overnight courier making receipted deliveries, or delivered by hand (provided a signed receipt is obtained), to address(es) herein stated above in Basic Sublease Definitions. Each party shall have the right upon ten (10) days’ prior written notice, to change, by notice in writing, the address to which such party’s notice is to be sent. Notices shall be deemed given upon receipt or first refusal thereof.

 

18.Quiet Enjoyment.

 

Sublessor covenants that Sublessee, upon paying the Base Rent, Additional Rent and any and all other sums due under this Sublease and performing all the terms, covenants, conditions, provisions and agreements hereunder, shall and may peacefully and quietly have, hold and enjoy the Sublet Premises for the Term aforesaid, free from any interference or hindrance by Sublessor, but subject to the exceptions, reservations and conditions hereof.

 

19.Surrender of Sublet Premises.

 

On the date upon which the term hereof shall expire and come to an end, whether on the Expiration Date, by lapse of time or otherwise, Sublessee, at Sublessee’s sole cost and expense, shall quit and surrender the Sublet Premises and all improvements thereon to Sublessor in the same good order and condition as Sublessor is delivering them to Sublessee, subject to the provisions of the Underlying Lease (including, without limitation, those provisions relating to restoration and/or holdover), (provided, however, Sublessee may remove any furniture, fixtures and equipment that Sublessee has purchased from Sublessor pursuant to this paragraph), reasonable wear and tear excepted, together with all keys and security cards. All property at the end of the Term remaining in the Sublet Premises shall be deemed abandoned and may, at the election of Sublessor, either be retained as Sublessor’s property or may be removed from the Sublet Premises by Sublessor, at Sublessee’s expense. Notwithstanding the foregoing, upon the expiration of this Sublease, and provided that Sublessee is not in default of any obligation of this Sublease or the Underlying Lease, Sublessee shall have the option to purchase those certain items of laboratory furniture, fixtures and equipment listed and described on Exhibit B attached hereto for an amount equal to One Dollar and 00/100 ($1.00). All items listed on Exhibit B shall be in an “As-Is: condition and sublessee shall not be responsible for repair or replacement of any items listed in Exhibit B during the term of the Sublease. To exercise such option, Sublessee must deliver written notice of its election thereto to Sublessor no less than sixty (60) days prior to the expiration or sooner termination of this Sublease and any such purchase by Sublessee shall be conditioned upon the mutual execution of a commercially reasonable form of bill of sale, prepared by Sublessor, in connection therewith.

 

10

 

 

Sublessor and Sublessee recognize that Sublessor’s damages resulting from Sublessee’s failure to timely surrender possession of the Sublet Premises may be substantial, may exceed the amount of the Base Rent payable hereunder, and will be impossible to accurately measure. Accordingly, if possession of the Sublet Premises is not surrendered to Sublessor on the Expiration Date or sooner termination of this Sublease, in addition to any other rights or remedies Sublessor may have hereunder or at law, Sublessee shall pay to Sublessor for each month (or any portion thereof) during which Sublessee holds over in the Sublet Premises after the Expiration Date or sooner termination of this Sublease, a sum equal to one hundred fifty percent (150%) of the Base Rent payable under this Sublease for the last full calendar month of the Term, and Sublessee shall indemnify and hold harmless Sublessor from and against all damages incurred by Sublessor on account of Sublessee’s holding over. No holding-over by Sublessee, nor the payment to Sublessor of the amounts specified above, shall operate to extend the Term hereof. Nothing herein contained shall be deemed to permit Sublessee to retain possession of the Sublet Premises after the Expiration Date or sooner termination of this Sublease, and no acceptance by Sublessor of payments from Sublessee after the Expiration Date or sooner termination of this Sublease shall be deemed to be other than on account of the amount to be paid by Sublessee in accordance with the provisions of this paragraph.

 

20.Brokers.

 

Sublessee represents and warrants to Sublessor and Sublessor represents and warrants to Sublessee that the Brokers referenced in the Basic Sublease Definitions are the only brokers with whom each party dealt in relation to this transaction and that neither party has had any dealings, either direct or indirect, with any other real estate agent or broker in connection with this transaction. The breaching party agrees to indemnify, defend and hold the non- breaching party harmless from any loss, liability and expense incurred by the non-breaching party as a result of any claim made against the breaching party, which is based upon a breach of said representation by the breaching party, which indemnification obligation hereunder shall survive the Expiration Date or sooner termination of this Sublease..

 

21.Excluded Provisions.

 

The following provisions of the Underlying Lease are deemed to be Excluded Provisions: Lease Addendum No. 1.

 

22.Successors and Assigns.

 

This Sublease shall be binding upon and, except as prohibited by this Sublease or the Underlying Lease, inure to the benefit of the parties hereto and their respective successors and assigns.

 

23.No Modifications.

 

This Sublease may not be modified except by written agreement signed by Sublessor and Sublessee.

 

11

 

 

24.Security Deposit.

 

Upon Sublessee’s execution of this Sublease, Sublessee shall deposit with Sublessor, the Security Deposit for the faithful performance and observance by Sublessee of the terms, covenants, conditions, provisions and agreements of this Sublease. The Security Deposit shall not be required to be deposited in an interest bearing account. It is agreed that in the event Sublessee defaults in respect of any of the terms, covenants, conditions, provisions and agreements of this Sublease, including, but not limited to, the payment of Base Rent and Additional Rent, beyond any notice and/or grace period set forth in this Sublease, Sublessor may use, apply or retain the whole or any part of the Security Deposit to the extent required for the payment of any Base Rent and Additional Rent or any other sum as to which Sublessee is in default or for any sum which Sublessor may expend or may be required to expend by reason of Sublessee’s default in respect of any of the terms, covenants, conditions, provisions and agreements of this Sublease beyond any notice and/or grace period set forth in this Sublease, including but not limited to, any damages or deficiency in the reletting of the Sublet Premises, whether such damages or deficiency accrued before or after summary proceedings or other re-entry by Sublessor. If Sublessor so applies or retains any part of the Security Deposit during the Term of this Sublease, Sublessee shall, upon demand, promptly deposit with Sublessor the amount so applied or retained so that Sublessor shall have the full Security Deposit on hand at all times during the term of this Sublease. In the event that Sublessee shall fully and faithfully comply with all of the terms, covenants, conditions, provisions and agreements of this Sublease, the Security Deposit shall be returned to Sublessee within sixty (60) days after the Expiration Date and after delivery of entire possession of the Sublet Premises to Sublessor. In the event of an assignment by Sublessor of its interest under the Underlying Lease, Sublessor shall have the right to transfer the Security Deposit and Sublessee agrees to look to the new Sublessor solely for the return of said Security Deposit and it is agreed that the provisions hereof shall apply to every transfer or assignment made of the Security Deposit to a new Sublessor. Sublessee further covenants that it shall not assign or encumber or attempt to assign or encumber the monies deposited herein as security and that neither Sublessor nor its successors or assigns shall be bound by any such assignment, encumbrance, attempted assignment or attempted encumbrance.

 

25.Signage.

 

Sublessee hereby acknowledges and agrees that any and all signage rights available to Sublessor pursuant to the Underlying Lease, including but not limited to those signage rights described in Section 6 of the Underlying Lease, are personal to Sublessor. Notwithstanding the foregoing, Sublessor shall use commercially reasonable efforts, at no cost to Sublessor whatsoever, to cooperate with Sublessee and Underlying Landlord in order to effectuate the transfer, assignment or otherwise granting of any signage rights available to Sublessor pursuant to the Underlying Lease to Sublessee during the Term of this Sublease, unless otherwise terminated as provided herein; provided, however, that Sublessee express acknowledges and agrees that Sublessor makes no representation, warranty or guaranty of any kind that: (i) Underlying Landlord will consent to the transfer, assignment or granting of such signage rights to Sublessee; or (ii) any such signage rights shall be ultimately be transferred, assigned or granted to Sublessee.

 

26.Parking.

 

At no charge to Sublessee, Sublessee shall be entitled to the non-exclusive use of all parking areas serving the Sublet Premises as of the Commencement Date of this Sublease, in the condition as the same are situated as of the Commencement Date hereof. Sublessee acknowledges and agrees that Sublessor shall not be liable for: (i) any damage to motor vehicles of Sublessee or any of Sublessee’s agents, representatives, contractors, employees, customers and visitors, (ii) any loss of property from within those motor vehicles, or (iii) for any injury to Sublessee, its agents, representatives, contractors, employees, customers and visitors, unless caused by Sublessor’s sole active negligence or willful misconduct. Sublessee expressly acknowledges and agrees that any and all such parking rights granted to Sublessee remain subject to provisions of the Underlying Lease and the rights and privileges of Underlying Landlord set forth therein.

 

12

 

 

27.Inability to Perform; Delays.

 

If Sublessee shall be delayed in obtaining possession of the Sublet Premises because of delays in obtaining consent or in construction or for any other reason beyond the reasonable control of Sublessor, Sublessor shall not be subject to any liability, the effectiveness of this Sublease shall not be affected and the Term hereof shall not be extended; provided, however, in the event that Sublessor is unable to obtain the Underlying Landlord’s consent to this Sublease on or before October 1, 2023, Sublessee shall have the one-time right to terminate this Sublease upon delivering written notice of Sublessee’s election thereof no later than October 1, 2023.

 

28.Notice of Accidents.

 

Sublessee shall give Sublessor and Underlying Landlord notice of any fire, casualty or accident in or about the Sublet Premises promptly after Sublessee becomes aware of such event.

 

29.Destruction by Fire or Other Casualty. Condemnation.

 

If the Sublet Premises or the Building shall be partially or totally damaged or destroyed by fire or other casualty, Sublessee shall have no right to terminate this Sublease and this Sublease shall not be terminated by reason of such casualty unless the Underlying Lease is terminated by Sublessor or Underlying Landlord pursuant to the provisions of the Underlying Lease.

 

If the Sublet Premises are partially or totally damaged by fire or other casualty as a consequence of which Sublessor shall receive an abatement of rent or additional rent relating to the Sublet Premises, then in such event, there shall be a corresponding abatement of the Base Rent payable hereunder.

 

If the Underlying Lease is terminated pursuant to the provisions thereof as the result of a taking of all or any portion of the Building by condemnation (or deed in lieu thereof), this Sublease shall likewise terminate. In such event, Sublessee shall have no claim to any portion of the award with respect to any such taking, except to file a claim for the value of its fixtures or for moving expenses; provided, however, that Sublessor’s award is not thereby reduced or otherwise adversely affected.

 

30.Bankruptcy.

 

In the event Sublessee becomes the subject of proceedings involving bankruptcy, insolvency or reorganization of Sublessee, or if Sublessee makes an assignment for the benefit of creditors, or petitions for, or enters into an arrangement with creditors, Sublessor shall have the same rights as to Sublessee as are afforded Underlying Landlord under the Underlying Lease under similar circumstances involving Sublessor. In the event that Sublessor becomes the subject of proceedings involving bankruptcy, insolvency or reorganization of Sublessor, or if Sublessor makes an assignment for the benefit of creditors, or petitions for, or enters into an arrangement with creditors, then, upon the request of Sublessee, Sublessor agrees to cooperate with Sublessee’s direct assumption of the Underlying Lease.

 

31.No Waiver; Jury Waiver.

 

No agreement to accept a surrender of this Sublease shall be valid unless in writing and signed by Sublessor. The failure of Sublessor or Sublessee to enforce any terms, covenants, conditions, provisions or agreements of this Sublease shall not prevent the later enforcement thereof or a subsequent act which would have constituted a violation from having all the force and effect of an original violation. The receipt by Sublessor or payment by Sublessee of Base Rent or Additional Rent or other sums or charges with knowledge of the breach of any covenant of this Sublease shall not be deemed a waiver of such breach. The parties hereto, to the fullest extent permitted by law, waive trial by jury in any action or proceeding relating hereto and consent to the jurisdiction of the applicable court system of the jurisdiction in which the Sublet Premises is situated. Sublessee hereby waives any right to interpose any counterclaim in any action brought by Sublessor in connection herewith. The foregoing shall not be deemed a waiver by Sublessee of the right o interpose any counterclaim to the extent failure to interpose the same would prohibit Sublessee from bringing the claim, which is the basis thereof, in a separate action.

 

13

 

 

32.Limitations on Sublessee’s Remedies.

 

With respect to any provision of this Sublease which specifically requires that Sublessor shall not unreasonably withhold or unreasonably delay its consent or approval, Sublessee in no event shall be entitled to make, nor shall Sublessee make, any claim, and Sublessee hereby waives any claim, for any sum of money whatsoever as damages, costs, expenses, attorneys’ fees or disbursements, whether affirmatively or by way of setoff, counterclaim or defense, based upon any claim or assertion by Sublessee that Sublessor has unreasonably withheld or unreasonably delayed such consent or approval. Sublessee’s sole remedy for claimed unreasonable withholding or unreasonable delaying by Sublessor of its consent or approval shall be an action or proceeding brought and prosecuted solely at Sublessee’s own cost and expense to enforce such provision, for specific performance, injunction or declaratory judgment.

 

33.Occupancy Tax; Personal Property Tax.

 

To the extent applicable, Sublessee shall pay (a) directly to the local authority, all occupancy and rent taxes which may be payable by Sublessee to the local authority in respect of the rent reserved by this Sublease, if any, and will pay all other taxes, the payment of which shall be imposed directly upon any occupant of the Sublet Premises, and (b) all personal property taxes applicable to the personal property of Sublessee in the Sublet Premises, if any.

 

34.Rules and Regulations.

 

Sublessee agrees to comply with all rules and regulations that Underlying Landlord has made or may hereafter from time to time promulgate for the Building and any common or parking areas servicing the Building. Sublessor shall not be liable in any way for damage caused by the non-observance by any of the other tenants of such similar covenants in their leases or of such rules and regulations.

 

35.Entire Agreement; Miscellaneous.

 

A. This Sublease shall be governed by and construed in accordance with the laws of the state in which the Sublet Premises are situated, without regard to the conflicts of law principles thereof.

 

B. The paragraph headings in this Sublease are inserted only as a matter of convenience for reference and are not to be given any effect in construing this Sublease.

 

C. If any of the provisions of this Sublease or the application thereof to any person or circumstance shall be, to any extent, held to be invalid or unenforceable, the remainder of this Sublease shall not be affected thereby and shall be valid and enforceable to the fullest extent permitted by law.

 

D. All of the terms and provisions of this Sublease shall be binding upon and, except as prohibited by Paragraph 12 hereof, inure to the benefit of the parties hereto and their respective permitted successors and assigns.

 

E. All prior negotiations and agreements relating to this Sublease and the Sublet Premises are merged into this Sublease. This Sublease may not be amended, modified or terminated, in whole or in part, nor may any of the provisions be waived, except by a written instrument executed by the party against whom enforcement of such amendment, modification, termination or waiver is sought and unless the same is permitted under the provisions of the Underlying Lease.

 

F. Each of Sublessor and Sublessee represents and warrants to the other that each person executing this Sublease is a duly authorized representative of Sublessor or Sublessee, as the case may be, and has full authority to execute and deliver this Sublease.

 

14

 

 

G. This Sublease shall have no binding force and effect and shall not confer any rights or impose any obligations upon either party unless and until both parties have executed it and Sublessor shall have obtained Underlying Landlord’s written consent to this Sublease pursuant to the provisions hereof and delivered to Sublessee an executed copy of such consent. Under no circumstances shall the submission of this Sublease in draft form by or to either party be deemed to constitute an offer for the subleasing of the Sublet Premises.

 

H. This Sublease may be executed in several counterparts each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

 

I. This Sublease and all the obligations of Sublessee to pay Base Rent, Additional Rent and any other sums due hereunder and perform all of its other covenants and agreements hereunder shall in no way be affected, impaired, delayed or excused because Sublessor or Underlying Landlord are unable to fulfill any of their respective obligations hereunder, either explicit or implicit, if Sublessor or Underlying Landlord is prevented or delayed from so doing by reason of strikes or labor trouble or by accident, adjustment of insurance or by any cause whatsoever reasonably beyond Sublessor’s or Underlying Landlord’s control.

 

J. Each and every right and remedy of Sublessor under this Sublease shall be cumulative and in addition to every other right and remedy herein contained or now or hereafter existing at law or in equity, by statute or otherwise.

 

K. At any time and from time to time Sublessee shall, within ten (10) days after written request by Sublessor, execute, acknowledge and deliver to Sublessor a written statement which certifies: (i) that this Sublease has not been modified and is in full force and effect or, if modified, that this Sublease is in full force and effect as modified, and specifying such modification(s), (ii) the dates to which the Base Rent and other charges have been paid, (iii) that, to the best of Sublessee’s knowledge, no defaults exist under this Sublease or, if any do exist, the nature of such default(s) and (iv) as to such other matters as Sublessor may reasonably request.

 

L. In no event shall Sublessor be liable for, and Sublessee each hereby waives any claim for, any indirect, consequential or punitive damages arising under or in connection with this Sublease.

 

M. In the event of any legal action or proceeding brought by either party against the other arising out of this Sublease (an “Action”), the prevailing party shall be entitled to the payment by the losing party of its reasonable attorneys’ fees, court costs, and litigation expenses, as determined by the court.

 

[Signatures on following page]

 

15

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Sublease as of the day and year first above written.

 

  SUBLESSOR:
   
  ONCOCYTE CORPORATION,
  a California corporation
   
  By: /s/ Josh Riggs
  Name:  Josh Riggs
  Title: Chief Executive Officer
   
  SUBLESSEE:
   
  INDUCE BIOLOGICS USA, INC.,
  a Michigan corporation
   
  By: /s/ David Campagnari
  Name: David Campagnari
  Title: President

 

16

 

 

EXHIBIT A

 

Underlying Lease

 

17

 

 

EXHIBIT B

 

List of Purchased FF&E

 

18

EX-31.1 3 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION

 

I, Joshua Riggs, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Oncocyte Corporation;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this periodic report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
   
  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 9, 2023

 

/s/ Joshua Riggs  
Joshua Riggs  

President and Chief Executive Officer

(Principal Executive Officer)

 

 

 
EX-31.2 4 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION

 

I, James Liu, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Oncocyte Corporation;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this periodic report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
   
  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 9, 2023

 

/s/ James Liu  
James Liu  

Controller, Principal Accounting Officer and interim Principal Financial Officer

(Principal Financial Officer)

 

 

 
EX-32.1 5 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of Oncocyte Corporation (the “Company”) for the quarter ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Joshua Riggs, President and Chief Executive Officer, and James Liu, Controller, Principal Accounting Officer and interim Principal Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
   
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 9, 2023

 

/s/ Joshua Riggs  
Joshua Riggs  

President and Chief Executive Officer

(Principal Executive Officer)

 
   
/s/ James Liu  
James Liu  

Controller, Principal Accounting Officer and interim Principal Financial Officer

(Principal Financial Officer)

 

 

 

EX-101.SCH 6 ocx-20230930.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Organization, Description of the Business and Liquidity link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Loan Payable to Silicon Valley Bank link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Shareholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Co-Development Agreement with Life Technologies Corporation link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Discontinued Operations of Razor link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Business Combinations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Discontinued Operations of Razor (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Organization, Description of the Business and Liquidity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Schedule of Fair Value Measurement of Financial Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Schedule of Disaggregation Of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Schedule of Concentration Of Risk (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Schedule of Fair Value of Contingent Consideration Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Schedule of Contingent Consideration, Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Business Combinations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Schedule of Goodwill and Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Schedule of Intangible Assets Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Intangible Assets, Net (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Loan Payable to Silicon Valley Bank (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Shareholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Summary of Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Co-Development Agreement with Life Technologies Corporation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Schedule of Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Schedule of Assets and Liabilities Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Discontinued Operations of Razor (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 ocx-20230930_cal.xml INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 ocx-20230930_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 ocx-20230930_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Series A Redeemable Convertible Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Investment, Name [Axis] Razor Genomics, Inc. [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Razor Stock Purchase Agreement [Member] Dragon Scientific LLC [Member] Razor [Member] Title of Individual [Axis] Dragon [Member] At The Market Sales Agreement [Member] Legal Entity [Axis] BTIG, LLC [Member] Securities Purchase Agreement [Member] Underwriting Agreement [Member] Underwriter [Member] Statistical Measurement [Axis] Minimum [Member] Registered Direct Offering [Member] Board Members [Member] Maximum [Member] Other Investors [Member] Consolidated Entities [Axis] Lineage and AgeX [Member] Long-Lived Tangible Asset [Axis] Machinery and Equipment [Member] Equipment [Member] Pharma Services [Member] Segments [Axis] Medicare And Medicare Advantage [Member] Concentration Risk Benchmark [Axis] Accounts Receivable [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Customer [Axis] Pharma Services Customers One [Member] Pharma Services Customers Two [Member] Marketable Equity Securities [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Contingent Consideration Liabilities [Member] Income Statement Location [Axis] Laboratory Developed Test Services [Member] Revenue Benchmark [Member] Product Concentration Risk [Member] Product and Service [Axis] Pharma Services Company A [Member] Pharma Services Company B [Member] Pharma Services Company C [Member] Pharma Services Company D [Member] Geographical [Axis] UNITED STATES Outside United States Pharma Services [Member] United States Laboratory Developed Test Services [Member] Antidilutive Securities [Axis] Equity Option [Member] Restricted Stock Units (RSUs) [Member] Warrant [Member] Business Acquisition [Axis] Insight Merger [Member] Chronix Merger [Member] Milestone 1 [Member] Milestone 2 [Member] Milestone 3 [Member] Royalty 1 [Member] Royalty 2 [Member] Valuation Approach and Technique [Axis] Valuation Technique, Discounted Cash Flow [Member] Merger Agreement [Member] Chronix Biomedical Inc [Member] Chronix Equity [Member] Chronix Milestone [Member] Chronix [Member] MPEEM Valuation Approach [Member] DetermaIO [Member] DetermaCNI and VitaGraft [Member] Finite-Lived Intangible Assets by Major Class [Axis] Customer Relationships [Member] Amended Loan Agreement [Member] Vesting [Axis] Share-Based Payment Arrangement, Tranche One [Member] Share-Based Payment Arrangement, Tranche Two [Member] Loan Deferral Agreement [Member] Bank Warrant [Member] Class of Warrant or Right [Axis] Office Lease Agreement [Member] Scenario [Axis] Monthly Rent [Member] First Ten Calendar [Member] Landlord [Member] Lease Agreement [Member] Laboratory Equipment [Member] Executive Officers [Member] Lease Contractual Term [Axis] Operating and Financing Leases [Member] Investors [Member] Series A Preferred Stock [Member] Oncocyte Corp [Member] Interest [Member] Security [Member] Sale of Stock [Axis] Over-Allotment Option [Member] April 2022 Warrants [Member] IPO [Member] Series B Preferred Stock [Member] Plan Name [Axis] 2010 Stock Option Plan [Member] 2018 Incentive Plan [Member] Monte Carlo Valuation Technique [Member] Performance-Based Options [Member] Award Type [Axis] Performance Shares [Member] Executive Officers And Employees [Member] Market Based Awards [Member] Vita Graft [Member] Determal O [Member] Determa CNI [Member] 2010 Plan Activity [Member] 2018 Paln Activity [Member] Employee And Non Employee [Member] Share-Based Payment Arrangement, Option [Member] Cost Of Revenues [Member] Research and Development Expense [Member] Selling and Marketing Expense [Member] Selling, General and Administrative Expenses [Member] Broadwood Capital LP [Member] Underwritten Offering [Member] Pura Vida Investments LLC [Member] Underwriters [Member] Halle Special Situations Fund LLC [Member] Broadwood Partners LP [Member] Pura Vida [Member] AVM [Member] Related Party Transaction [Axis] Arno [Member] Mr Gutfreund [Member] Life Technologies Corporation [Member] Disposal Group Classification [Axis] Discontinued Operations, Held-for-Sale [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash and cash equivalents Accounts receivable, net of allowance for credit losses of $178 and $154, respectively Marketable equity securities Prepaid expenses and other current assets Assets held for sale Current assets of discontinuing operations Total current assets NONCURRENT ASSETS Right-of-use and financing lease assets, net Machinery and equipment, net, and construction in progress Intangible assets, net Restricted cash Other noncurrent assets TOTAL ASSETS LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable Accrued compensation Accrued royalties Accrued expenses and other current liabilities Accrued severance from acquisition Accrued liabilities from acquisition Right-of-use and financing lease liabilities, current Current liabilities of discontinuing operations Total current liabilities NONCURRENT LIABILITIES Right-of-use and financing lease liabilities, noncurrent Contingent consideration liabilities TOTAL LIABILITIES Commitments and contingencies Series A Redeemable Convertible Preferred Stock, no par value; stated value $1,000 per share; 5 and 6 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively; aggregate liquidation preference of $5,217 and $6,091 as of September 30, 2023 and December 31, 2022, respectively SHAREHOLDERS’ EQUITY Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding Common stock, no par value, 230,000 shares authorized; 8,261 and 5,932 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively Accumulated other comprehensive income Accumulated deficit Total shareholders’ equity TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY Statement [Table] Statement [Line Items] Accounts receivable, allowance for credit loss Temporary equity, no par value Temporary equity, stated par value Temporary equity, shares issued Temporary equity, shares outstanding Temporary equity, liquidation preference Preferred stock, no par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, no par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Net revenue Cost of revenues Cost of revenues – amortization of acquired intangibles Gross profit Operating expenses: Research and development Sales and marketing General and administrative Change in fair value of contingent consideration Impairment losses Loss on disposal and held for sale assets Total operating expenses Loss from operations Other income (expenses): Interest income (expense), net Unrealized (loss) gain on marketable equity securities Other (expenses) income, net Total other income (expenses) Loss from continuing operations Loss from discontinuing operations Net loss Less: dividends and accretion of Series A redeemable convertible preferred stock Net loss attributable to common stockholders Net loss from continuing operations per share: basic Net loss from continuing operations per share: diluted Net loss from discontinuing operations per share: basic Net loss from discontinuing operations per share: diluted Net loss attributable to common stockholders per share: basic Net loss attributable to common stockholders per share: diluted Weighted average shares outstanding: basic Weighted average shares outstanding: diluted Net loss Foreign currency translation adjustments Comprehensive loss Balance Balance, shares Net Loss Foreign currency translation adjustment Stock-based compensation Vesting of bonus awards Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes Shares issued upon vesting of RSU, shares Shares issued for consultant services Shares issued for consultant services, shares Accretion of Series A convertible preferred stock to redemption value Sale of common shares, net of financing costs Sale of common shares, net of financing costs, shares Deemed dividend on Series A redeemable convertible preferred stock Redemption of Series A redeemable convertible preferred stock Redemption of SeriesA redeemable convertible preferred stock, shares Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares Issuance of Series A redeemable convertible preferred stock, net of financing costs Issuance of Series A redeemable convertible preferred stock, net of financing costs, shares Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization expense Amortization of intangible assets Stock-based compensation Equity compensation for bonus awards and consulting services Unrealized (gain) loss on marketable equity securities Amortization of debt issuance costs Change in fair value of Series A redeemable convertible preferred stock second tranche obligation Loss on disposal of discontinued operations Loss on disposal and held for sale assets Changes in operating assets and liabilities: Accounts receivable Prepaid expenses and other assets Accounts payable and accrued liabilities Accrued severance and liabilities from Chronix Biomedical acquisition Lease assets and liabilities Assets held for sale Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Proceeds from sale of equipment Construction in progress and purchases of furniture and equipment Cash sold in discontinued operations (Note 13) Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from sale of common shares Financing costs to issue common shares Proceeds from sale of redeemable convertible Series A preferred shares Redemption of redeemable convertible Series A preferred shares Financing costs to issue redeemable convertible Series A preferred shares Proceeds from sale of common shares under at-the-market transactions Financing costs for at-the-market sales Repayment of loan payable Repayment of financing lease obligations Net cash provided by financing activities NET CHANGE IN CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH, BEGINNING CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH, ENDING SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash paid for interest SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES Construction in progress, machinery and equipment purchases included in accounts payable and accrued liabilities Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Description of the Business and Liquidity Accounting Policies [Abstract] Summary of Significant Accounting Policies Business Combination and Asset Acquisition [Abstract] Business Combinations Property, Plant and Equipment [Abstract] Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets, Net Debt Disclosure [Abstract] Loan Payable to Silicon Valley Bank Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Equity [Abstract] Shareholders’ Equity Share-Based Payment Arrangement [Abstract] Stock-Based Compensation Income Tax Disclosure [Abstract] Income Taxes Related Party Transactions [Abstract] Related Party Transactions Co-development Agreement With Life Technologies Corporation Co-Development Agreement with Life Technologies Corporation Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations of Razor Accounting Principles Reclassifications Basis of Presentation Principles of Consolidation Use of Estimates Segments Fair Value Measurements, Business Combinations and Contingent Consideration Liabilities Cash, Cash Equivalents and Restricted Cash Marketable Equity Securities Investments in Capital Stock of Privately Held Companies Assets Held for Sale Machinery and Equipment, Net, and Construction in Progress Goodwill and Intangible Assets Long-Lived Intangible Assets Impairment of Long-Lived Assets Leases Revenue Recognition Cost of Revenues Research and Development Expenses Sales and Marketing Expenses General and Administrative Expenses Stock-Based Compensation Accounting for Warrants Net Loss Per Common Share Recent Accounting Pronouncements Schedule of Fair Value Measurement of Financial Assets and Liabilities Schedule of Disaggregation Of Revenue Schedule of Concentration Of Risk Schedule of Consolidated Revenues Generated by Unaffiliated Customers Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Schedule of Fair Value of Contingent Consideration Liability Schedule of Contingent Consideration, Measured at Fair Value Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress Schedule of Goodwill and Intangible Assets Schedule of Intangible Assets Future Amortization Expense Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases Schedule of Future Minimum Lease Commitments for Operating and Financing Leases Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Summary of Stock Option Activity Schedule of Assumptions Used to Calculate Fair Value of Stock Options Summary of Stock-based Compensation Expense Disposal Groups, Including Discontinued Operations [Table] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Schedule of Assets and Liabilities Discontinued Operations Equity interest Accumulated deficit Marketable equity securities fair value Gross proceeds from offering Fair value of common stock sold Sale of stock, price per share Conversion price Purchase of warrant Severance cost Shares issued price per share Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Assets, Fair Value Disclosure Liabilities, Fair Value Disclosure Total Schedule of Product Information [Table] Product Information [Line Items] Total Pharma services - Company D Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net loss attributable to Oncocyte Corporation Accretion of Series A redeemable convertible preferred stock Deemed dividend on Series A redeemable convertible preferred stock Net loss attributable to common stockholders - Basic Net loss attributable to common stockholders - diluted Weighted average number of shares outstanding, basic Weighted average number of shares outstanding, diluted Basic net loss per common share Earnings Per Share, diluted Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Reverse stock split Common stock, shares held as available for sale securities Fair value of equity securities Inventory write down Asset impairment charges Estimated useful life of plant and equipment Lease term Long-lived intangible assets, useful life Accounts receivable Accounts receivable Concentration risk percentage Contractual Value Fair Value on the Merger Date Beginning balance Change in estimated fair value Ending balance Fair value Unobservable Measurement Input, Uncertainty, Description Business combination consideration transferred Earnout percentage on collections for sales Earnout percentage on collections for sale or license Gross proceeds percentage Royalty payments Net deferred tax liabilities Goodwill Right-of-use assets Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Machinery and equipment Accumulated depreciation and amortization Right-of-use assets and machinery and equipment, net Construction in progress Right-of-use and financing lease assets, machinery and equipment, net, and construction in progress Depreciation expense Asset impairment charges Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Intangible assets acquired IPR&D Acquired intangible assets Total intangible assets Finite-lived intangible assets, accumulated amortization 2023 2024 2025 Total Schedule of Credit Derivatives [Table] Credit Derivatives [Line Items] Impairment of intangible Intangible asset amortization expense Line of credit, current Repayments of lines of credit Debt instrument, final payment Additional paid in capital Line of credit facility, maximum borrowing capacity Interest rate Debt instrument maturity date description Warrants to purchase, shares Warrant exercise price, per share Percentage for warrant exercise price per share Diluted equity outstanding Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Right-of-use assets, net Right-of-use lease liabilities, current Right-of-use lease liabilities, noncurrent Total operating lease liabilities Machinery and equipment Accumulated depreciation Machinery and equipment, net Current liabilities Noncurrent liabilities Total financing lease liabilities Weighted average remaining lease term, Operating lease Weighted average remaining lease term, Financing lease Operating lease Financing lease Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] 2023 2024 2025 2026 2027 Total minimum lease payments Less amounts representing interest Present value of net minimum lease payments Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] 2023 2024 2025 2025 2026 Total minimum lease payments Less amounts representing interest Operating cash flows from operating leases Operating cash flows from financing leases Financing cash flows from financing leases Area of Land Payments for rent Interest rate on lease agreement Obligated to pay expenses and taxes percentage Total tenant improvement allowance Percentage of administrative fee paid on original cost of equipment Security Deposit Line of Credit, Current Restricted cash lessee, operating sublease, residual value guarantee, description Payment obligation amount. Severance Costs Schedule of Stock by Class [Table] Class of Stock [Line Items] Convertible preferred shares Preferred stock offering Stated value per share Gross proceeds, closing Proceeds from issuance of common stock Conversion of stock, description Equity method investment, description of principal activities Conversion price percentage Preferred stock outstanding percentage Cash in hand Indebtedness expenses Dividends rate Ownership percentage Number of stock redeem, shares Net proceeds to immediately redeem Preferred stock, dividend rate, percentage Dividends, preferred stock Temporary equity, shares oustanding Common stock no par value Number of common stock purchase warrants Warrant exercise price per share Net proceeds Shares available for grant options, beginning of period Number of options outstanding, beginning of period Weighted average exercise price, options outstanding, beginning of period Shares available for grant options exercised Number of options outstanding, option exercised Weighted average exercise price, options exercised Shares available for grant options forfeited, cancelled and expired Number of options outstanding, options forfeited/expired Weighted average exercise price, options forfeited/expired Shares available for grant outstanding, end of period Number of options outstanding, end of period Weighted average exercise price, outstanding end of period Number of options outstanding, exercisable, end of period Weighted average exercise price, exercisable, end of period Number of RSUs Outstanding, beginning of period Shares available for grant options RSUs vested Number of options outstanding, option RSUs vested Number of RSUs Outstanding, option RSUs vested Weighted average exercise price, options exercised Shares available for grant options RSUs granted Number of options outstanding, option RSUs granted Number of RSUs Outstanding, option RSUs granted Weighted average exercise price, option RSUs granted Shares available for grant options granted Number of options outstanding, option granted Number of RSUs Outstanding, option granted Weighted average exercise price, option granted Shares available for grant options forfeited/expired Number of RSUs Outstanding, options forfeited/expired Shares available for grant RSUs forfeited/expired Number of options outstanding, RSUs forfeited/expired Number of RSUs Outstanding, RSUs forfeited/expired Weighted average exercise price, RSUs forfeited/expired Shares available for grant performance RSUs forfeited/expired Number of options outstanding, performance RSUs forfeited/expired Number of Performance RSUs Outstanding, performance RSUs forfeited/expired Weighted average exercise price, performance RSUs forfeited/expired Number of RSUs Outstanding, end of period Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Grants shares Expected life (in years) Risk-free interest rates Volatility Dividend yield Total Number of shares authorized Number of shares available for grant Expected Volatility Grant date fair value Share based awards vesting Vested percentage Share based payment award description Increase in fair value Share based payment award vesting rights description Stock option grant Fair value grants Number of restricted stock awards, shares Number of restricted stock awards, value Legal fees Sale of stock, shares Warrant exercise price Issuance of shares Related party transaction, description Total compensation paid Development costs Net revenue Cost of revenues Research and development Sales and marketing General and administrative Loss from impairment of held for sale assets Net loss from discontinued operations CURRENT ASSETS Cash and cash equivalents Prepaid expenses and other current assets Machinery and equipment, net, and construction in progress Intangible assets, net Impairment of held for sale assets Accounts payable Accrued compensation Accrued expenses and other current liabilities Total current liabilities CASH FLOWS FROM OPERATING ACTIVITIES: Net cash used in operating activities Net cash used in investing activities Number of shares issued Equity method investment ownership percentage Cash received on stock transaction Consideration transferred Loss on disposal Machinery and equipment net and construction in progress. Accrued severance from acquisition current. Right-of-use and financing lease liabilities, current. Right-of-use and financing lease liabilities, noncurrent. Temporary equity no par value. Series A Redeemable Convertible Preferred Stock [Member] Cost of revenues – amortization of acquired intangibles. Dividends and Accretion of Series A Redeemable Convertible Preferred Stock. Stock issued during period value vesting of bonus awards. Accretion of Series A convertible preferred stock to redemption value. Deemed dividend on Series A redeemable convertible preferred stock. Change in fair value of Series A redeemable convertible preferred stock second tranche obligation. Accrued Severance And Liabilities From Chronix Biomedical Acquisition. Equity compensation for bonus awards and consulting services. Cash sold in discontinued operations. Change in fair value of Series A redeemable convertible preferred stock second tranche obligation. Proceeds from sale of common shares under At the market transactions. Payment For Financing Costs For Atthemarket Sales. Repayment Of Financing Lease Obligations. Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability. Razor Genomics, Inc. [Member] Razor Stock Purchase Agreement [Member] Dragon Scientific LLC [Member] Razor [Member] Dragon [Member] At The Market Sales Agreement [Member] BTIG, LLC [Member] Securities Purchase Agreement [Member] Underwriting Agreement [Member] Underwriter [Member] Registered Direct Offering [Member] Board Members [Member] Reclassifications [Policy Text Block] Business Combinations and Fair Value Measurements [Policy Text Block] Segments [Policy Text Block] Marketable Equity Securities [Member] Contingent Consideration Liabilities [Member] Accounting Principles [Policy Text Block] Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury) held by the entity as available for sale securities. Lineage and AgeX [Member] Pharma Services [Member] Laboratory Developed Test Services [Member] Medicare And Medicare Advantage [Member] Sales and Marketing Expenses [Policy Text Block] Accounting For Warrants [Policy Text Block] Deemed dividend on preferred stock. Business Combination, Contingent Consideration, Liability Contractual value. Milestone 1 [Member] Milestone 2 [Member] Milestone 3 [Member] Royalty 1 [Member] Royalty 2 [Member] Fair value of contingent consideration. Schedule of contingent consideration measured at fair value [Table Text Block] Insight Merger [Member] Change in estimated fair value. Pharma Services Company A [Member] Pharma Services Company B [Member] Pharma Services Company C [Member] Pharma Services Company D [Member] United States Laboratory Developed Test Services [Member] Merger Agreement [Member] Chronix Biomedical Inc [Member] Earnout percentage on collections for sales. Earnout percentage on collections for sale or license. Chronix Equity [Member] Earnout percentage on collections for sale. Royalty payments percentage. Chronix Milestone [Member] Chronix [Member] Chronix Merger [Member] Right of use assets machinery and equipment continuing operations. DetermaI O [Member] DetermaCNI and VitaGraft [Member] Amended Loan Agreement [Member] Loan Deferral Agreement [Member] Bank Warrant [Member] Percentage for warrant exercise price per share. Diluted equity outstanding. Office Lease Agreement [Member] Refers to annual interest rate on capital lease agreement. Monthly Rent [Member] First Ten Calendar [Member] Obligated to pay expenses and taxes percentage. Percentage of administrative fee paid on original cost of equipment. Landlord [Member] Lease Agreement [Member] Payment obligation amount. Laboratory Equipment [Member] Schedule of operating and finance lease cashflow [Table Text Block] Schedule of operating and finance lease balance sheet [TableTextBlock] Operating and Financing Leases [Member] Schedule of future minimum lease commitments for operating and financing leases [Table Text Block] Present value of net minimum lease payments. Executive Officers [Member] Investors [Member] Oncocyte Corp [Member] Conversion price percentage. Preferred stock remains outstanding percentage. Indebtedness expenses. Dividends rate per percentage. Interest [Member] Security [Member] April 2022 Warrants [Member] Other Investors [Member] 2010 Stock Option Plan [Member] 2018 Incentive Plan [Member] Monte Carlo Valuation Technique [Member] Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value. Performance-Based Options [Member] Executive Officers And Employees [Member] Market Based Awards [Member] Vita Graft [Member] Determal O [Member] Determa CNI [Member] 2010 Plan Activity [Member] MPEEM Valuation Approach [Member] 2018 Paln Activity [Member] Share based compensation arrangement by share based payment award options available restricted stock options vested in period. Share based compensation arrangement by share based payment award options available restricted stock options grants in period gross. Share Based Compensation Arrangement By Share based Payment Award Options Available Grants In Period Gross. Stock issued during period shares stock options nonvested options forfeited. Sharebased compensation arrangement by sharebased payment award options nonvested restricted stock options forfeited number of shares. Share based compensation arrangement by share based payment award options nonvested performance restricted stock options forfeited number of shares. Share Based CompensationArrangement By Share Based Payment Award Restricted Stock Options Vested In Period Number of Options Outstanding, Option RSUs Granted. Sharebased compensation arrangement by sharebased payment award restricted stock units options forfeitures in period. Share based compensation arrangement by share based payment award performance restricted stock units options forfeitures in period. Number of RSUs Outstanding, option RSUs vested. Number of RSUs Outstanding, option RSUs granted. Share based compensation arrangement by share based payment award equity instruments other than options restricted stock options forfeited. Share based compensation arrangement by share based payment award equity instruments other than options performance restricted stock options forfeited. Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Vesting Price. Share based compensation arrangements by share based payment award restricted stock grants in period weighted average exercise price. Sharebased compensation arrangements by sharebased payment award restricted stock units options forfeitures in period weighted average exercise price. Share based compensation arrangements by share based payment award performance restricted stock units options forfeitures in period weighted average exercise price. Disaggregation Of Consolidated Revenue [Table Text Block] Outside United States Pharma Services [Member] Broadwood Capital LP [Member] Underwritten Offering [Member] Pura Vida Investments LLC [Member] Underwriters [Member] Halle Special Situations Fund LLC [Member] Broadwood Partners LP [Member] Pura Vida [Member] AVM [Member] Arno [Member] Mr Gutfreund [Member] Co development agreementwith life technologies corporation [TextBlock] Life Technologies Corporation [Member] Disposal group including discontinued operation research and development. Disposal group including discontinued operation sales and marketing. Disposal group including discontinued operation machinery and equipment. Disposal group including discontinued operation impairment of held for sale assets. Disposal group including discontinued operation accrued compensation. Disposal group including discontinued operation accrued expenses other current liabilities. Cash sold in discontinued operations. Employee And Non Employee [Member] Assets, Current Assets Liabilities Equity, Attributable to Parent Liabilities and Equity Gross Profit Gain (Loss) on Disposition of Other Assets Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Share-Based Payment Arrangement, Noncash Expense Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Gain (Loss) on Disposition of Assets Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Asset, Held-for-Sale Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Payments of Stock Issuance Costs Payments for Repurchase of Redeemable Convertible Preferred Stock FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares PaymentForFinancingCostsForAtthemarketSales Repayments of Debt RepaymentOfFinancingLeaseObligations Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Compensation Related Costs, Policy [Policy Text Block] Redeemable Preferred Stock Dividends DeemedDividendOnPreferredStock Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, Plant and Equipment, Net RightofuseAssetsMachineryAndEquipmentContinuingOperations Impairment of Leasehold Finite-Lived Intangible Assets, Net Operating Lease, Liability Finance Lease, Right-of-Use Asset, before Accumulated Amortization Finance Lease, Right-of-Use Asset, Accumulated Amortization Finance Lease, Liability Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Present value of net minimum lease payments Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Finance Lease, Liability, to be Paid, Year One Finance Lease, Liability, to be Paid, Year Two Finance Lease, Liability, to be Paid, Year Three Finance Lease, Liability, to be Paid, Year Four Finance Lease, Liability, to be Paid Finance Lease, Liability, Undiscounted Excess Amount Restricted Cash Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited Disposal Group, Including Discontinued Operation, Revenue Disposal Group, Including Discontinued Operation, Costs of Goods Sold DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing Disposal Group, Including Discontinued Operation, General and Administrative Expense Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment Disposal Group, Including Discontinued Operation, Intangible Assets, Current Disposal Group, Including Discontinued Operation, Accounts Payable, Current DisposalGroupIncludingDiscontinuedOperationAccruedCompensation DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities Equity Method Investment, Realized Gain (Loss) on Disposal EX-101.PRE 10 ocx-20230930_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
9 Months Ended
Sep. 30, 2023
Nov. 02, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2023  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --12-31  
Entity File Number 1-37648  
Entity Registrant Name Oncocyte Corporation  
Entity Central Index Key 0001642380  
Entity Tax Identification Number 27-1041563  
Entity Incorporation, State or Country Code CA  
Entity Address, Address Line One 15 Cushing  
Entity Address, City or Town Irvine  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92618  
City Area Code (949)  
Local Phone Number 409-7600  
Title of 12(b) Security Common Stock, no par value  
Trading Symbol OCX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   8,260,762
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
CURRENT ASSETS    
Cash and cash equivalents $ 13,783,000 $ 19,993,000
Accounts receivable, net of allowance for credit losses of $178 and $154, respectively 1,882,000 2,012,000
Marketable equity securities 441,000 433,000
Prepaid expenses and other current assets 672,000 977,000
Assets held for sale 139,000
Current assets of discontinuing operations 2,121,000
Total current assets 16,917,000 25,536,000
NONCURRENT ASSETS    
Right-of-use and financing lease assets, net 1,757,000 2,088,000
Machinery and equipment, net, and construction in progress 4,076,000 8,763,000
Intangible assets, net 56,617,000 61,633,000
Restricted cash 1,700,000 1,700,000
Other noncurrent assets 520,000 371,000
TOTAL ASSETS 81,587,000 100,091,000
CURRENT LIABILITIES    
Accounts payable 1,136,000 1,253,000
Accrued compensation 1,722,000 1,771,000
Accrued royalties 1,116,000 2,022,000
Accrued expenses and other current liabilities 826,000 1,817,000
Accrued severance from acquisition 2,314,000 2,314,000
Accrued liabilities from acquisition 109,000 109,000
Right-of-use and financing lease liabilities, current 720,000 815,000
Current liabilities of discontinuing operations 90,000 2,005,000
Total current liabilities 8,033,000 12,106,000
NONCURRENT LIABILITIES    
Right-of-use and financing lease liabilities, noncurrent 2,354,000 2,729,000
Contingent consideration liabilities 28,715,000 45,662,000
TOTAL LIABILITIES 39,102,000 60,497,000
Commitments and contingencies
Series A Redeemable Convertible Preferred Stock, no par value; stated value $1,000 per share; 5 and 6 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively; aggregate liquidation preference of $5,217 and $6,091 as of September 30, 2023 and December 31, 2022, respectively 4,923,000 5,302,000
SHAREHOLDERS’ EQUITY    
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding
Common stock, no par value, 230,000 shares authorized; 8,261 and 5,932 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively 309,995,000 294,929,000
Accumulated other comprehensive income 32,000 39,000
Accumulated deficit (272,465,000) (260,676,000)
Total shareholders’ equity 37,562,000 34,292,000
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 81,587,000 $ 100,091,000
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Accounts receivable, allowance for credit loss $ 178,000 $ 154,000
Preferred stock, no par value $ 0 $ 0
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, no par value $ 0 $ 0
Common stock, shares authorized 230,000,000 230,000,000
Common stock, shares issued 8,260,762 5,932,191
Common stock, shares outstanding 8,260,762 5,932,191
Series A Redeemable Convertible Preferred Stock [Member]    
Temporary equity, no par value $ 0 $ 0
Temporary equity, stated par value $ 1,000,000 $ 1,000,000
Temporary equity, shares issued 5,000 6,000
Temporary equity, shares outstanding 5,000 6,000
Temporary equity, liquidation preference $ 5,217,000 $ 6,091,000
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Net revenue $ 429 $ 67 $ 1,189 $ 684
Cost of revenues 159 314 593 602
Cost of revenues – amortization of acquired intangibles 22 22 66 73
Gross profit 248 (269) 530 9
Operating expenses:        
Research and development 2,185 1,472 6,747 5,923
Sales and marketing 713 405 2,213 798
General and administrative 2,487 5,702 9,430 16,794
Change in fair value of contingent consideration (435) (6,142) (16,947) (17,157)
Impairment losses 1,811 6,761
Loss on disposal and held for sale assets 1,283
Total operating expenses 6,761 1,437 9,487 6,358
Loss from operations (6,513) (1,706) (8,957) (6,349)
Other income (expenses):        
Interest income (expense), net 117 (14) 108 (65)
Unrealized (loss) gain on marketable equity securities (89) (160) 8 (485)
Other (expenses) income, net (4) 62 (22) 304
Total other income (expenses) 24 (112) 94 (246)
Loss from continuing operations (6,489) (1,818) (8,863) (6,595)
Loss from discontinuing operations (7,515) (2,926) (21,329)
Net loss (6,489) (9,333) (11,789) (27,924)
Less: dividends and accretion of Series A redeemable convertible preferred stock (198) (294) (739) (294)
Net loss attributable to common stockholders $ (6,687) $ (9,627) $ (12,528) $ (28,218)
Net loss from continuing operations per share: basic $ (0.79) $ (0.31) $ (1.19) $ (1.22)
Net loss from continuing operations per share: diluted (0.79) (0.31) (1.19) (1.22)
Net loss from discontinuing operations per share: basic (1.27) (0.39) (3.94)
Net loss from discontinuing operations per share: diluted (1.27) (0.39) (3.94)
Net loss attributable to common stockholders per share: basic (0.81) (1.62) (1.68) (5.22)
Net loss attributable to common stockholders per share: diluted $ (0.81) $ (1.62) $ (1.68) $ (5.22)
Weighted average shares outstanding: basic 8,256 5,931 7,446 5,408
Weighted average shares outstanding: diluted 8,256 5,931 7,446 5,408
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Net loss $ (6,489) $ (9,333) $ (11,789) $ (27,924)
Foreign currency translation adjustments (9) (12) (7) (18)
Comprehensive loss $ (6,498) $ (9,345) $ (11,796) $ (27,942)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Preferred Stock [Member]
Series A Redeemable Convertible Preferred Stock [Member]
Common Stock [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2021 $ 252,954 $ 37 $ (187,774) $ 65,217
Balance, shares at Dec. 31, 2021 4,612      
Net Loss (27,924) (27,924)
Foreign currency translation adjustment (18) (18)
Stock-based compensation 7,423 7,423
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes
Shares issued upon vesting of RSU, shares   5      
Accretion of Series A convertible preferred stock to redemption value 294 $ (294) (294)
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts $ 32,453 32,453
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares   1,314      
Issuance of Series A redeemable convertible preferred stock, net of financing costs $ 4,782
Issuance of Series A redeemable convertible preferred stock, net of financing costs, shares 6        
Balance at Sep. 30, 2022 $ 5,076 $ 292,536 19 (215,698) 76,857
Balance, shares at Sep. 30, 2022 6 5,931      
Balance at Jun. 30, 2022 $ 4,854 $ 289,649 31 (206,437) 83,243
Balance, shares at Jun. 30, 2022 6 5,930      
Net Loss (9,333) (9,333)
Foreign currency translation adjustment (12) (12)
Stock-based compensation 3,181 3,181
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes
Shares issued upon vesting of RSU, shares   1      
Accretion of Series A convertible preferred stock to redemption value 222 $ (294) 72 (222)
Balance at Sep. 30, 2022 $ 5,076 $ 292,536 19 (215,698) 76,857
Balance, shares at Sep. 30, 2022 6 5,931      
Balance at Dec. 31, 2022 $ 5,302 $ 294,929 39 (260,676) 34,292
Balance, shares at Dec. 31, 2022 6 5,932      
Net Loss (11,789) (11,789)
Foreign currency translation adjustment (7) (7)
Stock-based compensation 2,276 2,276
Vesting of bonus awards 72 72
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes
Shares issued upon vesting of RSU, shares   45      
Shares issued for consultant services $ 36 36
Shares issued for consultant services, shares   9      
Accretion of Series A convertible preferred stock to redemption value 621 $ (621) (621)
Sale of common shares, net of financing costs $ 13,421 13,421
Sale of common shares, net of financing costs, shares   2,275      
Deemed dividend on Series A redeemable convertible preferred stock $ (118) (118)
Redemption of Series A redeemable convertible preferred stock $ (1,000)
Redemption of SeriesA redeemable convertible preferred stock, shares (1)        
Balance at Sep. 30, 2023 $ 4,923 $ 309,995 32 (272,465) 37,562
Balance, shares at Sep. 30, 2023 5 8,261      
Balance at Jun. 30, 2023 $ 4,725 $ 309,535 41 (265,976) 43,600
Balance, shares at Jun. 30, 2023 5 8,250      
Net Loss (6,489) (6,489)
Foreign currency translation adjustment (9) (9)
Stock-based compensation 608 608
Vesting of bonus awards 14 14
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes
Shares issued upon vesting of RSU, shares   2      
Shares issued for consultant services $ 36 36
Shares issued for consultant services, shares   9      
Accretion of Series A convertible preferred stock to redemption value 198 $ (198) (198)
Balance at Sep. 30, 2023 $ 4,923 $ 309,995 $ 32 $ (272,465) $ 37,562
Balance, shares at Sep. 30, 2023 5 8,261      
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (11,789,000) $ (27,924,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization expense 1,289,000 1,062,000
Amortization of intangible assets 66,000 2,880,000
Stock-based compensation 2,276,000 7,423,000
Equity compensation for bonus awards and consulting services 108,000
Unrealized (gain) loss on marketable equity securities (8,000) 485,000
Amortization of debt issuance costs 12,000
Change in fair value of contingent consideration (16,947,000) (17,157,000)
Change in fair value of Series A redeemable convertible preferred stock second tranche obligation (352,000)
Impairment losses 6,761,000
Loss on disposal of discontinued operations 1,659,000
Loss on disposal and held for sale assets 1,283,000
Changes in operating assets and liabilities:    
Accounts receivable 130,000 (553,000)
Prepaid expenses and other assets 784,000 (745,000)
Accounts payable and accrued liabilities (4,193,000) 422,000
Accrued severance and liabilities from Chronix Biomedical acquisition (1,317,000)
Lease assets and liabilities (43,000) (156,000)
Assets held for sale (139,000)
Net cash used in operating activities (18,763,000) (35,920,000)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Proceeds from sale of equipment 354,000
Construction in progress and purchases of furniture and equipment (17,000) (3,538,000)
Cash sold in discontinued operations (Note 13) (1,510,000)
Net cash used in investing activities (1,173,000) (3,538,000)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from sale of common shares 13,848,000 32,812,000
Financing costs to issue common shares (427,000) (389,000)
Proceeds from sale of redeemable convertible Series A preferred shares 4,875,000
Redemption of redeemable convertible Series A preferred shares (1,118,000)
Financing costs to issue redeemable convertible Series A preferred shares (93,000)
Proceeds from sale of common shares under at-the-market transactions 31,000
Financing costs for at-the-market sales (1,000)
Repayment of loan payable (1,325,000)
Repayment of financing lease obligations (87,000) (4,000)
Net cash provided by financing activities 12,216,000 35,906,000
NET CHANGE IN CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH (7,720,000) (3,552,000)
CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH, BEGINNING 23,203,000 37,305,000
CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH, ENDING 15,483,000 33,753,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION    
Cash paid for interest 24,000
SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES    
Construction in progress, machinery and equipment purchases included in accounts payable and accrued liabilities $ 215,000 $ 1,032,000
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Organization, Description of the Business and Liquidity
9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization, Description of the Business and Liquidity

1. Organization, Description of the Business and Liquidity

 

Oncocyte Corporation (“Oncocyte,” the “Company,” “we” or “us”), incorporated in 2009 in the state of California, is a precision diagnostics company focused on developing and commercializing proprietary tests in three areas: VitaGraft is a blood-based solid organ transplantation monitoring test, DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients.

 

Oncocyte’s first product for commercial release was a proprietary treatment stratification test called DetermaRx that identifies which patients with early-stage non-small cell lung cancer may benefit from chemotherapy, resulting in a significantly higher, five-year survival rate. Beginning in September 2019 through February 23, 2021, Oncocyte held a 25% equity interest in Razor Genomics, Inc. (“Razor”), a privately held company, that had developed and licensed to Oncocyte the lung cancer treatment stratification laboratory test that Oncocyte was commercializing as DetermaRx. On February 24, 2021, Oncocyte completed the purchase of all the remaining issued and outstanding shares of common stock of Razor. As a result of the purchase of the Razor common stock, Oncocyte became the sole shareholder of Razor.

 

On December 15, 2022, the Company, entered into a Stock Purchase Agreement (the “Razor Stock Purchase Agreement”) with Dragon Scientific, LLC, a Delaware limited liability company (“Dragon”) and Razor. Pursuant to the Razor Stock Purchase Agreement, Oncocyte agreed to sell to Dragon, 3,188,181 shares of common stock of Razor, which constitutes approximately 70% of the issued and outstanding equity interests of Razor on a fully-diluted basis, and transfer to Razor all of the assets and liabilities related to DetermaRx (the “Razor Sale Transaction”).

 

Certain amounts in prior periods have been reclassified to reflect the impact of the discontinued operations treatment of Razor in order to conform to the current period presentation. As a result of the divestiture of Razor, the Company has retrospectively revised the consolidated statements of operations for the periods ended September 30, 2022, to reflect the operations and cash flows of Razor as discontinued operations and the related assets and liabilities disposed. See Note 13 for additional information.

 

On February 16, 2023, Oncocyte completed the Razor Sale Transaction (the “Razor Closing”). In connection with the Razor Closing, Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx. While no monetary consideration was received for the sale of 70% of the equity interests of Razor, the transaction allowed the Company to eliminate all development and commercialization costs with respect to DetermaRx. Following the Razor Closing, Oncocyte continues to own 1,366,364 shares of common stock of Razor, which constitutes approximately 30% of the issued and outstanding equity interests of Razor on a fully-diluted basis.

 

Liquidity and Going Concern

 

Oncocyte has incurred operating losses and negative cash flows since inception and had an accumulated deficit of $272.5 million as of September 30, 2023. Oncocyte expects to continue to incur operating losses and negative cash flows for the foreseeable future. Since its formation, Oncocyte has financed its operations primarily through the sale of shares of its common stock, convertible preferred stock and warrants to acquire common stock.

 

As of September 30, 2023, Oncocyte had $13.8 million of cash and cash equivalents. In addition, Oncocyte held shares of Lineage Cell Therapeutics, Inc. (“Lineage”) and AgeX Therapeutics, Inc. (“AgeX”) common stock as marketable equity securities with a combined fair market value of $441,000.

 

On June 11, 2021, Oncocyte entered into an at-the-market sales agreement with BTIG, LLC as sales agent and/or principal (the “Agent” or “BTIG”) pursuant to which Oncocyte may sell up to an aggregate of $50,000,000 of shares of Oncocyte common stock from time to time through the Agent (the “ATM Offering”).

 

 

Between July 1, 2021 and September 30, 2023, Oncocyte sold 56,167 shares of common stock at an average offering price of $111.60 per share, for gross proceeds of approximately $6.27 million through the ATM Offering. The most recent sale of common stock through the ATM Offering took place in January 2022. Oncocyte will need to raise additional capital to finance its operations, including the development and commercialization of its cancer diagnostic and other tests, until such time as it is able to generate sufficient revenues from the commercialization of one or more of its laboratory tests and other tests, and performing Pharma Services to cover its operating expenses.

 

On April 13, 2022, Oncocyte entered into a securities purchase agreement (the “Securities Purchase Agreement”) with institutional accredited investors (the “Investors”), including Broadwood Partners, L.P. (“Broadwood”), Oncocyte’s largest shareholder, in a registered direct offering of 11,765 shares of Series A Convertible Preferred Stock (the “Series A Preferred Stock”), which are convertible into a total of 384,477 shares of common stock, at a conversion price of $30.60 (the “Series A Preferred Stock Offering”).

 

Further, on April 13, 2022, Oncocyte entered into an underwriting agreement (the “Underwriting Agreement”) with BTIG, LLC, as representative of the underwriters named therein (the “Underwriters”), pursuant to which Oncocyte issued and sold to the Underwriters an aggregate of 1,313,320 shares of common stock, and 1,313,320 warrants to purchase up to 656,660 shares of common stock (“April 2022 Warrants”) (the “Underwritten Offering”). See Notes 8 and 11 for additional information about the Series A Preferred Stock Offering and Underwritten Offering.

 

In August 2022, the Company initiated a workforce reduction plan to strategically realign its operations and implement cost reduction programs to prioritize near term revenue generators and to manage and preserve cash. In connection with the reduction, the Company eliminated 14 positions, implemented tighter expense controls, and ceased non-core activities. Further, on December 16, 2022, Oncocyte initiated an additional reduction in work force involving over 40% of its full-time employees. The transition began on December 16, 2022 and was completed in February 2023. As of December 31, 2022, the Company incurred an aggregate of $1.9 million related to employee severance and benefits costs in connection with its reductions in force during fiscal year 2022.

 

On April 3, 2023, Oncocyte entered into an agreement with certain members of the Company’s board of directors, and several institutional and accredited investors, including Broadwood, the Company’s largest shareholder, relating to their purchase of an aggregate of up to 2,278,121 shares of its common stock at an offering price of $7.08 per share to board members and $6.03 per share to the other investors participating in the offering (the “April 2023 Offering”). See Notes 8 and 11 for additional information about the April 2023 Offering.

 

On April 12, 2023, Oncocyte announced a reduction in force involving approximately 20% of its workforce (the “April 2023 Reduction”), which management believes will extend Oncocyte’s cash runway into 2024. In connection with the April 2023 Reduction, we incurred approximately $300,000 related to employee severance and benefits costs during the second quarter of 2023.

 

As of September 30, 2023, Oncocyte is completing clinical development and planning commercialization of DetermaIO, although DetermaIO is currently available for biopharma diagnostic development and research use only as a companion test in immunotherapy drug development to select patients for clinical trials; and the clinical launch of VitaGraft. While Oncocyte plans to primarily market its laboratory tests in the United States through its own sales force, it is also beginning to make marketing arrangements with distributors in other countries. In order to reduce capital needs and to expedite the commercialization of any new laboratory tests that may become available for clinical use, Oncocyte may also pursue marketing arrangements with other diagnostic companies through which Oncocyte might receive licensing fees and royalty on sales, or through which it might form a joint venture to market its tests and share in net revenues, in the United States or abroad.

 

In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, we evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements included in this Report are issued. This evaluation initially does not take into consideration the potential mitigating effect of our plans that have not been fully implemented as of the date the consolidated financial statements included in this Report are issued. When substantial doubt exists under this methodology, we evaluate whether the mitigating effect of our plans sufficiently alleviates substantial doubt about our ability to continue as a going concern. The mitigating effect of our plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that such financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about our ability to continue as a going concern within one year after the date that such financial statements are issued. In performing this analysis, we excluded certain elements of our operating plan that cannot be considered probable.

 

 

Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that the consolidated financial statements are issued. Management intends to complete additional equity financings while maintaining reduced spending levels. However, due to several factors, including those outside management’s control, there can be no assurance that we will be able to complete additional equity financings. If we are unable to complete additional financings, management’s plans include further reducing or delaying operating expenses. We have concluded the likelihood that our plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

 

In addition to general economic and capital market trends and conditions, Oncocyte’s ability to raise sufficient additional capital to finance its operations from time to time will depend on a number of factors specific to Oncocyte’s operations such as operating revenues and expenses, progress in development of, or in obtaining reimbursement coverage from Medicare for DetermaIO and other future laboratory tests that Oncocyte may develop or acquire.

 

The unavailability or inadequacy of financing or revenues to meet future capital needs could force Oncocyte to modify, curtail, delay, or suspend some or all aspects of planned operations. Sales of additional equity securities could result in the dilution of the interests of its shareholders. Oncocyte cannot assure that adequate financing will be available on favorable terms, if at all.

 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

 

Accounting Principles

 

The consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (“GAAP”).

 

Reclassifications

 

Certain prior period amounts in the consolidated financial statements and notes to consolidated financial statements have been reclassified to conform to the current period presentation. These changes had no impact on the previously reported consolidated financial condition, results of operations or cash flows.

 

Basis of Presentation

 

The unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance with GAAP for financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations, certain information and footnote disclosures normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance sheet as of December 31, 2022 was derived from the audited consolidated financial statements at that date. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in Oncocyte’s Annual Report on Form 10-K for the year ended December 31, 2022. The accompanying unaudited condensed consolidated financial statements, in the opinion of management, include all adjustments of a normal recurring nature necessary for a fair presentation of Oncocyte’s financial condition and results of operations. The consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

 

 

On July 24, 2023, the Company implemented a 1-for-20 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230 million shares.

 

Principles of Consolidation

 

On January 31, 2020, with the acquisition of Insight Genetics, Inc. (“Insight”) through a merger with a newly incorporated wholly-owned subsidiary of Oncocyte (the “Insight Merger”) under the terms of an Agreement and Plan of Merger (the “Insight Merger Agreement”), Insight became a wholly-owned subsidiary of Oncocyte, and on that date Oncocyte began consolidating Insight’s operations and results with Oncocyte’s operations and results (see Note 3).

 

On April 15, 2021, with the acquisition of Chronix Biomedical, Inc. (“Chronix”) pursuant to an Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021 (as amended and restated, the “Chronix Merger Agreement”), by and among Oncocyte, CNI Monitor Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Oncocyte (“Merger Sub”), Chronix became a wholly-owned subsidiary of Oncocyte (the “Chronix Merger”), and on that date Oncocyte began consolidating Chronix’s operations and results with Oncocyte’s operations and results (see Note 3).

 

We have reflected the operations of Razor as discontinued operations for all periods presented. See Note 13 for further information. Amounts and disclosures throughout these Notes to consolidated financial statements relate solely to continuing operations and exclude all discontinued operations. Discontinued operations comprise activities that were disposed of or discontinued at the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting purposes and represent a strategic business shift having a major effect on the Company’s operations and financial results according to ASC Topic 205, Presentation of Financial Statements.

 

All material intercompany accounts and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and contingent assets and liabilities, at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including, but not limited to, valuation methods used, assumptions requiring the use of judgment to prepare financial projections, timing of potential commercialization of acquired in-process intangible assets, applicable discount rates, probabilities of the likelihood of multiple outcomes of certain events related to contingent consideration, comparable companies or transactions, determination of fair value of the assets acquired and liabilities assumed including those relating to contingent consideration, assumptions related to going concern assessments, allocation of direct and indirect expenses, useful lives associated with long-lived intangible assets, key assumptions in operating and financing leases including incremental borrowing rates, loss contingencies, valuation allowances related to deferred income taxes, allowances for credit losses, and assumptions used to value debt and stock-based awards and other equity instruments. Actual results may differ materially from those estimates.

 

Similarly, Oncocyte assessed certain accounting matters that generally require consideration of forecasted financial information. The accounting matters assessed included, but were not limited to, Oncocyte’s equity investments, the carrying value of goodwill, going concern assessment, acquired in-process intangible assets and other long-lived assets. Those assessments as well as other estimates referenced above were made in the context of information reasonably available to Oncocyte.

 

 

Segments

 

Oncocyte’s executive management team, as a group, represents the entity’s chief operating decision makers. To date, Oncocyte’s executive management team has viewed Oncocyte’s operations as one segment that includes the research, development and commercialization of diagnostic tests, including molecular diagnostic services to pharmaceutical customers. As a result, the financial information disclosed materially represents all of the financial information related to Oncocyte’s sole operating segment.

 

Fair Value Measurements, Business Combinations and Contingent Consideration Liabilities

 

Oncocyte accounts for business combinations in accordance with ASC 805, which requires the purchase consideration transferred to be measured at fair value on the acquisition date in accordance with ASC 820, Fair Value Measurement. ASC 820 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:

 

Level 1 – Quoted prices in active markets for identical assets and liabilities.

 

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

When a part of the purchase consideration consists of shares of Oncocyte common stock, Oncocyte calculates the purchase price attributable to those shares, a Level 1 security, by determining the fair value of those shares as of the acquisition date based on prices quoted on the principal national securities exchange on which the shares traded. Oncocyte recognizes estimated fair values of the tangible assets and identifiable intangible assets acquired, including in-process research and development, and liabilities assumed, including any contingent consideration, as of the acquisition date. Goodwill is recognized as any amount of the fair value of the tangible and identifiable intangible assets acquired and liabilities assumed in excess of the consideration transferred. ASC 805 precludes the recognition of an assembled workforce as an asset, effectively subsuming any assembled workforce value into goodwill.

 

In determining fair value, Oncocyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, Oncocyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for money market funds and marketable equity securities held by Oncocyte described below. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.

 

Certain of Oncocyte’s asset and business acquisitions involve the potential for future payment of consideration to third-parties and former selling shareholders in amounts determined as a percentage of future net revenues generated, or upon attainment of revenue milestones, from Pharma Services or laboratory tests, as applicable, or annual minimum royalties to certain licensors, as provided in the applicable agreements. The fair value of such liabilities is determined using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows. These obligations are referred to as contingent consideration, which are carried at fair value based on Level 3 inputs.

 

 

ASC 805 requires that contingent consideration be estimated and recorded at fair value as of the acquisition date as part of the total consideration transferred. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings, such as “earn-out” provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of certain revenues generated.

 

The fair value of contingent consideration after the acquisition date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in the consolidated statements of operations. Changes in key assumptions can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that Oncocyte records in its consolidated financial statements. See Note 3 for a full discussion of these liabilities and additional Level 3 fair value disclosures.

 

The following tables present the Company’s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy:

 

   As of September 30, 2023 
   Fair value   Level 1   Level 2   Level 3 
   (In thousands) 
Assets:                    
Marketable equity securities  $441   $441   $-   $- 
Total  $441   $441   $-   $- 
                     
Liabilities:                    
Contingent consideration liabilities (Note 3)  $28,715   $-   $-   $28,715 
Total  $28,715   $-   $-   $28,715 

 

   As of December 31, 2022 
   Fair value   Level 1   Level 2   Level 3 
   (In thousands) 
Assets:                    
Marketable equity securities  $433   $433   $-   $- 
Total  $433   $433   $-   $- 
                     
Liabilities:                    
Contingent consideration liabilities (Note 3)  $45,662   $-   $-   $45,662 
Total  $45,662   $-   $-   $45,662 

 

The carrying amounts of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.

 

In accordance with GAAP, from time to time, the Company measures certain assets at fair value on a nonrecurring basis. The Company reviews the carrying value of goodwill, intangibles, including in-process research and development (“IPR&D”) (see Note 5), and other long-lived assets for indications of impairment at least annually. Refer to related discussions of impairments below.

 

Cash, Cash Equivalents and Restricted Cash

 

Oncocyte considers all highly liquid securities with original maturities of three months or less when purchased to be cash equivalents. For the periods presented, Oncocyte’s cash equivalents are comprised of investments in AAA rated money market funds that invest in first-tier only securities, which primarily include domestic commercial paper and securities issued or guaranteed by the U.S. government or its agencies. Restricted cash relates to a bank letter of credit required under our office lease arrangement, refer to Note 7 for additional information.

 

 

Marketable Equity Securities

 

Oncocyte accounts for the shares of Lineage and AgeX common stock it holds as marketable equity securities in accordance with ASC 320-10-25, Investments – Debt and Equity Securities, as amended, as the shares have a readily determinable fair value quoted on the NYSE American and are held principally to meet future working capital purposes, as necessary. The securities are measured at fair value, with related gains and losses in the value of such securities recorded in the consolidated statements of operations in other income or expense, and are reported as current assets on the consolidated balance sheets based on the closing trading price of the security as of the date being presented.

 

As of September 30, 2023 and December 31, 2022, Oncocyte held 353,264 and 35,326 shares of common stock of Lineage and AgeX, respectively, as marketable equity securities, which had a combined fair market value of $441,000 and $433,000, respectively.

 

Investments in Capital Stock of Privately Held Companies

 

Oncocyte evaluates whether investments held in common stock of other companies require consolidation of the company under, first, the variable interest entity (“VIE”) model, and then under the voting interest model in accordance with accounting guidance for consolidations under ASC 810-10. If consolidation of the entity is not required under either the VIE model or the voting interest model, Oncocyte determines whether the equity method of accounting should be applied in accordance with ASC 323, Investments – Equity Method and Joint Ventures. The equity method applies to investments in common stock or in-substance common stock if Oncocyte exercises significant influence over, but does not control, the entity, where significant influence is typically represented by ownership of 20% or more, but less than majority ownership, of the voting interests of a company.

 

Oncocyte initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment balance based on Oncocyte’s pro rata share of earnings or losses from the investment.

 

From February 24, 2021, the date of Oncocyte’s acquisition of the remaining interests in Razor, through February 16, 2023 the date of its disposition, Razor entity’s financial statements were consolidated with Oncocyte. See Note 13 for additional information related to the discontinued operations of Razor.

 

Assets Held for Sale

 

Assets and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management, having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified as held for sale in the consolidated balance sheet. Assets classified as held for sale are reported at the lower of their carrying value or fair value less costs to sell. Depreciation and amortization of assets ceases upon designation as held for sale.

 

During the nine months ended September 30, 2023, the Company entered into various agreements to sell laboratory equipment. As a result, the Company classified the equipment as held for sale as current assets, in the consolidated balance sheet, as all the criteria of ASC subtopic 360-10, Property, Plant, and Equipment (“ASC 360-10”) have been met and the transactions were qualified as assets held for sale. The equipment was written down to its fair value, less cost to sell, the remainder of which was $139,000 as of September 30, 2023. As a result of these transactions, the Company recorded an impairment loss of $1.3 million on held for sale assets, in the consolidated statement of operations.

 

 

Machinery and Equipment, Net, and Construction in Progress

 

Machinery and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of 3 to 10 years. For equipment purchased under financing leases, Oncocyte depreciates the equipment based on the shorter of the useful life of the equipment or the term of the lease, ranging from 3 to 5 years, depending on the nature and classification of the financing lease. Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in Oncocyte’s results of operations.

 

Construction in progress, comprised primarily of leasehold improvements under construction, is not depreciated until the underlying asset is placed into service.

 

Goodwill and Intangible Assets

 

In accordance with ASC 350, Intangibles – Goodwill and Other, IPR&D projects acquired in a business combination that are not complete as of the acquisition date are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Oncocyte considers various factors and risks for potential impairment of IPR&D assets, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays or inability to obtain local determination coverage (“LCD”) from the Centers for Medicare and Medicaid Services (“CMS”) for Medicare reimbursement for a diagnostic test, the inability to bring a diagnostic test to market and the introduction or advancement of competitors’ diagnostic tests could result in partial or full impairment of the related intangible assets. Consequently, the eventual realized value of the IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. During the period between completion or abandonment, the IPR&D assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if Oncocyte becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts (see Note 5).

 

Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill, similar to IPR&D, is not amortized but is tested for impairment at least annually, or if circumstances indicate its value may no longer be recoverable. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors affecting Oncocyte’s business. Based on the qualitative assessment, if it is determined that the fair value of goodwill is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. Oncocyte continues to operate in one segment and considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at the enterprise level.

 

Oncocyte does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&D discussed in Notes 3 and 5. As of September 30, 2023, goodwill has been fully impaired and acquired IPR&D has been partially impaired.

 

Long-Lived Intangible Assets

 

Long-lived intangible assets, consisting primarily of acquired customer relationships, are stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful life of 5 years (see Note 5).

 

 

Impairment of Long-Lived Assets

 

Oncocyte assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. Oncocyte’s long-lived assets consist primarily of intangible assets, right-of-use assets for operating leases, customer relationships, and machinery and equipment. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. See Note 4 for additional information with respect to the impairment of leasehold improvements. See “Assets held for sale” above for additional impairment disclosures.

 

Leases

 

Oncocyte accounts for leases in accordance with ASC 842, Leases. Oncocyte determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. Under the available practical expedients for the adoption of ASC 842, Oncocyte accounts for the lease and non-lease components as a single lease component. Oncocyte recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheet. ROU assets represent the right to use an underlying asset during the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most leases do not provide an implicit rate, Oncocyte uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Oncocyte uses the implicit rate when it is readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that Oncocyte will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Operating leases include our office leases and are also included as right-of-use assets in machinery and equipment, and ROU lease liabilities, current and long-term, in the consolidated balance sheets. Financing leases are included in machinery and equipment, and in financing lease liabilities, current and long-term, in the consolidated balance sheets. Oncocyte discloses the amortization of our ROU assets and operating lease payments as a net amount in the consolidated statements of cash flows. Based on the available practical expedients under the standard, Oncocyte elected not to capitalize leases that have terms of twelve months or less.

 

During prior years, Oncocyte entered into various operating leases and an embedded operating lease in accordance with ASC 842 as discussed in Note 7. Oncocyte’s accounting for financing leases remained substantially unchanged.

 

Revenue Recognition

 

Pursuant to ASC 606, revenues are recognized when control of services performed is transferred to customers, in an amount that reflects the consideration Oncocyte expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes:

 

(i) identifying the contract with a customer,

(ii) identifying the performance obligations in the contract,

(iii) determining the transaction price,

(iv) allocating the transaction price to the performance obligations, and

(v) recognizing revenue when, or as, an entity satisfies a performance obligation.

 

Oncocyte determines transaction prices based on the amount of consideration we expect to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. The Company considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.

 

 

The following table presents consolidated revenues by service:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
   (In thousands) 
Pharma Services  $423   $67   $1,137   $684 
Laboratory developed test services   6    -    52    - 
Total  $429   $67   $1,189   $684 

 

Pharma Services Revenue

 

Revenues recognized include Pharma Services performed by Oncocyte’s Insight and Chronix subsidiaries for its pharmaceutical customers, including testing for biomarker discovery, assay design and development, clinical trial support, and a broad spectrum of biomarker tests. These Pharma Services are generally performed under individual scope of work (“SOW”) arrangements or license agreements (together with SOW the “Pharma Services Agreements”) with specific deliverables defined by the customer. Pharma Services are performed on a (i) time and materials basis or (ii) per test completed basis. Upon completion of the service to the customer in accordance with a Pharma Services Agreement, Oncocyte has the right to bill the customer for the agreed upon price (either on a per test or per deliverable basis) and recognizes Pharma Service revenue at that time. Insight identifies each sale of its Pharma Service offering as a single performance obligation. Chronix identifies the processing of test samples as a separate performance obligation (considered a series) within license agreements with customers.

 

Completion of the service and satisfaction of the performance obligation is typically evidenced by access to the report or test made available to the customer or any other form or applicable manner of delivery defined in the Pharma Services Agreements. However, for certain SOWs under which work is performed pursuant to the customer’s highly customized specifications, Oncocyte has the enforceable right to bill the customer for work completed, rather than upon completion of the SOW. For those SOWs, Oncocyte recognizes revenue over a period during which the work is performed using a formula that accounts for expended efforts, generally measured in labor hours, as a percentage of total estimated efforts for the completion of the SOW. As performance obligations are satisfied under the Pharma Services Agreements, any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed to the customer as of the date of Oncocyte’s consolidated financial statements are recorded as contract assets and are included in prepaids and other current assets as of the financial statement date. Amounts recorded in contract assets are reclassified to accounts receivable in Oncocyte’s consolidated balance sheets when the customer is invoiced according to the billing schedule in the contract.

 

As of September 30, 2023 and December 31, 2022, Oncocyte had accounts receivable from Pharma Services customers of $557,000 and $257,000, respectively.

 

Allowance for Credit Losses

 

Oncocyte establishes an allowance for credit losses based on the evaluation of the collectability of its Pharma Services accounts receivables after considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer’s ability to pay, such as a bankruptcy filing or deterioration in the customer’s operating results or financial position, reasonable and supportable forecast that affect the collectability of the reported amount, and historical experience. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. Oncocyte continuously monitors collections and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts, if any, based upon its historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are written off against the credit loss reserve accounts. As of September 30, 2023 and December 31, 2022, we had no allowance for credit losses related to Pharma Services.

 

 

Laboratory Developed Test Services

 

Prior to the Razor Sale Transaction, Oncocyte generated revenue from performing DetermaRx tests on clinical samples through orders received from physicians, hospitals, and other healthcare providers. In determining whether all the revenue recognition criteria (i) through (v) above are met with respect to DetermaRx tests, each test result is considered a single performance obligation and is generally considered complete when the test result is delivered or made available to the prescribing physician electronically, and, as such, there are no shipping or handling fees incurred by Oncocyte or billed to customers. Although Oncocyte has billed a list price for all tests ordered and completed for all payer types, Oncocyte considers constraints on the variable consideration when recognizing revenue for DetermaRx. Because DetermaRx is a novel test and there are no current reimbursement arrangements with third-party payers other than Medicare, the transaction price represents variable consideration. Application of the constraint for variable consideration is an area that requires significant judgment. For all payers other than Medicare, Oncocyte must consider the novelty of the test, the uncertainty of receiving payment, or being subject to claims for a refund, from payers with whom it does not have a sufficient payment collection history or contractual reimbursement agreements. Accordingly, for those payers, Oncocyte has recognized revenue upon payment because it has had insufficient history to reliably estimate payment patterns or has had contractual reimbursement arrangements, or both, in place.

 

As of September 30, 2023 and December 31, 2022, Oncocyte had accounts receivable of $1.5 million and $1.9 million, respectively, from Medicare and Medicare Advantage covered DetermaRx tests.

 

Allowance for Credit Losses

 

We maintain an allowance for credit losses related to laboratory developed test services at an amount we estimate to be sufficient to provide adequate protection against losses resulting from extending credit to our customers. We base this allowance, in the aggregate, on historical collection experience, age of receivables and general economic conditions. Our bad debt write-offs have not been significant and have been within management expectations. As of September 30, 2023 and December 31, 2022, we had an allowance for credit losses of $178,000 and $154,000, respectively, related to laboratory developed test services.

 

Licensing Revenue

 

Revenues recognized include licensing revenue derived from agreements with customers for exclusive rights to market Oncocyte’s proprietary testing technology. Under the agreements, Oncocyte grants exclusive rights to certain trademarks and technology of Oncocyte for the purpose of marketing Oncocyte’s tests within a defined geographic territory. A license agreement may specify milestone deliverables or performance obligations, for which Oncocyte recognizes revenue when its licensee confirms the completion of Oncocyte’s performance obligation. A licensing agreement may also include ongoing sales support from Oncocyte and typically includes non-refundable licensing fees and per-test Pharma Services revenues discussed above, for which Oncocyte treats the licensing of the technology, trademarks, and ongoing support as a single performance obligation satisfied by the passage of time over the term of the agreement.

 

Disaggregation of Revenues and Concentrations of Credit Risk

 

The following table presents the percentage of consolidated revenues by service:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
Pharma Services   99%   100%   96%   100%
Laboratory developed test services   1%   0%   4%   0%
Total   100%   100%   100%   100%

 

 

The following table presents the percentage of consolidated revenues generated by unaffiliated customers, based on the respective periods presented, that individually represented greater than ten percent of consolidated revenues:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
Pharma services - Company A   57%   28%   42%   60%
Pharma services - Company B   41%   22%   34%   11%
Pharma services - Company C    -*    22%   -*    -* 
Pharma services - Company D   -*    19%   -*    -* 

 

* Less than 10%

 

The following table presents the percentage of consolidated revenues attributable to geographical locations:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
United States – Pharma Services   42%   76%   54%   74%
Outside of the United States – Pharma Services   57%   24%   41%   26%
United States – Laboratory developed test services   1%   0%   4%   0%
Total   100%   100%   100%   100%

 

Financial instruments that potentially subject the Company to concentrations of credit risk are cash equivalents and accounts receivable. The Company places its cash equivalents primarily in highly rated money market funds. Cash and cash equivalents are also invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. The Company has not experienced any significant losses on its deposits of cash and cash equivalents.

 

Two Pharma Services customers individually represented approximately 54% and 45% of accounts receivable at September 30, 2023. Two Pharma Services customers individually represented approximately 59% and 30% of accounts receivable at December 31, 2022.

 

Cost of Revenues

 

Cost of revenues generally consists of cost of materials, direct labor including benefits, bonus and stock-based compensation, equipment and infrastructure expenses, clinical sample related costs associated with performing DetermaRx tests and Pharma Services, providing deliverables according to our licensing agreements, license fees due to third parties, and amortization of acquired intangible assets such as the customer relationship intangible assets. Infrastructure expenses include depreciation of laboratory equipment, allocated rent costs, leasehold improvements, and allocated information technology costs for operations at Oncocyte’s CLIA laboratories in California and Tennessee. Costs associated with generating the revenues are recorded as the tests or services are performed regardless of whether revenue was recognized. Royalties or revenue share payments for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expenses at the time the related revenues are recognized.

 

Research and Development Expenses

 

Research and development expenses are comprised of costs incurred to develop technology, which include salaries and benefits (including stock-based compensation), laboratory expenses (including reagents and supplies used in research and development laboratory work), infrastructure expenses (including allocated facility occupancy costs), and contract services and other outside costs. Indirect research and development expenses are allocated primarily based on headcount, as applicable, and include rent and utilities, common area maintenance, telecommunications, property taxes, and insurance. Research and development costs are expensed as incurred.

 

 

Sales and Marketing Expenses

 

Sales and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade show expenses, branding and positioning expenses, and consulting fees. Sales and marketing expenses also include indirect expenses for applicable overhead allocated based on headcount, and include allocated costs for rent and utilities, common area maintenance, telecommunications, property taxes, and insurance.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of compensation and related benefits (including stock-based compensation) for executive and corporate personnel, professional and consulting fees, rent and utilities, common area maintenance, telecommunications, property taxes, and insurance.

 

Stock-Based Compensation

 

Oncocyte recognizes compensation expense related to employee option grants and restricted stock grants in accordance with the Financial Accounting Standards Board (“FASB”) ASC 718, Compensation – Stock Compensation (“ASC 718”).

 

Oncocyte estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value over the requisite service period. For stock-based awards that vest only upon the attainment of one or more performance goals set by Oncocyte at the time of the grant (sometimes referred to as milestone vesting), compensation cost is recognized if and when Oncocyte determines that it is probable that the performance condition or conditions will be, or have been, achieved. Oncocyte uses the Black-Scholes option pricing model for estimating the fair value of options granted under Oncocyte’s equity plans. The fair value of each restricted stock unit (“RSU”) or award is determined based on the value of the common stock granted or sold. Oncocyte has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period. Forfeitures are accounted for as they occur. Refer to Note 9 for additional information.

 

The Black-Scholes option pricing model requires Oncocyte to make certain assumptions including the expected option term, the expected volatility, the risk-free interest rate and the dividend yield. The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. Oncocyte estimates the expected term of options granted based on its own experience. Oncocyte estimates the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of peer companies, for a period equal to the expected term of the options. The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of Oncocyte’s stock options. The dividend yield assumption is based on Oncocyte’s history and expectation of dividend payouts. Oncocyte has never declared or paid any cash dividends on its common stock, and Oncocyte does not anticipate paying any cash dividends in the foreseeable future.

 

All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as income tax benefit or expense, respectively, in the statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction. Because Oncocyte has a full valuation allowance for all periods presented (see Note 10), there was no impact to Oncocyte statements of operations for any excess tax benefits or deficiencies, as any excess benefit or deficiency would be offset by the change in the valuation allowance.

 

Accounting for Warrants

 

Oncocyte determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate Oncocyte to settle the warrants or the underlying shares by paying cash or other assets or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480, Oncocyte assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. This liability classification guidance also applies to financial instruments that may require cash or other form of settlement for transactions outside of the company’s control and, in which the form of consideration to the warrant holder may not be the same as to all other shareholders in connection with the transaction. However, if a transaction is not within the company’s control but the holder of the financial instrument can solely receive the same type or form of consideration as is being offered to all the shareholders in the transaction, then equity classification of the financial instrument is not precluded, if all other applicable equity classification criteria are met.

 

 

After all relevant assessments, Oncocyte concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. Based on the above guidance and, among other factors, the fact that our warrants cannot be cash settled under any circumstance but require share settlement, all of our outstanding warrants meet the equity classification criteria and have been classified as equity. Refer to Notes 6 and 8 for details about our outstanding warrants.

 

Net Loss Per Common Share

 

Basic loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of shares of common stock outstanding during the year. Diluted loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method or the if-converted method, or the two-class method for participating securities, whichever is more dilutive. Potential common shares are excluded from the computation if their effect is antidilutive.

 

All common stock equivalents are antidilutive because Oncocyte reported a net loss for all periods presented. The following table presents the calculation of basic and diluted loss per share of common stock:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
   (In thousands, except per share data) 
Numerator:                    
Net loss attributable to Oncocyte Corporation  $(6,489)  $(9,333)  $(11,789)  $(27,924)
Accretion of Series A redeemable convertible preferred stock   (198)   (294)   (621)   (294)
Deemed dividend on Series A redeemable convertible preferred stock   -    -    (118)   - 
Net loss attributable to common stockholders - basic and diluted  $(6,687)  $(9,627)  $(12,528)  $(28,218)
                     
Denominator:                    
Weighted average shares used in computing net loss per share attributable to common stockholders - basic and diluted   8,256    5,931    7,446    5,408 
                     
Basic and diluted net loss per common share  $(0.81)  $(1.62)  $(1.68)  $(5.22)
                     
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share:                    
Stock options   501    717    501    717 
RSUs   5    29    5    29 
Warrants   820    820    820    820 
Series A redeemable convertible preferred stock   5    4    5    4 
Total   1,331    1,570    1,331    1,570 

 

 

Recent Accounting Pronouncements

 

In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Previously, U.S. GAAP required entities to write down credit losses only when losses are probable and loss reversals are not permitted. The Company adopted this ASU in the first quarter of 2023. Adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.

 

In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, to provide specific guidance to eliminate diversity in practice on how to recognize and measure acquired contract assets and contract liabilities from revenue contracts from customers in a business combination consistent with revenue contracts with customers not acquired in an acquisition. The amendments in this update provide that the acquirer should consider the terms of the acquired contracts, such as timing of payment, identify each performance obligation in the contracts, and allocate the total transaction price to each identified performance obligation on a relative standalone selling price basis as of contract inception (that is, the date the acquiree entered into the contracts) or contract modification to determine what should be recorded at the acquisition date. The Company adopted this ASU in the first quarter of 2023. Adoption of this standard did not have an impact on the Company’s consolidated financial statements and related disclosures.

 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Business Combinations
9 Months Ended
Sep. 30, 2023
Business Combination and Asset Acquisition [Abstract]  
Business Combinations

3. Business Combinations

 

Acquisition of Insight Genetics, Inc.

 

On January 31, 2020 (the “Insight Merger Date”), Oncocyte completed its acquisition of Insight pursuant to the Insight Merger Agreement.

 

Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings, such as “earn-out” provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of revenues generated from DetermaIO and Insight Pharma Services over their respective useful life. Accordingly, Oncocyte determined there are two types of contingent consideration in connection with the Insight Merger, the Milestone Contingent Consideration and the Royalty Contingent Consideration discussed below, which are collectively referred to as the “Contingent Consideration”.

 

There are three milestones comprising the Milestone Contingent Consideration, collectively referred to as the Milestones, in connection with the Insight Merger which Oncocyte valued and recorded as part of Contingent Consideration as of the Insight Merger Date (see table below), which consist of (i) a payment for clinical trial completion and related data publication (“Milestone 1”), (ii) a payment for an affirmative final local coverage determination from CMS for a specified lung cancer test (“Milestone 2”), and (iii) a payment for achieving specified CMS reimbursement milestones (“Milestone 3”). If achieved, any respective Milestone will be paid at the contractual value shown below, with the payment made either in cash or in shares of Oncocyte common stock as determined by Oncocyte. There can be no assurance that any of the Milestones will be achieved.

 

 

The following table shows the Insight Merger Date contractual payment amounts, as applicable, and the corresponding fair value of each respective Contingent Consideration liability:

 

   Contractual   Fair Value on the 
   Value   Merger Date 
   (In thousands) 
Milestone 1  $1,500   $1,340 
Milestone 2   3,000    1,830 
Milestone 3 (a)   1,500    770 
Royalty 1 (b)   See(b)    5,980 
Royalty 2 (b)   See(b)    1,210 
Total  $6,000   $11,130 

 

(a) Indicates the maximum payable if the Milestone is achieved.
   
(b) As defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration.

 

The fair value of the Contingent Consideration after the Insight Merger Date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in Oncocyte’s consolidated statements of operations. Durning 2023, based on Oncocyte’s reassessment of significant assumptions, there was a decrease of approximately $3.1 million to the fair value of the Contingent Consideration primarily attributable to revised estimates of the timing of the possible future payouts and, accordingly, this decrease was recorded as change in fair value of contingent consideration in the consolidated statement of operations for the nine months ended September 30, 2023.

 

Oncocyte uses a discounted cash flow valuation technique to determine the fair value of its Level 3 contingent consideration liabilities. The significant unobservable inputs used in Insight’s contingent consideration valuation on September 30, 2023, included: (i) a discount period, based on the expected milestone payment dates, ranging from 0.5 years to 1.5 years, (ii) a discount rate of 15.2% to 15.4%, and (iii) a management probability estimate of 15% to 50%.

 

The following tables reflect the activity for the Insight Contingent Consideration measured at fair value using Level 3 inputs:

 

   Fair Value 
   (In thousands) 
Balance at December 31, 2021  $7,060 
Change in estimated fair value   420 
Balance at September 30, 2022  $7,480 
      
Balance at December 31, 2022  $5,370 
Change in estimated fair value   (3,080)
Balance at September 30, 2023  $2,290 

 

Contingent consideration is not deductible for tax purposes, even if paid; therefore, no deferred tax assets related to the Contingent Consideration were recorded.

 

Acquisition of Chronix Biomedical, Inc.

 

On April 15, 2021 (the “Chronix Merger Date”), Oncocyte completed its acquisition of Chronix pursuant the Chronix Merger Agreement.

 

As additional consideration for holders of certain classes and series of Chronix capital stock, the Chronix Merger Agreement originally required Oncocyte to pay “Chronix Contingent Consideration” consisting of (i) “Chronix Milestone Payments” of up to $14 million in any combination of cash or Oncocyte common stock if certain milestones specified in the Chronix Merger Agreement are achieved, (ii) “Royalty Payments” of up to 15% of net collections for sales of specified tests and products during the five-to-ten year earnout periods, and (iii) “Transplant Sale Payments” of up to 75% of net collections from the sale or license to a third party of Chronix’s patents for use in transplantation medicine during a seven-year earnout period.

 

 

On February 8, 2023, the Company and equity holder representative entered into Amendment No. 1 to the Merger Agreement (the “Chronix Amendment”), pursuant to which the parties agreed that (i) Chronix’s equity holders will be paid earnout consideration of 10% of net collections for sales of specified tests and products, until the expiration of intellectual property related to such tests and products, (ii) Chronix’s equity holders will be paid 5% of the gross proceeds received from any sale of all or substantially all of the rights, titles, and interests in and to Chronix’s patents for use in transplantation medicine to such third party, and (iii) the Chronix Milestone Payments, 15% Royalty Payments and Transplant Sale Payment obligations were eliminated.

 

The fair value of the Chronix Contingent Consideration after the Chronix Merger Date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in Oncocyte’s consolidated statements of operations. During 2023, based on Oncocyte’s reassessment of significant assumptions, there was a decrease of approximately $13.9 million to the fair value of the Contingent Consideration primarily attributable to revised estimates of the timing of the possible future payouts and, accordingly, this decrease was recorded as a change in fair value of contingent consideration in the consolidated statement of operations for the nine months ended September 30, 2023.

 

Oncocyte uses a discounted cash flow valuation technique to determine the fair value of its Level 3 contingent consideration liabilities. The significant unobservable inputs used in Chronix’s contingent consideration valuation on September 30, 2023, included: (i) a discount period, based on the related patent expiration dates, ranging from 0.4 years to 12.2 years, (ii) a discount rate of 15.5% to 16.4%, and (iii) a payout percentage of 10% based on the earnout provision.

 

The following tables reflect the activity for the Chronix Contingent Consideration measured at fair value using Level 3 inputs:

 

   Fair Value 
   (In thousands) 
Balance at December 31, 2021  $69,621 
Change in estimated fair value   (17,577)
Balance at September 30, 2022  $52,044 
      
Balance at December 31, 2022  $40,292 
Change in estimated fair value   (13,867)
Balance at September 30, 2023  $26,425 

 

Goodwill was calculated as the difference between the acquisition date fair value of the Aggregate Chronix Merger Consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill also included the $2.2 million of net deferred tax liabilities recorded principally related to the VitaGraft discussed above. Oncocyte recognized approximately $9.5 million of goodwill related to the Chronix acquisition. None of the goodwill recognized is expected to be deductible for income tax purposes. During 2022, the Company identified circumstances that could indicate a potential impairment and after a valuation of the Company’s assets and liabilities was performed, management concluded that goodwill was impaired as of December 31, 2022 (see Note 2).

 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress
9 Months Ended
Sep. 30, 2023
Property, Plant and Equipment [Abstract]  
Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress

4. Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress

 

Right-of-use and financing lease assets, machinery and equipment, net, and construction in progress were as follows:

 

   September 30, 2023   December 31, 2022 
   (In thousands) 
Right-of-use assets  $4,036   $3,499 
Machinery and equipment   6,908    9,408 
Accumulated depreciation and amortization   (5,819)   (4,196)
Right-of-use assets and machinery and equipment, net   5,125    8,711 
Construction in progress   708    2,140 
Right-of-use and financing lease assets, machinery and equipment, net, and construction in progress  $5,833   $10,851 

 

 

Fixed asset depreciation and amortization expense amounted to $404,000 and $391,000 for the three months ended September 30, 2023 and 2022, respectively, and $1.3 million and $1.1 million for the nine months ended September 30, 2023 and 2022, respectively.

 

During the third quarter of 2023, in connection with a new sublease arrangement (see Note 7), the Company identified circumstances that indicated a potential impairment of certain leasehold improvements (included in construction in progress) and after a valuation was performed, management concluded that such leasehold improvements were impaired. Accordingly, the Company recorded an impairment of approximately $1.8 million.

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Intangible Assets, Net
9 Months Ended
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets, Net

5. Intangible Assets, Net

 

As part of the Insight and Chronix acquisitions completed on January 31, 2020, and April 15, 2021, respectively, the Company has acquired IPR&D and customer relationships.

 

During the first quarter of 2023, due to changes in management and the economic condition of the Company, management shifted the Company’s business strategy to direct efforts on fewer studies and to transition from tests that are laboratory developed tests to research use only sales. Due to the change in strategy, the Company’s long range plan forecasts were updated and anticipated future benefits derived from the Company’s assets. The change in strategy represent a significant indicator for change in value of the Company’s long-lived assets. The original IPR&D balance was reassessed based on the updated long range plan, using the multi-period excess earnings method (“MPEEM”) approach, the results of the valuation noted that the carrying value of the DetermaIO related IPR&D intangible assets was greater than the fair market value, whereas the CNI and VitaGraft related IPR&D intangible assets carrying value was lower than the fair market value. Accordingly, the Company recorded an impairment of approximately $5.0 million.

 

The MPEEM valuation approach is a discounted cash flow valuation technique and was used to determine the Level 3 fair value of Insight’s IPR&D discussed above. The significant unobservable inputs used on March 31, 2023, included: (i) a discount period of 20.0 years, based on the expected life of patent, (ii) a royalty rate of 0.3%, (iii) a contributory asset rate of return of 30.0%, and (iv) a weighted average cost of capital rate of 30.0%. As market conditions change, the Company will re-evaluate assumptions used in the determination of fair value for IPR&D and is uncertain to the extent of the volatility in the unobservable inputs in the foreseeable future. Refer to Note 2, “Goodwill and Intangible Assets” for additional IPR&D information.

 

Intangible assets, net, consisted of the following:

 

   September 30, 2023   December 31, 2022 
   (In thousands) 
Intangible assets:          
Acquired IPR&D - DetermaIOTM (1)  $9,700   $14,650 
Acquired IPR&D - DetermaCNI™ and VitaGraft™ (2)   46,800    46,800 
           
Intangible assets subject to amortization:          
Acquired intangible assets - customer relationship   440    440 
Total intangible assets   56,940    61,890 
Accumulated amortization - customer relationship(3)   (323)   (257)
Intangible assets, net  $56,617   $61,633 

 

(1) See Note 3 for information on the Insight Merger.
(2) See Note 3 for information on the Chronix Merger.
(3) Amortization of intangible assets is included in “Cost of revenues – amortization of acquired intangibles” on the consolidated statements of operations because the intangible assets pertain directly to the revenues generated from the acquired intangibles.

 

Intangible asset amortization expense amounted to $22,000 and $976,000 for the three months ended September 30, 2023 and 2022, respectively, and $66,000 and $2.9 million for the nine months ended September 30, 2023 and 2022, respectively.

 

 

Future amortization expense of intangible assets subject to amortization is expected to be the following:

 

   Amortization 
   (In thousands) 
Year ending December 31,     
2023  $22 
2024   88 
2025   7 
Total  $117 

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Loan Payable to Silicon Valley Bank
9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Loan Payable to Silicon Valley Bank

6. Loan Payable to Silicon Valley Bank

 

Amended Loan Agreement

 

On October 17, 2019, Oncocyte entered into a First Amendment to Loan and Security Agreement (the “Amended Loan Agreement”) with Silicon Valley Bank (“the Bank”) pursuant to which Oncocyte obtained a new $3 million secured credit facility (“Tranche 1”), a portion of which was used to repay the remaining balance of approximately $400,000 on outstanding loans from the Bank, plus a final payment of $116,000, under the February 21, 2017 Loan Agreement. The credit line under the Amended Loan Agreement may be increased by an additional $2 million (“Tranche 2”) if Oncocyte obtains at least $20 million of additional equity capital, as was the case with the original Loan Agreement, and a positive final coverage determination is received from CMS for DetermaRx at a specified minimum price point per test (the “Tranche 2 Milestone”), and Oncocyte is not in default under the Amended Loan Agreement. As of September 30, 2023, Oncocyte had satisfied the Tranche 2 Milestone and was eligible to borrow the $2 million Tranche 2 funds. However, Oncocyte has not yet borrowed any funds under Tranche 2.

 

Payments of interest only on the principal balance were due monthly from the draw date through March 31, 2020, followed by 24 monthly payments of principal and interest, but the Bank has agreed to a deferral of principal payments, as discussed below. The outstanding principal balance of the loan will bear interest at a stated floating annual interest equal to the greater of (a) the prime rate or (b) 5% per annum. During August 2022, period in which the loan was paid off, the published prime rate was 5.5% per annum.

 

On April 2, 2020, as part of the Bank’s COVID-19 pandemic relief program, Oncocyte and the Bank entered into a Loan Deferral Agreement (“Loan Deferral”) with respect to the Amended Loan Agreement. Under the Loan Deferral Agreement, the Bank agreed to (i) extend the scheduled maturity date of the Amended Loan Agreement from March 31, 2022 to September 30, 2022, and (ii) deferred the principal payments by an additional 6 months whereby payments of interest only on the Bank loan principal balance will be due monthly from May 1, 2020 through October 1, 2020, followed by 23 monthly payments of principal and interest beginning on November 1, 2020, all provided at no additional fees to Oncocyte. No other terms of the Amended Loan Agreement were changed or modified. The Loan Deferral was accounted for as a modification of debt in accordance with ASC 470-50, Debt – Modifications and Extinguishments, thus there was no gain or loss recognized on the transaction.

 

At maturity of the loan, Oncocyte agreed to pay the Bank an additional final payment fee of $200,000, which was recorded as a deferred financing charge in October 2019 and is being amortized to interest expense over the term of the loan using the effective interest method. Since August 2022, there is no remaining unamortized deferred financing cost and the full principal balance of the loan in addition to the final payment fee have been paid off.

 

Bank Warrants

 

In 2017, in connection with the Loan Agreement, Oncocyte issued common stock purchase warrants to the Bank (the “2017 Bank Warrants”) entitling the Bank to purchase shares of Oncocyte common stock in tranches related to the loan tranches under the Loan Agreement. In conjunction with the availability of the loan, the Bank was issued warrants to purchase 412 shares of Oncocyte common stock at an exercise price of $97.00 per share, through February 21, 2027. On March 23, 2017, the Bank was issued warrants to purchase an additional 366 shares at an exercise price of $109.20 per share, through March 23, 2027. The Bank may elect to exercise the 2017 Bank Warrants on a “cashless exercise” basis and receive a number of shares determined by multiplying the number of shares for which the applicable tranche is being exercised by (A) the excess of the fair market value of the common stock over the applicable exercise price, divided by (B) the fair market value of the common stock. The fair market value of the common stock will be the last closing or sale price on a national securities exchange, inter-dealer quotation system, or over-the-counter market. These warrants meet the equity classification criteria and have been classified as equity, refer to Note 2 “Accounting for Warrants” for additional information.

 

 

On October 17, 2019, in conjunction with Tranche 1 becoming available under the Amended Loan Agreement, Oncocyte issued a common stock purchase warrant to the Bank (the “2019 Bank Warrant”) entitling the Bank to purchase 4,928 shares of Oncocyte common stock at the initial “Warrant Price” of $33.80 per share through October 17, 2029. The number of shares of common stock issuable upon the exercise of the 2019 Bank Warrant will increase on the date of each draw, if any, on Tranche 2. The number of additional shares of common stock issuable upon the exercise of the 2019 Bank Warrant will be equal to 0.02% of Oncocyte’s fully diluted equity outstanding for each $1 million draw under Tranche 2. The Warrant Price for Tranche 2 warrant shares will be determined upon each draw of Tranche 2 funds and will be closing price of Oncocyte common stock on the date immediately before the applicable date on which Oncocyte borrows funds under Tranche 2. The Bank may elect to exercise the 2019 Bank Warrant on a “cashless exercise” basis and receive a number of shares determined by multiplying the number of shares for which the 2019 Bank Warrant is being exercised by (A) the excess of the fair market value of the common stock over the applicable Warrant Price, divided by (B) the fair market value of the common stock. The fair market value of the common stock will be last closing or sale price on a national securities exchange, interdealer quotation system, or over-the-counter market. These warrants meet the equity classification criteria and have been classified as equity, refer to Note 2 “Accounting for Warrants” for additional information. As of September 30, 2023, Oncocyte has not borrowed any funds under Tranche 2.

 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies
9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

7. Commitments and Contingencies

 

Office and Facilities Leases

 

Irvine Office Lease

 

On December 23, 2019, Oncocyte and Cushing Ventures, LLC (“Landlord”) entered into an Office Lease Agreement (the “Irvine Lease”) of a building containing approximately 26,800 square feet of rentable space located at 15 Cushing in Irvine, California (the “Premises”) that serves as Oncocyte’s principal executive and administrative offices.

 

The Irvine Lease has an initial term of 89 calendar months (the “Term”), which commenced on June 1, 2020 (the “Commencement Date”). Oncocyte has an option to extend the Term for a period of five years (the “Extended Term”).

 

Oncocyte agreed to pay base monthly rent in the amount of $61,640 during the first 12 months of the Term. Base monthly rent increases annually, over the base monthly rent then in effect, by 3.5%. Oncocyte was entitled to an abatement of 50% of the base monthly rent during the first ten calendar months of the Term. If the Irvine Lease is terminated based on the occurrence of an “event of default,” Oncocyte will be obligated to pay the abated rent to the lessor.

 

If Oncocyte exercises its option to extend the Term, the initial base monthly rent during the Extended Term will be the greater of the base monthly rent in effect during the last year of the Term or the prevailing market rate. The prevailing market rate will be determined based on annual rental rates per square foot for comparable space in the area where the Premises are located. If Oncocyte does not agree with the prevailing market rate proposed by the lessor, the rate may be determined through an appraisal process. The base monthly rent during the Extended Term shall be subject to the same annual rent adjustment as applicable for base monthly rent during the Term.

 

In addition to base monthly rent, Oncocyte agreed to pay in monthly installments (a) all costs and expenses, other than certain excluded expenses, incurred by the lessor in each calendar year in connection with operating, maintaining, repairing (including replacements if repairs are not feasible or would not be effective) and managing the Premises and the building in which the Premises are located (“Expenses”), and (b) all real estate taxes and assessments on the Premises and the building in which the Premises are located, all personal property taxes for property that is owned by lessor and used in connection with the operation, maintenance and repair of the Premises, and costs and fees incurred in connection with seeking reductions in such tax liabilities (“Taxes”). Subject to certain exceptions, Expenses shall not be increased by more than 4% annually on a cumulative, compounded basis.

 

 

Oncocyte was entitled to an abatement of its obligations to pay Expenses and Taxes while constructing improvements to the Premises constituting “Tenant’s Work” under the Irvine Lease prior to the Commencement Date, except that Oncocyte was obligated to pay 43.7% of Expenses and Taxes during the period prior to the Commencement Date for its use of the second floor of the Premises, which was already built out as office space.

 

The lessor provided Oncocyte with a “Tenant Improvement Allowance” in the amount of $1.3 million to pay for the plan, design, permitting, and construction of the improvements constituting Tenant’s Work. The lessor retained 1.5% of the Tenant Improvement Allowance as an administrative fee as provided in the Irvine Lease. As of June 2021, the lessor had provided $1.3 million of the total Tenant Improvement Allowance, which is being amortized over the Term.

 

Oncocyte has provided the lessor with a security deposit in the amount of $150,000 and a letter of credit in the amount of $1.7 million. The lessor may apply the security deposit, in whole or in part, for the payment of rent and any other amount that Oncocyte is or becomes obligated to pay under the Irvine Lease but fails to pay when due and beyond any cure period. The lessor may draw on the letter of credit from time to time to pay any amount that is unpaid and due, or if the original issuing bank notifies the lessor that the letter of credit will not be renewed or extended for the period required under the Irvine Lease and Oncocyte fails to timely provide a replacement letter of credit, or an event of default under the Irvine Lease occurs and continues beyond the applicable cure period, or if certain insolvency or bankruptcy or insolvency with respect to Oncocyte occur. Oncocyte is required to restore any portion of the security deposit that is applied by the lessor to payments due under the Irvine Lease, and Oncocyte is required to restore the amount available under the letter of credit to the required amount if any portion of the letter of credit is drawn by the lessor. The Irvine Lease provides that commencing on the 34th month of the Term, (a) the amount of the letter of credit that Oncocyte is required to maintain shall be reduced on a monthly basis, in equal installments, to amortize the required amount to zero at the end of the Term, and (b) Oncocyte has the right to cancel the letter of credit at any time if it meets certain market capitalization and balance sheets thresholds; provided, in each case, that Oncocyte is not in then default under the Irvine Lease beyond any applicable notice and cure period and the lessor has not determined that an event exists that would lead to an event of default.

 

To obtain the letter of credit, Oncocyte has provided the issuing bank with a restricted cash deposit that the bank will hold to cover its obligation to pay any draws on the letter of credit by the lessor. The restricted cash may not be used for any other purpose, accordingly, Oncocyte has reflected $1.7 million as restricted cash in the accompanying consolidated balance sheets.

 

Irvine Office Sublease

 

On August 8, 2023, Oncocyte and Induce Biologics USA, Inc. (“Subtenant”) entered into a Sublease Agreement (the “Sublease Agreement”), which subsequently became effective as of September 14, 2023, upon the execution and delivery by the Company, Subtenant, and Landlord, of that certain Landlord’s Consent to Sublease dated September 12, 2023 (the “Consent Agreement”), under which Landlord consented to the Sublease Agreement, on the terms and subject to the conditions set forth therein. The Sublease Agreement is subject and subordinate to the Irvine Lease.

 

Under the Sublease Agreement, the Company agreed to initially sublet to Subtenant a portion of the Premises consisting of approximately 13,400 square feet of rentable space for a term (the “Initial Period”) commencing on the date that is 120 days after the effective date of the Consent Agreement (the “Commencement Date”) and ending on the date that is 18 months following the Commencement Date or such earlier date as Subtenant may elect upon the exercise of its one-time option to accelerate such date upon 90 days prior written notice to the Company (the date on which the Initial Period ends, the “Expansion Date”). On the Expansion Date, the portion of the Premises that is subleased to Subtenant under the Sublease Agreement will automatically increase to include the remaining portion of the Premises, which consists of approximately 13,400 square feet of additional rentable space for a term (the “Expansion Period”) beginning on the Expansion Date through the expiration of the Irvine Lease on October 31, 2027, unless earlier terminated.

 

 

The Sublease Agreement provides that, from and after the Commencement Date, Subtenant will pay to the Company monthly base rent in the following amounts: (i) $36,850.00 for rental periods beginning on the Commencement Date and ending on or before December 31, 2024 (subject to adjustment in the event that Subtenant exercises its option to accelerate the Expansion Date, such that the Expansion Period begins prior to December 31, 2024); (ii) $37,955.50 for rental periods beginning on or after January 1, 2025 and ending on or before June 20, 2025 (subject to adjustment in the event that Subtenant exercises its option to accelerate the Expansion Date, such that the Expansion Period begins prior to June 20, 2025); (iii) $75,844.00 for rental periods beginning on or after July 1, 2025 and ending on or before December 31, 2025; (iv) $78,188.33 for rental periods beginning on or after January 1, 2026 and ending on or before December 31, 2026; and (v) $80,533.98 for rental periods beginning on or after January 1, 2027 and ending on or before October 31, 2027.

 

Following the Commencement Date, Subtenant will be responsible for the payment of Additional Rent, including Expenses and Taxes (as each such term is defined in the Irvine Lease), provided that, with respect to the Initial Period, Subtenant will be responsible for only 50% of the Expenses and Taxes due. In addition, Subtenant will pay the Company a security deposit in the amount of $101,987.38 in connection with the transactions contemplated by the Sublease Agreement.

 

The Sublease Agreement contains customary provisions with respect to, among other things, Subtenant’s obligation to comply with the Irvine Lease and applicable laws, the payment of utilities and similar services utilized by Subtenant with respect its use of the Premises, the indemnification of the Company by Subtenant, and the right of the Company to terminate the Sublease Agreement in its entirety and retake the Premises if Subtenant fails to remedy certain defaults of its obligations under the Sublease Agreement within specified time periods.

 

Nashville Office Lease

 

On August 27, 2021, Oncocyte entered into a lease agreement to add an additional suite to its Nashville office space, containing approximately 1,928 square feet of rentable space located at 2 International Plaza, Suite 103, Nashville TN. The term of the lease commenced on October 1, 2021 and extends through April 9, 2024 and will serve as additional office space for Insight’s operations.

 

Embedded Operating Lease

 

On December 31, 2019, in connection with Oncocyte’s purchase of 25% of the outstanding equity of Razor, Oncocyte entered into a Laboratory Services Agreement with Razor and Encore Clinical, Inc. (“Encore”), a former stockholder of Razor (the “Laboratory Agreement”). Under the Laboratory Agreement (which expired on September 29, 2021), Oncocyte assumed all of Razor’s Laboratory Agreement payment obligations. Although Oncocyte is not a party to any lease agreement with Razor or Encore, under the terms of the Laboratory Agreement, Oncocyte received the landlord’s consent for the use of the laboratory at Razor’s Brisbane, California location (the “Brisbane Facility”) under the terms of a sublease to which Encore is the sublessee. The sublease expired on March 31, 2023 (the “Brisbane Lease”). The laboratory fee payments to Encore include both laboratory services and the use of the Brisbane Facility. Under the provisions of the Laboratory Agreement, if Oncocyte terminates the Laboratory Agreement prior to the expiration of the Brisbane Lease, Oncocyte shall assume the costs related to the subletting or early termination of the Brisbane Lease. The Laboratory Agreement terminated on March 31, 2023. Oncocyte determined that the Laboratory Agreement contains an embedded operating lease for the Brisbane Facility and Oncocyte allocated the aggregate payments to this lease component for purposes of calculating the net present value of the right-of-use asset and liability as of the inception of the Laboratory Agreement in accordance with ASC 842, as shown in the table below.

 

Our office leases are operating leases under ASC 842 and are included in the tables below. The tables below provide the amounts recorded in connection with the application of ASC 842 for Oncocyte’s operating and financing leases (see Note 2 for additional policy information).

 

 

Financing Lease

 

As of September 30, 2023, Oncocyte has one financing lease remaining through December 2023 for certain laboratory equipment with aggregate remaining payments of approximately $30,000 shown in the table below. Oncocyte’s lease obligations are collateralized by the equipment financed under the lease schedule.

 

Operating and Financing Leases

 

The following table presents supplemental balance sheet information related to operating and financing leases:

 

   September 30, 2023   December 31, 2022 
   (In thousands) 
Operating lease          
Right-of-use assets, net  $1,748   $2,088 
           
Right-of-use lease liabilities, current  $653   $698 
Right-of-use lease liabilities, noncurrent   2,252    2,730 
Total operating lease liabilities  $2,905   $3,428 
           
Financing lease          
Machinery and equipment  $537   $537 
Accumulated depreciation   (528)   (446)
Machinery and equipment, net  $9   $91 
           
Current liabilities  $30   $117 
Noncurrent liabilities   -    - 
Total financing lease liabilities  $30   $117 
           
Weighted average remaining lease term          
Operating lease   3.9 years    4.5 years 
Financing lease   0.3 years    1.0 years 
           
Weighted average discount rate          
Operating lease   11.29%   11.24%
Financing lease   11.55%   11.55%

 

Future minimum lease commitments are as follows:

 

   Operating   Financing 
   Leases   Leases 
   (In thousands) 
Year Ending December 31,          
2023  $255   $31 
2024   903    - 
2025   869    - 
2026   899    - 
2027   695    - 
Total minimum lease payments   3,621    31 
Less amounts representing interest   (716)   (1)
Present value of net minimum lease payments  $2,905   $30 

 

The following table presents supplemental cash flow information related to operating and financing leases:

 

   2023   2022 
   Nine Months Ended 
   September 30,  
   2023   2022 
   (In thousands) 
Cash paid for amounts included in the measurement of financing lease liabilities:          
Operating cash flows from operating leases  $793   $854 
Operating cash flows from financing leases  $7   $77 
Financing cash flows from financing leases  $86   $4 

 

 

Litigation – General

 

Oncocyte may be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and other matters. When Oncocyte is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, Oncocyte will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, Oncocyte discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material.

 

Tax Filings

 

Oncocyte tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes Oncocyte has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could be significantly different than the amounts recorded in the consolidated financial statements.

 

Employment Contracts

 

Oncocyte has entered into employment and severance benefit contracts with certain executive officers. Under the provisions of the contracts, Oncocyte may be required to incur severance obligations for matters relating to changes in control, as defined, and certain terminations of executives. As of September 30, 2023, Oncocyte accrued approximately $2.7 million in severance obligations for certain executive officers, in accordance with the severance benefit provisions of their respective employment and severance benefit agreements, primarily related to Oncocyte’s acquisition of Chronix in 2021.

 

Indemnification

 

In the normal course of business, Oncocyte may provide indemnification of varying scope under Oncocyte’s agreements with other companies or consultants, typically Oncocyte’s clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, Oncocyte will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with the use or testing of Oncocyte’s diagnostic tests. Indemnification provisions could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to Oncocyte’s diagnostic tests. Oncocyte’s office and laboratory facility leases also will generally contain indemnification obligations, including obligations for indemnification of the lessor for environmental law matters and injuries to persons or property of others, arising from Oncocyte’s use or occupancy of the leased property. The term of these indemnification agreements will generally continue in effect after the termination or expiration of the particular research, development, services, lease, or license agreement to which they relate. The Razor Stock Purchase Agreement also contains provisions under which Oncocyte has agreed to indemnify Razor and Encore from losses and expenses resulting from breaches or inaccuracy of Oncocyte’s representations and warranties and breaches or nonfulfillment of Oncocyte’s covenants, agreements, and obligations under the Razor Stock Purchase Agreement. Oncocyte periodically enters into underwriting and securities sales agreements with broker-dealers in connection with the offer and sale of Oncocyte securities. The terms of those underwriting and securities sales agreements include indemnification provisions pursuant to which Oncocyte agrees to indemnify the broker-dealers from certain liabilities, including liabilities arising under the Securities Act, in connection with the offer and sale of Oncocyte securities. The potential future payments Oncocyte could be required to make under these indemnification agreements will generally not be subject to any specified maximum amounts. Historically, Oncocyte has not been subject to any claims or demands for indemnification. Oncocyte also maintains various liability insurance policies that limit Oncocyte’s financial exposure. As a result, Oncocyte management believes that the fair value of these indemnification agreements is minimal. Accordingly, Oncocyte has not recorded any liabilities for these agreements as of September 30, 2023 and December 31, 2022.

 

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholders’ Equity
9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Shareholders’ Equity

8. Shareholders’ Equity

 

Series A Redeemable Convertible Preferred Stock

 

On April 13, 2022, the Company entered into the Securities Purchase Agreement with the Investors in a registered direct offering of 11,765 shares of the Company’s Series A Preferred Stock, which shares of Series A Preferred Stock are convertible into a total of 384,477 shares of common stock, at a conversion price of $30.60. The purchase price of each share of Series A Preferred Stock was $850, which included an original issue discount to the stated value of $1,000 per share. The rights, preferences and privileges of the Series A Preferred Stock are set forth in the Company’s Certificate of Determination, which the Company filed with the Secretary of State of the State of California. The Securities Purchase Agreement provides that the closing of the Series A Preferred Stock Offering will occur, subject to the satisfaction of certain closing conditions, in two equal tranches of $5,000,000 each for aggregate gross proceeds from both closings of $10,000,000. The first closing occurred on June 1, 2022, and Oncocyte received net proceeds of approximately $4.9 million from the Series A Preferred Stock issued from the first tranche. The second closing would occur, subject to the satisfaction of certain closing conditions (including but not limited to a requirement that the Company has not received, in the 12 months preceding the second closing, a notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the listing and maintenance and listing requirements of Nasdaq), on the earlier of (a) the second trading day following the date that Oncocyte receives notice from an Investor to accelerate the second closing and (b) a date selected by Oncocyte on or after October 8, 2022 and on or prior to March 8, 2023. On August 9, 2022, Oncocyte received a letter from Nasdaq indicating that the Company no longer met the minimum bid price requirement of the Nasdaq continued listing requirements. Accordingly, the second closing did not occur and no additional proceeds were received under the Securities Purchase Agreement. On August 8, 2023, the Company received a letter from Nasdaq indicating that the Company had regained compliance with the minimum bid price requirement of the Nasdaq continued listing requirements.

 

The Series A Preferred Stock is convertible into shares of the Company’s common stock at any time at the holder’s option. The conversion price will be subject to customary anti-dilution adjustments for matters such as stock splits, stock dividends and other distributions on our common stock, and recapitalizations. A holder is prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of our common stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership limitation solely as to itself up to 19.99% of the number of shares of our common stock outstanding immediately after giving effect to the conversion, provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect to the issuance of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer apply to the holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval). On July 15, 2022, the Company received such shareholder approval to remove the beneficial ownership limitation with respect to the Series A Preferred Stock held by Broadwood. The Company may force the conversion of up to one-third of the shares of Series A Preferred Stock originally issued, subject to customary equity conditions, if the daily volume weighted average price of our common stock for 20 out of 30 trading days exceeds 140% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or exceeds 20,000 shares of our common stock. The Company may only effect one forced conversion during any 30-trading day period.

 

In the event of the Company’s liquidation, dissolution, or winding up, holders of Series A Preferred Stock will receive a payment equal to the stated value of the Series A Preferred Stock plus accrued but unpaid dividends and any other amounts that may have become payable on the Series A Preferred Stock due to any failure or delay that may have occurred in issuing shares of common stock upon conversion of a portion of the Series A Preferred Stock, before any distribution or payment to the holders of common stock or any of our other junior equity.

 

 

Shares of Series A Preferred Stock generally have no voting rights, except as required by law and except that the consent of holders of a majority of the outstanding Series A Preferred Stock will be required to amend any provision of our certificate of incorporation that would have a materially adverse effect on the rights of the holders of the Series A Preferred Stock. Additionally, as long as any shares of Series A Preferred Stock remain outstanding, unless the holders of at least 51% of the then outstanding shares of Series A Preferred Stock shall have otherwise given prior written consent, we, on a consolidated basis with our subsidiaries, are not permitted to (1) have less than $8 million of unrestricted, unencumbered cash on hand (“Cash Minimum Requirement”); (2) other than certain permitted indebtedness, incur indebtedness to the extent that our aggregate indebtedness exceeds $15 million; (3) enter into any agreement (including any indenture, credit agreement or other debt instrument) that by its terms prohibits, prevents, or otherwise limits our ability to pay dividends on, or redeem, the Series A Preferred Stock in accordance with the terms of the Certificate of Determination; or (4) authorize or issue any class or series of preferred stock or other capital stock of the Company that ranks senior or pari passu with the Series A Preferred Stock.

 

Shares of Series A Preferred Stock are entitled to receive cumulative dividends at a rate per share (as a percentage of stated value) of 6% per annum, payable quarterly in cash or, at our option, by accreting such dividends to the stated value.

 

The Company is required to redeem, for cash, the shares of Series A Preferred Stock on the earlier to occur of (1) April 8, 2024, (2) the commencement of certain a voluntary or involuntary bankruptcy, receivership, or similar proceedings against the Company or its assets, (3) a Change of Control Transaction (as defined herein) and (4) at the election and upon notice of 51% in interest of the holders, if the Company fails to meet the Cash Minimum Requirement. A “Change of Control Transaction” means the occurrence of any of (a) an acquisition by an individual or legal entity or “group” (as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective control (whether through legal or beneficial ownership of capital stock of the Company, by contract or otherwise) of in excess of 50% of the voting securities of the Company (other than by means of conversion of Series A Preferred Stock), (b) the Company merges into or consolidates with any other person, or any person merges into or consolidates with the Company and, after giving effect to such transaction, the stockholders of the Company immediately prior to such transaction own less than 50% of the aggregate voting power of the Company or the successor entity of such transaction, or (c) the Company sells or transfers all or substantially all of its assets to another person. Additionally, the Company has the right to redeem the Series A Preferred Stock for cash upon 30 days prior notice to the holders; provided if the Company undertakes a capital raise in connection with such redemption, the Investors will have the right to participate in such financing. On April 5, 2023, the Company redeemed 1,064 shares of the Series A Preferred Stock for approximately $1.1 million.

 

The issuance and sale of the Series A Preferred Stock was completed pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-256650), filed with the SEC on May 28, 2021 and declared effective by the SEC on June 8, 2021, and an accompanying prospectus dated June 8, 2021 as supplemented by a prospectus supplement dated April 13, 2022.

 

The Series A Preferred Stock dividend for all issued and outstanding shares is set at 6% per annum per share. As of September 30, 2023, the Company elected to accrete dividends of $399,000, net of the April 2023 redemption, with respect to shares of Series A Preferred Stock.

 

As of September 30, 2023 and December 31, 2022, Oncocyte had 4,818 and 5,882, shares issued and outstanding, respectively. The future right or obligation associated with the Series A Preferred Stock to be issued in the second closing was written off in the prior year since the second closing was not completed.

 

Common Stock

 

As of September 30, 2023 and December 31, 2022, Oncocyte has 230,000,000 shares of common stock, no-par value, authorized. As of September 30, 2023 and December 31, 2022, Oncocyte had 8,260,762 and 5,932,191 shares of common stock issued and outstanding, respectively.

 

Underwritten Offering

 

On April 13, 2022, Oncocyte entered into the Underwriting Agreement with the Underwriters, pursuant to which the Company agreed to issue and sell to the Underwriters an aggregate of 1,313,320 shares of common stock and 1,313,320 April 2022 Warrants to purchase up to 656,660 shares of common stock. Each share of common stock and the accompanying April 2022 Warrant was sold at a combined offering price of $26.65, representing an offering price of $26.45 per share of common stock and $0.20 per accompanying April 2022 Warrant, before underwriting discounts and commissions.

 

 

Under the terms of the Underwriting Agreement, the Company also granted to the Underwriters an over-allotment option, exercisable in whole or in part at any time for a period of 30 days from the date of the Underwriting Agreement, to purchase up to an additional 196,998 shares of common stock and 196,998 April 2022 Warrants to purchase 98,499 shares of common stock to cover over-allotments, if any. The over-allotment option may be exercised separately for shares of common stock at a price to the underwriters of $24.85 per share, and April 2022 Warrants at a price of $0.20 per April 2022 Warrant. On April 14, 2022, the Underwriters exercised their option to purchase the 196,998 April 2022 Warrants pursuant to the over-allotment option but did not exercise their option to purchase the additional 196,998 shares of common stock.

 

The Company received net proceeds of approximately $32.8 million from the Underwritten Offering, which includes the April 2022 Warrants sold upon the exercise of the Underwriters’ overallotment option. The Underwritten Offering closed on April 19, 2022. Refer to Note 11 for additional information.

 

The Underwritten Offering was made pursuant to the Company’s effective “shelf” registration statement on Form S-3 (Registration No. 333-256650) filed with the SEC Commission on May 28, 2021 and declared effective by the SEC on June 8, 2021, and an accompanying prospectus dated June 8, 2021 as supplemented by a prospectus supplement dated April 13, 2022.

 

April 2023 Offering

 

On April 3, 2023, Oncocyte entered into an agreement with certain members of the Company’s board of directors, and several institutional and accredited investors, including Broadwood, the Company’s largest shareholder, and certain members of the Company’s board of directors (and certain of their affiliated parties), relating to their purchase of an aggregate of up to 2,278,121 shares of its common stock at an offering price of $7.08 per share to board members and $6.03 per share to the other investors participating in the April 2023 Offering. The April 2023 Offering was intended to be priced at-the-market for purposes of complying with applicable Nasdaq Listing Rules. The Company issued an aggregate of 2,274,709 shares of common stock from this offering, as further discussed in Note 11. The aggregate gross proceeds from the offering were approximately $13.9 million. The Company used approximately $1.1 million of the net proceeds to immediately redeem an aggregate of 1,064 shares of its Series A Preferred Stock and may thereafter elect to redeem additional shares.

 

Common Stock Purchase Warrants

 

As of September 30, 2023, Oncocyte had an aggregate of 819,767 common stock purchase warrants issued and outstanding with exercise prices ranging from $30.60 to $109.20 per warrant. The warrants will expire on various dates ranging from February 2024 to October 2029. Certain warrants have “cashless exercise” provisions meaning that the value of a portion of warrant shares may be used to pay the exercise price rather than payment in cash, which may be exercised under any circumstances in the case of the 2017 Bank Warrants and 2019 Bank Warrants (see Note 6) or, in the case of certain other warrants, only if a registration statement for the warrants and underlying shares of common stock is not effective under the Securities Act or a prospectus in the registration statement is not available for the issuance of shares upon the exercise of the warrants. All of the outstanding warrants meet the equity classification criteria and have been classified as equity, refer to Note 2 for additional information.

 

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation
9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation

9. Stock-Based Compensation

 

Equity Incentive Plans

 

Oncocyte had a 2010 Stock Option Plan (the “2010 Plan”) under which 260,000 shares of common stock were authorized for the grant of stock options or the sale of restricted stock. On August 27, 2018, Oncocyte shareholders approved a new Equity Incentive Plan (the “2018 Incentive Plan”) to replace the 2010 Plan. In adopting the 2018 Incentive Plan, Oncocyte terminated the 2010 Plan and will not grant any additional stock options or sell any stock under restricted stock purchase agreements under the 2010 Plan; however, stock options issued under the 2010 Plan will continue in effect in accordance with their terms and the terms of the 2010 Plan until the exercise or expiration of the individual options.

 

 

As of September 30, 2023, 1,050,000 shares of common stock were reserved under the 2018 Incentive Plan for the grant of stock options or the sale of restricted stock or for the settlement of RSUs. Oncocyte may also grant stock appreciation rights under the 2018 Incentive Plan. As of September 30, 2023, 387,000 shares are available for grant under the 2018 Incentive Plan.

 

2022 Equity Awards

 

During the year ended December 31, 2022, the Company awarded executive share-based payment awards under the 2018 Plan to certain executive officers and employees with time-based, market-based and performance-based vesting conditions (“2022 equity awards”).

 

The fair value of the RSU 2022 equity awards with performance-based vesting condition was estimated using the Black-Scholes option-pricing model assuming that performance goals will be achieved. If such performance conditions are not met, no compensation cost is recognized and any recognized compensation cost is reversed. The probability of 2022 equity awards performance-based vesting conditions will be evaluated each reporting period and the Company will true-up the amount of cumulative cost recognized for the 2022 performance-based awards at each reporting period based on the most up-to-date probability estimates. The Company will recognize the compensation expense for 2022 performance-based awards expected to vest on a straight-line basis over the respective service period for each separately vesting tranche.

 

The fair value of the RSU 2022 equity awards with market-based and time-based vesting conditions were estimated using the Monte Carlo simulation model. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated period to achievement of the performance and market conditions, which are subject to the achievement of the market-based goals established by the Company and the continued employment of the participant. These awards vest only to the extent that the market-based conditions are satisfied as specified in the vesting conditions. Unlike the performance-based awards, the grant date fair value and associated compensation cost of the market-based awards reflect the probability of the market condition being achieved, and the Company will recognize this compensation cost regardless of the actual achievement of the market condition. Assumptions utilized in connection with the Monte Carlo valuation technique included: estimated risk-free interest rate of 2.0 percent; term of 2.8 years; expected volatility of 100 percent; and expected dividend yield of 0 percent. The risk-free interest rate was determined based on the yields available on U.S. Treasury zero-coupon issues. The expected stock price volatility was determined using historical volatility. The expected dividend yield was based on expectations regarding dividend payments. The total grant date fair value of the market-based awards was $117,625.

 

2022 Modifications

 

In May 2022, the Company approved amendments to vesting conditions of 61,875 performance-based and 12,500 market-based awards of certain executive officers and employees. The performance-based awards were modified such that the stock awards will be eligible to vest as follows: (i) 50% will vest on December 31, 2023 if the Company achieves LCD reimbursement for VitaGraft (formerly TheraSure Transplant Monitor) for one organ no later than December 31, 2022 and (ii) 50% will vest on December 31, 2023 if DetermaIO or DetermaCNI (formerly TheraSure - CNI Monitor) submission for LCD is completed no later than December 31, 2022. Additional performance-based RSU awards were modified to be eligible to vest upon the achievement by the Company of average market capitalization minimum, target, and maximum goals of (i) $300 million; (ii) $400 million; and (iii) $500 million, respectively, during the period beginning on January 1, 2022 and ending on December 31, 2024. The market-based RSU awards were modified such that the awards will be eligible to vest upon the achievement of product commercial launch minimum, target, and maximum goals as follows: (i) one laboratory test product in the US; (ii) two laboratory test products in US, and (iii) three laboratory test products in the US, respectively.

 

In accordance with ASC 718, the Company calculated the fair value of the market-based awards on the date of modification, noting an increase in the fair value of approximately $58,500, with the incremental increase in fair value representing additional stock-based compensation expense. The following assumptions were used in calculating the fair value of the market-based options on the date of modification: estimated risk-free interest rate of 2.72 percent, term of 2.6 years, expected volatility of 95.0 percent and expected dividend yield of 0 percent.

 

 

In July 2022, the Company approved amendments to vesting conditions of 23,750 performance-based awards of certain executive officers and employees. Certain performance-based awards were modified such that the stock awards will be eligible to vest as follows: (i) fifty percent (50%) of the options will vest on December 31, 2023 (the “Vesting Date”), subject to Continuous Service through the Vesting Date, if local coverage determination is issued and priced for VitaGraft (Transplant) with respect to one organ no later than December 31, 2022; and (ii) fifty percent (50%) of the options will vest on the Vesting Date, subject to Continuous Service through the Vesting Date, if the Company submits a local coverage determination request for DetermaIO or DetermaCNI no later than December 31, 2022. Additional performance-based stock awards were modified to be eligible to vest upon the achievement of performance minimum, target, and maximum goals of (i) 90% of revenue goal; (ii) 100% of revenue goal; and (iii) exceed revenue goal by up to 150%, respectively, during fiscal year 2022. These same awards contained budget performance goals which were modified to be eligible to vest upon the achievement of performance minimum, target, and maximum goals of (i) complete fiscal year 2022 with sufficient cash to continue operations for 12 months; (ii) complete fiscal year 2022 with sufficient cash to continue operations for 15 months; and (iii) complete fiscal year 2022 with sufficient cash to continue operations for 16 months, respectively.

 

As of December 31, 2022, 50% of the performance-based were forfeited since the Company did not achieve LCD reimbursement for VitaGraft. The remaining 50% is eligible to vest on December 31, 2023, since the Company completed the LCD submission for DetermaCNI on December 16, 2022.

 

During the year ended December 31, 2022, the Company accelerated the vesting of certain equity awards in accordance with the 2018 Incentive Plan after the departure of officers of the Company and the adoption of the workforce reduction plan. Due to the acceleration of such awards all associated unrecognized compensation was accelerated and recognized in full.

 

2010 Plan Activity

 

A summary of Oncocyte’s 2010 Plan activity and related information follows:

 

   Shares   Number   Weighted 
   Available   of Options   Average 
Options  for Grant   Outstanding   Exercise Price 
   (In thousands, except weighted average exercise price) 
Balance at December 31, 2022   -    30   $80.78 
Exercised   -    -   $- 
Cancelled   -    (20)  $- 
Balance at September 30, 2023   -    10   $73.22 
Exercisable at September 30, 2023        10   $73.22 

 

2018 Plan Activity

 

A summary of Oncocyte’s 2018 Incentive Plan activity and related information follows:

 

  

Shares

Available

for Grant

  

Number

of Options

Outstanding

  

Number

of RSUs

Outstanding

  

Weighted

Average

Exercise Price

 
   (In thousands, except weighted average exercise price) 
Balance at December 31, 2022   442    428    22   $59.23 
RSUs vested   -    -    (14)  $- 
RSUs granted   (9)   -    5   $- 
Options granted   (298)   298    -   $5.96 
Options forfeited/expired   235    (235)   -   $- 
RSUs forfeited/expired   2    -    (1)  $- 
Performance RSUs forfeited/expired   15    -    (7)  $- 
Balance at September 30, 2023   387    491    5   $27.31 
Options exercisable at September 30, 2023        140        $98.80 

 

 

During the nine months ended September 30, 2023, the Company granted 178,000 employee and non-employee stock option awards. The assumptions used to calculate the Black-Scholes grant date fair value of such awards were as follows:

 

   Nine Months Ended 
   September 30, 
   2023   2022 
Expected life (in years)   6.25    5.98 
Risk-free interest rates   3.76%   2.29%
Volatility   105.99%   106.85%
Dividend yield   0%   0%

 

In August 2023, the Company awarded 120,000 stock option grants with market-based and time-based vesting conditions to certain executives. The fair value of such awards was estimated using the Monte Carlo simulation model. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated period to achievement of the performance and market conditions, which are subject to the achievement of the market-based goals established by the Company and the continued employment of the executives through December 31, 2025. These awards vest only to the extent that the market-based conditions are satisfied as specified in the vesting conditions. The grant date fair value and associated compensation cost of the market-based awards reflect the probability of the market condition being achieved, and the Company will recognize this compensation cost regardless of the actual achievement of the market condition. Assumptions utilized in connection with the Monte Carlo valuation technique included: estimated risk-free interest rate of 4.81 percent; term of 6.19 years; expected volatility of 91.0 percent; and expected dividend yield of 0 percent. The risk-free interest rate was determined based on the yields available on U.S. Treasury zero-coupon issues. The expected stock price volatility was determined using historical volatility. The expected dividend yield was based on expectations regarding dividend payments. Based on the market-based conditions, the grant date fair values of these awards ranged from $1.09 to $1.74, amounting to a total fair value of approximately $156,000.

 

Oncocyte recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
   (In thousands) 
Cost of revenues  $(2)  $94   $10   $239 
Research and development   294    521    931    1,416 
Sales and marketing   64    942    216    1,681 
General and administrative   252    1,624    1,119    4,087 
Total  $608   $3,181   $2,276   $7,423 

 

In August 2023, the Company issued 9,091 restricted stock awards in connection with a consulting service arrangement for a total fair value of $36,000.

 

The determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If Oncocyte had made different assumptions, its stock-based compensation expense and net loss for the three and nine months ended September 30, 2023, and 2022 may have been significantly different. Refer to Note 2 for additional information.

 

Oncocyte does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when a disqualified disposition has occurred.

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes
9 Months Ended
Sep. 30, 2023
Income Tax Disclosure [Abstract]  
Income Taxes

10. Income Taxes

 

The provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270, Income Taxes, Interim Reporting. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where Oncocyte conducts business.

 

 

Oncocyte did not record any provision or benefit for income taxes for the nine months ended September 30, 2023 and 2022, as Oncocyte had a full valuation allowance for the periods presented.

 

A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. Oncocyte established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carry-forwards and other deferred tax assets.

 

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions
9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Related Party Transactions

11. Related Party Transactions

 

Financing Transactions

 

On April 13, 2022, Oncocyte entered into the Securities Purchase Agreement with the Investors, including Broadwood and John Peter Gutfreund, a former director of Oncocyte, for the Series A Preferred Stock Offering. Each of Broadwood and Mr. Gutfreund has a direct material interest in the Series A Preferred Stock Offering and agreed to purchase 5,882.35 and 1,176.48 shares, respectively, in the Series A Preferred Stock Offering and on the same terms as other investors. Additionally, Halle Capital Management, L.P. received $85,000 from the Company as reimbursement for its legal fees and expenses. Mr. Gutfreund is the Managing Partner of Halle Capital Management, L.P. See Note 8 for additional information about the Series A Preferred Stock Offering.

 

Further, on April 13, 2022, Oncocyte entered into the Underwriting Agreement with the Underwriters for the Underwritten Offering. Pursuant to the Underwritten Offering, Broadwood acquired from us (i) 261,032 shares of common stock, and (ii) 300,187 April 2022 Warrants to purchase up to 150,093 shares of common stock at an exercise price of $30.60 per share. However, the total number of shares of common stock that Broadwood purchased in the Underwritten Offering was 300,187, of which 39,154 existing shares were acquired by the underwriters in the open market and re-sold to Broadwood. Pura Vida acquired from us (i) 249,204 shares of common stock, and (ii) 286,585 April 2022 Warrants to purchase up to 143,292 shares of common stock. However, the total number of shares of common stock that Pura Vida purchased in the Underwritten Offering was 286,585, of which 37,380 existing shares were acquired by the underwriters in the open market and re-sold to Pura Vida. Halle Special Situations Fund LLC purchased from us (i) 309,976 shares of common stock, and (ii) 356,472 2022 Warrants to purchase up to 178,236 shares of common stock. Mr. Gutfreund is the investment manager and a control person of Halle Capital Partners GP LLC, the managing member of Halle Special Situations Fund LLC. However, the total number of shares of common stock that Halle Special Situations Fund LLC purchased in the Underwritten was 356,472, of which 46,496 existing shares were acquired by the underwriters in the open market and re-sold to Halle Special Situations Fund LLC. See Note 8 for additional information about the Underwritten Offering.

 

On April 3, 2023, Oncocyte entered into a securities purchase agreement (the “2023 Securities Purchase Agreement”) with certain investors, including Broadwood, Pura Vida and entities affiliated with AWM, and certain individuals, including our Chairman Andrew Arno and former director John Peter Gutfreund (and certain of their affiliated parties), which provides for the sale and issuance by the Company of an aggregate of 2,274,709 shares of common stock at an offering price of: (i) $6.03 to investors who are not considered to be “insiders” of the Company pursuant to Nasdaq Listing Rules (“Insiders”), which amount reflects the average closing price of the Common Stock on Nasdaq during the five trading day period immediately prior to pricing, and (ii) $7.08 to Insiders, which amount reflects the final closing price of the Common Stock on Nasdaq on the last trading day immediately prior to pricing (the “2023 Registered Direct Offering”). Broadwood purchased 1,341,381 shares of common stock for $8,093,361.84, Pura Vida purchased 33,150 shares of common stock for $200,013.84 and entities affiliated with AVM purchased 472,354 shares of common stock for $2,849,999.92. Mr. Arno and his affiliated parties purchased 21,162 shares of common stock for $150,000.51, and Mr. Gutfreund and his affiliated parties purchased 85,250 for $604,252.00.

 

On April 5, 2023, Oncocyte redeemed all of the 588.23529 shares of Series A Preferred Stock held by Mr. Gutfreund for $618,672.34. Mr. Gutfreund is no longer a related party as of June 23, 2023.

 

 

Company Employee

 

The Company previously employed the son of Andrew Arno, Chairman of the Board as its Senior Manager, Investor Relations, Corporate Planning & Development. The total compensation paid by the Company to Mr. Arno’s son since January 1, 2022 is approximately $200,000. Mr. Arno’s son is no longer an employee of the Company as of July 28, 2023.

 

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Co-Development Agreement with Life Technologies Corporation
9 Months Ended
Sep. 30, 2023
Co-development Agreement With Life Technologies Corporation  
Co-Development Agreement with Life Technologies Corporation

12. Co-Development Agreement with Life Technologies Corporation

 

On January 13, 2022, Oncocyte entered into a Collaboration Agreement (the “LTC Agreement”) with Life Technologies Corporation, a Delaware corporation and subsidiary of Thermo Fisher Scientific (“LTC” and together with Oncocyte, the “Parties” or individually, a “Party”), in order to partner in the development and collaborate in the commercialization of Thermo Fisher Scientific’s existing Oncomine Comprehensive Assay Plus and Oncocyte’s DetermaIO assay for use with LTC’s Ion TorrentTM GenexusTM Integrated Sequencer and LTC’s Ion TorrentTM GenexusTM Purification System (“Genexus system”) in order to obtain in vitro diagnostic regulatory approval. On February 7, 2023, Oncocyte entered into a Termination Agreement with LTC, pursuant to which the parties terminated the LTC Agreement. As of the termination date, Oncocyte was responsible for reimbursing LTC for $749,000 of certain development costs under the terms of the LTC Agreement, which have been fully paid.

 

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Discontinued Operations of Razor
9 Months Ended
Sep. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations of Razor

13. Discontinued Operations of Razor

 

On December 15, 2022, the Company entered into the Razor Stock Purchase Agreement with Dragon and Razor. Pursuant to the Razor Stock Purchase Agreement, Oncocyte agreed to sell, and Dragon agreed to purchase, 3,188,181 shares of common stock of Razor, which constitutes approximately 70% of the issued and outstanding equity interests of Razor on a fully-diluted basis. On February 16, 2023, Oncocyte completed the Razor Sale Transaction. In connection with the Razor Closing, Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx. While no monetary consideration was received for the sale of 70% of the equity interests of Razor, the transaction allows the Company to eliminate all development and commercialization costs with respect to DetermaRx. Following the Razor Closing, Oncocyte continues to own 1,366,364 shares of common stock of Razor, which constitutes approximately 30% of the issued and outstanding equity interests of Razor on a fully-diluted basis.

 

In addition to the transfer of 70% of the equity interests of Razor, the Razor Stock Purchase Agreement provided that Dragon would purchase furniture, fixtures, and equipment from the Company for a cash consideration of $115,660. Upon the Razor Closing, the Company deconsolidated the assets and liabilities of Razor as control of Razor has transferred to Dragon.

 

The Company recorded the final adjustment related to the disposal, including final working capital adjustments, and recognized a loss of $1.3 million during the first quarter of 2023. Including the impairment losses we recognized as of December 31, 2022 related to this transaction, we recorded an overall loss of $27.2 million. The operating results for Razor have been recorded in discontinued operations of the accompanying consolidated statements of operations for all periods presented, and we have reclassified their assets and liabilities as discontinued operations in the accompanying balance sheets. We have retrospectively adjusted the amounts reported for the period ended September 30, 2022, in the following table to give effect to such reporting of discontinued operations. For the period ended September 30, 2023, discontinued operations reflect operating results of Razor up to the closing of the sale.

 

The Company’s consolidated balance sheets and consolidated statements of operations report discontinued operations separate from continuing operations. Our consolidated statements of comprehensive loss, statements of shareholders’ equity and statements of cash flows combined continuing and discontinued operations. A summary of financial information related to the Company’s discontinued operations is as follows.

 

 

The following table represents the results of the discontinued operations of Razor:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
   (In thousands) 
Net revenue  $-   $950   $421   $3,824 
                     
Cost of revenues   -    1,855    507    5,854 
Research and development   -    2,949    702    9,200 
Sales and marketing   -    3,600    498    9,966 
General and administrative   -    61    329    133 
Loss from impairment of held for sale assets   -    -    1,311    - 
Net loss from discontinued operations  $-   $(7,515)  $(2,926)  $(21,329)

 

The following table represents the carrying amounts of the assets and liabilities of the discontinued operations of Razor:

 

   September 30,   December 31, 
   2023   2022 
   (In thousands) 
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents  $-   $1,510 
Prepaid expenses and other current assets   -    346 
Machinery and equipment, net, and construction in progress   -    211 
Intangible assets, net   -    25,920 
Impairment of held for sale assets   -    (25,866)
TOTAL ASSETS  $-   $2,121 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Accounts payable  $90   $492 
Accrued compensation   -    248 
Accrued expenses and other current liabilities   -    1,265 
Total current liabilities   90    2,005 
           
TOTAL LIABILITIES  $90   $2,005 

 

The following table summarizes cash used related to the discontinued operations of Razor:

 

   2023   2022 
   Nine Months Ended 
   September 30, 
   2023   2022 
   (In thousands) 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net cash used in operating activities  $(4,357)  $(15,744)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Net cash used in investing activities  $-   $(96)

 

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Accounting Principles

Accounting Principles

 

The consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (“GAAP”).

 

Reclassifications

Reclassifications

 

Certain prior period amounts in the consolidated financial statements and notes to consolidated financial statements have been reclassified to conform to the current period presentation. These changes had no impact on the previously reported consolidated financial condition, results of operations or cash flows.

 

Basis of Presentation

Basis of Presentation

 

The unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance with GAAP for financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations, certain information and footnote disclosures normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance sheet as of December 31, 2022 was derived from the audited consolidated financial statements at that date. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in Oncocyte’s Annual Report on Form 10-K for the year ended December 31, 2022. The accompanying unaudited condensed consolidated financial statements, in the opinion of management, include all adjustments of a normal recurring nature necessary for a fair presentation of Oncocyte’s financial condition and results of operations. The consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

 

 

On July 24, 2023, the Company implemented a 1-for-20 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230 million shares.

 

Principles of Consolidation

Principles of Consolidation

 

On January 31, 2020, with the acquisition of Insight Genetics, Inc. (“Insight”) through a merger with a newly incorporated wholly-owned subsidiary of Oncocyte (the “Insight Merger”) under the terms of an Agreement and Plan of Merger (the “Insight Merger Agreement”), Insight became a wholly-owned subsidiary of Oncocyte, and on that date Oncocyte began consolidating Insight’s operations and results with Oncocyte’s operations and results (see Note 3).

 

On April 15, 2021, with the acquisition of Chronix Biomedical, Inc. (“Chronix”) pursuant to an Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021 (as amended and restated, the “Chronix Merger Agreement”), by and among Oncocyte, CNI Monitor Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Oncocyte (“Merger Sub”), Chronix became a wholly-owned subsidiary of Oncocyte (the “Chronix Merger”), and on that date Oncocyte began consolidating Chronix’s operations and results with Oncocyte’s operations and results (see Note 3).

 

We have reflected the operations of Razor as discontinued operations for all periods presented. See Note 13 for further information. Amounts and disclosures throughout these Notes to consolidated financial statements relate solely to continuing operations and exclude all discontinued operations. Discontinued operations comprise activities that were disposed of or discontinued at the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting purposes and represent a strategic business shift having a major effect on the Company’s operations and financial results according to ASC Topic 205, Presentation of Financial Statements.

 

All material intercompany accounts and transactions have been eliminated in consolidation.

 

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and contingent assets and liabilities, at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including, but not limited to, valuation methods used, assumptions requiring the use of judgment to prepare financial projections, timing of potential commercialization of acquired in-process intangible assets, applicable discount rates, probabilities of the likelihood of multiple outcomes of certain events related to contingent consideration, comparable companies or transactions, determination of fair value of the assets acquired and liabilities assumed including those relating to contingent consideration, assumptions related to going concern assessments, allocation of direct and indirect expenses, useful lives associated with long-lived intangible assets, key assumptions in operating and financing leases including incremental borrowing rates, loss contingencies, valuation allowances related to deferred income taxes, allowances for credit losses, and assumptions used to value debt and stock-based awards and other equity instruments. Actual results may differ materially from those estimates.

 

Similarly, Oncocyte assessed certain accounting matters that generally require consideration of forecasted financial information. The accounting matters assessed included, but were not limited to, Oncocyte’s equity investments, the carrying value of goodwill, going concern assessment, acquired in-process intangible assets and other long-lived assets. Those assessments as well as other estimates referenced above were made in the context of information reasonably available to Oncocyte.

 

 

Segments

Segments

 

Oncocyte’s executive management team, as a group, represents the entity’s chief operating decision makers. To date, Oncocyte’s executive management team has viewed Oncocyte’s operations as one segment that includes the research, development and commercialization of diagnostic tests, including molecular diagnostic services to pharmaceutical customers. As a result, the financial information disclosed materially represents all of the financial information related to Oncocyte’s sole operating segment.

 

Fair Value Measurements, Business Combinations and Contingent Consideration Liabilities

Fair Value Measurements, Business Combinations and Contingent Consideration Liabilities

 

Oncocyte accounts for business combinations in accordance with ASC 805, which requires the purchase consideration transferred to be measured at fair value on the acquisition date in accordance with ASC 820, Fair Value Measurement. ASC 820 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:

 

Level 1 – Quoted prices in active markets for identical assets and liabilities.

 

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

When a part of the purchase consideration consists of shares of Oncocyte common stock, Oncocyte calculates the purchase price attributable to those shares, a Level 1 security, by determining the fair value of those shares as of the acquisition date based on prices quoted on the principal national securities exchange on which the shares traded. Oncocyte recognizes estimated fair values of the tangible assets and identifiable intangible assets acquired, including in-process research and development, and liabilities assumed, including any contingent consideration, as of the acquisition date. Goodwill is recognized as any amount of the fair value of the tangible and identifiable intangible assets acquired and liabilities assumed in excess of the consideration transferred. ASC 805 precludes the recognition of an assembled workforce as an asset, effectively subsuming any assembled workforce value into goodwill.

 

In determining fair value, Oncocyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, Oncocyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for money market funds and marketable equity securities held by Oncocyte described below. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.

 

Certain of Oncocyte’s asset and business acquisitions involve the potential for future payment of consideration to third-parties and former selling shareholders in amounts determined as a percentage of future net revenues generated, or upon attainment of revenue milestones, from Pharma Services or laboratory tests, as applicable, or annual minimum royalties to certain licensors, as provided in the applicable agreements. The fair value of such liabilities is determined using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows. These obligations are referred to as contingent consideration, which are carried at fair value based on Level 3 inputs.

 

 

ASC 805 requires that contingent consideration be estimated and recorded at fair value as of the acquisition date as part of the total consideration transferred. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings, such as “earn-out” provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of certain revenues generated.

 

The fair value of contingent consideration after the acquisition date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in the consolidated statements of operations. Changes in key assumptions can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that Oncocyte records in its consolidated financial statements. See Note 3 for a full discussion of these liabilities and additional Level 3 fair value disclosures.

 

The following tables present the Company’s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy:

 

   As of September 30, 2023 
   Fair value   Level 1   Level 2   Level 3 
   (In thousands) 
Assets:                    
Marketable equity securities  $441   $441   $-   $- 
Total  $441   $441   $-   $- 
                     
Liabilities:                    
Contingent consideration liabilities (Note 3)  $28,715   $-   $-   $28,715 
Total  $28,715   $-   $-   $28,715 

 

   As of December 31, 2022 
   Fair value   Level 1   Level 2   Level 3 
   (In thousands) 
Assets:                    
Marketable equity securities  $433   $433   $-   $- 
Total  $433   $433   $-   $- 
                     
Liabilities:                    
Contingent consideration liabilities (Note 3)  $45,662   $-   $-   $45,662 
Total  $45,662   $-   $-   $45,662 

 

The carrying amounts of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.

 

In accordance with GAAP, from time to time, the Company measures certain assets at fair value on a nonrecurring basis. The Company reviews the carrying value of goodwill, intangibles, including in-process research and development (“IPR&D”) (see Note 5), and other long-lived assets for indications of impairment at least annually. Refer to related discussions of impairments below.

 

Cash, Cash Equivalents and Restricted Cash

Cash, Cash Equivalents and Restricted Cash

 

Oncocyte considers all highly liquid securities with original maturities of three months or less when purchased to be cash equivalents. For the periods presented, Oncocyte’s cash equivalents are comprised of investments in AAA rated money market funds that invest in first-tier only securities, which primarily include domestic commercial paper and securities issued or guaranteed by the U.S. government or its agencies. Restricted cash relates to a bank letter of credit required under our office lease arrangement, refer to Note 7 for additional information.

 

 

Marketable Equity Securities

Marketable Equity Securities

 

Oncocyte accounts for the shares of Lineage and AgeX common stock it holds as marketable equity securities in accordance with ASC 320-10-25, Investments – Debt and Equity Securities, as amended, as the shares have a readily determinable fair value quoted on the NYSE American and are held principally to meet future working capital purposes, as necessary. The securities are measured at fair value, with related gains and losses in the value of such securities recorded in the consolidated statements of operations in other income or expense, and are reported as current assets on the consolidated balance sheets based on the closing trading price of the security as of the date being presented.

 

As of September 30, 2023 and December 31, 2022, Oncocyte held 353,264 and 35,326 shares of common stock of Lineage and AgeX, respectively, as marketable equity securities, which had a combined fair market value of $441,000 and $433,000, respectively.

 

Investments in Capital Stock of Privately Held Companies

Investments in Capital Stock of Privately Held Companies

 

Oncocyte evaluates whether investments held in common stock of other companies require consolidation of the company under, first, the variable interest entity (“VIE”) model, and then under the voting interest model in accordance with accounting guidance for consolidations under ASC 810-10. If consolidation of the entity is not required under either the VIE model or the voting interest model, Oncocyte determines whether the equity method of accounting should be applied in accordance with ASC 323, Investments – Equity Method and Joint Ventures. The equity method applies to investments in common stock or in-substance common stock if Oncocyte exercises significant influence over, but does not control, the entity, where significant influence is typically represented by ownership of 20% or more, but less than majority ownership, of the voting interests of a company.

 

Oncocyte initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment balance based on Oncocyte’s pro rata share of earnings or losses from the investment.

 

From February 24, 2021, the date of Oncocyte’s acquisition of the remaining interests in Razor, through February 16, 2023 the date of its disposition, Razor entity’s financial statements were consolidated with Oncocyte. See Note 13 for additional information related to the discontinued operations of Razor.

 

Assets Held for Sale

Assets Held for Sale

 

Assets and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management, having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified as held for sale in the consolidated balance sheet. Assets classified as held for sale are reported at the lower of their carrying value or fair value less costs to sell. Depreciation and amortization of assets ceases upon designation as held for sale.

 

During the nine months ended September 30, 2023, the Company entered into various agreements to sell laboratory equipment. As a result, the Company classified the equipment as held for sale as current assets, in the consolidated balance sheet, as all the criteria of ASC subtopic 360-10, Property, Plant, and Equipment (“ASC 360-10”) have been met and the transactions were qualified as assets held for sale. The equipment was written down to its fair value, less cost to sell, the remainder of which was $139,000 as of September 30, 2023. As a result of these transactions, the Company recorded an impairment loss of $1.3 million on held for sale assets, in the consolidated statement of operations.

 

 

Machinery and Equipment, Net, and Construction in Progress

Machinery and Equipment, Net, and Construction in Progress

 

Machinery and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of 3 to 10 years. For equipment purchased under financing leases, Oncocyte depreciates the equipment based on the shorter of the useful life of the equipment or the term of the lease, ranging from 3 to 5 years, depending on the nature and classification of the financing lease. Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in Oncocyte’s results of operations.

 

Construction in progress, comprised primarily of leasehold improvements under construction, is not depreciated until the underlying asset is placed into service.

 

Goodwill and Intangible Assets

Goodwill and Intangible Assets

 

In accordance with ASC 350, Intangibles – Goodwill and Other, IPR&D projects acquired in a business combination that are not complete as of the acquisition date are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Oncocyte considers various factors and risks for potential impairment of IPR&D assets, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays or inability to obtain local determination coverage (“LCD”) from the Centers for Medicare and Medicaid Services (“CMS”) for Medicare reimbursement for a diagnostic test, the inability to bring a diagnostic test to market and the introduction or advancement of competitors’ diagnostic tests could result in partial or full impairment of the related intangible assets. Consequently, the eventual realized value of the IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. During the period between completion or abandonment, the IPR&D assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if Oncocyte becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts (see Note 5).

 

Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill, similar to IPR&D, is not amortized but is tested for impairment at least annually, or if circumstances indicate its value may no longer be recoverable. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors affecting Oncocyte’s business. Based on the qualitative assessment, if it is determined that the fair value of goodwill is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. Oncocyte continues to operate in one segment and considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at the enterprise level.

 

Oncocyte does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&D discussed in Notes 3 and 5. As of September 30, 2023, goodwill has been fully impaired and acquired IPR&D has been partially impaired.

 

Long-Lived Intangible Assets

Long-Lived Intangible Assets

 

Long-lived intangible assets, consisting primarily of acquired customer relationships, are stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful life of 5 years (see Note 5).

 

 

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

 

Oncocyte assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. Oncocyte’s long-lived assets consist primarily of intangible assets, right-of-use assets for operating leases, customer relationships, and machinery and equipment. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. See Note 4 for additional information with respect to the impairment of leasehold improvements. See “Assets held for sale” above for additional impairment disclosures.

 

Leases

Leases

 

Oncocyte accounts for leases in accordance with ASC 842, Leases. Oncocyte determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. Under the available practical expedients for the adoption of ASC 842, Oncocyte accounts for the lease and non-lease components as a single lease component. Oncocyte recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheet. ROU assets represent the right to use an underlying asset during the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most leases do not provide an implicit rate, Oncocyte uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Oncocyte uses the implicit rate when it is readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that Oncocyte will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Operating leases include our office leases and are also included as right-of-use assets in machinery and equipment, and ROU lease liabilities, current and long-term, in the consolidated balance sheets. Financing leases are included in machinery and equipment, and in financing lease liabilities, current and long-term, in the consolidated balance sheets. Oncocyte discloses the amortization of our ROU assets and operating lease payments as a net amount in the consolidated statements of cash flows. Based on the available practical expedients under the standard, Oncocyte elected not to capitalize leases that have terms of twelve months or less.

 

During prior years, Oncocyte entered into various operating leases and an embedded operating lease in accordance with ASC 842 as discussed in Note 7. Oncocyte’s accounting for financing leases remained substantially unchanged.

 

Revenue Recognition

Revenue Recognition

 

Pursuant to ASC 606, revenues are recognized when control of services performed is transferred to customers, in an amount that reflects the consideration Oncocyte expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes:

 

(i) identifying the contract with a customer,

(ii) identifying the performance obligations in the contract,

(iii) determining the transaction price,

(iv) allocating the transaction price to the performance obligations, and

(v) recognizing revenue when, or as, an entity satisfies a performance obligation.

 

Oncocyte determines transaction prices based on the amount of consideration we expect to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. The Company considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.

 

 

The following table presents consolidated revenues by service:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
   (In thousands) 
Pharma Services  $423   $67   $1,137   $684 
Laboratory developed test services   6    -    52    - 
Total  $429   $67   $1,189   $684 

 

Pharma Services Revenue

 

Revenues recognized include Pharma Services performed by Oncocyte’s Insight and Chronix subsidiaries for its pharmaceutical customers, including testing for biomarker discovery, assay design and development, clinical trial support, and a broad spectrum of biomarker tests. These Pharma Services are generally performed under individual scope of work (“SOW”) arrangements or license agreements (together with SOW the “Pharma Services Agreements”) with specific deliverables defined by the customer. Pharma Services are performed on a (i) time and materials basis or (ii) per test completed basis. Upon completion of the service to the customer in accordance with a Pharma Services Agreement, Oncocyte has the right to bill the customer for the agreed upon price (either on a per test or per deliverable basis) and recognizes Pharma Service revenue at that time. Insight identifies each sale of its Pharma Service offering as a single performance obligation. Chronix identifies the processing of test samples as a separate performance obligation (considered a series) within license agreements with customers.

 

Completion of the service and satisfaction of the performance obligation is typically evidenced by access to the report or test made available to the customer or any other form or applicable manner of delivery defined in the Pharma Services Agreements. However, for certain SOWs under which work is performed pursuant to the customer’s highly customized specifications, Oncocyte has the enforceable right to bill the customer for work completed, rather than upon completion of the SOW. For those SOWs, Oncocyte recognizes revenue over a period during which the work is performed using a formula that accounts for expended efforts, generally measured in labor hours, as a percentage of total estimated efforts for the completion of the SOW. As performance obligations are satisfied under the Pharma Services Agreements, any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed to the customer as of the date of Oncocyte’s consolidated financial statements are recorded as contract assets and are included in prepaids and other current assets as of the financial statement date. Amounts recorded in contract assets are reclassified to accounts receivable in Oncocyte’s consolidated balance sheets when the customer is invoiced according to the billing schedule in the contract.

 

As of September 30, 2023 and December 31, 2022, Oncocyte had accounts receivable from Pharma Services customers of $557,000 and $257,000, respectively.

 

Allowance for Credit Losses

 

Oncocyte establishes an allowance for credit losses based on the evaluation of the collectability of its Pharma Services accounts receivables after considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer’s ability to pay, such as a bankruptcy filing or deterioration in the customer’s operating results or financial position, reasonable and supportable forecast that affect the collectability of the reported amount, and historical experience. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. Oncocyte continuously monitors collections and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts, if any, based upon its historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are written off against the credit loss reserve accounts. As of September 30, 2023 and December 31, 2022, we had no allowance for credit losses related to Pharma Services.

 

 

Laboratory Developed Test Services

 

Prior to the Razor Sale Transaction, Oncocyte generated revenue from performing DetermaRx tests on clinical samples through orders received from physicians, hospitals, and other healthcare providers. In determining whether all the revenue recognition criteria (i) through (v) above are met with respect to DetermaRx tests, each test result is considered a single performance obligation and is generally considered complete when the test result is delivered or made available to the prescribing physician electronically, and, as such, there are no shipping or handling fees incurred by Oncocyte or billed to customers. Although Oncocyte has billed a list price for all tests ordered and completed for all payer types, Oncocyte considers constraints on the variable consideration when recognizing revenue for DetermaRx. Because DetermaRx is a novel test and there are no current reimbursement arrangements with third-party payers other than Medicare, the transaction price represents variable consideration. Application of the constraint for variable consideration is an area that requires significant judgment. For all payers other than Medicare, Oncocyte must consider the novelty of the test, the uncertainty of receiving payment, or being subject to claims for a refund, from payers with whom it does not have a sufficient payment collection history or contractual reimbursement agreements. Accordingly, for those payers, Oncocyte has recognized revenue upon payment because it has had insufficient history to reliably estimate payment patterns or has had contractual reimbursement arrangements, or both, in place.

 

As of September 30, 2023 and December 31, 2022, Oncocyte had accounts receivable of $1.5 million and $1.9 million, respectively, from Medicare and Medicare Advantage covered DetermaRx tests.

 

Allowance for Credit Losses

 

We maintain an allowance for credit losses related to laboratory developed test services at an amount we estimate to be sufficient to provide adequate protection against losses resulting from extending credit to our customers. We base this allowance, in the aggregate, on historical collection experience, age of receivables and general economic conditions. Our bad debt write-offs have not been significant and have been within management expectations. As of September 30, 2023 and December 31, 2022, we had an allowance for credit losses of $178,000 and $154,000, respectively, related to laboratory developed test services.

 

Licensing Revenue

 

Revenues recognized include licensing revenue derived from agreements with customers for exclusive rights to market Oncocyte’s proprietary testing technology. Under the agreements, Oncocyte grants exclusive rights to certain trademarks and technology of Oncocyte for the purpose of marketing Oncocyte’s tests within a defined geographic territory. A license agreement may specify milestone deliverables or performance obligations, for which Oncocyte recognizes revenue when its licensee confirms the completion of Oncocyte’s performance obligation. A licensing agreement may also include ongoing sales support from Oncocyte and typically includes non-refundable licensing fees and per-test Pharma Services revenues discussed above, for which Oncocyte treats the licensing of the technology, trademarks, and ongoing support as a single performance obligation satisfied by the passage of time over the term of the agreement.

 

Disaggregation of Revenues and Concentrations of Credit Risk

 

The following table presents the percentage of consolidated revenues by service:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
Pharma Services   99%   100%   96%   100%
Laboratory developed test services   1%   0%   4%   0%
Total   100%   100%   100%   100%

 

 

The following table presents the percentage of consolidated revenues generated by unaffiliated customers, based on the respective periods presented, that individually represented greater than ten percent of consolidated revenues:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
Pharma services - Company A   57%   28%   42%   60%
Pharma services - Company B   41%   22%   34%   11%
Pharma services - Company C    -*    22%   -*    -* 
Pharma services - Company D   -*    19%   -*    -* 

 

* Less than 10%

 

The following table presents the percentage of consolidated revenues attributable to geographical locations:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
United States – Pharma Services   42%   76%   54%   74%
Outside of the United States – Pharma Services   57%   24%   41%   26%
United States – Laboratory developed test services   1%   0%   4%   0%
Total   100%   100%   100%   100%

 

Financial instruments that potentially subject the Company to concentrations of credit risk are cash equivalents and accounts receivable. The Company places its cash equivalents primarily in highly rated money market funds. Cash and cash equivalents are also invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. The Company has not experienced any significant losses on its deposits of cash and cash equivalents.

 

Two Pharma Services customers individually represented approximately 54% and 45% of accounts receivable at September 30, 2023. Two Pharma Services customers individually represented approximately 59% and 30% of accounts receivable at December 31, 2022.

 

Cost of Revenues

Cost of Revenues

 

Cost of revenues generally consists of cost of materials, direct labor including benefits, bonus and stock-based compensation, equipment and infrastructure expenses, clinical sample related costs associated with performing DetermaRx tests and Pharma Services, providing deliverables according to our licensing agreements, license fees due to third parties, and amortization of acquired intangible assets such as the customer relationship intangible assets. Infrastructure expenses include depreciation of laboratory equipment, allocated rent costs, leasehold improvements, and allocated information technology costs for operations at Oncocyte’s CLIA laboratories in California and Tennessee. Costs associated with generating the revenues are recorded as the tests or services are performed regardless of whether revenue was recognized. Royalties or revenue share payments for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expenses at the time the related revenues are recognized.

 

Research and Development Expenses

Research and Development Expenses

 

Research and development expenses are comprised of costs incurred to develop technology, which include salaries and benefits (including stock-based compensation), laboratory expenses (including reagents and supplies used in research and development laboratory work), infrastructure expenses (including allocated facility occupancy costs), and contract services and other outside costs. Indirect research and development expenses are allocated primarily based on headcount, as applicable, and include rent and utilities, common area maintenance, telecommunications, property taxes, and insurance. Research and development costs are expensed as incurred.

 

 

Sales and Marketing Expenses

Sales and Marketing Expenses

 

Sales and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade show expenses, branding and positioning expenses, and consulting fees. Sales and marketing expenses also include indirect expenses for applicable overhead allocated based on headcount, and include allocated costs for rent and utilities, common area maintenance, telecommunications, property taxes, and insurance.

 

General and Administrative Expenses

General and Administrative Expenses

 

General and administrative expenses consist primarily of compensation and related benefits (including stock-based compensation) for executive and corporate personnel, professional and consulting fees, rent and utilities, common area maintenance, telecommunications, property taxes, and insurance.

 

Stock-Based Compensation

Stock-Based Compensation

 

Oncocyte recognizes compensation expense related to employee option grants and restricted stock grants in accordance with the Financial Accounting Standards Board (“FASB”) ASC 718, Compensation – Stock Compensation (“ASC 718”).

 

Oncocyte estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value over the requisite service period. For stock-based awards that vest only upon the attainment of one or more performance goals set by Oncocyte at the time of the grant (sometimes referred to as milestone vesting), compensation cost is recognized if and when Oncocyte determines that it is probable that the performance condition or conditions will be, or have been, achieved. Oncocyte uses the Black-Scholes option pricing model for estimating the fair value of options granted under Oncocyte’s equity plans. The fair value of each restricted stock unit (“RSU”) or award is determined based on the value of the common stock granted or sold. Oncocyte has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period. Forfeitures are accounted for as they occur. Refer to Note 9 for additional information.

 

The Black-Scholes option pricing model requires Oncocyte to make certain assumptions including the expected option term, the expected volatility, the risk-free interest rate and the dividend yield. The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. Oncocyte estimates the expected term of options granted based on its own experience. Oncocyte estimates the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of peer companies, for a period equal to the expected term of the options. The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of Oncocyte’s stock options. The dividend yield assumption is based on Oncocyte’s history and expectation of dividend payouts. Oncocyte has never declared or paid any cash dividends on its common stock, and Oncocyte does not anticipate paying any cash dividends in the foreseeable future.

 

All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as income tax benefit or expense, respectively, in the statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction. Because Oncocyte has a full valuation allowance for all periods presented (see Note 10), there was no impact to Oncocyte statements of operations for any excess tax benefits or deficiencies, as any excess benefit or deficiency would be offset by the change in the valuation allowance.

 

Accounting for Warrants

Accounting for Warrants

 

Oncocyte determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate Oncocyte to settle the warrants or the underlying shares by paying cash or other assets or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480, Oncocyte assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. This liability classification guidance also applies to financial instruments that may require cash or other form of settlement for transactions outside of the company’s control and, in which the form of consideration to the warrant holder may not be the same as to all other shareholders in connection with the transaction. However, if a transaction is not within the company’s control but the holder of the financial instrument can solely receive the same type or form of consideration as is being offered to all the shareholders in the transaction, then equity classification of the financial instrument is not precluded, if all other applicable equity classification criteria are met.

 

 

After all relevant assessments, Oncocyte concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. Based on the above guidance and, among other factors, the fact that our warrants cannot be cash settled under any circumstance but require share settlement, all of our outstanding warrants meet the equity classification criteria and have been classified as equity. Refer to Notes 6 and 8 for details about our outstanding warrants.

 

Net Loss Per Common Share

Net Loss Per Common Share

 

Basic loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of shares of common stock outstanding during the year. Diluted loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method or the if-converted method, or the two-class method for participating securities, whichever is more dilutive. Potential common shares are excluded from the computation if their effect is antidilutive.

 

All common stock equivalents are antidilutive because Oncocyte reported a net loss for all periods presented. The following table presents the calculation of basic and diluted loss per share of common stock:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
   (In thousands, except per share data) 
Numerator:                    
Net loss attributable to Oncocyte Corporation  $(6,489)  $(9,333)  $(11,789)  $(27,924)
Accretion of Series A redeemable convertible preferred stock   (198)   (294)   (621)   (294)
Deemed dividend on Series A redeemable convertible preferred stock   -    -    (118)   - 
Net loss attributable to common stockholders - basic and diluted  $(6,687)  $(9,627)  $(12,528)  $(28,218)
                     
Denominator:                    
Weighted average shares used in computing net loss per share attributable to common stockholders - basic and diluted   8,256    5,931    7,446    5,408 
                     
Basic and diluted net loss per common share  $(0.81)  $(1.62)  $(1.68)  $(5.22)
                     
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share:                    
Stock options   501    717    501    717 
RSUs   5    29    5    29 
Warrants   820    820    820    820 
Series A redeemable convertible preferred stock   5    4    5    4 
Total   1,331    1,570    1,331    1,570 

 

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Previously, U.S. GAAP required entities to write down credit losses only when losses are probable and loss reversals are not permitted. The Company adopted this ASU in the first quarter of 2023. Adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.

 

In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, to provide specific guidance to eliminate diversity in practice on how to recognize and measure acquired contract assets and contract liabilities from revenue contracts from customers in a business combination consistent with revenue contracts with customers not acquired in an acquisition. The amendments in this update provide that the acquirer should consider the terms of the acquired contracts, such as timing of payment, identify each performance obligation in the contracts, and allocate the total transaction price to each identified performance obligation on a relative standalone selling price basis as of contract inception (that is, the date the acquiree entered into the contracts) or contract modification to determine what should be recorded at the acquisition date. The Company adopted this ASU in the first quarter of 2023. Adoption of this standard did not have an impact on the Company’s consolidated financial statements and related disclosures.

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Schedule of Fair Value Measurement of Financial Assets and Liabilities

The following tables present the Company’s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy:

 

   As of September 30, 2023 
   Fair value   Level 1   Level 2   Level 3 
   (In thousands) 
Assets:                    
Marketable equity securities  $441   $441   $-   $- 
Total  $441   $441   $-   $- 
                     
Liabilities:                    
Contingent consideration liabilities (Note 3)  $28,715   $-   $-   $28,715 
Total  $28,715   $-   $-   $28,715 

 

   As of December 31, 2022 
   Fair value   Level 1   Level 2   Level 3 
   (In thousands) 
Assets:                    
Marketable equity securities  $433   $433   $-   $- 
Total  $433   $433   $-   $- 
                     
Liabilities:                    
Contingent consideration liabilities (Note 3)  $45,662   $-   $-   $45,662 
Total  $45,662   $-   $-   $45,662 
Schedule of Disaggregation Of Revenue

The following table presents consolidated revenues by service:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
   (In thousands) 
Pharma Services  $423   $67   $1,137   $684 
Laboratory developed test services   6    -    52    - 
Total  $429   $67   $1,189   $684 
Schedule of Concentration Of Risk

The following table presents the percentage of consolidated revenues by service:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
Pharma Services   99%   100%   96%   100%
Laboratory developed test services   1%   0%   4%   0%
Total   100%   100%   100%   100%
Schedule of Consolidated Revenues Generated by Unaffiliated Customers

The following table presents the percentage of consolidated revenues generated by unaffiliated customers, based on the respective periods presented, that individually represented greater than ten percent of consolidated revenues:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
Pharma services - Company A   57%   28%   42%   60%
Pharma services - Company B   41%   22%   34%   11%
Pharma services - Company C    -*    22%   -*    -* 
Pharma services - Company D   -*    19%   -*    -* 

 

* Less than 10%
Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations

The following table presents the percentage of consolidated revenues attributable to geographical locations:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
United States – Pharma Services   42%   76%   54%   74%
Outside of the United States – Pharma Services   57%   24%   41%   26%
United States – Laboratory developed test services   1%   0%   4%   0%
Total   100%   100%   100%   100%

Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock

All common stock equivalents are antidilutive because Oncocyte reported a net loss for all periods presented. The following table presents the calculation of basic and diluted loss per share of common stock:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
   (In thousands, except per share data) 
Numerator:                    
Net loss attributable to Oncocyte Corporation  $(6,489)  $(9,333)  $(11,789)  $(27,924)
Accretion of Series A redeemable convertible preferred stock   (198)   (294)   (621)   (294)
Deemed dividend on Series A redeemable convertible preferred stock   -    -    (118)   - 
Net loss attributable to common stockholders - basic and diluted  $(6,687)  $(9,627)  $(12,528)  $(28,218)
                     
Denominator:                    
Weighted average shares used in computing net loss per share attributable to common stockholders - basic and diluted   8,256    5,931    7,446    5,408 
                     
Basic and diluted net loss per common share  $(0.81)  $(1.62)  $(1.68)  $(5.22)
                     
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share:                    
Stock options   501    717    501    717 
RSUs   5    29    5    29 
Warrants   820    820    820    820 
Series A redeemable convertible preferred stock   5    4    5    4 
Total   1,331    1,570    1,331    1,570 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Business Combinations (Tables)
9 Months Ended
Sep. 30, 2023
Business Acquisition [Line Items]  
Schedule of Fair Value of Contingent Consideration Liability

The following table shows the Insight Merger Date contractual payment amounts, as applicable, and the corresponding fair value of each respective Contingent Consideration liability:

 

   Contractual   Fair Value on the 
   Value   Merger Date 
   (In thousands) 
Milestone 1  $1,500   $1,340 
Milestone 2   3,000    1,830 
Milestone 3 (a)   1,500    770 
Royalty 1 (b)   See(b)    5,980 
Royalty 2 (b)   See(b)    1,210 
Total  $6,000   $11,130 

 

(a) Indicates the maximum payable if the Milestone is achieved.
   
(b) As defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration.
Insight Merger [Member]  
Business Acquisition [Line Items]  
Schedule of Contingent Consideration, Measured at Fair Value

The following tables reflect the activity for the Insight Contingent Consideration measured at fair value using Level 3 inputs:

 

   Fair Value 
   (In thousands) 
Balance at December 31, 2021  $7,060 
Change in estimated fair value   420 
Balance at September 30, 2022  $7,480 
      
Balance at December 31, 2022  $5,370 
Change in estimated fair value   (3,080)
Balance at September 30, 2023  $2,290 

Chronix Merger [Member]  
Business Acquisition [Line Items]  
Schedule of Contingent Consideration, Measured at Fair Value

The following tables reflect the activity for the Chronix Contingent Consideration measured at fair value using Level 3 inputs:

 

   Fair Value 
   (In thousands) 
Balance at December 31, 2021  $69,621 
Change in estimated fair value   (17,577)
Balance at September 30, 2022  $52,044 
      
Balance at December 31, 2022  $40,292 
Change in estimated fair value   (13,867)
Balance at September 30, 2023  $26,425 

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress (Tables)
9 Months Ended
Sep. 30, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress

Right-of-use and financing lease assets, machinery and equipment, net, and construction in progress were as follows:

 

   September 30, 2023   December 31, 2022 
   (In thousands) 
Right-of-use assets  $4,036   $3,499 
Machinery and equipment   6,908    9,408 
Accumulated depreciation and amortization   (5,819)   (4,196)
Right-of-use assets and machinery and equipment, net   5,125    8,711 
Construction in progress   708    2,140 
Right-of-use and financing lease assets, machinery and equipment, net, and construction in progress  $5,833   $10,851 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Intangible Assets, Net (Tables)
9 Months Ended
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill and Intangible Assets

Intangible assets, net, consisted of the following:

 

   September 30, 2023   December 31, 2022 
   (In thousands) 
Intangible assets:          
Acquired IPR&D - DetermaIOTM (1)  $9,700   $14,650 
Acquired IPR&D - DetermaCNI™ and VitaGraft™ (2)   46,800    46,800 
           
Intangible assets subject to amortization:          
Acquired intangible assets - customer relationship   440    440 
Total intangible assets   56,940    61,890 
Accumulated amortization - customer relationship(3)   (323)   (257)
Intangible assets, net  $56,617   $61,633 

 

(1) See Note 3 for information on the Insight Merger.
(2) See Note 3 for information on the Chronix Merger.
(3) Amortization of intangible assets is included in “Cost of revenues – amortization of acquired intangibles” on the consolidated statements of operations because the intangible assets pertain directly to the revenues generated from the acquired intangibles.
Schedule of Intangible Assets Future Amortization Expense

Future amortization expense of intangible assets subject to amortization is expected to be the following:

 

   Amortization 
   (In thousands) 
Year ending December 31,     
2023  $22 
2024   88 
2025   7 
Total  $117 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies (Tables)
9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases

The following table presents supplemental balance sheet information related to operating and financing leases:

 

   September 30, 2023   December 31, 2022 
   (In thousands) 
Operating lease          
Right-of-use assets, net  $1,748   $2,088 
           
Right-of-use lease liabilities, current  $653   $698 
Right-of-use lease liabilities, noncurrent   2,252    2,730 
Total operating lease liabilities  $2,905   $3,428 
           
Financing lease          
Machinery and equipment  $537   $537 
Accumulated depreciation   (528)   (446)
Machinery and equipment, net  $9   $91 
           
Current liabilities  $30   $117 
Noncurrent liabilities   -    - 
Total financing lease liabilities  $30   $117 
           
Weighted average remaining lease term          
Operating lease   3.9 years    4.5 years 
Financing lease   0.3 years    1.0 years 
           
Weighted average discount rate          
Operating lease   11.29%   11.24%
Financing lease   11.55%   11.55%
Schedule of Future Minimum Lease Commitments for Operating and Financing Leases

Future minimum lease commitments are as follows:

 

   Operating   Financing 
   Leases   Leases 
   (In thousands) 
Year Ending December 31,          
2023  $255   $31 
2024   903    - 
2025   869    - 
2026   899    - 
2027   695    - 
Total minimum lease payments   3,621    31 
Less amounts representing interest   (716)   (1)
Present value of net minimum lease payments  $2,905   $30 
Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease

The following table presents supplemental cash flow information related to operating and financing leases:

 

   2023   2022 
   Nine Months Ended 
   September 30,  
   2023   2022 
   (In thousands) 
Cash paid for amounts included in the measurement of financing lease liabilities:          
Operating cash flows from operating leases  $793   $854 
Operating cash flows from financing leases  $7   $77 
Financing cash flows from financing leases  $86   $4 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Summary of Stock Option Activity

A summary of Oncocyte’s 2018 Incentive Plan activity and related information follows:

 

  

Shares

Available

for Grant

  

Number

of Options

Outstanding

  

Number

of RSUs

Outstanding

  

Weighted

Average

Exercise Price

 
   (In thousands, except weighted average exercise price) 
Balance at December 31, 2022   442    428    22   $59.23 
RSUs vested   -    -    (14)  $- 
RSUs granted   (9)   -    5   $- 
Options granted   (298)   298    -   $5.96 
Options forfeited/expired   235    (235)   -   $- 
RSUs forfeited/expired   2    -    (1)  $- 
Performance RSUs forfeited/expired   15    -    (7)  $- 
Balance at September 30, 2023   387    491    5   $27.31 
Options exercisable at September 30, 2023        140        $98.80 
Schedule of Assumptions Used to Calculate Fair Value of Stock Options

During the nine months ended September 30, 2023, the Company granted 178,000 employee and non-employee stock option awards. The assumptions used to calculate the Black-Scholes grant date fair value of such awards were as follows:

 

   Nine Months Ended 
   September 30, 
   2023   2022 
Expected life (in years)   6.25    5.98 
Risk-free interest rates   3.76%   2.29%
Volatility   105.99%   106.85%
Dividend yield   0%   0%
Summary of Stock-based Compensation Expense

Oncocyte recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
   (In thousands) 
Cost of revenues  $(2)  $94   $10   $239 
Research and development   294    521    931    1,416 
Sales and marketing   64    942    216    1,681 
General and administrative   252    1,624    1,119    4,087 
Total  $608   $3,181   $2,276   $7,423 
2010 Plan Activity [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Summary of Stock Option Activity

A summary of Oncocyte’s 2010 Plan activity and related information follows:

 

   Shares   Number   Weighted 
   Available   of Options   Average 
Options  for Grant   Outstanding   Exercise Price 
   (In thousands, except weighted average exercise price) 
Balance at December 31, 2022   -    30   $80.78 
Exercised   -    -   $- 
Cancelled   -    (20)  $- 
Balance at September 30, 2023   -    10   $73.22 
Exercisable at September 30, 2023        10   $73.22 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Discontinued Operations of Razor (Tables)
9 Months Ended
Sep. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Assets and Liabilities Discontinued Operations

The following table represents the results of the discontinued operations of Razor:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
   (In thousands) 
Net revenue  $-   $950   $421   $3,824 
                     
Cost of revenues   -    1,855    507    5,854 
Research and development   -    2,949    702    9,200 
Sales and marketing   -    3,600    498    9,966 
General and administrative   -    61    329    133 
Loss from impairment of held for sale assets   -    -    1,311    - 
Net loss from discontinued operations  $-   $(7,515)  $(2,926)  $(21,329)
Discontinued Operations, Held-for-Sale [Member]  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Assets and Liabilities Discontinued Operations

The following table represents the carrying amounts of the assets and liabilities of the discontinued operations of Razor:

 

   September 30,   December 31, 
   2023   2022 
   (In thousands) 
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents  $-   $1,510 
Prepaid expenses and other current assets   -    346 
Machinery and equipment, net, and construction in progress   -    211 
Intangible assets, net   -    25,920 
Impairment of held for sale assets   -    (25,866)
TOTAL ASSETS  $-   $2,121 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Accounts payable  $90   $492 
Accrued compensation   -    248 
Accrued expenses and other current liabilities   -    1,265 
Total current liabilities   90    2,005 
           
TOTAL LIABILITIES  $90   $2,005 

 

The following table summarizes cash used related to the discontinued operations of Razor:

 

   2023   2022 
   Nine Months Ended 
   September 30, 
   2023   2022 
   (In thousands) 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net cash used in operating activities  $(4,357)  $(15,744)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Net cash used in investing activities  $-   $(96)
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Organization, Description of the Business and Liquidity (Details Narrative) - USD ($)
9 Months Ended 12 Months Ended 27 Months Ended
Apr. 12, 2023
Apr. 03, 2023
Feb. 16, 2023
Feb. 16, 2023
Dec. 15, 2022
Dec. 15, 2022
Apr. 13, 2022
Apr. 12, 2022
Jun. 11, 2021
Sep. 30, 2022
Dec. 31, 2022
Sep. 30, 2023
Feb. 23, 2021
Accumulated deficit                     $ 260,676,000 $ 272,465,000  
Cash and cash equivalents                     19,993,000 13,783,000  
Marketable equity securities fair value                     433,000 $ 441,000  
Purchase of warrant                       819,767  
Severance cost $ 300,000                   $ 1,900,000    
BTIG, LLC [Member]                          
Gross proceeds from offering                       $ 6,270,000  
Fair value of common stock sold                       56,167  
Sale of stock, price per share                       $ 111.60  
Common Stock [Member]                          
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares                   1,314,000      
Shares issued price per share             $ 0.20            
Razor Stock Purchase Agreement [Member] | Common Stock [Member]                          
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares       1,366,364                  
Razor Stock Purchase Agreement [Member] | Common Stock [Member] | Dragon [Member]                          
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares           3,188,181              
At The Market Sales Agreement [Member] | BTIG, LLC [Member]                          
Gross proceeds from offering                 $ 50,000,000        
Securities Purchase Agreement [Member] | Series A Redeemable Convertible Preferred Stock [Member]                          
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares             11,765            
Issuance of Series A redeemable convertible preferred stock, net of financing costs, shares             384,477            
Conversion price             $ 30.60            
Underwriting Agreement [Member]                          
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares             196,998            
Shares issued price per share             $ 24.85            
Underwriting Agreement [Member] | Underwriter [Member] | Series A Redeemable Convertible Preferred Stock [Member]                          
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares               1,313,320          
Purchase of warrant               1,313,320          
Underwriting Agreement [Member] | Underwriter [Member] | Series A Redeemable Convertible Preferred Stock [Member] | Minimum [Member]                          
Purchase of warrant               656,660          
Underwriting Agreement [Member] | Common Stock [Member]                          
Purchase of warrant             98,499            
Registered Direct Offering [Member] | Maximum [Member]                          
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares   2,278,121                      
Registered Direct Offering [Member] | Board Members [Member]                          
Shares issued price per share   $ 7.08                      
Registered Direct Offering [Member] | Board Members [Member] | Maximum [Member]                          
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares   2,278,121                      
Registered Direct Offering [Member] | Other Investors [Member]                          
Shares issued price per share   $ 6.03                      
Razor Genomics, Inc. [Member]                          
Equity interest                         25.00%
Dragon Scientific LLC [Member] | Razor Stock Purchase Agreement [Member]                          
Equity interest         70.00% 70.00%              
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares         3,188,181                
Razor [Member] | Razor Stock Purchase Agreement [Member]                          
Equity interest     30.00% 30.00%                  
Razor [Member] | Razor Stock Purchase Agreement [Member] | Common Stock [Member]                          
Equity interest     30.00% 30.00%                  
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares     1,366,364                    
Razor [Member] | Razor Stock Purchase Agreement [Member] | Common Stock [Member] | Dragon [Member]                          
Equity interest     70.00% 70.00% 70.00% 70.00%              
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Fair Value Measurement of Financial Assets and Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Assets, Fair Value Disclosure $ 441 $ 433
Liabilities, Fair Value Disclosure 28,715 45,662
Fair Value, Inputs, Level 1 [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Assets, Fair Value Disclosure 441 433
Liabilities, Fair Value Disclosure
Fair Value, Inputs, Level 2 [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Assets, Fair Value Disclosure
Liabilities, Fair Value Disclosure
Fair Value, Inputs, Level 3 [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Assets, Fair Value Disclosure
Liabilities, Fair Value Disclosure 28,715 45,662
Marketable Equity Securities [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Assets, Fair Value Disclosure 441 433
Marketable Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Assets, Fair Value Disclosure 441 433
Marketable Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Assets, Fair Value Disclosure
Marketable Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Assets, Fair Value Disclosure
Contingent Consideration Liabilities [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Liabilities, Fair Value Disclosure 28,715 45,662
Contingent Consideration Liabilities [Member] | Fair Value, Inputs, Level 1 [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Liabilities, Fair Value Disclosure
Contingent Consideration Liabilities [Member] | Fair Value, Inputs, Level 2 [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Liabilities, Fair Value Disclosure
Contingent Consideration Liabilities [Member] | Fair Value, Inputs, Level 3 [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Liabilities, Fair Value Disclosure $ 28,715 $ 45,662
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Disaggregation Of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Total $ 429 $ 67 $ 1,189 $ 684
Pharma Services [Member]        
Total 423 67 1,137 684
Laboratory Developed Test Services [Member]        
Total $ 6 $ 52
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Concentration Of Risk (Details) - Revenue Benchmark [Member] - Product Concentration Risk [Member]
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Product Information [Line Items]        
Total 100.00% 100.00% 100.00% 100.00%
Pharma Services [Member]        
Product Information [Line Items]        
Total 99.00% 100.00% 96.00% 100.00%
Laboratory Developed Test Services [Member]        
Product Information [Line Items]        
Total 1.00% 0.00% 4.00% 0.00%
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details) - Revenue Benchmark [Member] - Customer Concentration Risk [Member]
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Pharma Services Company A [Member]        
Product Information [Line Items]        
Pharma services - Company D 57.00% 28.00% 42.00% 60.00%
Pharma Services Company B [Member]        
Product Information [Line Items]        
Pharma services - Company D 41.00% 22.00% 34.00% 11.00%
Pharma Services Company C [Member]        
Product Information [Line Items]        
Pharma services - Company D [1] 22.00% [1] [1]
Pharma Services Company D [Member]        
Product Information [Line Items]        
Pharma services - Company D [1] 19.00% [1] [1]
[1] Less than 10%
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details) - Revenue Benchmark [Member] - Product Concentration Risk [Member]
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Product Information [Line Items]        
Total 100.00% 100.00% 100.00% 100.00%
UNITED STATES        
Product Information [Line Items]        
Total 42.00% 76.00% 54.00% 74.00%
Outside United States Pharma Services [Member]        
Product Information [Line Items]        
Total 57.00% 24.00% 41.00% 26.00%
United States Laboratory Developed Test Services [Member]        
Product Information [Line Items]        
Total 1.00% 0.00% 4.00% 0.00%
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Net loss attributable to Oncocyte Corporation $ (6,489) $ (9,333) $ (11,789) $ (27,924)
Accretion of Series A redeemable convertible preferred stock (198) (294) (621) (294)
Deemed dividend on Series A redeemable convertible preferred stock (118)
Net loss attributable to common stockholders - Basic (6,687) (9,627) (12,528) (28,218)
Net loss attributable to common stockholders - diluted $ (6,687) $ (9,627) $ (12,528) $ (28,218)
Weighted average number of shares outstanding, basic 8,256 5,931 7,446 5,408
Weighted average number of shares outstanding, diluted 8,256 5,931 7,446 5,408
Basic net loss per common share $ (0.81) $ (1.62) $ (1.68) $ (5.22)
Earnings Per Share, diluted $ (0.81) $ (1.62) $ (1.68) $ (5.22)
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share 1,331,000 1,570,000 1,331,000 1,570,000
Equity Option [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share 501,000 717,000 501,000 717,000
Restricted Stock Units (RSUs) [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share 5,000 29,000 5,000 29,000
Warrant [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share 820,000 820,000 820,000 820,000
Series A Redeemable Convertible Preferred Stock [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share 5,000 4,000 5,000 4,000
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
9 Months Ended 12 Months Ended
Jul. 24, 2023
Sep. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]      
Reverse stock split 1-for-20 reverse stock split    
Common stock, shares authorized 230,000,000 230,000,000 230,000,000
Fair value of equity securities   $ 441,000 $ 433,000
Inventory write down   139,000  
Asset impairment charges   $ 1,300,000  
Long-lived intangible assets, useful life   5 years  
Accounts receivable   $ 1,882,000 2,012,000
Accounts receivable, allowance for credit loss   $ 178,000 $ 154,000
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Pharma Services Customers One [Member]      
Property, Plant and Equipment [Line Items]      
Concentration risk percentage   54.00% 59.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Pharma Services Customers Two [Member]      
Property, Plant and Equipment [Line Items]      
Concentration risk percentage   45.00% 30.00%
Medicare And Medicare Advantage [Member]      
Property, Plant and Equipment [Line Items]      
Accounts receivable   $ 1,500,000 $ 1,900,000
Pharma Services [Member]      
Property, Plant and Equipment [Line Items]      
Accounts receivable   $ 557,000 $ 257,000
Machinery and Equipment [Member] | Minimum [Member]      
Property, Plant and Equipment [Line Items]      
Estimated useful life of plant and equipment   3 years  
Machinery and Equipment [Member] | Maximum [Member]      
Property, Plant and Equipment [Line Items]      
Estimated useful life of plant and equipment   10 years  
Equipment [Member] | Minimum [Member]      
Property, Plant and Equipment [Line Items]      
Lease term   3 years  
Equipment [Member] | Maximum [Member]      
Property, Plant and Equipment [Line Items]      
Lease term   5 years  
Lineage and AgeX [Member]      
Property, Plant and Equipment [Line Items]      
Common stock, shares held as available for sale securities   353,264 35,326
Fair value of equity securities   $ 441,000 $ 433,000
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Fair Value of Contingent Consideration Liability (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
Business Acquisition [Line Items]  
Contractual Value $ 6,000
Fair Value on the Merger Date 11,130
Milestone 1 [Member]  
Business Acquisition [Line Items]  
Contractual Value 1,500
Fair Value on the Merger Date 1,340
Milestone 2 [Member]  
Business Acquisition [Line Items]  
Contractual Value 3,000
Fair Value on the Merger Date 1,830
Milestone 3 [Member]  
Business Acquisition [Line Items]  
Contractual Value 1,500 [1]
Fair Value on the Merger Date 770 [1]
Royalty 1 [Member]  
Business Acquisition [Line Items]  
Fair Value on the Merger Date 5,980 [2]
Royalty 2 [Member]  
Business Acquisition [Line Items]  
Fair Value on the Merger Date $ 1,210 [2]
[1] Indicates the maximum payable if the Milestone is achieved.
[2] As defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration.
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Contingent Consideration, Measured at Fair Value (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Business Acquisition [Line Items]    
Ending balance $ 11,130  
Fair Value, Inputs, Level 3 [Member] | Insight Merger [Member]    
Business Acquisition [Line Items]    
Beginning balance 5,370 $ 7,060
Change in estimated fair value (3,080) 420
Ending balance 2,290 7,480
Fair Value, Inputs, Level 3 [Member] | Chronix Merger [Member]    
Business Acquisition [Line Items]    
Beginning balance 40,292 69,621
Change in estimated fair value (13,867) (17,577)
Ending balance $ 26,425 $ 52,044
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Business Combinations (Details Narrative) - USD ($)
$ in Millions
9 Months Ended
Feb. 08, 2023
Apr. 15, 2021
Sep. 30, 2023
Business Acquisition [Line Items]      
Fair value     $ 3.1
Chronix [Member]      
Business Acquisition [Line Items]      
Fair value     $ 13.9
Merger Agreement [Member] | Chronix Equity [Member]      
Business Acquisition [Line Items]      
Earnout percentage on collections for sales 10.00%    
Gross proceeds percentage 5.00%    
Merger Agreement [Member] | Chronix Milestone [Member]      
Business Acquisition [Line Items]      
Royalty payments 15.00%    
Maximum [Member] | Merger Agreement [Member] | Chronix Biomedical Inc [Member]      
Business Acquisition [Line Items]      
Business combination consideration transferred   $ 14.0  
Earnout percentage on collections for sales   15.00%  
Earnout percentage on collections for sale or license   75.00%  
Insight Merger [Member] | Valuation Technique, Discounted Cash Flow [Member]      
Business Acquisition [Line Items]      
Unobservable Measurement Input, Uncertainty, Description     The significant unobservable inputs used in Insight’s contingent consideration valuation on September 30, 2023, included: (i) a discount period, based on the expected milestone payment dates, ranging from 0.5 years to 1.5 years, (ii) a discount rate of 15.2% to 15.4%, and (iii) a management probability estimate of 15% to 50%.
Chronix Merger [Member] | Valuation Technique, Discounted Cash Flow [Member]      
Business Acquisition [Line Items]      
Unobservable Measurement Input, Uncertainty, Description     The significant unobservable inputs used in Chronix’s contingent consideration valuation on September 30, 2023, included: (i) a discount period, based on the related patent expiration dates, ranging from 0.4 years to 12.2 years, (ii) a discount rate of 15.5% to 16.4%, and (iii) a payout percentage of 10% based on the earnout provision.
Chronix Biomedical Inc [Member]      
Business Acquisition [Line Items]      
Net deferred tax liabilities     $ 2.2
Goodwill     $ 9.5
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Abstract]    
Right-of-use assets $ 4,036 $ 3,499
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Machinery and equipment, net, and construction in progress Machinery and equipment, net, and construction in progress
Machinery and equipment $ 6,908 $ 9,408
Accumulated depreciation and amortization (5,819) (4,196)
Right-of-use assets and machinery and equipment, net 5,125 8,711
Construction in progress 708 2,140
Right-of-use and financing lease assets, machinery and equipment, net, and construction in progress $ 5,833 $ 10,851
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Property, Plant and Equipment [Abstract]        
Depreciation expense $ 404,000 $ 391,000 $ 1,300,000 $ 1,100,000
Asset impairment charges $ 1,800,000      
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Goodwill and Intangible Assets (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets $ 56,940 $ 61,890
Intangible assets, net 56,617 61,633
Customer Relationships [Member]    
Finite-Lived Intangible Assets [Line Items]    
Acquired intangible assets 440 440
Finite-lived intangible assets, accumulated amortization [1] (323) (257)
DetermaIO [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets acquired IPR&D [2] 9,700 14,650
DetermaCNI and VitaGraft [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets acquired IPR&D [3] $ 46,800 $ 46,800
[1] Amortization of intangible assets is included in “Cost of revenues – amortization of acquired intangibles” on the consolidated statements of operations because the intangible assets pertain directly to the revenues generated from the acquired intangibles.
[2] See Note 3 for information on the Insight Merger.
[3] See Note 3 for information on the Chronix Merger.
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Intangible Assets Future Amortization Expense (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2023 $ 22
2024 88
2025 7
Total $ 117
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Intangible Assets, Net (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Credit Derivatives [Line Items]          
Impairment of intangible       $ 5,000,000.0  
Intangible asset amortization expense $ 22,000   $ 976,000 $ 66,000 $ 2,880,000
MPEEM Valuation Approach [Member]          
Credit Derivatives [Line Items]          
Unobservable Measurement Input, Uncertainty, Description   The significant unobservable inputs used on March 31, 2023, included: (i) a discount period of 20.0 years, based on the expected life of patent, (ii) a royalty rate of 0.3%, (iii) a contributory asset rate of return of 30.0%, and (iv) a weighted average cost of capital rate of 30.0%. As market conditions change, the Company will re-evaluate assumptions used in the determination of fair value for IPR&D and is uncertain to the extent of the volatility in the unobservable inputs in the foreseeable future.      
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Loan Payable to Silicon Valley Bank (Details Narrative) - USD ($)
Apr. 02, 2020
Oct. 17, 2019
Sep. 30, 2023
Oct. 31, 2019
Dec. 31, 2017
Mar. 23, 2017
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Interest rate     5.50%      
Warrants to purchase, shares     819,767      
Warrant [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Warrants to purchase, shares         412 366
Warrant exercise price, per share         $ 97.00 $ 109.20
Amended Loan Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Interest rate   5.00%        
Amended Loan Agreement [Member] | Bank Warrant [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Debt instrument, final payment       $ 200,000    
Warrants to purchase, shares   4,928        
Warrant exercise price, per share   $ 33.80        
Amended Loan Agreement [Member] | Share-Based Payment Arrangement, Tranche One [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Line of credit, current   $ 3,000,000        
Repayments of lines of credit   400,000        
Debt instrument, final payment   116,000        
Amended Loan Agreement [Member] | Share-Based Payment Arrangement, Tranche Two [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Line of credit, current   2,000,000        
Additional paid in capital   $ 20,000,000        
Line of credit facility, maximum borrowing capacity     $ 2      
Amended Loan Agreement [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | Bank Warrant [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Percentage for warrant exercise price per share   0.02%        
Diluted equity outstanding   $ 1,000,000        
Loan Deferral Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Debt instrument maturity date description Under the Loan Deferral Agreement, the Bank agreed to (i) extend the scheduled maturity date of the Amended Loan Agreement from March 31, 2022 to September 30, 2022, and (ii) deferred the principal payments by an additional 6 months whereby payments of interest only on the Bank loan principal balance will be due monthly from May 1, 2020 through October 1, 2020, followed by 23 monthly payments of principal and interest beginning on November 1, 2020, all provided at no additional fees to Oncocyte.          
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Lessee, Lease, Description [Line Items]    
Right-of-use assets, net $ 4,036 $ 3,499
Machinery and equipment, net 1,757 2,088
Total financing lease liabilities 30  
Operating and Financing Leases [Member]    
Lessee, Lease, Description [Line Items]    
Right-of-use assets, net 1,748 2,088
Right-of-use lease liabilities, current 653 698
Right-of-use lease liabilities, noncurrent 2,252 2,730
Total operating lease liabilities 2,905 3,428
Machinery and equipment 537 537
Accumulated depreciation (528) (446)
Machinery and equipment, net 9 91
Current liabilities 30 117
Noncurrent liabilities
Total financing lease liabilities $ 30 $ 117
Weighted average remaining lease term, Operating lease 3 years 10 months 24 days 4 years 6 months
Weighted average remaining lease term, Financing lease 3 months 18 days 1 year
Operating lease 11.29% 11.24%
Financing lease 11.55% 11.55%
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]  
2023 $ 255
2024 903
2025 869
2026 899
2027 695
Total minimum lease payments 3,621
Less amounts representing interest (716)
Present value of net minimum lease payments 2,905
Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]  
2023 31
2024
2025
2025
2026
Total minimum lease payments 31
Less amounts representing interest (1)
Total financing lease liabilities $ 30
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]    
Operating cash flows from operating leases $ 793 $ 854
Operating cash flows from financing leases 7 77
Financing cash flows from financing leases $ 86 $ 4
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies (Details Narrative)
9 Months Ended 12 Months Ended
Apr. 12, 2023
USD ($)
Dec. 23, 2019
USD ($)
ft²
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Aug. 08, 2023
ft²
Aug. 27, 2021
ft²
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Restricted cash     $ 1,700,000      
lessee, operating sublease, residual value guarantee, description     The Sublease Agreement provides that, from and after the Commencement Date, Subtenant will pay to the Company monthly base rent in the following amounts: (i) $36,850.00 for rental periods beginning on the Commencement Date and ending on or before December 31, 2024 (subject to adjustment in the event that Subtenant exercises its option to accelerate the Expansion Date, such that the Expansion Period begins prior to December 31, 2024); (ii) $37,955.50 for rental periods beginning on or after January 1, 2025 and ending on or before June 20, 2025 (subject to adjustment in the event that Subtenant exercises its option to accelerate the Expansion Date, such that the Expansion Period begins prior to June 20, 2025); (iii) $75,844.00 for rental periods beginning on or after July 1, 2025 and ending on or before December 31, 2025; (iv) $78,188.33 for rental periods beginning on or after January 1, 2026 and ending on or before December 31, 2026; and (v) $80,533.98 for rental periods beginning on or after January 1, 2027 and ending on or before October 31, 2027      
Severance Costs $ 300,000     $ 1,900,000    
Laboratory Equipment [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Payment obligation amount.     $ 30,000      
Executive Officers [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Severance Costs     2,700,000      
Office Lease Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Area of Land | ft²   26,800     13,400  
Payments for rent   $ 61,640        
Total tenant improvement allowance   $ 1,300,000        
Percentage of administrative fee paid on original cost of equipment   1.50%        
Security Deposit   $ 150,000 101,987.38      
Line of Credit, Current   $ 1,700,000        
Office Lease Agreement [Member] | Landlord [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Total tenant improvement allowance     $ 1,300,000      
Office Lease Agreement [Member] | Monthly Rent [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Interest rate on lease agreement   3.50%        
Obligated to pay expenses and taxes percentage   43.70% 50.00%      
Office Lease Agreement [Member] | First Ten Calendar [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Interest rate on lease agreement   50.00%        
Lease Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Area of Land | ft²           1,928
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholders’ Equity (Details Narrative) - USD ($)
9 Months Ended
Apr. 05, 2023
Apr. 05, 2023
Apr. 03, 2023
Jul. 15, 2022
Apr. 19, 2022
Apr. 13, 2022
Sep. 30, 2023
Sep. 30, 2022
Jul. 24, 2023
Dec. 31, 2022
Class of Stock [Line Items]                    
Preferred stock offering               $ 32,453,000    
Proceeds from issuance of common stock             $ 13,848,000 $ 32,812,000    
Conversion of stock, description             A holder is prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of our common stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership limitation solely as to itself up to 19.99% of the number of shares of our common stock outstanding immediately after giving effect to the conversion, provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect to the issuance of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer apply to the holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval).      
Conversion price percentage       140.00%            
Net proceeds to immediately redeem                  
Common stock, shares authorized             230,000,000   230,000,000 230,000,000
Common stock no par value             $ 0     $ 0
Common stock, shares issued             8,260,762     5,932,191
Common stock, shares outstanding             8,260,762     5,932,191
Number of common stock purchase warrants             819,767      
Maximum [Member]                    
Class of Stock [Line Items]                    
Warrant exercise price per share             $ 109.20      
Minimum [Member]                    
Class of Stock [Line Items]                    
Warrant exercise price per share             $ 30.60      
Over-Allotment Option [Member]                    
Class of Stock [Line Items]                    
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares           196,998        
Net proceeds         $ 32,800,000          
April 2022 Warrants [Member] | Over-Allotment Option [Member]                    
Class of Stock [Line Items]                    
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares           1,313,320        
April 2022 Warrants [Member] | IPO [Member]                    
Class of Stock [Line Items]                    
Number of common stock purchase warrants           1,313,320        
Sale of stock, price per share           $ 26.65        
Common Stock [Member]                    
Class of Stock [Line Items]                    
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares               1,314,000    
Preferred stock offering               $ 32,453,000    
Net proceeds to immediately redeem                  
Shares issued price per share           $ 0.20        
Common Stock [Member] | IPO [Member]                    
Class of Stock [Line Items]                    
Number of common stock purchase warrants           656,660        
Shares issued price per share           $ 26.45        
Warrant [Member] | IPO [Member]                    
Class of Stock [Line Items]                    
Warrant exercise price per share           $ 0.20        
Registered Direct Offering [Member]                    
Class of Stock [Line Items]                    
Proceeds from issuance of common stock     $ 13,900,000              
Registered Direct Offering [Member] | Maximum [Member]                    
Class of Stock [Line Items]                    
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares     2,278,121              
Registered Direct Offering [Member] | Board Members [Member]                    
Class of Stock [Line Items]                    
Shares issued price per share     $ 7.08              
Registered Direct Offering [Member] | Board Members [Member] | Maximum [Member]                    
Class of Stock [Line Items]                    
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares     2,278,121              
Registered Direct Offering [Member] | Other Investors [Member]                    
Class of Stock [Line Items]                    
Shares issued price per share     $ 6.03              
Underwriting Agreement [Member]                    
Class of Stock [Line Items]                    
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares           196,998        
Shares issued price per share           $ 24.85        
Underwriting Agreement [Member] | April 2022 Warrants [Member]                    
Class of Stock [Line Items]                    
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares           196,998        
Underwriting Agreement [Member] | Common Stock [Member]                    
Class of Stock [Line Items]                    
Number of common stock purchase warrants           98,499        
Underwriting Agreement [Member] | Warrant [Member]                    
Class of Stock [Line Items]                    
Number of common stock purchase warrants           196,998        
Series A Redeemable Convertible Preferred Stock [Member]                    
Class of Stock [Line Items]                    
Preferred stock outstanding percentage           51.00%        
Cash in hand           $ 8,000,000        
Indebtedness expenses           $ 15,000,000        
Dividends rate           6.00%        
Temporary equity, shares issued             5,000     6,000
Temporary equity, shares oustanding             5,000     6,000
Series A Redeemable Convertible Preferred Stock [Member] | Preferred Stock [Member]                    
Class of Stock [Line Items]                    
Convertible preferred shares               6,000    
Preferred stock offering                  
Number of stock redeem, shares             (1,000)      
Net proceeds to immediately redeem             $ (1,000,000)      
Temporary equity, shares issued             4,818     5,882
Temporary equity, shares oustanding             4,818     5,882
Series A Redeemable Convertible Preferred Stock [Member] | Oncocyte Corp [Member] | Preferred Stock [Member]                    
Class of Stock [Line Items]                    
Ownership percentage           50.00%        
Series A Redeemable Convertible Preferred Stock [Member] | Interest [Member] | Preferred Stock [Member]                    
Class of Stock [Line Items]                    
Ownership percentage           51.00%        
Series A Redeemable Convertible Preferred Stock [Member] | Security [Member] | Preferred Stock [Member]                    
Class of Stock [Line Items]                    
Ownership percentage           50.00%        
Series A Redeemable Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member]                    
Class of Stock [Line Items]                    
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares           11,765        
Convertible preferred shares           384,477        
Conversion price           $ 30.60        
Preferred stock offering           $ 850        
Stated value per share           $ 1,000        
Gross proceeds, closing           $ 10,000,000        
Proceeds from issuance of common stock           4,900,000        
Series A Redeemable Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member] | Share-Based Payment Arrangement, Tranche Two [Member]                    
Class of Stock [Line Items]                    
Preferred stock offering           $ 5,000,000        
Series A Redeemable Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member] | Investors [Member]                    
Class of Stock [Line Items]                    
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares           11,765        
Series A Preferred Stock [Member]                    
Class of Stock [Line Items]                    
Convertible preferred shares 588.23529                  
Preferred stock, dividend rate, percentage             6.00%      
Dividends, preferred stock             $ 399,000      
Series A Preferred Stock [Member] | Oncocyte Corp [Member]                    
Class of Stock [Line Items]                    
Equity method investment, description of principal activities             if the daily volume weighted average price of our common stock for 20 out of 30 trading days exceeds 140% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or exceeds 20,000 shares of our common stock      
Series A Preferred Stock [Member] | Registered Direct Offering [Member]                    
Class of Stock [Line Items]                    
Number of stock redeem, shares   1,064                
Net proceeds to immediately redeem   $ 1,100,000                
Common Stock [Member] | Securities Purchase Agreement [Member]                    
Class of Stock [Line Items]                    
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares     2,274,709              
Series B Preferred Stock [Member] | Registered Direct Offering [Member]                    
Class of Stock [Line Items]                    
Number of stock redeem, shares     1,064              
Net proceeds to immediately redeem     $ 1,100,000              
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Stock Option Activity (Details)
shares in Thousands
9 Months Ended
Sep. 30, 2023
$ / shares
shares
2010 Plan Activity [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Shares available for grant options, beginning of period
Number of options outstanding, beginning of period 30
Weighted average exercise price, options outstanding, beginning of period | $ / shares $ 80.78
Shares available for grant options exercised
Number of options outstanding, option exercised
Weighted average exercise price, options exercised | $ / shares
Shares available for grant options forfeited, cancelled and expired
Number of options outstanding, options forfeited/expired (20)
Weighted average exercise price, options forfeited/expired | $ / shares
Shares available for grant outstanding, end of period
Number of options outstanding, end of period 10
Weighted average exercise price, outstanding end of period | $ / shares $ 73.22
Number of options outstanding, exercisable, end of period 10
Weighted average exercise price, exercisable, end of period | $ / shares $ 73.22
2018 Paln Activity [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Shares available for grant options, beginning of period 442
Number of options outstanding, beginning of period 428
Weighted average exercise price, options outstanding, beginning of period | $ / shares $ 59.23
Number of options outstanding, options forfeited/expired (235)
Weighted average exercise price, options forfeited/expired | $ / shares
Shares available for grant outstanding, end of period 387
Number of options outstanding, end of period 491
Weighted average exercise price, outstanding end of period | $ / shares $ 27.31
Number of options outstanding, exercisable, end of period 140
Weighted average exercise price, exercisable, end of period | $ / shares $ 98.80
Number of RSUs Outstanding, beginning of period 22
Shares available for grant options RSUs vested
Number of options outstanding, option RSUs vested
Number of RSUs Outstanding, option RSUs vested (14)
Weighted average exercise price, options exercised | $ / shares
Shares available for grant options RSUs granted (9)
Number of options outstanding, option RSUs granted
Number of RSUs Outstanding, option RSUs granted 5
Weighted average exercise price, option RSUs granted | $ / shares
Shares available for grant options granted (298)
Number of options outstanding, option granted 298
Number of RSUs Outstanding, option granted
Weighted average exercise price, option granted | $ / shares $ 5.96
Shares available for grant options forfeited/expired 235
Number of RSUs Outstanding, options forfeited/expired
Shares available for grant RSUs forfeited/expired 2
Number of options outstanding, RSUs forfeited/expired
Number of RSUs Outstanding, RSUs forfeited/expired (1)
Weighted average exercise price, RSUs forfeited/expired | $ / shares
Shares available for grant performance RSUs forfeited/expired 15
Number of options outstanding, performance RSUs forfeited/expired
Number of Performance RSUs Outstanding, performance RSUs forfeited/expired (7)
Weighted average exercise price, performance RSUs forfeited/expired | $ / shares
Number of RSUs Outstanding, end of period 5
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details) - shares
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Expected life (in years) 6 years 3 months 5 years 11 months 23 days
Risk-free interest rates 3.76% 2.29%
Volatility 105.99% 106.85%
Dividend yield 0.00% 0.00%
Employee And Non Employee [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Grants shares 178,000  
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Total $ 608 $ 3,181 $ 2,276 $ 7,423
Share-Based Payment Arrangement, Option [Member] | Cost Of Revenues [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Total (2) 94 10 239
Share-Based Payment Arrangement, Option [Member] | Research and Development Expense [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Total 294 521 931 1,416
Share-Based Payment Arrangement, Option [Member] | Selling and Marketing Expense [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Total 64 942 216 1,681
Share-Based Payment Arrangement, Option [Member] | Selling, General and Administrative Expenses [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Total $ 252 $ 1,624 $ 1,119 $ 4,087
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation (Details Narrative) - USD ($)
1 Months Ended 9 Months Ended 12 Months Ended
Dec. 16, 2022
Aug. 31, 2023
Jul. 31, 2022
May 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Risk-free interest rates         3.76% 2.29%  
Expected life (in years)         6 years 3 months 5 years 11 months 23 days  
Expected Volatility         105.99% 106.85%  
Dividend yield         0.00% 0.00%  
Share based payment award description     the achievement of performance minimum, target, and maximum goals of (i) 90% of revenue goal; (ii) 100% of revenue goal; and (iii) exceed revenue goal by up to 150%, respectively, during fiscal year 2022 the Company of average market capitalization minimum, target, and maximum goals of (i) $300 million; (ii) $400 million; and (iii) $500 million, respectively, during the period beginning on January 1, 2022 and ending on December 31, 2024      
Increase in fair value         $ 58,500    
Number of restricted stock awards, shares   9,091          
Number of restricted stock awards, value   $ 36,000          
Vita Graft [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Vested percentage     50.00% 50.00%      
Determal O [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Vested percentage     50.00% 50.00%      
Determa CNI [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Share based payment award vesting rights description The remaining 50% is eligible to vest on December 31, 2023, since the Company completed the LCD submission for DetermaCNI on December 16, 2022            
Performance Shares [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Share based payment award description             50
Performance Shares [Member] | Executive Officers And Employees [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Share based awards vesting     23,750 61,875      
Market Based Awards [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Risk-free interest rates         2.72%    
Expected life (in years)         2 years 7 months 6 days    
Expected Volatility         95.00%    
Dividend yield         0.00%    
Market Based Awards [Member] | Executive Officers And Employees [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Share based awards vesting       12,500      
Monte Carlo Valuation Technique [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Risk-free interest rates         4.81%   2.00%
Expected life (in years)         6 years 2 months 8 days   2 years 9 months 18 days
Expected Volatility         91.00%   100.00%
Dividend yield         0.00%   0.00%
Monte Carlo Valuation Technique [Member] | Minimum [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Fair value grants         $ 1.09    
Monte Carlo Valuation Technique [Member] | Maximum [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Fair value grants         $ 1.74    
2010 Stock Option Plan [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Number of shares authorized         260,000    
2018 Incentive Plan [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Number of shares authorized         1,050,000    
Number of shares available for grant         387,000    
Performance-Based Options [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Grant date fair value         $ 156,000   $ 117,625
Stock option grant   120,000          
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Apr. 05, 2023
Apr. 03, 2023
Apr. 13, 2022
Apr. 13, 2022
Apr. 12, 2022
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Purchase of warrant           819,767   819,767  
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts                 $ 32,453,000
Issuance of Series A redeemable convertible preferred stock, net of financing costs                
Total compensation paid           $ 608,000 $ 3,181,000 $ 2,276,000 $ 7,423,000
Arno [Member]                  
Total compensation paid               $ 200,000  
Maximum [Member]                  
Warrant exercise price           $ 109.20   $ 109.20  
Common Stock [Member]                  
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares                 1,314,000
Issuance of shares               2,275,000  
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts                 $ 32,453,000
Issuance of Series A redeemable convertible preferred stock, net of financing costs                
Broadwood Capital LP [Member] | Underwritten Offering [Member]                  
Purchase of warrant     300,187 300,187          
Warrant exercise price     $ 30.60 $ 30.60          
Broadwood Capital LP [Member] | Underwritten Offering [Member] | Underwriters [Member]                  
Purchase of warrant     39,154 39,154          
Broadwood Capital LP [Member] | Underwritten Offering [Member] | Maximum [Member]                  
Sale of stock, shares       143,292          
Broadwood Capital LP [Member] | Underwritten Offering [Member] | Common Stock [Member]                  
Sale of stock, shares       261,032          
Pura Vida Investments LLC [Member] | Underwritten Offering [Member]                  
Purchase of warrant     286,585 286,585          
Pura Vida Investments LLC [Member] | Underwritten Offering [Member] | Underwriters [Member]                  
Issuance of shares       37,380          
Pura Vida Investments LLC [Member] | Underwritten Offering [Member] | Maximum [Member]                  
Purchase of warrant     150,093 150,093          
Pura Vida Investments LLC [Member] | Underwritten Offering [Member] | Common Stock [Member]                  
Sale of stock, shares       249,204          
Issuance of shares       286,585          
Halle Special Situations Fund LLC [Member] | Underwritten Offering [Member]                  
Purchase of warrant     356,472 356,472          
Halle Special Situations Fund LLC [Member] | Underwritten Offering [Member] | Underwriters [Member]                  
Issuance of shares       46,496          
Halle Special Situations Fund LLC [Member] | Underwritten Offering [Member] | Maximum [Member]                  
Purchase of warrant     178,236 178,236          
Halle Special Situations Fund LLC [Member] | Underwritten Offering [Member] | Common Stock [Member]                  
Sale of stock, shares       309,976          
Series A Preferred Stock [Member]                  
Issuance of Series A redeemable convertible preferred stock, net of financing costs, shares 588.23529                
Issuance of Series A redeemable convertible preferred stock, net of financing costs $ 618,672.34                
Securities Purchase Agreement [Member] | Series A Preferred Stock [Member] | Broadwood Capital LP [Member]                  
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares     1,176.48   5,882.35        
Legal fees     $ 85,000            
Securities Purchase Agreement [Member] | Common Stock [Member]                  
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares   2,274,709              
Related party transaction, description   (i) $6.03 to investors who are not considered to be “insiders” of the Company pursuant to Nasdaq Listing Rules (“Insiders”), which amount reflects the average closing price of the Common Stock on Nasdaq during the five trading day period immediately prior to pricing, and (ii) $7.08 to Insiders, which amount reflects the final closing price of the Common Stock on Nasdaq on the last trading day immediately prior to pricing (the “2023 Registered Direct Offering”)              
Securities Purchase Agreement [Member] | Common Stock [Member] | Arno [Member]                  
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares   21,162              
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts   $ 150,000.51              
Securities Purchase Agreement [Member] | Common Stock [Member] | Mr Gutfreund [Member]                  
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares   85,250              
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts   $ 604,252.00              
Securities Purchase Agreement [Member] | Common Stock [Member] | Broadwood Partners LP [Member]                  
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares   1,341,381              
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts   $ 8,093,361.84              
Securities Purchase Agreement [Member] | Common Stock [Member] | Pura Vida [Member]                  
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares   33,150              
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts   $ 200,013.84              
Securities Purchase Agreement [Member] | Common Stock [Member] | AVM [Member]                  
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares   472,354              
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts   $ 2,849,999.92              
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Co-Development Agreement with Life Technologies Corporation (Details Narrative)
9 Months Ended
Sep. 30, 2023
USD ($)
Life Technologies Corporation [Member]  
Development costs $ 749,000
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Discontinued Operations (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]        
Net revenue $ 950 $ 421 $ 3,824
Cost of revenues 1,855 507 5,854
Research and development 2,949 702 9,200
Sales and marketing 3,600 498 9,966
General and administrative 61 329 133
Loss from impairment of held for sale assets 1,311
Net loss from discontinued operations $ (7,515) $ (2,926) $ (21,329)
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Assets and Liabilities Discontinued Operations (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
CURRENT ASSETS      
TOTAL ASSETS $ 81,587   $ 100,091
LIABILITIES AND SHAREHOLDERS’ EQUITY      
Total current liabilities 8,033   12,106
TOTAL LIABILITIES 39,102   60,497
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net cash used in operating activities (4,357) $ (15,744)  
CASH FLOWS FROM INVESTING ACTIVITIES:      
Net cash used in investing activities $ (96)  
Discontinued Operations, Held-for-Sale [Member]      
CURRENT ASSETS      
Cash and cash equivalents   1,510
Prepaid expenses and other current assets   346
Machinery and equipment, net, and construction in progress   211
Intangible assets, net   25,920
Impairment of held for sale assets   (25,866)
TOTAL ASSETS   2,121
LIABILITIES AND SHAREHOLDERS’ EQUITY      
Accounts payable 90   492
Accrued compensation   248
Accrued expenses and other current liabilities   1,265
Total current liabilities 90   2,005
TOTAL LIABILITIES $ 90   $ 2,005
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.23.3
Discontinued Operations of Razor (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Feb. 16, 2023
Feb. 16, 2023
Dec. 15, 2022
Mar. 31, 2023
Sep. 30, 2022
Dec. 31, 2022
Common Stock [Member]            
Number of shares issued         1,314,000  
Razor Stock Purchase Agreement [Member] | Razor [Member]            
Equity method investment ownership percentage 30.00% 30.00%        
Razor Stock Purchase Agreement [Member] | Common Stock [Member]            
Number of shares issued   1,366,364        
Razor Stock Purchase Agreement [Member] | Common Stock [Member] | Razor [Member]            
Consideration transferred $ 115,660          
Razor Stock Purchase Agreement [Member] | Common Stock [Member] | Razor [Member]            
Number of shares issued 1,366,364          
Equity method investment ownership percentage 30.00% 30.00%        
Loss on disposal       $ 1,300,000   $ 27,200,000
Razor Stock Purchase Agreement [Member] | Common Stock [Member] | Dragon [Member]            
Number of shares issued     3,188,181      
Razor Stock Purchase Agreement [Member] | Common Stock [Member] | Dragon [Member] | Razor [Member]            
Equity method investment ownership percentage 70.00% 70.00% 70.00%      
XML 70 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001642380 2023-01-01 2023-09-30 0001642380 2023-11-02 0001642380 2023-09-30 0001642380 2022-12-31 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember 2023-09-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember 2022-12-31 0001642380 2023-07-01 2023-09-30 0001642380 2022-07-01 2022-09-30 0001642380 2022-01-01 2022-09-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001642380 us-gaap:CommonStockMember 2023-06-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001642380 us-gaap:RetainedEarningsMember 2023-06-30 0001642380 2023-06-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0001642380 us-gaap:CommonStockMember 2022-06-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001642380 us-gaap:RetainedEarningsMember 2022-06-30 0001642380 2022-06-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001642380 us-gaap:CommonStockMember 2022-12-31 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001642380 us-gaap:RetainedEarningsMember 2022-12-31 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001642380 us-gaap:CommonStockMember 2021-12-31 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001642380 us-gaap:RetainedEarningsMember 2021-12-31 0001642380 2021-12-31 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001642380 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001642380 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0001642380 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001642380 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-09-30 0001642380 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001642380 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-09-30 0001642380 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0001642380 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0001642380 us-gaap:CommonStockMember 2023-09-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001642380 us-gaap:RetainedEarningsMember 2023-09-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-09-30 0001642380 us-gaap:CommonStockMember 2022-09-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001642380 us-gaap:RetainedEarningsMember 2022-09-30 0001642380 2022-09-30 0001642380 OCX:RazorGenomicsIncMember 2021-02-23 0001642380 OCX:DragonScientificLLCMember OCX:RazorStockPurchaseAgreementMember 2022-12-15 2022-12-15 0001642380 OCX:DragonScientificLLCMember OCX:RazorStockPurchaseAgreementMember 2022-12-15 0001642380 OCX:RazorMember OCX:DragonMember us-gaap:CommonStockMember OCX:RazorStockPurchaseAgreementMember 2023-02-16 0001642380 us-gaap:CommonStockMember OCX:RazorStockPurchaseAgreementMember 2023-02-15 2023-02-16 0001642380 OCX:RazorMember OCX:RazorStockPurchaseAgreementMember 2023-02-16 0001642380 OCX:AtTheMarketSalesAgreementMember OCX:BTIGLLCMember 2021-06-10 2021-06-11 0001642380 OCX:BTIGLLCMember 2021-07-01 2023-09-30 0001642380 OCX:BTIGLLCMember 2023-09-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember OCX:SecuritiesPurchaseAgreementMember 2022-04-12 2022-04-13 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember OCX:SecuritiesPurchaseAgreementMember 2022-04-13 0001642380 OCX:UnderwriterMember OCX:SeriesARedeemableConvertiblePreferredStockMember OCX:UnderwritingAgreementMember 2022-04-12 2022-04-12 0001642380 OCX:UnderwriterMember OCX:SeriesARedeemableConvertiblePreferredStockMember OCX:UnderwritingAgreementMember 2022-04-12 0001642380 srt:MinimumMember OCX:UnderwriterMember OCX:SeriesARedeemableConvertiblePreferredStockMember OCX:UnderwritingAgreementMember 2022-04-12 0001642380 2022-01-01 2022-12-31 0001642380 srt:MaximumMember OCX:BoardMembersMember OCX:RegisteredDirectOfferingMember 2023-04-03 2023-04-03 0001642380 OCX:BoardMembersMember OCX:RegisteredDirectOfferingMember 2023-04-03 0001642380 OCX:OtherInvestorsMember OCX:RegisteredDirectOfferingMember 2023-04-03 0001642380 2023-04-01 2023-04-12 0001642380 2023-07-23 2023-07-24 0001642380 2023-07-24 0001642380 OCX:LineageAndAgeXMember 2023-09-30 0001642380 OCX:LineageAndAgeXMember 2022-12-31 0001642380 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2023-09-30 0001642380 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2023-09-30 0001642380 srt:MinimumMember us-gaap:EquipmentMember 2023-09-30 0001642380 srt:MaximumMember us-gaap:EquipmentMember 2023-09-30 0001642380 OCX:PharmaServicesMember 2023-01-01 2023-09-30 0001642380 OCX:PharmaServicesMember 2022-01-01 2022-12-31 0001642380 OCX:MedicareAndMedicareAdvantageMember 2023-09-30 0001642380 OCX:MedicareAndMedicareAdvantageMember 2022-12-31 0001642380 OCX:PharmaServicesCustomersOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 OCX:PharmaServicesCustomersTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 OCX:PharmaServicesCustomersOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001642380 OCX:PharmaServicesCustomersTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001642380 OCX:MarketableEquitySecuritiesMember 2023-09-30 0001642380 us-gaap:FairValueInputsLevel1Member OCX:MarketableEquitySecuritiesMember 2023-09-30 0001642380 us-gaap:FairValueInputsLevel2Member OCX:MarketableEquitySecuritiesMember 2023-09-30 0001642380 us-gaap:FairValueInputsLevel3Member OCX:MarketableEquitySecuritiesMember 2023-09-30 0001642380 us-gaap:FairValueInputsLevel1Member 2023-09-30 0001642380 us-gaap:FairValueInputsLevel2Member 2023-09-30 0001642380 us-gaap:FairValueInputsLevel3Member 2023-09-30 0001642380 OCX:ContingentConsiderationLiabilitiesMember 2023-09-30 0001642380 us-gaap:FairValueInputsLevel1Member OCX:ContingentConsiderationLiabilitiesMember 2023-09-30 0001642380 us-gaap:FairValueInputsLevel2Member OCX:ContingentConsiderationLiabilitiesMember 2023-09-30 0001642380 us-gaap:FairValueInputsLevel3Member OCX:ContingentConsiderationLiabilitiesMember 2023-09-30 0001642380 OCX:MarketableEquitySecuritiesMember 2022-12-31 0001642380 us-gaap:FairValueInputsLevel1Member OCX:MarketableEquitySecuritiesMember 2022-12-31 0001642380 us-gaap:FairValueInputsLevel2Member OCX:MarketableEquitySecuritiesMember 2022-12-31 0001642380 us-gaap:FairValueInputsLevel3Member OCX:MarketableEquitySecuritiesMember 2022-12-31 0001642380 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001642380 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001642380 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001642380 OCX:ContingentConsiderationLiabilitiesMember 2022-12-31 0001642380 us-gaap:FairValueInputsLevel1Member OCX:ContingentConsiderationLiabilitiesMember 2022-12-31 0001642380 us-gaap:FairValueInputsLevel2Member OCX:ContingentConsiderationLiabilitiesMember 2022-12-31 0001642380 us-gaap:FairValueInputsLevel3Member OCX:ContingentConsiderationLiabilitiesMember 2022-12-31 0001642380 OCX:PharmaServicesMember 2023-07-01 2023-09-30 0001642380 OCX:PharmaServicesMember 2022-07-01 2022-09-30 0001642380 OCX:PharmaServicesMember 2023-01-01 2023-09-30 0001642380 OCX:PharmaServicesMember 2022-01-01 2022-09-30 0001642380 OCX:LaboratoryDevelopedTestServicesMember 2023-07-01 2023-09-30 0001642380 OCX:LaboratoryDevelopedTestServicesMember 2022-07-01 2022-09-30 0001642380 OCX:LaboratoryDevelopedTestServicesMember 2023-01-01 2023-09-30 0001642380 OCX:LaboratoryDevelopedTestServicesMember 2022-01-01 2022-09-30 0001642380 OCX:PharmaServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 OCX:PharmaServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0001642380 OCX:PharmaServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 OCX:PharmaServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0001642380 OCX:LaboratoryDevelopedTestServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 OCX:LaboratoryDevelopedTestServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0001642380 OCX:LaboratoryDevelopedTestServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 OCX:LaboratoryDevelopedTestServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0001642380 OCX:PharmaServicesCompanyAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 OCX:PharmaServicesCompanyAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001642380 OCX:PharmaServicesCompanyAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 OCX:PharmaServicesCompanyAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001642380 OCX:PharmaServicesCompanyBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 OCX:PharmaServicesCompanyBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001642380 OCX:PharmaServicesCompanyBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 OCX:PharmaServicesCompanyBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001642380 OCX:PharmaServicesCompanyCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 OCX:PharmaServicesCompanyCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001642380 OCX:PharmaServicesCompanyCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 OCX:PharmaServicesCompanyCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001642380 OCX:PharmaServicesCompanyDMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 OCX:PharmaServicesCompanyDMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001642380 OCX:PharmaServicesCompanyDMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 OCX:PharmaServicesCompanyDMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001642380 country:US us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 country:US us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0001642380 country:US us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 country:US us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0001642380 OCX:OutsideUnitedStatesPharmaServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 OCX:OutsideUnitedStatesPharmaServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0001642380 OCX:OutsideUnitedStatesPharmaServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 OCX:OutsideUnitedStatesPharmaServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0001642380 OCX:UnitedStatesLaboratoryDevelopedTestServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 OCX:UnitedStatesLaboratoryDevelopedTestServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0001642380 OCX:UnitedStatesLaboratoryDevelopedTestServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 OCX:UnitedStatesLaboratoryDevelopedTestServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0001642380 us-gaap:StockOptionMember 2023-07-01 2023-09-30 0001642380 us-gaap:StockOptionMember 2022-07-01 2022-09-30 0001642380 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001642380 us-gaap:StockOptionMember 2022-01-01 2022-09-30 0001642380 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001642380 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0001642380 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001642380 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001642380 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001642380 us-gaap:WarrantMember 2022-07-01 2022-09-30 0001642380 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001642380 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember 2023-07-01 2023-09-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember 2022-07-01 2022-09-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember 2023-01-01 2023-09-30 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember 2022-01-01 2022-09-30 0001642380 OCX:InsightMergerMember 2023-01-01 2023-09-30 0001642380 OCX:ChronixMergerMember 2023-01-01 2023-09-30 0001642380 OCX:MilestoneOneMember 2023-09-30 0001642380 OCX:MilestoneTwoMember 2023-09-30 0001642380 OCX:MilestoneThreeMember 2023-09-30 0001642380 OCX:RoyaltyOneMember 2023-09-30 0001642380 OCX:RoyaltyTwoMember 2023-09-30 0001642380 OCX:InsightMergerMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-01-01 2023-09-30 0001642380 srt:MaximumMember OCX:MergerAgreementMember OCX:ChronixBiomedicalIncMember 2021-04-14 2021-04-15 0001642380 OCX:MergerAgreementMember OCX:ChronixEquityMember 2023-02-07 2023-02-08 0001642380 OCX:MergerAgreementMember OCX:ChronixMilestoneMember 2023-02-07 2023-02-08 0001642380 OCX:ChronixMember 2023-01-01 2023-09-30 0001642380 OCX:ChronixMergerMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-01-01 2023-09-30 0001642380 OCX:ChronixBiomedicalIncMember 2023-09-30 0001642380 OCX:InsightMergerMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001642380 OCX:InsightMergerMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-09-30 0001642380 OCX:InsightMergerMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001642380 OCX:InsightMergerMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001642380 OCX:InsightMergerMember us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-09-30 0001642380 OCX:InsightMergerMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0001642380 OCX:ChronixMergerMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001642380 OCX:ChronixMergerMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-09-30 0001642380 OCX:ChronixMergerMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001642380 OCX:ChronixMergerMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001642380 OCX:ChronixMergerMember us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-09-30 0001642380 OCX:ChronixMergerMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0001642380 OCX:MPEEMValuationApproachMember 2023-01-01 2023-03-31 0001642380 OCX:DetermaIOMember 2023-01-01 2023-09-30 0001642380 OCX:DetermaIOMember 2022-01-01 2022-12-31 0001642380 OCX:DetermaCNIAndVitaGraftMember 2023-01-01 2023-09-30 0001642380 OCX:DetermaCNIAndVitaGraftMember 2022-01-01 2022-12-31 0001642380 us-gaap:CustomerRelationshipsMember 2023-09-30 0001642380 us-gaap:CustomerRelationshipsMember 2022-12-31 0001642380 OCX:AmendedLoanAgreementMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-10-17 0001642380 OCX:AmendedLoanAgreementMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-10-16 2019-10-17 0001642380 OCX:AmendedLoanAgreementMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-10-17 0001642380 OCX:AmendedLoanAgreementMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-09-30 0001642380 OCX:AmendedLoanAgreementMember 2019-10-17 0001642380 OCX:LoanDeferralAgreementMember 2020-04-01 2020-04-02 0001642380 OCX:BankWarrantMember OCX:AmendedLoanAgreementMember 2019-10-31 0001642380 us-gaap:WarrantMember 2017-12-31 0001642380 us-gaap:WarrantMember 2017-03-23 0001642380 OCX:BankWarrantMember OCX:AmendedLoanAgreementMember 2019-10-17 0001642380 OCX:BankWarrantMember OCX:AmendedLoanAgreementMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-10-16 2019-10-17 0001642380 OCX:OfficeLeaseAgreementMember 2019-12-23 0001642380 OCX:OfficeLeaseAgreementMember 2019-12-22 2019-12-23 0001642380 OCX:MonthlyRentMember OCX:OfficeLeaseAgreementMember 2019-12-22 2019-12-23 0001642380 OCX:FirstTenCalendarMember OCX:OfficeLeaseAgreementMember 2019-12-22 2019-12-23 0001642380 OCX:LandlordMember OCX:OfficeLeaseAgreementMember 2023-01-01 2023-09-30 0001642380 OCX:OfficeLeaseAgreementMember 2023-08-08 0001642380 OCX:MonthlyRentMember OCX:OfficeLeaseAgreementMember 2023-01-01 2023-09-30 0001642380 OCX:OfficeLeaseAgreementMember 2023-09-30 0001642380 OCX:LeaseAgreementMember 2021-08-27 0001642380 OCX:LaboratoryEquipmentMember 2023-09-30 0001642380 OCX:ExecutiveOfficersMember 2023-01-01 2023-09-30 0001642380 OCX:OperatingAndFinancingLeasesMember 2023-09-30 0001642380 OCX:OperatingAndFinancingLeasesMember 2022-12-31 0001642380 OCX:InvestorsMember OCX:SeriesARedeemableConvertiblePreferredStockMember OCX:SecuritiesPurchaseAgreementMember 2022-04-12 2022-04-13 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember OCX:SecuritiesPurchaseAgreementMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2022-04-12 2022-04-13 0001642380 OCX:OncocyteCorpMember us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-09-30 0001642380 2022-07-14 2022-07-15 0001642380 OCX:SeriesARedeemableConvertiblePreferredStockMember 2022-04-13 0001642380 OCX:InterestMember OCX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-04-13 0001642380 OCX:OncocyteCorpMember OCX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-04-13 0001642380 OCX:SecurityMember OCX:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-04-13 0001642380 us-gaap:SeriesAPreferredStockMember OCX:RegisteredDirectOfferingMember 2023-04-04 2023-04-05 0001642380 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-09-30 0001642380 OCX:AprilTwoThousandTwentyTwoWarrantsMember us-gaap:OverAllotmentOptionMember 2022-04-12 2022-04-13 0001642380 OCX:AprilTwoThousandTwentyTwoWarrantsMember us-gaap:IPOMember 2022-04-13 0001642380 us-gaap:CommonStockMember us-gaap:IPOMember 2022-04-13 0001642380 us-gaap:WarrantMember us-gaap:IPOMember 2022-04-13 0001642380 OCX:AprilTwoThousandTwentyTwoWarrantsMember OCX:UnderwritingAgreementMember 2022-04-12 2022-04-13 0001642380 us-gaap:WarrantMember OCX:UnderwritingAgreementMember 2022-04-13 0001642380 us-gaap:CommonStockMember OCX:UnderwritingAgreementMember 2022-04-13 0001642380 OCX:UnderwritingAgreementMember 2022-04-13 0001642380 us-gaap:CommonStockMember 2022-04-13 0001642380 OCX:UnderwritingAgreementMember 2022-04-12 2022-04-13 0001642380 us-gaap:OverAllotmentOptionMember 2022-04-12 2022-04-13 0001642380 us-gaap:OverAllotmentOptionMember 2022-04-18 2022-04-19 0001642380 srt:MaximumMember OCX:RegisteredDirectOfferingMember 2023-04-03 2023-04-03 0001642380 us-gaap:CommonStockMember OCX:SecuritiesPurchaseAgreementMember 2023-04-03 2023-04-03 0001642380 OCX:RegisteredDirectOfferingMember 2023-04-03 2023-04-03 0001642380 us-gaap:SeriesBPreferredStockMember OCX:RegisteredDirectOfferingMember 2023-04-03 2023-04-03 0001642380 srt:MinimumMember 2023-09-30 0001642380 srt:MaximumMember 2023-09-30 0001642380 OCX:TwoThousandTenStockOptionPlanMember 2023-09-30 0001642380 OCX:TwoThousandEighteenIncentivePlanMember 2023-09-30 0001642380 OCX:MonteCarloValuationTechniqueMember 2022-01-01 2022-12-31 0001642380 OCX:PerformanceBasedOptionsMember 2022-01-01 2022-12-31 0001642380 OCX:ExecutiveOfficersAndEmployeesMember us-gaap:PerformanceSharesMember 2022-05-01 2022-05-31 0001642380 OCX:ExecutiveOfficersAndEmployeesMember OCX:MarketBasedAwardsMember 2022-05-01 2022-05-31 0001642380 OCX:VitaGraftMember 2022-05-01 2022-05-31 0001642380 OCX:DetermalOMember 2022-05-01 2022-05-31 0001642380 2022-05-01 2022-05-31 0001642380 OCX:MarketBasedAwardsMember 2023-01-01 2023-09-30 0001642380 OCX:ExecutiveOfficersAndEmployeesMember us-gaap:PerformanceSharesMember 2022-07-01 2022-07-31 0001642380 OCX:VitaGraftMember 2022-07-01 2022-07-31 0001642380 OCX:DetermalOMember 2022-07-01 2022-07-31 0001642380 2022-07-01 2022-07-31 0001642380 us-gaap:PerformanceSharesMember 2022-01-01 2022-12-31 0001642380 OCX:DetermaCNIMember 2022-12-14 2022-12-16 0001642380 OCX:PerformanceBasedOptionsMember 2023-08-01 2023-08-31 0001642380 OCX:MonteCarloValuationTechniqueMember 2023-01-01 2023-09-30 0001642380 srt:MinimumMember OCX:MonteCarloValuationTechniqueMember 2023-01-01 2023-09-30 0001642380 srt:MaximumMember OCX:MonteCarloValuationTechniqueMember 2023-01-01 2023-09-30 0001642380 OCX:PerformanceBasedOptionsMember 2023-01-01 2023-09-30 0001642380 2023-08-01 2023-08-31 0001642380 OCX:TwoThousandTenPlanActivityMember 2023-01-01 2023-09-30 0001642380 OCX:TwoThousandTenPlanActivityMember 2022-12-31 0001642380 OCX:TwoThousandTenPlanActivityMember 2023-09-30 0001642380 OCX:TwoThousandEighteenPalnActivityMember 2022-12-31 0001642380 OCX:TwoThousandEighteenPalnActivityMember 2023-01-01 2023-09-30 0001642380 OCX:TwoThousandEighteenPalnActivityMember 2023-09-30 0001642380 OCX:EmployeeAndNonEmployeeMember 2023-01-01 2023-09-30 0001642380 us-gaap:EmployeeStockOptionMember OCX:CostOfRevenuesMember 2023-07-01 2023-09-30 0001642380 us-gaap:EmployeeStockOptionMember OCX:CostOfRevenuesMember 2022-07-01 2022-09-30 0001642380 us-gaap:EmployeeStockOptionMember OCX:CostOfRevenuesMember 2023-01-01 2023-09-30 0001642380 us-gaap:EmployeeStockOptionMember OCX:CostOfRevenuesMember 2022-01-01 2022-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2023-07-01 2023-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2022-07-01 2022-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2022-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0001642380 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0001642380 us-gaap:SeriesAPreferredStockMember OCX:SecuritiesPurchaseAgreementMember OCX:BroadwoodCapitalLPMember 2022-04-12 2022-04-12 0001642380 us-gaap:SeriesAPreferredStockMember OCX:SecuritiesPurchaseAgreementMember OCX:BroadwoodCapitalLPMember 2022-04-13 2022-04-13 0001642380 us-gaap:CommonStockMember OCX:UnderwrittenOfferingMember OCX:BroadwoodCapitalLPMember 2022-04-12 2022-04-13 0001642380 OCX:UnderwrittenOfferingMember OCX:BroadwoodCapitalLPMember 2022-04-13 0001642380 srt:MaximumMember OCX:UnderwrittenOfferingMember OCX:PuraVidaInvestmentsLLCMember 2022-04-13 0001642380 OCX:UnderwritersMember OCX:UnderwrittenOfferingMember OCX:BroadwoodCapitalLPMember 2022-04-13 0001642380 us-gaap:CommonStockMember OCX:UnderwrittenOfferingMember OCX:PuraVidaInvestmentsLLCMember 2022-04-12 2022-04-13 0001642380 OCX:UnderwrittenOfferingMember OCX:PuraVidaInvestmentsLLCMember 2022-04-13 0001642380 srt:MaximumMember OCX:UnderwrittenOfferingMember OCX:BroadwoodCapitalLPMember 2022-04-12 2022-04-13 0001642380 OCX:UnderwritersMember OCX:UnderwrittenOfferingMember OCX:PuraVidaInvestmentsLLCMember 2022-04-12 2022-04-13 0001642380 us-gaap:CommonStockMember OCX:UnderwrittenOfferingMember OCX:HalleSpecialSituationsFundLLCMember 2022-04-12 2022-04-13 0001642380 OCX:UnderwrittenOfferingMember OCX:HalleSpecialSituationsFundLLCMember 2022-04-13 0001642380 srt:MaximumMember OCX:UnderwrittenOfferingMember OCX:HalleSpecialSituationsFundLLCMember 2022-04-13 0001642380 OCX:UnderwritersMember OCX:UnderwrittenOfferingMember OCX:HalleSpecialSituationsFundLLCMember 2022-04-12 2022-04-13 0001642380 us-gaap:CommonStockMember OCX:SecuritiesPurchaseAgreementMember OCX:BroadwoodPartnersLPMember 2023-04-03 2023-04-03 0001642380 us-gaap:CommonStockMember OCX:SecuritiesPurchaseAgreementMember OCX:PuraVidaMember 2023-04-03 2023-04-03 0001642380 us-gaap:CommonStockMember OCX:SecuritiesPurchaseAgreementMember OCX:AVMMember 2023-04-03 2023-04-03 0001642380 OCX:ArnoMember us-gaap:CommonStockMember OCX:SecuritiesPurchaseAgreementMember 2023-04-03 2023-04-03 0001642380 OCX:MrGutfreundMember us-gaap:CommonStockMember OCX:SecuritiesPurchaseAgreementMember 2023-04-03 2023-04-03 0001642380 us-gaap:SeriesAPreferredStockMember 2023-04-05 2023-04-05 0001642380 OCX:ArnoMember 2023-01-01 2023-09-30 0001642380 OCX:LifeTechnologiesCorporationMember 2023-01-01 2023-09-30 0001642380 OCX:DragonMember us-gaap:CommonStockMember OCX:RazorStockPurchaseAgreementMember 2022-12-14 2022-12-15 0001642380 OCX:RazorMember OCX:DragonMember us-gaap:CommonStockMember OCX:RazorStockPurchaseAgreementMember 2022-12-15 0001642380 OCX:RazorMember us-gaap:CommonStockMember OCX:RazorStockPurchaseAgreementMember 2023-02-16 2023-02-16 0001642380 OCX:RazorMember us-gaap:CommonStockMember OCX:RazorStockPurchaseAgreementMember 2023-02-16 0001642380 OCX:RazorMember us-gaap:CommonStockMember OCX:RazorStockPurchaseAgreementMember 2023-02-16 2023-02-16 0001642380 OCX:RazorMember us-gaap:CommonStockMember OCX:RazorStockPurchaseAgreementMember 2023-01-01 2023-03-31 0001642380 OCX:RazorMember us-gaap:CommonStockMember OCX:RazorStockPurchaseAgreementMember 2022-01-01 2022-12-31 0001642380 us-gaap:DiscontinuedOperationsHeldforsaleMember 2023-01-01 2023-09-30 0001642380 us-gaap:DiscontinuedOperationsHeldforsaleMember 2023-09-30 0001642380 us-gaap:DiscontinuedOperationsHeldforsaleMember 2022-12-31 iso4217:USD shares iso4217:USD shares utr:sqft OCX:Number iso4217:EUR pure false Q3 --12-31 0001642380 http://oncocyte.com/20230930#MachineryAndEquipmentNetAndConstructionInProgress http://oncocyte.com/20230930#MachineryAndEquipmentNetAndConstructionInProgress 10-Q true 2023-09-30 2023 false 1-37648 Oncocyte Corporation CA 27-1041563 15 Cushing Irvine CA 92618 (949) 409-7600 Common Stock, no par value OCX NASDAQ Yes Yes Non-accelerated Filer true false false 8260762 13783000 19993000 178000 154000 1882000 2012000 441000 433000 672000 977000 139000 2121000 16917000 25536000 1757000 2088000 4076000 8763000 56617000 61633000 1700000 1700000 520000 371000 81587000 100091000 1136000 1253000 1722000 1771000 1116000 2022000 826000 1817000 2314000 2314000 109000 109000 720000 815000 90000 2005000 8033000 12106000 2354000 2729000 28715000 45662000 39102000 60497000 0 0 1000000 1000000 5000 5000 6000 6000 5217000 6091000 4923000 5302000 0 0 5000000 5000000 0 0 0 0 0 0 230000000 230000000 8261000 8261000 5932000 5932000 309995000 294929000 32000 39000 -272465000 -260676000 37562000 34292000 81587000 100091000 429000 67000 1189000 684000 159000 314000 593000 602000 22000 22000 66000 73000 248000 -269000 530000 9000 2185000 1472000 6747000 5923000 713000 405000 2213000 798000 2487000 5702000 9430000 16794000 -435000 -6142000 -16947000 -17157000 1811000 6761000 -1283000 6761000 1437000 9487000 6358000 -6513000 -1706000 -8957000 -6349000 117000 -14000 108000 -65000 -89000 -160000 8000 -485000 -4000 62000 -22000 304000 24000 -112000 94000 -246000 -6489000 -1818000 -8863000 -6595000 -7515000 -2926000 -21329000 -6489000 -9333000 -11789000 -27924000 -198000 -294000 -739000 -294000 -6687000 -9627000 -12528000 -28218000 -0.79 -0.79 -0.31 -0.31 -1.19 -1.19 -1.22 -1.22 -1.27 -1.27 -0.39 -0.39 -3.94 -3.94 -0.81 -0.81 -1.62 -1.62 -1.68 -1.68 -5.22 -5.22 8256 8256 5931 5931 7446 7446 5408 5408 -6489000 -9333000 -11789000 -27924000 -9000 -12000 -7000 -18000 -6498000 -9345000 -11796000 -27942000 5000 4725000 8250000 309535000 41000 -265976000 43600000 -6489000 -6489000 -9000 -9000 608000 608000 14000 14000 2000 9000 36000 36000 198000 -198000 -198000 5000 4923000 8261000 309995000 32000 -272465000 37562000 6000 4854000 5930000 289649000 31000 -206437000 83243000 -9333000 -9333000 -12000 -12000 3181000 3181000 1000 222000 -294000 72000 -222000 6000 5076000 5931000 292536000 19000 -215698000 76857000 6000 5302000 5932000 294929000 39000 -260676000 34292000 -11789000 -11789000 -7000 -7000 2276000 2276000 72000 72000 2275000 13421000 13421000 -118000 -118000 45000 9000 36000 36000 -1000 -1000000 621000 -621000 -621000 5000 4923000 8261000 309995000 32000 -272465000 37562000 4612000 252954000 37000 -187774000 65217000 4612000 252954000 37000 -187774000 65217000 -27924000 -27924000 -18000 -18000 7423000 7423000 5000 1314000 32453000 32453000 6000 4782000 294000 -294000 -294000 6000 5076000 5931000 292536000 19000 -215698000 76857000 6000 5076000 5931000 292536000 19000 -215698000 76857000 -11789000 -27924000 1289000 1062000 66000 2880000 2276000 7423000 108000 8000 -485000 12000 -16947000 -17157000 -352000 6761000 -1659000 -1283000 -130000 553000 -784000 745000 -4193000 422000 -1317000 -43000 -156000 139000 -18763000 -35920000 354000 17000 3538000 -1510000 -1173000 -3538000 13848000 32812000 427000 389000 4875000 1118000 93000 31000 1000 1325000 87000 4000 12216000 35906000 -7720000 -3552000 23203000 37305000 15483000 33753000 24000 215000 1032000 <p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zxK12cTvaILa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_821_zMmGUGGC1YNg">Organization, Description of the Business and Liquidity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte Corporation (“Oncocyte,” the “Company,” “we” or “us”), incorporated in 2009 in the state of California, is a precision diagnostics company focused on developing and commercializing proprietary tests in three areas: VitaGraft is a blood-based solid organ transplantation monitoring test, DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte’s first product for commercial release was a proprietary treatment stratification test called DetermaRx that identifies which patients with early-stage non-small cell lung cancer may benefit from chemotherapy, resulting in a significantly higher, five-year survival rate. Beginning in September 2019 through February 23, 2021, Oncocyte held a <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210223__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorGenomicsIncMember_z7EEUIsoxGdk" title="Equity ownership percentage">25</span>% equity interest in Razor Genomics, Inc. (“Razor”), a privately held company, that had developed and licensed to Oncocyte the lung cancer treatment stratification laboratory test that Oncocyte was commercializing as DetermaRx. On February 24, 2021, Oncocyte completed the purchase of all the remaining issued and outstanding shares of common stock of Razor. As a result of the purchase of the Razor common stock, Oncocyte became the sole shareholder of Razor.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 15, 2022, the Company, entered into a Stock Purchase Agreement (the “Razor Stock Purchase Agreement”) with Dragon Scientific, LLC, a Delaware limited liability company (“Dragon”) and Razor. Pursuant to the Razor Stock Purchase Agreement, Oncocyte agreed to sell to Dragon, <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221215__20221215__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DragonScientificLLCMember_zkTA4TKZq2Ld" title="Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares">3,188,181</span> shares of common stock of Razor, which constitutes approximately <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221215__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DragonScientificLLCMember_zi86EOxOfgf2" title="Equity ownership percentage">70</span>% of the issued and outstanding equity interests of Razor on a fully-diluted basis, and transfer to Razor all of the assets and liabilities related to DetermaRx (the “Razor Sale Transaction”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts in prior periods have been reclassified to reflect the impact of the discontinued operations treatment of Razor in order to conform to the current period presentation. As a result of the divestiture of Razor, the Company has retrospectively revised the consolidated statements of operations for the periods ended September 30, 2022, to reflect the operations and cash flows of Razor as discontinued operations and the related assets and liabilities disposed. See Note 13 for additional information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 16, 2023, Oncocyte completed the Razor Sale Transaction (the “Razor Closing”). In connection with the Razor Closing, Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx. While no monetary consideration was received for the sale of <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--DragonMember_zdwSL2UXjqh9" title="Equity ownership percentage">70</span>% of the equity interests of Razor, the transaction allowed the Company to eliminate all development and commercialization costs with respect to DetermaRx. Following the Razor Closing, Oncocyte continues to own <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230215__20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAojsOMZqHI3" title="Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares">1,366,364</span> shares of common stock of Razor, which constitutes approximately <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zZCTR6y1jNUl" title="Equity interest">30</span>% of the issued and outstanding equity interests of Razor on a fully-diluted basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and Going Concern</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte has incurred operating losses and negative cash flows since inception and had an accumulated deficit of $<span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20230930_zXYUu5cO6pA3" title="Accumulated deficit">272.5</span> million as of September 30, 2023. Oncocyte expects to continue to incur operating losses and negative cash flows for the foreseeable future. Since its formation, Oncocyte has financed its operations primarily through the sale of shares of its common stock, convertible preferred stock and warrants to acquire common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, Oncocyte had $<span id="xdx_904_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20230930_zPmWTHrBBYD6" title="Cash and cash equivalents">13.8</span> million of cash and cash equivalents. In addition, Oncocyte held shares of Lineage Cell Therapeutics, Inc. (“Lineage”) and AgeX Therapeutics, Inc. (“AgeX”) common stock as marketable equity securities with a combined fair market value of $<span id="xdx_906_eus-gaap--EquitySecuritiesFvNi_iI_c20230930_zJCnohELVZge" title="Marketable equity securities fair value">441,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 11, 2021, Oncocyte entered into an at-the-market sales agreement with BTIG, LLC as sales agent and/or principal (the “Agent” or “BTIG”) pursuant to which Oncocyte may sell up to an aggregate of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20210610__20210611__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketSalesAgreementMember__dei--LegalEntityAxis__custom--BTIGLLCMember_zAG3dNdEvsEd" title="Fair value of common stock sold">50,000,000 </span>of shares of Oncocyte common stock from time to time through the Agent (the “ATM Offering”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between July 1, 2021 and September 30, 2023, Oncocyte sold <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20210701__20230930__dei--LegalEntityAxis__custom--BTIGLLCMember_z2ZySMD0LFnc" title="Fair value of common stock sold">56,167</span> shares of common stock at an average offering price of $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230930__dei--LegalEntityAxis__custom--BTIGLLCMember_zlRaNAlhqag" title="Sale of stock, price per share">111.60</span> per share, for gross proceeds of approximately $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn4n6_c20210701__20230930__dei--LegalEntityAxis__custom--BTIGLLCMember_zF9PeUA2Va31" title="Gross proceeds from offering">6.27</span> million through the ATM Offering. The most recent sale of common stock through the ATM Offering took place in January 2022. Oncocyte will need to raise additional capital to finance its operations, including the development and commercialization of its cancer diagnostic and other tests, until such time as it is able to generate sufficient revenues from the commercialization of one or more of its laboratory tests and other tests, and performing Pharma Services to cover its operating expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 13, 2022, Oncocyte entered into a securities purchase agreement (the “Securities Purchase Agreement”) with institutional accredited investors (the “Investors”), including Broadwood Partners, L.P. (“Broadwood”), Oncocyte’s largest shareholder, in a registered direct offering of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zTvpCPCXd6D4" title="Issuance of Series A redeemable convertible preferred stock, net of financing costs, shares">11,765</span> shares of Series A Convertible Preferred Stock (the “Series A Preferred Stock”), which are convertible into a total of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zFocxEwz8bN" title="Issuance of Series A redeemable convertible preferred stock, net of financing costs, shares">384,477</span> shares of common stock, at a conversion price of $<span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z5T0I2IB83Sl" title="Conversion price">30.60</span> (the “Series A Preferred Stock Offering”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further, on April 13, 2022, Oncocyte entered into an underwriting agreement (the “Underwriting Agreement”) with BTIG, LLC, as representative of the underwriters named therein (the “Underwriters”), pursuant to which Oncocyte issued and sold to the Underwriters an aggregate of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220412__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zdn9fJFJeL98" title="Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares">1,313,320</span> shares of common stock, and <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220412__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_z7YBpxidfkVe" title="Purchase of warrant">1,313,320</span> warrants to purchase up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220412__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember__srt--RangeAxis__srt--MinimumMember_zK3q6p4gic6a" title="Purchase of warrant">656,660</span> shares of common stock (“April 2022 Warrants”) (the “Underwritten Offering”). See Notes 8 and 11 for additional information about the Series A Preferred Stock Offering and Underwritten Offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2022, the Company initiated a workforce reduction plan to strategically realign its operations and implement cost reduction programs to prioritize near term revenue generators and to manage and preserve cash. In connection with the reduction, the Company eliminated 14 positions, implemented tighter expense controls, and ceased non-core activities. Further, on December 16, 2022, Oncocyte initiated an additional reduction in work force involving over 40% of its full-time employees. The transition began on December 16, 2022 and was completed in February 2023. As of December 31, 2022, the Company incurred an aggregate of $<span id="xdx_90D_eus-gaap--SeveranceCosts1_pn5n6_c20220101__20221231_zM2546TDFMmj" title="Employee severance">1.9</span> million related to employee severance and benefits costs in connection with its reductions in force during fiscal year 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 3, 2023, Oncocyte entered into an agreement with certain members of the Company’s board of directors, and several institutional and accredited investors, including Broadwood, the Company’s largest shareholder, relating to their purchase of an aggregate of up to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--BoardMembersMember__srt--RangeAxis__srt--MaximumMember_zJUdRoRQruXh" title="Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares">2,278,121</span> shares of its common stock at an offering price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--BoardMembersMember_zbjTAG5rlQlb" title="Shares issued price per share">7.08</span> per share to board members and $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--OtherInvestorsMember_z3SHxiOggkH2" title="Shares issued price per share">6.03</span> per share to the other investors participating in the offering (the “April 2023 Offering”). See Notes 8 and 11 for additional information about the April 2023 Offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 12, 2023, Oncocyte announced a reduction in force involving approximately 20% of its workforce (the “April 2023 Reduction”), which management believes will extend Oncocyte’s cash runway into 2024. In connection with the April 2023 Reduction, we incurred approximately $<span id="xdx_903_eus-gaap--SeveranceCosts1_c20230401__20230412_zAvfgXxT8uQ7" title="Severance cost">300,000</span> related to employee severance and benefits costs during the second quarter of 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, Oncocyte is completing clinical development and planning commercialization of DetermaIO, although DetermaIO is currently available for biopharma diagnostic development and research use only as a companion test in immunotherapy drug development to select patients for clinical trials; and the clinical launch of VitaGraft. While Oncocyte plans to primarily market its laboratory tests in the United States through its own sales force, it is also beginning to make marketing arrangements with distributors in other countries. In order to reduce capital needs and to expedite the commercialization of any new laboratory tests that may become available for clinical use, Oncocyte may also pursue marketing arrangements with other diagnostic companies through which Oncocyte might receive licensing fees and royalty on sales, or through which it might form a joint venture to market its tests and share in net revenues, in the United States or abroad.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with Accounting Standards Codification (“ASC”) 205-40, <i>Going Concern</i>, we evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements included in this Report are issued. This evaluation initially does not take into consideration the potential mitigating effect of our plans that have not been fully implemented as of the date the consolidated financial statements included in this Report are issued. When substantial doubt exists under this methodology, we evaluate whether the mitigating effect of our plans sufficiently alleviates substantial doubt about our ability to continue as a going concern. The mitigating effect of our plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that such financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about our ability to continue as a going concern within one year after the date that such financial statements are issued. In performing this analysis, we excluded certain elements of our operating plan that cannot be considered probable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that the consolidated financial statements are issued. Management intends to complete additional equity financings while maintaining reduced spending levels. However, due to several factors, including those outside management’s control, there can be no assurance that we will be able to complete additional equity financings. If we are unable to complete additional financings, management’s plans include further reducing or delaying operating expenses. We have concluded the likelihood that our plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to general economic and capital market trends and conditions, Oncocyte’s ability to raise sufficient additional capital to finance its operations from time to time will depend on a number of factors specific to Oncocyte’s operations such as operating revenues and expenses, progress in development of, or in obtaining reimbursement coverage from Medicare for DetermaIO and other future laboratory tests that Oncocyte may develop or acquire.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unavailability or inadequacy of financing or revenues to meet future capital needs could force Oncocyte to modify, curtail, delay, or suspend some or all aspects of planned operations. Sales of additional equity securities could result in the dilution of the interests of its shareholders. Oncocyte cannot assure that adequate financing will be available on favorable terms, if at all.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.25 3188181 0.70 0.70 1366364 0.30 -272500000 13800000 441000 50000000 56167 111.60 6270000 11765 384477 30.60 1313320 1313320 656660 1900000 2278121 7.08 6.03 300000 <p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zbC2QYqNlhvf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. <span id="xdx_821_zfMYT7O8TCVj">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--AccountingPrinciplesPolicyTextBlock_zfb5eDpmpapa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_z2DiMlv20CG9">Accounting Principles</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (“GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84C_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zCiqLzJH5LT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zmiqcBt337G6">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts in the consolidated financial statements and notes to consolidated financial statements have been reclassified to conform to the current period presentation. These changes had no impact on the previously reported consolidated financial condition, results of operations or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zRc7qshVy0ld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zJFZzRGLztJ5">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance with GAAP for financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations, certain information and footnote disclosures normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance sheet as of December 31, 2022 was derived from the audited consolidated financial statements at that date. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in Oncocyte’s Annual Report on Form 10-K for the year ended December 31, 2022. The accompanying unaudited condensed consolidated financial statements, in the opinion of management, include all adjustments of a normal recurring nature necessary for a fair presentation of Oncocyte’s financial condition and results of operations. The consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2023, the Company implemented a <span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20230723__20230724_zmq9qd6VocIf" title="Reverse stock split">1-for-20 reverse stock split</span> of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pn6n6_c20230724_zerteWzY8qKj" title="Common stock, shares authorized">230</span> million shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zOVwoH3j7Vkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_86F_z23bZpZWjUXj">Principles of Consolidation</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 31, 2020, with the acquisition of Insight Genetics, Inc. (“Insight”) through a merger with a newly incorporated wholly-owned subsidiary of Oncocyte (the “Insight Merger”) under the terms of an Agreement and Plan of Merger (the “Insight Merger Agreement”), Insight became a wholly-owned subsidiary of Oncocyte, and on that date Oncocyte began consolidating Insight’s operations and results with Oncocyte’s operations and results (see Note 3).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 15, 2021, with the acquisition of Chronix Biomedical, Inc. (“Chronix”) pursuant to an Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021 (as amended and restated, the “Chronix Merger Agreement”), by and among Oncocyte, CNI Monitor Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Oncocyte (“Merger Sub”), Chronix became a wholly-owned subsidiary of Oncocyte (the “Chronix Merger”), and on that date Oncocyte began consolidating Chronix’s operations and results with Oncocyte’s operations and results (see Note 3).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have reflected the operations of Razor as discontinued operations for all periods presented. See Note 13 for further information. Amounts and disclosures throughout these Notes to consolidated financial statements relate solely to continuing operations and exclude all discontinued operations. Discontinued operations comprise activities that were disposed of or discontinued at the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting purposes and represent a strategic business shift having a major effect on the Company’s operations and financial results according to ASC Topic 205, <i>Presentation of Financial Statements</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All material intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--UseOfEstimates_zCHWMUvEJmI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zUWR4Q4Op9F8">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and contingent assets and liabilities, at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including, but not limited to, valuation methods used, assumptions requiring the use of judgment to prepare financial projections, timing of potential commercialization of acquired in-process intangible assets, applicable discount rates, probabilities of the likelihood of multiple outcomes of certain events related to contingent consideration, comparable companies or transactions, determination of fair value of the assets acquired and liabilities assumed including those relating to contingent consideration, assumptions related to going concern assessments, allocation of direct and indirect expenses, useful lives associated with long-lived intangible assets, key assumptions in operating and financing leases including incremental borrowing rates, loss contingencies, valuation allowances related to deferred income taxes, allowances for credit losses, and assumptions used to value debt and stock-based awards and other equity instruments. Actual results may differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly, Oncocyte assessed certain accounting matters that generally require consideration of forecasted financial information. The accounting matters assessed included, but were not limited to, Oncocyte’s equity investments, the carrying value of goodwill, going concern assessment, acquired in-process intangible assets and other long-lived assets. Those assessments as well as other estimates referenced above were made in the context of information reasonably available to Oncocyte.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p id="xdx_847_ecustom--SegmentsPolicyTextBlock_zbDLupCwMiOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_z96MWr9dxVs8">Segments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte’s executive management team, as a group, represents the entity’s chief operating decision makers. To date, Oncocyte’s executive management team has viewed Oncocyte’s operations as one segment that includes the research, development and commercialization of diagnostic tests, including molecular diagnostic services to pharmaceutical customers. As a result, the financial information disclosed materially represents all of the financial information related to Oncocyte’s sole operating segment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_ecustom--BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock_zGyM3yNaJ1Ba" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_z3l81aImYp65">Fair Value Measurements, Business Combinations and Contingent Consideration Liabilities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte accounts for business combinations in accordance with ASC 805, which requires the purchase consideration transferred to be measured at fair value on the acquisition date in accordance with ASC 820, <i>Fair Value Measurement</i>. ASC 820 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● <i>Level 1 </i>– Quoted prices in active markets for identical assets and liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● <i>Level 2 </i>– Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● <i>Level 3 </i>– Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When a part of the purchase consideration consists of shares of Oncocyte common stock, Oncocyte calculates the purchase price attributable to those shares, a Level 1 security, by determining the fair value of those shares as of the acquisition date based on prices quoted on the principal national securities exchange on which the shares traded. Oncocyte recognizes estimated fair values of the tangible assets and identifiable intangible assets acquired, including in-process research and development, and liabilities assumed, including any contingent consideration, as of the acquisition date. Goodwill is recognized as any amount of the fair value of the tangible and identifiable intangible assets acquired and liabilities assumed in excess of the consideration transferred. ASC 805 precludes the recognition of an assembled workforce as an asset, effectively subsuming any assembled workforce value into goodwill.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining fair value, Oncocyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, Oncocyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for money market funds and marketable equity securities held by Oncocyte described below. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain of Oncocyte’s asset and business acquisitions involve the potential for future payment of consideration to third-parties and former selling shareholders in amounts determined as a percentage of future net revenues generated, or upon attainment of revenue milestones, from Pharma Services or laboratory tests, as applicable, or annual minimum royalties to certain licensors, as provided in the applicable agreements. The fair value of such liabilities is determined using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows. These obligations are referred to as contingent consideration, which are carried at fair value based on Level 3 inputs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 805 requires that contingent consideration be estimated and recorded at fair value as of the acquisition date as part of the total consideration transferred. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings, such as “earn-out” provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of certain revenues generated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of contingent consideration after the acquisition date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in the consolidated statements of operations. Changes in key assumptions can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that Oncocyte records in its consolidated financial statements. See Note 3 for a full discussion of these liabilities and additional Level 3 fair value disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z1f6c6Ti82gj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables present the Company’s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zdjQu3ulOgLc" style="display: none">Schedule of Fair Value Measurement of Financial Assets and Liabilities</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of September 30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(In thousands)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Marketable equity securities</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zQ8iV4rtuO79" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">441</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_z6oEvqwvnd2e" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">441</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_ziDUQuRz7VM7" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0913">-</span></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zgjacTNZEkr3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0914">-</span></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20230930_zh6bf8oarEc5" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">441</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zS2JnDbckrFj" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">441</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0L9jHL2BwTk" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0917">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_znhgKXCvyI69" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0918">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Contingent consideration liabilities (Note 3)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zApHPZ8dNXp8" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,715</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_z8LhT77AAm5k" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0920">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_znMYiXliknRc" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0921">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zY1JXY377V8j" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,715</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930_zm6mdVSqrwY4" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,715</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJQn623SQZxh" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSvmVsr0zSb7" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0925">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNHgv6naB4dh" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,715</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(In thousands)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Marketable equity securities</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zsyKXGyp0K84" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">433</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zNyLXel1V0jd" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">433</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zrX92Gi3Fmdl" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zQtidnaZznnj" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0930">-</span></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_zTMOVEDP9q8l" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">433</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z2d7KoWt8cUa" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">433</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFACYnGDynh1" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAu7LWZe8Lde" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0934">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Contingent consideration liabilities (Note 3)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zMrsQfB95m72" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,662</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_z2swoRNNu0V5" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0936">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_z0NJreNb4Wyh" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zOULThUSByKj" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,662</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231_zZmMdlolOCE9" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,662</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpPeSH7YTbc2" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0940">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zy9EvgW98n82" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCbD4hV2f68l" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,662</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A1_zhbALWIoDHB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with GAAP, from time to time, the Company measures certain assets at fair value on a nonrecurring basis. The Company reviews the carrying value of goodwill, intangibles, including in-process research and development (“IPR&amp;D”) (see Note 5), and other long-lived assets for indications of impairment at least annually. Refer to related discussions of impairments below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zcTdTK3VPrF9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zMpmMRaupgFj">Cash, Cash Equivalents and Restricted Cash</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte considers all highly liquid securities with original maturities of three months or less when purchased to be cash equivalents. For the periods presented, Oncocyte’s cash equivalents are comprised of investments in AAA rated money market funds that invest in first-tier only securities, which primarily include domestic commercial paper and securities issued or guaranteed by the U.S. government or its agencies. Restricted cash relates to a bank letter of credit required under our office lease arrangement, refer to Note 7 for additional information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p id="xdx_842_eus-gaap--MarketableSecuritiesPolicy_zeSwau2WsHVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zzzhqWHDa9og">Marketable Equity Securities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte accounts for the shares of Lineage and AgeX common stock it holds as marketable equity securities in accordance with ASC 320-10-25, <i>Investments – Debt and Equity Securities</i>, as amended, as the shares have a readily determinable fair value quoted on the NYSE American and are held principally to meet future working capital purposes, as necessary. The securities are measured at fair value, with related gains and losses in the value of such securities recorded in the consolidated statements of operations in other income or expense, and are reported as current assets on the consolidated balance sheets based on the closing trading price of the security as of the date being presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023 and December 31, 2022, Oncocyte held <span id="xdx_904_ecustom--CommonStockSharesHeldAsAvailableForSaleSecurities_iI_pid_c20230930__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zLOwGs7uYQb5" title="Common stock, shares held as available for sale securities">353,264</span> and <span id="xdx_908_ecustom--CommonStockSharesHeldAsAvailableForSaleSecurities_iI_pid_c20221231__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_z9XcBFaYpHI9" title="Common stock, shares held as available for sale securities">35,326</span> shares of common stock of Lineage and AgeX, respectively, as marketable equity securities, which had a combined fair market value of $<span id="xdx_900_eus-gaap--EquitySecuritiesFvNi_iI_c20230930__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zBvTIRdJFAOe" title="Fair value of equity securities">441,000</span> and $<span id="xdx_904_eus-gaap--EquitySecuritiesFvNi_iI_c20221231__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_znCTHPSH2qB2" title="Fair value of equity securities">433,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--EquityMethodInvestmentsPolicy_zK3OYEM3ykR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zefaDoYapx12">Investments in Capital Stock of Privately Held Companies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte evaluates whether investments held in common stock of other companies require consolidation of the company under, first, the variable interest entity (“VIE”) model, and then under the voting interest model in accordance with accounting guidance for consolidations under ASC 810-10. If consolidation of the entity is not required under either the VIE model or the voting interest model, Oncocyte determines whether the equity method of accounting should be applied in accordance with ASC 323, <i>Investments – Equity Method and Joint Ventures</i>. The equity method applies to investments in common stock or in-substance common stock if Oncocyte exercises significant influence over, but does not control, the entity, where significant influence is typically represented by ownership of 20% or more, but less than majority ownership, of the voting interests of a company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment balance based on Oncocyte’s pro rata share of earnings or losses from the investment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From February 24, 2021, the date of Oncocyte’s acquisition of the remaining interests in Razor, through February 16, 2023 the date of its disposition, Razor entity’s financial statements were consolidated with Oncocyte. See Note 13 for additional information related to the discontinued operations of Razor.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zFcV7dZuKvH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zpte7MSD5Oec">Assets Held for Sale</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management, having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified as held for sale in the consolidated balance sheet. Assets classified as held for sale are reported at the lower of their carrying value or fair value less costs to sell. Depreciation and amortization of assets ceases upon designation as held for sale.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2023, the Company entered into various agreements to sell laboratory equipment. As a result, the Company classified the equipment as held for sale as current assets, in the consolidated balance sheet, as all the criteria of ASC subtopic 360-10, <i>Property, Plant, and Equipment</i> (“ASC 360-10”) have been met and the transactions were qualified as assets held for sale. The equipment was written down to its fair value, less cost to sell, the remainder of which was $<span id="xdx_90B_eus-gaap--InventoryWriteDown_c20230101__20230930_zSmtbRsQnyb9" title="Inventory write down">139,000</span> as of September 30, 2023. As a result of these transactions, the Company recorded an impairment loss of $<span id="xdx_905_eus-gaap--AssetImpairmentCharges_pn5n6_c20230101__20230930_z5LRp3wJ1fLl" title="Asset impairment charges">1.3</span> million on held for sale assets, in the consolidated statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zlgr7u4YiyHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zufVRbZqogLb">Machinery and Equipment, Net, and Construction in Progress</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zGCY6shCwsC1" title="Estimated useful life of plant and equipment">3</span> to <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtYp_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_z0utKDcfIlQ1" title="Estimated useful life of plant and equipment">10</span> years. For equipment purchased under financing leases, Oncocyte depreciates the equipment based on the shorter of the useful life of the equipment or the term of the lease, ranging from <span id="xdx_909_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zz9kRh9nmAIf" title="Lease term">3</span> to <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zCNZaLYQrO2e" title="Lease term">5</span> years, depending on the nature and classification of the financing lease. Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in Oncocyte’s results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction in progress, comprised primarily of leasehold improvements under construction, is not depreciated until the underlying asset is placed into service.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_ziwpqWfuyHF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zy28Bhg55JW2">Goodwill and Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 350, <i>Intangibles – Goodwill and Other</i>, IPR&amp;D projects acquired in a business combination that are not complete as of the acquisition date are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Oncocyte considers various factors and risks for potential impairment of IPR&amp;D assets, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays or inability to obtain local determination coverage (“LCD”) from the Centers for Medicare and Medicaid Services (“CMS”) for Medicare reimbursement for a diagnostic test, the inability to bring a diagnostic test to market and the introduction or advancement of competitors’ diagnostic tests could result in partial or full impairment of the related intangible assets. Consequently, the eventual realized value of the IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges may occur in future periods. During the period between completion or abandonment, the IPR&amp;D assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if Oncocyte becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts (see Note 5).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill, similar to IPR&amp;D, is not amortized but is tested for impairment at least annually, or if circumstances indicate its value may no longer be recoverable. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors affecting Oncocyte’s business. Based on the qualitative assessment, if it is determined that the fair value of goodwill is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. Oncocyte continues to operate in one segment and considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at the enterprise level.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;D discussed in Notes 3 and 5. As of September 30, 2023, goodwill has been fully impaired and acquired IPR&amp;D has been partially impaired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z2bkHAEHqNWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zNkrCzyM01sf">Long-Lived Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived intangible assets, consisting primarily of acquired customer relationships, are stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful life of <span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230930_zHaAMifhVGAf" title="Long-lived intangible assets, useful life">5</span> years (see Note 5).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zpfkbg4ehOnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zzze8crzdKq7">Impairment of Long-Lived Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. Oncocyte’s long-lived assets consist primarily of intangible assets, right-of-use assets for operating leases, customer relationships, and machinery and equipment. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. See Note 4 for additional information with respect to the impairment of leasehold improvements. See “Assets held for sale” above for additional impairment disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--LesseeLeasesPolicyTextBlock_zUOMpq1SKrt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zCa13ec4mcZa">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte accounts for leases in accordance with ASC 842, <i>Leases</i>. Oncocyte determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. Under the available practical expedients for the adoption of ASC 842, Oncocyte accounts for the lease and non-lease components as a single lease component. Oncocyte recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheet. ROU assets represent the right to use an underlying asset during the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most leases do not provide an implicit rate, Oncocyte uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Oncocyte uses the implicit rate when it is readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that Oncocyte will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Operating leases include our office leases and are also included as right-of-use assets in machinery and equipment, and ROU lease liabilities, current and long-term, in the consolidated balance sheets. Financing leases are included in machinery and equipment, and in financing lease liabilities, current and long-term, in the consolidated balance sheets. Oncocyte discloses the amortization of our ROU assets and operating lease payments as a net amount in the consolidated statements of cash flows. Based on the available practical expedients under the standard, Oncocyte elected not to capitalize leases that have terms of twelve months or less.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During prior years, Oncocyte entered into various operating leases and an embedded operating lease in accordance with ASC 842 as discussed in Note 7. Oncocyte’s accounting for financing leases remained substantially unchanged.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zedbBOWrgtxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zYomQQgBaWri">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to ASC 606, revenues are recognized when control of services performed is transferred to customers, in an amount that reflects the consideration Oncocyte expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) identifying the contract with a customer,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) identifying the performance obligations in the contract,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) determining the transaction price,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) allocating the transaction price to the performance obligations, and</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) recognizing revenue when, or as, an entity satisfies a performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte determines transaction prices based on the amount of consideration we expect to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. The Company considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_ecustom--DisaggregationOfConsolidatedRevenueTableTextBlock_zSYaaYtXvuad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents consolidated revenues by service:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B1_zRT8i6Ja8Ue" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Disaggregation Of Revenue</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20230701__20230930_z1zT1O2876jg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20220701__20220930_zVHjA70t5Ih2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_496_20230101__20230930_z8tYavh1BEz2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20220101__20220930_zzR4hvV0clD1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Nine Months Ended</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">September 30,</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">September 30,</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(In thousands)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--IncomeStatementLocationAxis__custom--PharmaServicesMember_maGPzvxw_zLd8LB5TQwjd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pharma Services</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">423</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">67</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,137</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">684</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--IncomeStatementLocationAxis__custom--LaboratoryDevelopedTestServicesMember_maGPzvxw_zohPnKlsISU4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Laboratory developed test services</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0994">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPzvxw_zVfkdoctZci5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">429</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">67</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,189</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">684</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A6_zx6UGBtI93eb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pharma Services Revenue</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues recognized include Pharma Services performed by Oncocyte’s Insight and Chronix subsidiaries for its pharmaceutical customers, including testing for biomarker discovery, assay design and development, clinical trial support, and a broad spectrum of biomarker tests. These Pharma Services are generally performed under individual scope of work (“SOW”) arrangements or license agreements (together with SOW the “Pharma Services Agreements”) with specific deliverables defined by the customer. Pharma Services are performed on a (i) time and materials basis or (ii) per test completed basis. Upon completion of the service to the customer in accordance with a Pharma Services Agreement, Oncocyte has the right to bill the customer for the agreed upon price (either on a per test or per deliverable basis) and recognizes Pharma Service revenue at that time. Insight identifies each sale of its Pharma Service offering as a single performance obligation. Chronix identifies the processing of test samples as a separate performance obligation (considered a series) within license agreements with customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of the service and satisfaction of the performance obligation is typically evidenced by access to the report or test made available to the customer or any other form or applicable manner of delivery defined in the Pharma Services Agreements. However, for certain SOWs under which work is performed pursuant to the customer’s highly customized specifications, Oncocyte has the enforceable right to bill the customer for work completed, rather than upon completion of the SOW. For those SOWs, Oncocyte recognizes revenue over a period during which the work is performed using a formula that accounts for expended efforts, generally measured in labor hours, as a percentage of total estimated efforts for the completion of the SOW. As performance obligations are satisfied under the Pharma Services Agreements, any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed to the customer as of the date of Oncocyte’s consolidated financial statements are recorded as contract assets and are included in prepaids and other current assets as of the financial statement date. Amounts recorded in contract assets are reclassified to accounts receivable in Oncocyte’s consolidated balance sheets when the customer is invoiced according to the billing schedule in the contract.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023 and December 31, 2022, Oncocyte had accounts receivable from Pharma Services customers of $<span id="xdx_909_eus-gaap--AccountsReceivableSale_c20230101__20230930__srt--TitleOfIndividualAxis__custom--PharmaServicesMember_zIjil22yFHf4" title="Accounts receivable">557,000</span> and $<span id="xdx_905_eus-gaap--AccountsReceivableSale_c20220101__20221231__srt--TitleOfIndividualAxis__custom--PharmaServicesMember_z5jPQ1MpL7p3" title="Accounts receivable">257,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Allowance for Credit Losses</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte establishes an allowance for credit losses based on the evaluation of the collectability of its Pharma Services accounts receivables after considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer’s ability to pay, such as a bankruptcy filing or deterioration in the customer’s operating results or financial position, reasonable and supportable forecast that affect the collectability of the reported amount, and historical experience. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. Oncocyte continuously monitors collections and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts, if any, based upon its historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are written off against the credit loss reserve accounts. As of September 30, 2023 and December 31, 2022, we had no allowance for credit losses related to Pharma Services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Laboratory Developed Test Services</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the Razor Sale Transaction, Oncocyte generated revenue from performing DetermaRx tests on clinical samples through orders received from physicians, hospitals, and other healthcare providers. In determining whether all the revenue recognition criteria (i) through (v) above are met with respect to DetermaRx tests, each test result is considered a single performance obligation and is generally considered complete when the test result is delivered or made available to the prescribing physician electronically, and, as such, there are no shipping or handling fees incurred by Oncocyte or billed to customers. Although Oncocyte has billed a list price for all tests ordered and completed for all payer types, Oncocyte considers constraints on the variable consideration when recognizing revenue for DetermaRx. Because DetermaRx is a novel test and there are no current reimbursement arrangements with third-party payers other than Medicare, the transaction price represents variable consideration. Application of the constraint for variable consideration is an area that requires significant judgment. For all payers other than Medicare, Oncocyte must consider the novelty of the test, the uncertainty of receiving payment, or being subject to claims for a refund, from payers with whom it does not have a sufficient payment collection history or contractual reimbursement agreements. Accordingly, for those payers, Oncocyte has recognized revenue upon payment because it has had insufficient history to reliably estimate payment patterns or has had contractual reimbursement arrangements, or both, in place.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023 and December 31, 2022, Oncocyte had accounts receivable of $<span id="xdx_90F_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20230930__us-gaap--StatementBusinessSegmentsAxis__custom--MedicareAndMedicareAdvantageMember_z7Xpq2P3XCB5" title="Accounts receivable">1.5</span> million and $<span id="xdx_90F_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20221231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicareAndMedicareAdvantageMember_zagGc3xHNu0k" title="Accounts receivable">1.9</span> million, respectively, from Medicare and Medicare Advantage covered DetermaRx tests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Allowance for Credit Losses</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We maintain an allowance for credit losses related to laboratory developed test services at an amount we estimate to be sufficient to provide adequate protection against losses resulting from extending credit to our customers. We base this allowance, in the aggregate, on historical collection experience, age of receivables and general economic conditions. Our bad debt write-offs have not been significant and have been within management expectations. As of September 30, 2023 and December 31, 2022, we had an allowance for credit losses of $<span id="xdx_90A_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20230930_zExlDuy6azLh" title="Accounts receivable, allowance for credit loss">178,000</span> and $<span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20221231_z9mbrYkE4Ja9" title="Accounts receivable, allowance for credit loss">154,000</span>, respectively, related to laboratory developed test services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Licensing Revenue</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues recognized include licensing revenue derived from agreements with customers for exclusive rights to market Oncocyte’s proprietary testing technology. Under the agreements, Oncocyte grants exclusive rights to certain trademarks and technology of Oncocyte for the purpose of marketing Oncocyte’s tests within a defined geographic territory. A license agreement may specify milestone deliverables or performance obligations, for which Oncocyte recognizes revenue when its licensee confirms the completion of Oncocyte’s performance obligation. A licensing agreement may also include ongoing sales support from Oncocyte and typically includes non-refundable licensing fees and per-test Pharma Services revenues discussed above, for which Oncocyte treats the licensing of the technology, trademarks, and ongoing support as a single performance obligation satisfied by the passage of time over the term of the agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disaggregation of Revenues and Concentrations of Credit Risk</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_z5W7VSLsGtN7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the percentage of consolidated revenues by service:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zOZw2O6NrThe" style="display: none">Schedule of  Concentration Of Risk</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20230701__20230930_zNtMDCuXxJqf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20220701__20220930_zjV6lenQRIy8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20230101__20230930_zy8mqwbRJXce" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20220101__20220930_zB5odJLzJ7Zk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Three Months Ended</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Nine Months Ended</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--PharmaServicesMember_z6IV7aPgWmJc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pharma Services</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">99</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">96</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--LaboratoryDevelopedTestServicesMember_zbHbApF7RsB" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Laboratory developed test services</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zmPLGX839KG" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> <p id="xdx_8AC_zMu7hM4SZdoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--DisaggregationOfRevenueTableTextBlock_zGygchjkhpHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the percentage of consolidated revenues generated by unaffiliated customers, based on the respective periods presented, that individually represented greater than ten percent of consolidated revenues:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_z6u0vLQ87zb" style="display: none">Schedule of Consolidated Revenues Generated by Unaffiliated Customers</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20230701__20230930_zKbK3X5LiGbl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20220701__20220930_zjX5l5JN2nvj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_496_20230101__20230930_zcIfmScNgsB6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20220101__20220930_zYjX1rbfKd13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>Three Months Ended</b></span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>Nine Months Ended</b></span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCompanyAMember_zHt5A9Vz2jD7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pharma services - Company A</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">57</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">42</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">60</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_408_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCompanyBMember_zx1vAi11kHj6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pharma services - Company B</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">41</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_40E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCompanyCMember_zLhF97lJc7D2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pharma services - Company C </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1044">-</span></span><span id="xdx_F25_zeZEiUCVpdBd">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1046">-</span></span><span id="xdx_F2B_zqNoOHe2AFW6">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></span><span id="xdx_F2F_zKdw8sIz59q5">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCompanyDMember_zE5o9uhACJNj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pharma services - Company D</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></span><span id="xdx_F2B_zj4rXjPMcOt1">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1051">-</span></span><span id="xdx_F21_zQCm5xGr2cYk">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></span><span id="xdx_F23_zIKb0HGtJKy2"><sup>*</sup></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F02_zQoIspkX54i5">*</i></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F1F_ziPuyYqQ23kl">Less than 10%</i></span></td></tr> </table> <p id="xdx_8AB_zey0CYMHXIM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zvGCymuXZEpe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the percentage of consolidated revenues attributable to geographical locations:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zkheHOsLKRUg" style="display: none">Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49B_20230701__20230930_zBiHIacALmK8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_497_20220701__20220930_z0OT2nWGHlE4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20230101__20230930_zdAAxq4b3G35" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20220101__20220930_zGRmSr3SWq86" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Three Months Ended</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Nine Months Ended</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__country--US__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z2J4sdhbMRv4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">United States – Pharma Services</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">42</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">76</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">54</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_409_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--OutsideUnitedStatesPharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z1Gh6KOVBhec" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outside of the United States – Pharma Services</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">57</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">41</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">26</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_401_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--UnitedStatesLaboratoryDevelopedTestServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z6JKVhLdJxD6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">United States – Laboratory developed test services</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_407_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z4TvCumWTg4e" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p id="xdx_8A2_zVl19FvyJvv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk are cash equivalents and accounts receivable. The Company places its cash equivalents primarily in highly rated money market funds. Cash and cash equivalents are also invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. The Company has not experienced any significant losses on its deposits of cash and cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two Pharma Services customers individually represented approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCustomersOneMember_zfX1Tl3r5s0b" title="Concentration risk percentage">54</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCustomersTwoMember_zKjs5aiyzdS8" title="Concentration risk percentage">45</span>% of accounts receivable at September 30, 2023. Two Pharma Services customers individually represented approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCustomersOneMember_zPOuUgQxiRp7" title="Concentration risk percentage">59</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCustomersTwoMember_zbnoVu7Tg876" title="Concentration risk percentage">30</span>% of accounts receivable at December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--CostOfSalesPolicyTextBlock_zvy8ZBEAuj6k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_z42qjj01PnF8">Cost of Revenues</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of revenues generally consists of cost of materials, direct labor including benefits, bonus and stock-based compensation, equipment and infrastructure expenses, clinical sample related costs associated with performing DetermaRx tests and Pharma Services, providing deliverables according to our licensing agreements, license fees due to third parties, and amortization of acquired intangible assets such as the customer relationship intangible assets. Infrastructure expenses include depreciation of laboratory equipment, allocated rent costs, leasehold improvements, and allocated information technology costs for operations at Oncocyte’s CLIA laboratories in California and Tennessee. Costs associated with generating the revenues are recorded as the tests or services are performed regardless of whether revenue was recognized. Royalties or revenue share payments for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expenses at the time the related revenues are recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zs4wvwnObbfi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zB0uYBh7YVja">Research and Development Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses are comprised of costs incurred to develop technology, which include salaries and benefits (including stock-based compensation), laboratory expenses (including reagents and supplies used in research and development laboratory work), infrastructure expenses (including allocated facility occupancy costs), and contract services and other outside costs. Indirect research and development expenses are allocated primarily based on headcount, as applicable, and include rent and utilities, common area maintenance, telecommunications, property taxes, and insurance. Research and development costs are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--SalesAndMarketingExpensesPolicyTextBlock_zCmpLbzljNd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zbecX1NtmyAc">Sales and Marketing Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade show expenses, branding and positioning expenses, and consulting fees. Sales and marketing expenses also include indirect expenses for applicable overhead allocated based on headcount, and include allocated costs for rent and utilities, common area maintenance, telecommunications, property taxes, and insurance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zqaxzXCCu02d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z5lq29RC2WZ">General and Administrative Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses consist primarily of compensation and related benefits (including stock-based compensation) for executive and corporate personnel, professional and consulting fees, rent and utilities, common area maintenance, telecommunications, property taxes, and insurance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zAahipD5IdQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zRv45oGiV1Hl">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte recognizes compensation expense related to employee option grants and restricted stock grants in accordance with the Financial Accounting Standards Board (“FASB”) ASC 718, <i>Compensation – Stock Compensation</i> (“ASC 718”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value over the requisite service period. For stock-based awards that vest only upon the attainment of one or more performance goals set by Oncocyte at the time of the grant (sometimes referred to as milestone vesting), compensation cost is recognized if and when Oncocyte determines that it is probable that the performance condition or conditions will be, or have been, achieved. Oncocyte uses the Black-Scholes option pricing model for estimating the fair value of options granted under Oncocyte’s equity plans. The fair value of each restricted stock unit (“RSU”) or award is determined based on the value of the common stock granted or sold. Oncocyte has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period. Forfeitures are accounted for as they occur. Refer to Note 9 for additional information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Black-Scholes option pricing model requires Oncocyte to make certain assumptions including the expected option term, the expected volatility, the risk-free interest rate and the dividend yield. The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. Oncocyte estimates the expected term of options granted based on its own experience. Oncocyte estimates the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of peer companies, for a period equal to the expected term of the options. The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of Oncocyte’s stock options. The dividend yield assumption is based on Oncocyte’s history and expectation of dividend payouts. Oncocyte has never declared or paid any cash dividends on its common stock, and Oncocyte does not anticipate paying any cash dividends in the foreseeable future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as income tax benefit or expense, respectively, in the statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction. Because Oncocyte has a full valuation allowance for all periods presented (see Note 10), there was no impact to Oncocyte statements of operations for any excess tax benefits or deficiencies, as any excess benefit or deficiency would be offset by the change in the valuation allowance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_ecustom--AccountingForWarrantsPolicyTextBlock_zhXtEMCo2Vgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_z7AL9TWcOKJ2">Accounting for Warrants</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, <i>Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</i>, then in accordance with ASC 815-40, <i>Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock</i>. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate Oncocyte to settle the warrants or the underlying shares by paying cash or other assets or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480, Oncocyte assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. This liability classification guidance also applies to financial instruments that may require cash or other form of settlement for transactions outside of the company’s control and, in which the form of consideration to the warrant holder may not be the same as to all other shareholders in connection with the transaction. However, if a transaction is not within the company’s control but the holder of the financial instrument can solely receive the same type or form of consideration as is being offered to all the shareholders in the transaction, then equity classification of the financial instrument is not precluded, if all other applicable equity classification criteria are met.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After all relevant assessments, Oncocyte concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. Based on the above guidance and, among other factors, the fact that our warrants cannot be cash settled under any circumstance but require share settlement, all of our outstanding warrants meet the equity classification criteria and have been classified as equity. Refer to Notes 6 and 8 for details about our outstanding warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zKbO4CGdXq72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z0m0OwOb9B38">Net Loss Per Common Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of shares of common stock outstanding during the year. Diluted loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method or the if-converted method, or the two-class method for participating securities, whichever is more dilutive. Potential common shares are excluded from the computation if their effect is antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zMmMn8xJv1x7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All common stock equivalents are antidilutive because Oncocyte reported a net loss for all periods presented. The following table presents the calculation of basic and diluted loss per share of common stock:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z5aXUlD9qvei" style="display: none">Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_490_20230701__20230930_zZA6ODJeY7Kg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20220701__20220930_zz8MSzBZCjC1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20230101__20230930_zXLXuR6Xh0F1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20220101__20220930_z5ZV9quSZ95c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Nine Months Ended</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">September 30,</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">September 30,</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(In thousands, except per share data)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Numerator:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--IncomeLossIncludingPortionAttributableToNoncontrollingInterest_zSLtJQ09NbY3" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss attributable to Oncocyte Corporation</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(6,489</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(9,333</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,789</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(27,924</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40C_eus-gaap--RedeemablePreferredStockDividends_iN_pn3n3_di_zllEL9P91tK4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accretion of Series A redeemable convertible preferred stock</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(198</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(294</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(621</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(294</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_402_ecustom--DeemedDividendOnPreferredStock_iN_pn3n3_di_zUrRU0pgZPD5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Deemed dividend on Series A redeemable convertible preferred stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1112">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(118</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net loss attributable to common stockholders - basic and diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20230701__20230930_zbnHKyJwPGn8" title="Net loss attributable to common stockholders - Basic"><span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230701__20230930_zdzH2qvPcJqc" title="Net loss attributable to common stockholders - diluted">(6,687</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20220701__20220930_zUYdLpkbEO37" title="Net loss attributable to common stockholders - Basic"><span id="xdx_909_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220701__20220930_zY6rX1oXUTJh" title="Net loss attributable to common stockholders - diluted">(9,627</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20230101__20230930_zihU4D4ZM6b4" title="Net loss attributable to common stockholders - Basic"><span id="xdx_90F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230101__20230930_zkO6Wa2jsEzk" title="Net loss attributable to common stockholders - diluted">(12,528</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20220101__20220930_zwn9XHuWnpcb" title="Net loss attributable to common stockholders - Basic"><span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220101__20220930_zgKmOaBdCrl9" title="Net loss attributable to common stockholders - diluted">(28,218</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Denominator:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average shares used in computing net loss per share attributable to common stockholders - basic and diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930_zXcL8Fke1Vj7" title="Weighted average number of shares outstanding, basic"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930_zFtVTYcc6G42" title="Weighted average number of shares outstanding, diluted">8,256</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220701__20220930_zf1zzGzuYRVe" title="Weighted average number of shares outstanding, basic"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220701__20220930_zSNicEz3xETl" title="Weighted average number of shares outstanding, diluted">5,931</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930_z5X5kWjOfFY2" title="Weighted average number of shares outstanding, basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930_zsGNGA5NWx88" title="Weighted average number of shares outstanding, diluted">7,446</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20220930_zdr9e3nvKNNd" title="Weighted average number of shares outstanding, basic"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20220930_zK5IEjB12863" title="Weighted average number of shares outstanding, diluted">5,408</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Basic and diluted net loss per common share</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20230701__20230930_zjkq9QCO4o56" title="Basic net loss per common share"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pid_c20230701__20230930_zTFtPVSxsgN2" title="Earnings Per Share, diluted">(0.81</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_pid_c20220701__20220930_zja5zi12y1f4" title="Basic net loss per common share"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20220701__20220930_zaecgsXnA4Y9" title="Earnings Per Share, diluted">(1.62</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pid_c20230101__20230930_zH0GpM57yhU8" title="Basic net loss per common share"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230930_zn5VZdmDIQ9e" title="Earnings Per Share, diluted">(1.68</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pid_c20220101__20220930_zkb7zKpa8OE6" title="Basic net loss per common share"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20220930_zlu14b6t7Vod" title="Earnings Per Share, diluted">(5.22</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z4kvjPitVMXi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">501</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">717</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">501</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">717</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zibbvOCLlKIk" style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">RSUs</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">29</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">29</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zo8L4oLa3Sca" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">820</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">820</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">820</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">820</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zxMXvga6M2qh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Series A redeemable convertible preferred stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zh9kUAjfYpYj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,331</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,570</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,331</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,570</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zH9MRBJmbRkf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,331</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,570</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,331</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,570</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A0_zyjyzMoryuo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrvoP7WQXSL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zl7CWiNxZgwg">Recent Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, <i>Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Previously, U.S. GAAP required entities to write down credit losses only when losses are probable and loss reversals are not permitted. The Company adopted this ASU in the first quarter of 2023. Adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): <i>Accounting for Contract Assets and Contract Liabilities from Contracts with Customers,</i> to provide specific guidance to eliminate diversity in practice on how to recognize and measure acquired contract assets and contract liabilities from revenue contracts from customers in a business combination consistent with revenue contracts with customers not acquired in an acquisition. The amendments in this update provide that the acquirer should consider the terms of the acquired contracts, such as timing of payment, identify each performance obligation in the contracts, and allocate the total transaction price to each identified performance obligation on a relative standalone selling price basis as of contract inception (that is, the date the acquiree entered into the contracts) or contract modification to determine what should be recorded at the acquisition date. The Company adopted this ASU in the first quarter of 2023. Adoption of this standard did not have an impact on the Company’s consolidated financial statements and related disclosures.</span></p> <p id="xdx_851_zYAyZPuxGs1e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--AccountingPrinciplesPolicyTextBlock_zfb5eDpmpapa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_z2DiMlv20CG9">Accounting Principles</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (“GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84C_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zCiqLzJH5LT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zmiqcBt337G6">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts in the consolidated financial statements and notes to consolidated financial statements have been reclassified to conform to the current period presentation. These changes had no impact on the previously reported consolidated financial condition, results of operations or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zRc7qshVy0ld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zJFZzRGLztJ5">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance with GAAP for financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations, certain information and footnote disclosures normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance sheet as of December 31, 2022 was derived from the audited consolidated financial statements at that date. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in Oncocyte’s Annual Report on Form 10-K for the year ended December 31, 2022. The accompanying unaudited condensed consolidated financial statements, in the opinion of management, include all adjustments of a normal recurring nature necessary for a fair presentation of Oncocyte’s financial condition and results of operations. The consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2023, the Company implemented a <span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20230723__20230724_zmq9qd6VocIf" title="Reverse stock split">1-for-20 reverse stock split</span> of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pn6n6_c20230724_zerteWzY8qKj" title="Common stock, shares authorized">230</span> million shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1-for-20 reverse stock split 230000000 <p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zOVwoH3j7Vkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_86F_z23bZpZWjUXj">Principles of Consolidation</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 31, 2020, with the acquisition of Insight Genetics, Inc. (“Insight”) through a merger with a newly incorporated wholly-owned subsidiary of Oncocyte (the “Insight Merger”) under the terms of an Agreement and Plan of Merger (the “Insight Merger Agreement”), Insight became a wholly-owned subsidiary of Oncocyte, and on that date Oncocyte began consolidating Insight’s operations and results with Oncocyte’s operations and results (see Note 3).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 15, 2021, with the acquisition of Chronix Biomedical, Inc. (“Chronix”) pursuant to an Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021 (as amended and restated, the “Chronix Merger Agreement”), by and among Oncocyte, CNI Monitor Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Oncocyte (“Merger Sub”), Chronix became a wholly-owned subsidiary of Oncocyte (the “Chronix Merger”), and on that date Oncocyte began consolidating Chronix’s operations and results with Oncocyte’s operations and results (see Note 3).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have reflected the operations of Razor as discontinued operations for all periods presented. See Note 13 for further information. Amounts and disclosures throughout these Notes to consolidated financial statements relate solely to continuing operations and exclude all discontinued operations. Discontinued operations comprise activities that were disposed of or discontinued at the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting purposes and represent a strategic business shift having a major effect on the Company’s operations and financial results according to ASC Topic 205, <i>Presentation of Financial Statements</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All material intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--UseOfEstimates_zCHWMUvEJmI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zUWR4Q4Op9F8">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and contingent assets and liabilities, at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including, but not limited to, valuation methods used, assumptions requiring the use of judgment to prepare financial projections, timing of potential commercialization of acquired in-process intangible assets, applicable discount rates, probabilities of the likelihood of multiple outcomes of certain events related to contingent consideration, comparable companies or transactions, determination of fair value of the assets acquired and liabilities assumed including those relating to contingent consideration, assumptions related to going concern assessments, allocation of direct and indirect expenses, useful lives associated with long-lived intangible assets, key assumptions in operating and financing leases including incremental borrowing rates, loss contingencies, valuation allowances related to deferred income taxes, allowances for credit losses, and assumptions used to value debt and stock-based awards and other equity instruments. Actual results may differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly, Oncocyte assessed certain accounting matters that generally require consideration of forecasted financial information. The accounting matters assessed included, but were not limited to, Oncocyte’s equity investments, the carrying value of goodwill, going concern assessment, acquired in-process intangible assets and other long-lived assets. Those assessments as well as other estimates referenced above were made in the context of information reasonably available to Oncocyte.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p id="xdx_847_ecustom--SegmentsPolicyTextBlock_zbDLupCwMiOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_z96MWr9dxVs8">Segments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte’s executive management team, as a group, represents the entity’s chief operating decision makers. To date, Oncocyte’s executive management team has viewed Oncocyte’s operations as one segment that includes the research, development and commercialization of diagnostic tests, including molecular diagnostic services to pharmaceutical customers. As a result, the financial information disclosed materially represents all of the financial information related to Oncocyte’s sole operating segment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_ecustom--BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock_zGyM3yNaJ1Ba" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_z3l81aImYp65">Fair Value Measurements, Business Combinations and Contingent Consideration Liabilities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte accounts for business combinations in accordance with ASC 805, which requires the purchase consideration transferred to be measured at fair value on the acquisition date in accordance with ASC 820, <i>Fair Value Measurement</i>. ASC 820 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● <i>Level 1 </i>– Quoted prices in active markets for identical assets and liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● <i>Level 2 </i>– Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● <i>Level 3 </i>– Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When a part of the purchase consideration consists of shares of Oncocyte common stock, Oncocyte calculates the purchase price attributable to those shares, a Level 1 security, by determining the fair value of those shares as of the acquisition date based on prices quoted on the principal national securities exchange on which the shares traded. Oncocyte recognizes estimated fair values of the tangible assets and identifiable intangible assets acquired, including in-process research and development, and liabilities assumed, including any contingent consideration, as of the acquisition date. Goodwill is recognized as any amount of the fair value of the tangible and identifiable intangible assets acquired and liabilities assumed in excess of the consideration transferred. ASC 805 precludes the recognition of an assembled workforce as an asset, effectively subsuming any assembled workforce value into goodwill.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining fair value, Oncocyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, Oncocyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for money market funds and marketable equity securities held by Oncocyte described below. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain of Oncocyte’s asset and business acquisitions involve the potential for future payment of consideration to third-parties and former selling shareholders in amounts determined as a percentage of future net revenues generated, or upon attainment of revenue milestones, from Pharma Services or laboratory tests, as applicable, or annual minimum royalties to certain licensors, as provided in the applicable agreements. The fair value of such liabilities is determined using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows. These obligations are referred to as contingent consideration, which are carried at fair value based on Level 3 inputs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 805 requires that contingent consideration be estimated and recorded at fair value as of the acquisition date as part of the total consideration transferred. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings, such as “earn-out” provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of certain revenues generated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of contingent consideration after the acquisition date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in the consolidated statements of operations. Changes in key assumptions can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that Oncocyte records in its consolidated financial statements. See Note 3 for a full discussion of these liabilities and additional Level 3 fair value disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z1f6c6Ti82gj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables present the Company’s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zdjQu3ulOgLc" style="display: none">Schedule of Fair Value Measurement of Financial Assets and Liabilities</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of September 30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(In thousands)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Marketable equity securities</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zQ8iV4rtuO79" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">441</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_z6oEvqwvnd2e" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">441</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_ziDUQuRz7VM7" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0913">-</span></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zgjacTNZEkr3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0914">-</span></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20230930_zh6bf8oarEc5" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">441</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zS2JnDbckrFj" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">441</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0L9jHL2BwTk" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0917">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_znhgKXCvyI69" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0918">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Contingent consideration liabilities (Note 3)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zApHPZ8dNXp8" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,715</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_z8LhT77AAm5k" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0920">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_znMYiXliknRc" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0921">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zY1JXY377V8j" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,715</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930_zm6mdVSqrwY4" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,715</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJQn623SQZxh" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSvmVsr0zSb7" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0925">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNHgv6naB4dh" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,715</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(In thousands)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Marketable equity securities</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zsyKXGyp0K84" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">433</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zNyLXel1V0jd" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">433</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zrX92Gi3Fmdl" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zQtidnaZznnj" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0930">-</span></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_zTMOVEDP9q8l" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">433</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z2d7KoWt8cUa" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">433</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFACYnGDynh1" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAu7LWZe8Lde" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0934">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Contingent consideration liabilities (Note 3)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zMrsQfB95m72" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,662</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_z2swoRNNu0V5" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0936">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_z0NJreNb4Wyh" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zOULThUSByKj" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,662</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231_zZmMdlolOCE9" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,662</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpPeSH7YTbc2" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0940">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zy9EvgW98n82" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCbD4hV2f68l" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,662</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A1_zhbALWIoDHB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with GAAP, from time to time, the Company measures certain assets at fair value on a nonrecurring basis. The Company reviews the carrying value of goodwill, intangibles, including in-process research and development (“IPR&amp;D”) (see Note 5), and other long-lived assets for indications of impairment at least annually. Refer to related discussions of impairments below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z1f6c6Ti82gj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables present the Company’s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zdjQu3ulOgLc" style="display: none">Schedule of Fair Value Measurement of Financial Assets and Liabilities</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of September 30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(In thousands)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Marketable equity securities</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zQ8iV4rtuO79" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">441</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_z6oEvqwvnd2e" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">441</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_ziDUQuRz7VM7" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0913">-</span></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zgjacTNZEkr3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0914">-</span></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20230930_zh6bf8oarEc5" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">441</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zS2JnDbckrFj" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">441</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0L9jHL2BwTk" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0917">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_znhgKXCvyI69" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0918">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Contingent consideration liabilities (Note 3)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zApHPZ8dNXp8" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,715</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_z8LhT77AAm5k" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0920">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_znMYiXliknRc" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0921">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zY1JXY377V8j" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,715</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930_zm6mdVSqrwY4" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,715</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJQn623SQZxh" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSvmVsr0zSb7" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0925">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNHgv6naB4dh" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,715</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(In thousands)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Marketable equity securities</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zsyKXGyp0K84" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">433</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zNyLXel1V0jd" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">433</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zrX92Gi3Fmdl" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zQtidnaZznnj" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0930">-</span></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_zTMOVEDP9q8l" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">433</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z2d7KoWt8cUa" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">433</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFACYnGDynh1" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAu7LWZe8Lde" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0934">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Contingent consideration liabilities (Note 3)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zMrsQfB95m72" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,662</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_z2swoRNNu0V5" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0936">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_z0NJreNb4Wyh" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zOULThUSByKj" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,662</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231_zZmMdlolOCE9" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,662</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpPeSH7YTbc2" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0940">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zy9EvgW98n82" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCbD4hV2f68l" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,662</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 441000 441000 441000 441000 28715000 28715000 28715000 28715000 433000 433000 433000 433000 45662000 45662000 45662000 45662000 <p id="xdx_845_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zcTdTK3VPrF9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zMpmMRaupgFj">Cash, Cash Equivalents and Restricted Cash</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte considers all highly liquid securities with original maturities of three months or less when purchased to be cash equivalents. For the periods presented, Oncocyte’s cash equivalents are comprised of investments in AAA rated money market funds that invest in first-tier only securities, which primarily include domestic commercial paper and securities issued or guaranteed by the U.S. government or its agencies. Restricted cash relates to a bank letter of credit required under our office lease arrangement, refer to Note 7 for additional information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p id="xdx_842_eus-gaap--MarketableSecuritiesPolicy_zeSwau2WsHVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zzzhqWHDa9og">Marketable Equity Securities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte accounts for the shares of Lineage and AgeX common stock it holds as marketable equity securities in accordance with ASC 320-10-25, <i>Investments – Debt and Equity Securities</i>, as amended, as the shares have a readily determinable fair value quoted on the NYSE American and are held principally to meet future working capital purposes, as necessary. The securities are measured at fair value, with related gains and losses in the value of such securities recorded in the consolidated statements of operations in other income or expense, and are reported as current assets on the consolidated balance sheets based on the closing trading price of the security as of the date being presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023 and December 31, 2022, Oncocyte held <span id="xdx_904_ecustom--CommonStockSharesHeldAsAvailableForSaleSecurities_iI_pid_c20230930__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zLOwGs7uYQb5" title="Common stock, shares held as available for sale securities">353,264</span> and <span id="xdx_908_ecustom--CommonStockSharesHeldAsAvailableForSaleSecurities_iI_pid_c20221231__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_z9XcBFaYpHI9" title="Common stock, shares held as available for sale securities">35,326</span> shares of common stock of Lineage and AgeX, respectively, as marketable equity securities, which had a combined fair market value of $<span id="xdx_900_eus-gaap--EquitySecuritiesFvNi_iI_c20230930__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zBvTIRdJFAOe" title="Fair value of equity securities">441,000</span> and $<span id="xdx_904_eus-gaap--EquitySecuritiesFvNi_iI_c20221231__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_znCTHPSH2qB2" title="Fair value of equity securities">433,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 353264 35326 441000 433000 <p id="xdx_841_eus-gaap--EquityMethodInvestmentsPolicy_zK3OYEM3ykR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zefaDoYapx12">Investments in Capital Stock of Privately Held Companies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte evaluates whether investments held in common stock of other companies require consolidation of the company under, first, the variable interest entity (“VIE”) model, and then under the voting interest model in accordance with accounting guidance for consolidations under ASC 810-10. If consolidation of the entity is not required under either the VIE model or the voting interest model, Oncocyte determines whether the equity method of accounting should be applied in accordance with ASC 323, <i>Investments – Equity Method and Joint Ventures</i>. The equity method applies to investments in common stock or in-substance common stock if Oncocyte exercises significant influence over, but does not control, the entity, where significant influence is typically represented by ownership of 20% or more, but less than majority ownership, of the voting interests of a company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment balance based on Oncocyte’s pro rata share of earnings or losses from the investment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From February 24, 2021, the date of Oncocyte’s acquisition of the remaining interests in Razor, through February 16, 2023 the date of its disposition, Razor entity’s financial statements were consolidated with Oncocyte. See Note 13 for additional information related to the discontinued operations of Razor.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zFcV7dZuKvH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zpte7MSD5Oec">Assets Held for Sale</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management, having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified as held for sale in the consolidated balance sheet. Assets classified as held for sale are reported at the lower of their carrying value or fair value less costs to sell. Depreciation and amortization of assets ceases upon designation as held for sale.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2023, the Company entered into various agreements to sell laboratory equipment. As a result, the Company classified the equipment as held for sale as current assets, in the consolidated balance sheet, as all the criteria of ASC subtopic 360-10, <i>Property, Plant, and Equipment</i> (“ASC 360-10”) have been met and the transactions were qualified as assets held for sale. The equipment was written down to its fair value, less cost to sell, the remainder of which was $<span id="xdx_90B_eus-gaap--InventoryWriteDown_c20230101__20230930_zSmtbRsQnyb9" title="Inventory write down">139,000</span> as of September 30, 2023. As a result of these transactions, the Company recorded an impairment loss of $<span id="xdx_905_eus-gaap--AssetImpairmentCharges_pn5n6_c20230101__20230930_z5LRp3wJ1fLl" title="Asset impairment charges">1.3</span> million on held for sale assets, in the consolidated statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> 139000 1300000 <p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zlgr7u4YiyHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zufVRbZqogLb">Machinery and Equipment, Net, and Construction in Progress</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zGCY6shCwsC1" title="Estimated useful life of plant and equipment">3</span> to <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtYp_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_z0utKDcfIlQ1" title="Estimated useful life of plant and equipment">10</span> years. For equipment purchased under financing leases, Oncocyte depreciates the equipment based on the shorter of the useful life of the equipment or the term of the lease, ranging from <span id="xdx_909_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zz9kRh9nmAIf" title="Lease term">3</span> to <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zCNZaLYQrO2e" title="Lease term">5</span> years, depending on the nature and classification of the financing lease. Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in Oncocyte’s results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction in progress, comprised primarily of leasehold improvements under construction, is not depreciated until the underlying asset is placed into service.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P3Y P10Y P3Y P5Y <p id="xdx_84C_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_ziwpqWfuyHF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zy28Bhg55JW2">Goodwill and Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 350, <i>Intangibles – Goodwill and Other</i>, IPR&amp;D projects acquired in a business combination that are not complete as of the acquisition date are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Oncocyte considers various factors and risks for potential impairment of IPR&amp;D assets, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays or inability to obtain local determination coverage (“LCD”) from the Centers for Medicare and Medicaid Services (“CMS”) for Medicare reimbursement for a diagnostic test, the inability to bring a diagnostic test to market and the introduction or advancement of competitors’ diagnostic tests could result in partial or full impairment of the related intangible assets. Consequently, the eventual realized value of the IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges may occur in future periods. During the period between completion or abandonment, the IPR&amp;D assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if Oncocyte becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts (see Note 5).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill, similar to IPR&amp;D, is not amortized but is tested for impairment at least annually, or if circumstances indicate its value may no longer be recoverable. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors affecting Oncocyte’s business. Based on the qualitative assessment, if it is determined that the fair value of goodwill is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. Oncocyte continues to operate in one segment and considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at the enterprise level.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;D discussed in Notes 3 and 5. As of September 30, 2023, goodwill has been fully impaired and acquired IPR&amp;D has been partially impaired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z2bkHAEHqNWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zNkrCzyM01sf">Long-Lived Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived intangible assets, consisting primarily of acquired customer relationships, are stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful life of <span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230930_zHaAMifhVGAf" title="Long-lived intangible assets, useful life">5</span> years (see Note 5).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> P5Y <p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zpfkbg4ehOnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zzze8crzdKq7">Impairment of Long-Lived Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. Oncocyte’s long-lived assets consist primarily of intangible assets, right-of-use assets for operating leases, customer relationships, and machinery and equipment. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. See Note 4 for additional information with respect to the impairment of leasehold improvements. See “Assets held for sale” above for additional impairment disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--LesseeLeasesPolicyTextBlock_zUOMpq1SKrt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zCa13ec4mcZa">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte accounts for leases in accordance with ASC 842, <i>Leases</i>. Oncocyte determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. Under the available practical expedients for the adoption of ASC 842, Oncocyte accounts for the lease and non-lease components as a single lease component. Oncocyte recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheet. ROU assets represent the right to use an underlying asset during the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most leases do not provide an implicit rate, Oncocyte uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Oncocyte uses the implicit rate when it is readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that Oncocyte will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Operating leases include our office leases and are also included as right-of-use assets in machinery and equipment, and ROU lease liabilities, current and long-term, in the consolidated balance sheets. Financing leases are included in machinery and equipment, and in financing lease liabilities, current and long-term, in the consolidated balance sheets. Oncocyte discloses the amortization of our ROU assets and operating lease payments as a net amount in the consolidated statements of cash flows. Based on the available practical expedients under the standard, Oncocyte elected not to capitalize leases that have terms of twelve months or less.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During prior years, Oncocyte entered into various operating leases and an embedded operating lease in accordance with ASC 842 as discussed in Note 7. Oncocyte’s accounting for financing leases remained substantially unchanged.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zedbBOWrgtxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zYomQQgBaWri">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to ASC 606, revenues are recognized when control of services performed is transferred to customers, in an amount that reflects the consideration Oncocyte expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) identifying the contract with a customer,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) identifying the performance obligations in the contract,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) determining the transaction price,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) allocating the transaction price to the performance obligations, and</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) recognizing revenue when, or as, an entity satisfies a performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte determines transaction prices based on the amount of consideration we expect to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. The Company considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_ecustom--DisaggregationOfConsolidatedRevenueTableTextBlock_zSYaaYtXvuad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents consolidated revenues by service:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B1_zRT8i6Ja8Ue" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Disaggregation Of Revenue</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20230701__20230930_z1zT1O2876jg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20220701__20220930_zVHjA70t5Ih2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_496_20230101__20230930_z8tYavh1BEz2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20220101__20220930_zzR4hvV0clD1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Nine Months Ended</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">September 30,</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">September 30,</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(In thousands)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--IncomeStatementLocationAxis__custom--PharmaServicesMember_maGPzvxw_zLd8LB5TQwjd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pharma Services</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">423</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">67</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,137</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">684</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--IncomeStatementLocationAxis__custom--LaboratoryDevelopedTestServicesMember_maGPzvxw_zohPnKlsISU4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Laboratory developed test services</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0994">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPzvxw_zVfkdoctZci5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">429</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">67</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,189</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">684</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A6_zx6UGBtI93eb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pharma Services Revenue</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues recognized include Pharma Services performed by Oncocyte’s Insight and Chronix subsidiaries for its pharmaceutical customers, including testing for biomarker discovery, assay design and development, clinical trial support, and a broad spectrum of biomarker tests. These Pharma Services are generally performed under individual scope of work (“SOW”) arrangements or license agreements (together with SOW the “Pharma Services Agreements”) with specific deliverables defined by the customer. Pharma Services are performed on a (i) time and materials basis or (ii) per test completed basis. Upon completion of the service to the customer in accordance with a Pharma Services Agreement, Oncocyte has the right to bill the customer for the agreed upon price (either on a per test or per deliverable basis) and recognizes Pharma Service revenue at that time. Insight identifies each sale of its Pharma Service offering as a single performance obligation. Chronix identifies the processing of test samples as a separate performance obligation (considered a series) within license agreements with customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of the service and satisfaction of the performance obligation is typically evidenced by access to the report or test made available to the customer or any other form or applicable manner of delivery defined in the Pharma Services Agreements. However, for certain SOWs under which work is performed pursuant to the customer’s highly customized specifications, Oncocyte has the enforceable right to bill the customer for work completed, rather than upon completion of the SOW. For those SOWs, Oncocyte recognizes revenue over a period during which the work is performed using a formula that accounts for expended efforts, generally measured in labor hours, as a percentage of total estimated efforts for the completion of the SOW. As performance obligations are satisfied under the Pharma Services Agreements, any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed to the customer as of the date of Oncocyte’s consolidated financial statements are recorded as contract assets and are included in prepaids and other current assets as of the financial statement date. Amounts recorded in contract assets are reclassified to accounts receivable in Oncocyte’s consolidated balance sheets when the customer is invoiced according to the billing schedule in the contract.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023 and December 31, 2022, Oncocyte had accounts receivable from Pharma Services customers of $<span id="xdx_909_eus-gaap--AccountsReceivableSale_c20230101__20230930__srt--TitleOfIndividualAxis__custom--PharmaServicesMember_zIjil22yFHf4" title="Accounts receivable">557,000</span> and $<span id="xdx_905_eus-gaap--AccountsReceivableSale_c20220101__20221231__srt--TitleOfIndividualAxis__custom--PharmaServicesMember_z5jPQ1MpL7p3" title="Accounts receivable">257,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Allowance for Credit Losses</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte establishes an allowance for credit losses based on the evaluation of the collectability of its Pharma Services accounts receivables after considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer’s ability to pay, such as a bankruptcy filing or deterioration in the customer’s operating results or financial position, reasonable and supportable forecast that affect the collectability of the reported amount, and historical experience. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. Oncocyte continuously monitors collections and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts, if any, based upon its historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are written off against the credit loss reserve accounts. As of September 30, 2023 and December 31, 2022, we had no allowance for credit losses related to Pharma Services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Laboratory Developed Test Services</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the Razor Sale Transaction, Oncocyte generated revenue from performing DetermaRx tests on clinical samples through orders received from physicians, hospitals, and other healthcare providers. In determining whether all the revenue recognition criteria (i) through (v) above are met with respect to DetermaRx tests, each test result is considered a single performance obligation and is generally considered complete when the test result is delivered or made available to the prescribing physician electronically, and, as such, there are no shipping or handling fees incurred by Oncocyte or billed to customers. Although Oncocyte has billed a list price for all tests ordered and completed for all payer types, Oncocyte considers constraints on the variable consideration when recognizing revenue for DetermaRx. Because DetermaRx is a novel test and there are no current reimbursement arrangements with third-party payers other than Medicare, the transaction price represents variable consideration. Application of the constraint for variable consideration is an area that requires significant judgment. For all payers other than Medicare, Oncocyte must consider the novelty of the test, the uncertainty of receiving payment, or being subject to claims for a refund, from payers with whom it does not have a sufficient payment collection history or contractual reimbursement agreements. Accordingly, for those payers, Oncocyte has recognized revenue upon payment because it has had insufficient history to reliably estimate payment patterns or has had contractual reimbursement arrangements, or both, in place.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023 and December 31, 2022, Oncocyte had accounts receivable of $<span id="xdx_90F_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20230930__us-gaap--StatementBusinessSegmentsAxis__custom--MedicareAndMedicareAdvantageMember_z7Xpq2P3XCB5" title="Accounts receivable">1.5</span> million and $<span id="xdx_90F_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20221231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicareAndMedicareAdvantageMember_zagGc3xHNu0k" title="Accounts receivable">1.9</span> million, respectively, from Medicare and Medicare Advantage covered DetermaRx tests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Allowance for Credit Losses</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We maintain an allowance for credit losses related to laboratory developed test services at an amount we estimate to be sufficient to provide adequate protection against losses resulting from extending credit to our customers. We base this allowance, in the aggregate, on historical collection experience, age of receivables and general economic conditions. Our bad debt write-offs have not been significant and have been within management expectations. As of September 30, 2023 and December 31, 2022, we had an allowance for credit losses of $<span id="xdx_90A_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20230930_zExlDuy6azLh" title="Accounts receivable, allowance for credit loss">178,000</span> and $<span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20221231_z9mbrYkE4Ja9" title="Accounts receivable, allowance for credit loss">154,000</span>, respectively, related to laboratory developed test services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Licensing Revenue</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues recognized include licensing revenue derived from agreements with customers for exclusive rights to market Oncocyte’s proprietary testing technology. Under the agreements, Oncocyte grants exclusive rights to certain trademarks and technology of Oncocyte for the purpose of marketing Oncocyte’s tests within a defined geographic territory. A license agreement may specify milestone deliverables or performance obligations, for which Oncocyte recognizes revenue when its licensee confirms the completion of Oncocyte’s performance obligation. A licensing agreement may also include ongoing sales support from Oncocyte and typically includes non-refundable licensing fees and per-test Pharma Services revenues discussed above, for which Oncocyte treats the licensing of the technology, trademarks, and ongoing support as a single performance obligation satisfied by the passage of time over the term of the agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disaggregation of Revenues and Concentrations of Credit Risk</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_z5W7VSLsGtN7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the percentage of consolidated revenues by service:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zOZw2O6NrThe" style="display: none">Schedule of  Concentration Of Risk</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20230701__20230930_zNtMDCuXxJqf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20220701__20220930_zjV6lenQRIy8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20230101__20230930_zy8mqwbRJXce" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20220101__20220930_zB5odJLzJ7Zk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Three Months Ended</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Nine Months Ended</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--PharmaServicesMember_z6IV7aPgWmJc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pharma Services</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">99</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">96</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--LaboratoryDevelopedTestServicesMember_zbHbApF7RsB" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Laboratory developed test services</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zmPLGX839KG" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> <p id="xdx_8AC_zMu7hM4SZdoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--DisaggregationOfRevenueTableTextBlock_zGygchjkhpHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the percentage of consolidated revenues generated by unaffiliated customers, based on the respective periods presented, that individually represented greater than ten percent of consolidated revenues:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_z6u0vLQ87zb" style="display: none">Schedule of Consolidated Revenues Generated by Unaffiliated Customers</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20230701__20230930_zKbK3X5LiGbl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20220701__20220930_zjX5l5JN2nvj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_496_20230101__20230930_zcIfmScNgsB6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20220101__20220930_zYjX1rbfKd13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>Three Months Ended</b></span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>Nine Months Ended</b></span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCompanyAMember_zHt5A9Vz2jD7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pharma services - Company A</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">57</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">42</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">60</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_408_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCompanyBMember_zx1vAi11kHj6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pharma services - Company B</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">41</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_40E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCompanyCMember_zLhF97lJc7D2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pharma services - Company C </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1044">-</span></span><span id="xdx_F25_zeZEiUCVpdBd">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1046">-</span></span><span id="xdx_F2B_zqNoOHe2AFW6">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></span><span id="xdx_F2F_zKdw8sIz59q5">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCompanyDMember_zE5o9uhACJNj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pharma services - Company D</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></span><span id="xdx_F2B_zj4rXjPMcOt1">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1051">-</span></span><span id="xdx_F21_zQCm5xGr2cYk">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></span><span id="xdx_F23_zIKb0HGtJKy2"><sup>*</sup></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F02_zQoIspkX54i5">*</i></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F1F_ziPuyYqQ23kl">Less than 10%</i></span></td></tr> </table> <p id="xdx_8AB_zey0CYMHXIM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zvGCymuXZEpe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the percentage of consolidated revenues attributable to geographical locations:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zkheHOsLKRUg" style="display: none">Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49B_20230701__20230930_zBiHIacALmK8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_497_20220701__20220930_z0OT2nWGHlE4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20230101__20230930_zdAAxq4b3G35" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20220101__20220930_zGRmSr3SWq86" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Three Months Ended</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Nine Months Ended</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__country--US__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z2J4sdhbMRv4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">United States – Pharma Services</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">42</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">76</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">54</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_409_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--OutsideUnitedStatesPharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z1Gh6KOVBhec" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outside of the United States – Pharma Services</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">57</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">41</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">26</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_401_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--UnitedStatesLaboratoryDevelopedTestServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z6JKVhLdJxD6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">United States – Laboratory developed test services</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_407_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z4TvCumWTg4e" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p id="xdx_8A2_zVl19FvyJvv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk are cash equivalents and accounts receivable. The Company places its cash equivalents primarily in highly rated money market funds. Cash and cash equivalents are also invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. The Company has not experienced any significant losses on its deposits of cash and cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two Pharma Services customers individually represented approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCustomersOneMember_zfX1Tl3r5s0b" title="Concentration risk percentage">54</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCustomersTwoMember_zKjs5aiyzdS8" title="Concentration risk percentage">45</span>% of accounts receivable at September 30, 2023. Two Pharma Services customers individually represented approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCustomersOneMember_zPOuUgQxiRp7" title="Concentration risk percentage">59</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCustomersTwoMember_zbnoVu7Tg876" title="Concentration risk percentage">30</span>% of accounts receivable at December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_ecustom--DisaggregationOfConsolidatedRevenueTableTextBlock_zSYaaYtXvuad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents consolidated revenues by service:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B1_zRT8i6Ja8Ue" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Disaggregation Of Revenue</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20230701__20230930_z1zT1O2876jg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20220701__20220930_zVHjA70t5Ih2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_496_20230101__20230930_z8tYavh1BEz2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20220101__20220930_zzR4hvV0clD1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Nine Months Ended</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">September 30,</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">September 30,</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(In thousands)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--IncomeStatementLocationAxis__custom--PharmaServicesMember_maGPzvxw_zLd8LB5TQwjd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pharma Services</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">423</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">67</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,137</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">684</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--IncomeStatementLocationAxis__custom--LaboratoryDevelopedTestServicesMember_maGPzvxw_zohPnKlsISU4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Laboratory developed test services</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0994">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPzvxw_zVfkdoctZci5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">429</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">67</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,189</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">684</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 423000 67000 1137000 684000 6000 52000 429000 67000 1189000 684000 557000 257000 1500000 1900000 178000 154000 <p id="xdx_89E_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_z5W7VSLsGtN7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the percentage of consolidated revenues by service:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zOZw2O6NrThe" style="display: none">Schedule of  Concentration Of Risk</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20230701__20230930_zNtMDCuXxJqf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20220701__20220930_zjV6lenQRIy8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20230101__20230930_zy8mqwbRJXce" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20220101__20220930_zB5odJLzJ7Zk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Three Months Ended</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Nine Months Ended</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--PharmaServicesMember_z6IV7aPgWmJc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pharma Services</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">99</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">96</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--LaboratoryDevelopedTestServicesMember_zbHbApF7RsB" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Laboratory developed test services</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zmPLGX839KG" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> 0.99 1 0.96 1 0.01 0 0.04 0 1 1 1 1 <p id="xdx_890_eus-gaap--DisaggregationOfRevenueTableTextBlock_zGygchjkhpHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the percentage of consolidated revenues generated by unaffiliated customers, based on the respective periods presented, that individually represented greater than ten percent of consolidated revenues:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_z6u0vLQ87zb" style="display: none">Schedule of Consolidated Revenues Generated by Unaffiliated Customers</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20230701__20230930_zKbK3X5LiGbl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20220701__20220930_zjX5l5JN2nvj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_496_20230101__20230930_zcIfmScNgsB6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20220101__20220930_zYjX1rbfKd13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>Three Months Ended</b></span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>Nine Months Ended</b></span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCompanyAMember_zHt5A9Vz2jD7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pharma services - Company A</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">57</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">42</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">60</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_408_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCompanyBMember_zx1vAi11kHj6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pharma services - Company B</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">41</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_40E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCompanyCMember_zLhF97lJc7D2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pharma services - Company C </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1044">-</span></span><span id="xdx_F25_zeZEiUCVpdBd">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1046">-</span></span><span id="xdx_F2B_zqNoOHe2AFW6">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></span><span id="xdx_F2F_zKdw8sIz59q5">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--PharmaServicesCompanyDMember_zE5o9uhACJNj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pharma services - Company D</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></span><span id="xdx_F2B_zj4rXjPMcOt1">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1051">-</span></span><span id="xdx_F21_zQCm5xGr2cYk">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></span><span id="xdx_F23_zIKb0HGtJKy2"><sup>*</sup></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F02_zQoIspkX54i5">*</i></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F1F_ziPuyYqQ23kl">Less than 10%</i></span></td></tr> </table> 0.57 0.28 0.42 0.60 0.41 0.22 0.34 0.11 0.22 0.19 <p id="xdx_896_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zvGCymuXZEpe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the percentage of consolidated revenues attributable to geographical locations:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zkheHOsLKRUg" style="display: none">Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49B_20230701__20230930_zBiHIacALmK8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_497_20220701__20220930_z0OT2nWGHlE4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20230101__20230930_zdAAxq4b3G35" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20220101__20220930_zGRmSr3SWq86" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Three Months Ended</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Nine Months Ended</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__country--US__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z2J4sdhbMRv4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">United States – Pharma Services</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">42</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">76</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">54</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_409_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--OutsideUnitedStatesPharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z1Gh6KOVBhec" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outside of the United States – Pharma Services</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">57</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">41</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">26</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_401_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--UnitedStatesLaboratoryDevelopedTestServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z6JKVhLdJxD6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">United States – Laboratory developed test services</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_407_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z4TvCumWTg4e" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> 0.42 0.76 0.54 0.74 0.57 0.24 0.41 0.26 0.01 0 0.04 0 1 1 1 1 0.54 0.45 0.59 0.30 <p id="xdx_840_eus-gaap--CostOfSalesPolicyTextBlock_zvy8ZBEAuj6k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_z42qjj01PnF8">Cost of Revenues</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of revenues generally consists of cost of materials, direct labor including benefits, bonus and stock-based compensation, equipment and infrastructure expenses, clinical sample related costs associated with performing DetermaRx tests and Pharma Services, providing deliverables according to our licensing agreements, license fees due to third parties, and amortization of acquired intangible assets such as the customer relationship intangible assets. Infrastructure expenses include depreciation of laboratory equipment, allocated rent costs, leasehold improvements, and allocated information technology costs for operations at Oncocyte’s CLIA laboratories in California and Tennessee. Costs associated with generating the revenues are recorded as the tests or services are performed regardless of whether revenue was recognized. Royalties or revenue share payments for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expenses at the time the related revenues are recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zs4wvwnObbfi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zB0uYBh7YVja">Research and Development Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses are comprised of costs incurred to develop technology, which include salaries and benefits (including stock-based compensation), laboratory expenses (including reagents and supplies used in research and development laboratory work), infrastructure expenses (including allocated facility occupancy costs), and contract services and other outside costs. Indirect research and development expenses are allocated primarily based on headcount, as applicable, and include rent and utilities, common area maintenance, telecommunications, property taxes, and insurance. Research and development costs are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--SalesAndMarketingExpensesPolicyTextBlock_zCmpLbzljNd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zbecX1NtmyAc">Sales and Marketing Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade show expenses, branding and positioning expenses, and consulting fees. Sales and marketing expenses also include indirect expenses for applicable overhead allocated based on headcount, and include allocated costs for rent and utilities, common area maintenance, telecommunications, property taxes, and insurance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zqaxzXCCu02d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z5lq29RC2WZ">General and Administrative Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses consist primarily of compensation and related benefits (including stock-based compensation) for executive and corporate personnel, professional and consulting fees, rent and utilities, common area maintenance, telecommunications, property taxes, and insurance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zAahipD5IdQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zRv45oGiV1Hl">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte recognizes compensation expense related to employee option grants and restricted stock grants in accordance with the Financial Accounting Standards Board (“FASB”) ASC 718, <i>Compensation – Stock Compensation</i> (“ASC 718”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value over the requisite service period. For stock-based awards that vest only upon the attainment of one or more performance goals set by Oncocyte at the time of the grant (sometimes referred to as milestone vesting), compensation cost is recognized if and when Oncocyte determines that it is probable that the performance condition or conditions will be, or have been, achieved. Oncocyte uses the Black-Scholes option pricing model for estimating the fair value of options granted under Oncocyte’s equity plans. The fair value of each restricted stock unit (“RSU”) or award is determined based on the value of the common stock granted or sold. Oncocyte has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period. Forfeitures are accounted for as they occur. Refer to Note 9 for additional information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Black-Scholes option pricing model requires Oncocyte to make certain assumptions including the expected option term, the expected volatility, the risk-free interest rate and the dividend yield. The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. Oncocyte estimates the expected term of options granted based on its own experience. Oncocyte estimates the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of peer companies, for a period equal to the expected term of the options. The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of Oncocyte’s stock options. The dividend yield assumption is based on Oncocyte’s history and expectation of dividend payouts. Oncocyte has never declared or paid any cash dividends on its common stock, and Oncocyte does not anticipate paying any cash dividends in the foreseeable future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as income tax benefit or expense, respectively, in the statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction. Because Oncocyte has a full valuation allowance for all periods presented (see Note 10), there was no impact to Oncocyte statements of operations for any excess tax benefits or deficiencies, as any excess benefit or deficiency would be offset by the change in the valuation allowance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_ecustom--AccountingForWarrantsPolicyTextBlock_zhXtEMCo2Vgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_z7AL9TWcOKJ2">Accounting for Warrants</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, <i>Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</i>, then in accordance with ASC 815-40, <i>Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock</i>. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate Oncocyte to settle the warrants or the underlying shares by paying cash or other assets or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480, Oncocyte assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. This liability classification guidance also applies to financial instruments that may require cash or other form of settlement for transactions outside of the company’s control and, in which the form of consideration to the warrant holder may not be the same as to all other shareholders in connection with the transaction. However, if a transaction is not within the company’s control but the holder of the financial instrument can solely receive the same type or form of consideration as is being offered to all the shareholders in the transaction, then equity classification of the financial instrument is not precluded, if all other applicable equity classification criteria are met.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After all relevant assessments, Oncocyte concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. Based on the above guidance and, among other factors, the fact that our warrants cannot be cash settled under any circumstance but require share settlement, all of our outstanding warrants meet the equity classification criteria and have been classified as equity. Refer to Notes 6 and 8 for details about our outstanding warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zKbO4CGdXq72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z0m0OwOb9B38">Net Loss Per Common Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of shares of common stock outstanding during the year. Diluted loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method or the if-converted method, or the two-class method for participating securities, whichever is more dilutive. Potential common shares are excluded from the computation if their effect is antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zMmMn8xJv1x7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All common stock equivalents are antidilutive because Oncocyte reported a net loss for all periods presented. The following table presents the calculation of basic and diluted loss per share of common stock:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z5aXUlD9qvei" style="display: none">Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_490_20230701__20230930_zZA6ODJeY7Kg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20220701__20220930_zz8MSzBZCjC1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20230101__20230930_zXLXuR6Xh0F1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20220101__20220930_z5ZV9quSZ95c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Nine Months Ended</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">September 30,</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">September 30,</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(In thousands, except per share data)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Numerator:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--IncomeLossIncludingPortionAttributableToNoncontrollingInterest_zSLtJQ09NbY3" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss attributable to Oncocyte Corporation</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(6,489</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(9,333</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,789</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(27,924</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40C_eus-gaap--RedeemablePreferredStockDividends_iN_pn3n3_di_zllEL9P91tK4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accretion of Series A redeemable convertible preferred stock</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(198</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(294</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(621</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(294</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_402_ecustom--DeemedDividendOnPreferredStock_iN_pn3n3_di_zUrRU0pgZPD5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Deemed dividend on Series A redeemable convertible preferred stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1112">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(118</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net loss attributable to common stockholders - basic and diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20230701__20230930_zbnHKyJwPGn8" title="Net loss attributable to common stockholders - Basic"><span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230701__20230930_zdzH2qvPcJqc" title="Net loss attributable to common stockholders - diluted">(6,687</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20220701__20220930_zUYdLpkbEO37" title="Net loss attributable to common stockholders - Basic"><span id="xdx_909_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220701__20220930_zY6rX1oXUTJh" title="Net loss attributable to common stockholders - diluted">(9,627</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20230101__20230930_zihU4D4ZM6b4" title="Net loss attributable to common stockholders - Basic"><span id="xdx_90F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230101__20230930_zkO6Wa2jsEzk" title="Net loss attributable to common stockholders - diluted">(12,528</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20220101__20220930_zwn9XHuWnpcb" title="Net loss attributable to common stockholders - Basic"><span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220101__20220930_zgKmOaBdCrl9" title="Net loss attributable to common stockholders - diluted">(28,218</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Denominator:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average shares used in computing net loss per share attributable to common stockholders - basic and diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930_zXcL8Fke1Vj7" title="Weighted average number of shares outstanding, basic"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930_zFtVTYcc6G42" title="Weighted average number of shares outstanding, diluted">8,256</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220701__20220930_zf1zzGzuYRVe" title="Weighted average number of shares outstanding, basic"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220701__20220930_zSNicEz3xETl" title="Weighted average number of shares outstanding, diluted">5,931</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930_z5X5kWjOfFY2" title="Weighted average number of shares outstanding, basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930_zsGNGA5NWx88" title="Weighted average number of shares outstanding, diluted">7,446</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20220930_zdr9e3nvKNNd" title="Weighted average number of shares outstanding, basic"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20220930_zK5IEjB12863" title="Weighted average number of shares outstanding, diluted">5,408</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Basic and diluted net loss per common share</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20230701__20230930_zjkq9QCO4o56" title="Basic net loss per common share"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pid_c20230701__20230930_zTFtPVSxsgN2" title="Earnings Per Share, diluted">(0.81</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_pid_c20220701__20220930_zja5zi12y1f4" title="Basic net loss per common share"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20220701__20220930_zaecgsXnA4Y9" title="Earnings Per Share, diluted">(1.62</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pid_c20230101__20230930_zH0GpM57yhU8" title="Basic net loss per common share"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230930_zn5VZdmDIQ9e" title="Earnings Per Share, diluted">(1.68</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pid_c20220101__20220930_zkb7zKpa8OE6" title="Basic net loss per common share"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20220930_zlu14b6t7Vod" title="Earnings Per Share, diluted">(5.22</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z4kvjPitVMXi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">501</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">717</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">501</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">717</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zibbvOCLlKIk" style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">RSUs</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">29</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">29</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zo8L4oLa3Sca" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">820</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">820</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">820</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">820</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zxMXvga6M2qh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Series A redeemable convertible preferred stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zh9kUAjfYpYj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,331</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,570</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,331</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,570</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zH9MRBJmbRkf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,331</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,570</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,331</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,570</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A0_zyjyzMoryuo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zMmMn8xJv1x7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All common stock equivalents are antidilutive because Oncocyte reported a net loss for all periods presented. The following table presents the calculation of basic and diluted loss per share of common stock:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z5aXUlD9qvei" style="display: none">Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_490_20230701__20230930_zZA6ODJeY7Kg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20220701__20220930_zz8MSzBZCjC1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20230101__20230930_zXLXuR6Xh0F1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20220101__20220930_z5ZV9quSZ95c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Nine Months Ended</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">September 30,</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">September 30,</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(In thousands, except per share data)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Numerator:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--IncomeLossIncludingPortionAttributableToNoncontrollingInterest_zSLtJQ09NbY3" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss attributable to Oncocyte Corporation</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(6,489</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(9,333</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,789</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(27,924</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40C_eus-gaap--RedeemablePreferredStockDividends_iN_pn3n3_di_zllEL9P91tK4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accretion of Series A redeemable convertible preferred stock</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(198</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(294</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(621</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(294</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_402_ecustom--DeemedDividendOnPreferredStock_iN_pn3n3_di_zUrRU0pgZPD5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Deemed dividend on Series A redeemable convertible preferred stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1112">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(118</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net loss attributable to common stockholders - basic and diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20230701__20230930_zbnHKyJwPGn8" title="Net loss attributable to common stockholders - Basic"><span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230701__20230930_zdzH2qvPcJqc" title="Net loss attributable to common stockholders - diluted">(6,687</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20220701__20220930_zUYdLpkbEO37" title="Net loss attributable to common stockholders - Basic"><span id="xdx_909_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220701__20220930_zY6rX1oXUTJh" title="Net loss attributable to common stockholders - diluted">(9,627</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20230101__20230930_zihU4D4ZM6b4" title="Net loss attributable to common stockholders - Basic"><span id="xdx_90F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230101__20230930_zkO6Wa2jsEzk" title="Net loss attributable to common stockholders - diluted">(12,528</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20220101__20220930_zwn9XHuWnpcb" title="Net loss attributable to common stockholders - Basic"><span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220101__20220930_zgKmOaBdCrl9" title="Net loss attributable to common stockholders - diluted">(28,218</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Denominator:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average shares used in computing net loss per share attributable to common stockholders - basic and diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930_zXcL8Fke1Vj7" title="Weighted average number of shares outstanding, basic"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930_zFtVTYcc6G42" title="Weighted average number of shares outstanding, diluted">8,256</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220701__20220930_zf1zzGzuYRVe" title="Weighted average number of shares outstanding, basic"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220701__20220930_zSNicEz3xETl" title="Weighted average number of shares outstanding, diluted">5,931</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930_z5X5kWjOfFY2" title="Weighted average number of shares outstanding, basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930_zsGNGA5NWx88" title="Weighted average number of shares outstanding, diluted">7,446</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20220930_zdr9e3nvKNNd" title="Weighted average number of shares outstanding, basic"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20220930_zK5IEjB12863" title="Weighted average number of shares outstanding, diluted">5,408</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Basic and diluted net loss per common share</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20230701__20230930_zjkq9QCO4o56" title="Basic net loss per common share"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pid_c20230701__20230930_zTFtPVSxsgN2" title="Earnings Per Share, diluted">(0.81</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_pid_c20220701__20220930_zja5zi12y1f4" title="Basic net loss per common share"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20220701__20220930_zaecgsXnA4Y9" title="Earnings Per Share, diluted">(1.62</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pid_c20230101__20230930_zH0GpM57yhU8" title="Basic net loss per common share"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230930_zn5VZdmDIQ9e" title="Earnings Per Share, diluted">(1.68</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pid_c20220101__20220930_zkb7zKpa8OE6" title="Basic net loss per common share"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20220930_zlu14b6t7Vod" title="Earnings Per Share, diluted">(5.22</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z4kvjPitVMXi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">501</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">717</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">501</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">717</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zibbvOCLlKIk" style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">RSUs</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">29</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">29</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zo8L4oLa3Sca" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">820</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">820</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">820</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">820</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zxMXvga6M2qh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Series A redeemable convertible preferred stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zh9kUAjfYpYj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,331</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,570</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,331</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,570</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zH9MRBJmbRkf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,331</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,570</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,331</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,570</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> -6489000 -9333000 -11789000 -27924000 198000 294000 621000 294000 118000 -6687000 -6687000 -9627000 -9627000 -12528000 -12528000 -28218000 -28218000 8256 8256 5931 5931 7446 7446 5408 5408 -0.81 -0.81 -1.62 -1.62 -1.68 -1.68 -5.22 -5.22 501000 717000 501000 717000 5000 29000 5000 29000 820000 820000 820000 820000 5000 4000 5000 4000 1331000 1570000 1331000 1570000 1331000 1570000 1331000 1570000 <p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrvoP7WQXSL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zl7CWiNxZgwg">Recent Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, <i>Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Previously, U.S. GAAP required entities to write down credit losses only when losses are probable and loss reversals are not permitted. The Company adopted this ASU in the first quarter of 2023. Adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): <i>Accounting for Contract Assets and Contract Liabilities from Contracts with Customers,</i> to provide specific guidance to eliminate diversity in practice on how to recognize and measure acquired contract assets and contract liabilities from revenue contracts from customers in a business combination consistent with revenue contracts with customers not acquired in an acquisition. The amendments in this update provide that the acquirer should consider the terms of the acquired contracts, such as timing of payment, identify each performance obligation in the contracts, and allocate the total transaction price to each identified performance obligation on a relative standalone selling price basis as of contract inception (that is, the date the acquiree entered into the contracts) or contract modification to determine what should be recorded at the acquisition date. The Company adopted this ASU in the first quarter of 2023. Adoption of this standard did not have an impact on the Company’s consolidated financial statements and related disclosures.</span></p> <p id="xdx_804_eus-gaap--BusinessCombinationDisclosureTextBlock_zMQiONd7OJHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. <span id="xdx_82B_zef7erBixB4b">Business Combinations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquisition of Insight Genetics, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 31, 2020 (the “Insight Merger Date”), Oncocyte completed its acquisition of Insight pursuant to the Insight Merger Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings, such as “earn-out” provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of revenues generated from DetermaIO and Insight Pharma Services over their respective useful life. Accordingly, Oncocyte determined there are two types of contingent consideration in connection with the Insight Merger, the Milestone Contingent Consideration and the Royalty Contingent Consideration discussed below, which are collectively referred to as the “Contingent Consideration”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are three milestones comprising the Milestone Contingent Consideration, collectively referred to as the Milestones, in connection with the Insight Merger which Oncocyte valued and recorded as part of Contingent Consideration as of the Insight Merger Date (see table below), which consist of (i) a payment for clinical trial completion and related data publication (“Milestone 1”), (ii) a payment for an affirmative final local coverage determination from CMS for a specified lung cancer test (“Milestone 2”), and (iii) a payment for achieving specified CMS reimbursement milestones (“Milestone 3”). If achieved, any respective Milestone will be paid at the contractual value shown below, with the payment made either in cash or in shares of Oncocyte common stock as determined by Oncocyte. There can be no assurance that any of the Milestones will be achieved.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_znan0mJ0AMz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table shows the Insight Merger Date contractual payment amounts, as applicable, and the corresponding fair value of each respective Contingent Consideration liability:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zliVsq5lWeo6" style="display: none">Schedule of Fair Value of Contingent Consideration Liability</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair Value on the</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Merger Date</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">(In thousands)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Milestone 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230930__us-gaap--BusinessAcquisitionAxis__custom--MilestoneOneMember_z4bMOVhk4Dsc" style="width: 14%; text-align: right" title="Contractual Value">1,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230930__us-gaap--BusinessAcquisitionAxis__custom--MilestoneOneMember_zZhQnsFn4Icg" style="width: 14%; text-align: right" title="Fair Value on the Merger Date">1,340</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Milestone 2</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230930__us-gaap--BusinessAcquisitionAxis__custom--MilestoneTwoMember_zpII7QNCRnh4" style="text-align: right" title="Contractual Value">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230930__us-gaap--BusinessAcquisitionAxis__custom--MilestoneTwoMember_zQVltBM0DoV1" style="text-align: right" title="Fair Value on the Merger Date">1,830</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestone 3 <span id="xdx_F27_z3lUnlCOaCx"><sup>(</sup></span></span><sup><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230930__us-gaap--BusinessAcquisitionAxis__custom--MilestoneThreeMember_fKGEp_zHACNEHzUwm6" style="text-align: right" title="Contractual Value">1,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230930__us-gaap--BusinessAcquisitionAxis__custom--MilestoneThreeMember_fKGEp_zuRnx4lhuNpf" style="text-align: right" title="Fair Value on the Merger Date">770</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalty 1 <span id="xdx_F2F_zv3vSG7QD8Kl"><sup>(</sup></span></span><sup><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></sup></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See(b)</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230930__us-gaap--BusinessAcquisitionAxis__custom--RoyaltyOneMember_fKGIp_z1GmABug8oAa" style="text-align: right" title="Fair Value on the Merger Date">5,980</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalty 2 <span id="xdx_F2D_z2Jkchv2aDe5"><sup>(</sup></span></span><sup><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></sup></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See(b)</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230930__us-gaap--BusinessAcquisitionAxis__custom--RoyaltyTwoMember_fKGIp_z2IUauoDMfBg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value on the Merger Date">1,210</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230930_zfgVDCumL1u5" style="border-bottom: Black 2.5pt double; text-align: right" title="Contractual Value">6,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230930_zq4a4GS2FUee" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value on the Merger Date">11,130</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0D_z7QJbvyQQp6c">(a)</sup></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zGA2w3bK0IHe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates the maximum payable if the Milestone is achieved.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F05_zy1Ybnsgayz8">(b)</sup></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_z4dZMwKzWyM6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration.</span></td></tr> </table> <p id="xdx_8AE_zhsJShcapUte" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Contingent Consideration after the Insight Merger Date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in Oncocyte’s consolidated statements of operations. Durning 2023, based on Oncocyte’s reassessment of significant assumptions, there was a decrease of approximately $<span id="xdx_909_ecustom--FairValueOfContingentConsideration_pn5n6_c20230101__20230930_zvfH08oMidcl" title="Fair value of contingent consideration">3.1</span> million to the fair value of the Contingent Consideration primarily attributable to revised estimates of the timing of the possible future payouts and, accordingly, this decrease was recorded as change in fair value of contingent consideration in the consolidated statement of operations for the nine months ended September 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte uses a discounted cash flow valuation technique to determine the fair value of its Level 3 contingent consideration liabilities. <span id="xdx_90B_eus-gaap--FairValueMeasurementsSensitivityAnalysisDescription_c20230101__20230930__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember_ziq9EusO1dlk" title="Unobservable Measurement Input, Uncertainty, Description">The significant unobservable inputs used in Insight’s contingent consideration valuation on September 30, 2023, included: (i) a discount period, based on the expected milestone payment dates, ranging from 0.5 years to 1.5 years, (ii) a discount rate of 15.2% to 15.4%, and (iii) a management probability estimate of 15% to 50%.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_ecustom--ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zIQpQJNTRL4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables reflect the activity for the Insight Contingent Consideration measured at fair value using Level 3 inputs:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zkc2rApGcaP7" style="display: none">Schedule of Contingent Consideration, Measured at Fair Value</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">(In thousands)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%">Balance at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zsyLmu3mBER6" style="width: 14%; text-align: right" title="Beginning balance">7,060</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in estimated fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zBUi6C6mo8Bh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in estimated fair value">420</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zLmYPTxJ4H0h" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance">7,480</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20230101__20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zmJEZwh8Dzdg" style="text-align: right" title="Beginning balance">5,370</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in estimated fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20230101__20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zUp2nJ0YU7l6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in estimated fair value">(3,080</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20230101__20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_z8VnrN3Df4Lb" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance">2,290</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_8AB_z4j5AUbErhP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingent consideration is not deductible for tax purposes, even if paid; therefore, no deferred tax assets related to the Contingent Consideration were recorded.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquisition of Chronix Biomedical, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 15, 2021 (the “Chronix Merger Date”), Oncocyte completed its acquisition of Chronix pursuant the Chronix Merger Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As additional consideration for holders of certain classes and series of Chronix capital stock, the Chronix Merger Agreement originally required Oncocyte to pay “Chronix Contingent Consideration” consisting of (i) “Chronix Milestone Payments” of up to $<span id="xdx_900_eus-gaap--BusinessCombinationConsiderationTransferred1_pn6n6_c20210414__20210415__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixBiomedicalIncMember_zvUfFndbkI0c" title="Business combination consideration transferred">14</span> million in any combination of cash or Oncocyte common stock if certain milestones specified in the Chronix Merger Agreement are achieved, (ii) “Royalty Payments” of up to <span id="xdx_906_ecustom--EarnoutPercentageOnCollectionsForSales_pid_dp_uPure_c20210414__20210415__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixBiomedicalIncMember_zijmFaD1shtd" title="Earnout percentage on collections for sales">15</span>% of net collections for sales of specified tests and products during the five-to-ten year earnout periods, and (iii) “Transplant Sale Payments” of up to <span id="xdx_905_ecustom--EarnoutPercentageOnCollectionsForSaleOrLicense_pid_dp_uPure_c20210414__20210415__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixBiomedicalIncMember_zZWkBxa9zWgf" title="Earnout percentage on collections for sale or license">75</span>% of net collections from the sale or license to a third party of Chronix’s patents for use in transplantation medicine during a seven-year earnout period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 8, 2023, the Company and equity holder representative entered into Amendment No. 1 to the Merger Agreement (the “Chronix Amendment”), pursuant to which the parties agreed that (i) Chronix’s equity holders will be paid earnout consideration of <span id="xdx_90D_ecustom--EarnoutPercentageOnCollectionsForSales_pid_dp_uPure_c20230207__20230208__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixEquityMember_zu52ZNkUBLJ8" title="Earnout percentage on collections for sales">10</span>% of net collections for sales of specified tests and products, until the expiration of intellectual property related to such tests and products, (ii) Chronix’s equity holders will be paid <span id="xdx_90C_ecustom--EarnoutPercentageOnCollectionsForSale_pid_dp_uPure_c20230207__20230208__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixEquityMember_zpbGDcWmUVna" title="Gross proceeds percentage">5</span>% of the gross proceeds received from any sale of all or substantially all of the rights, titles, and interests in and to Chronix’s patents for use in transplantation medicine to such third party, and (iii) the Chronix Milestone Payments, <span id="xdx_901_ecustom--RoyaltyPaymentsPercentage_pid_dp_uPure_c20230207__20230208__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixMilestoneMember_zbMyUPmNiLie" title="Royalty payments">15</span>% Royalty Payments and Transplant Sale Payment obligations were eliminated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Chronix Contingent Consideration after the Chronix Merger Date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in Oncocyte’s consolidated statements of operations. During 2023, based on Oncocyte’s reassessment of significant assumptions, there was a decrease of approximately $<span id="xdx_906_ecustom--FairValueOfContingentConsideration_pn5n6_c20230101__20230930__dei--LegalEntityAxis__custom--ChronixMember_zAMCz0YGTtG7" title="Fair value">13.9</span> million to the fair value of the Contingent Consideration primarily attributable to revised estimates of the timing of the possible future payouts and, accordingly, this decrease was recorded as a change in fair value of contingent consideration in the consolidated statement of operations for the nine months ended September 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte uses a discounted cash flow valuation technique to determine the fair value of its Level 3 contingent consideration liabilities. <span id="xdx_908_eus-gaap--FairValueMeasurementsSensitivityAnalysisDescription_c20230101__20230930__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember_zvZQkXZxb9Bf" title="Unobservable Measurement Input, Uncertainty, Description">The significant unobservable inputs used in Chronix’s contingent consideration valuation on September 30, 2023, included: (i) a discount period, based on the related patent expiration dates, ranging from 0.4 years to 12.2 years, (ii) a discount rate of 15.5% to 16.4%, and (iii) a payout percentage of 10% based on the earnout provision.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_ecustom--ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zYB2eBRZd1pk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables reflect the activity for the Chronix Contingent Consideration measured at fair value using Level 3 inputs:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zW5YngkfAFb2" style="display: none">Schedule of Contingent Consideration, Measured at Fair Value</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">(In thousands)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%">Balance at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zdtk6KNqPPr7" style="width: 14%; text-align: right" title="Beginning balance">69,621</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in estimated fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zRo9jDOPWNXj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in estimated fair value">(17,577</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zZP8JbYdr26d" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">52,044</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20230101__20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zRyNYOlNtRG6" style="text-align: right" title="Beginning balance">40,292</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in estimated fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20230101__20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zWHHShVlC5a3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in estimated fair value">(13,867</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20230101__20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zQNx4cDmoai2" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">26,425</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_8A4_zkrWgQslKmbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill was calculated as the difference between the acquisition date fair value of the Aggregate Chronix Merger Consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill also included the $<span id="xdx_901_eus-gaap--DeferredTaxLiabilities_iI_pn5n6_c20230930__us-gaap--BusinessAcquisitionAxis__custom--ChronixBiomedicalIncMember_zQYeOuqIKc4d" title="Net deferred tax liabilities">2.2</span> million of net deferred tax liabilities recorded principally related to the VitaGraft discussed above. Oncocyte recognized approximately $<span id="xdx_908_eus-gaap--Goodwill_iI_pn5n6_c20230930__us-gaap--BusinessAcquisitionAxis__custom--ChronixBiomedicalIncMember_zs9wfLjEojXl" title="Goodwill">9.5</span> million of goodwill related to the Chronix acquisition. None of the goodwill recognized is expected to be deductible for income tax purposes. During 2022, the Company identified circumstances that could indicate a potential impairment and after a valuation of the Company’s assets and liabilities was performed, management concluded that goodwill was impaired as of December 31, 2022 (see Note 2).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_znan0mJ0AMz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table shows the Insight Merger Date contractual payment amounts, as applicable, and the corresponding fair value of each respective Contingent Consideration liability:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zliVsq5lWeo6" style="display: none">Schedule of Fair Value of Contingent Consideration Liability</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair Value on the</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Merger Date</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">(In thousands)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Milestone 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230930__us-gaap--BusinessAcquisitionAxis__custom--MilestoneOneMember_z4bMOVhk4Dsc" style="width: 14%; text-align: right" title="Contractual Value">1,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230930__us-gaap--BusinessAcquisitionAxis__custom--MilestoneOneMember_zZhQnsFn4Icg" style="width: 14%; text-align: right" title="Fair Value on the Merger Date">1,340</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Milestone 2</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230930__us-gaap--BusinessAcquisitionAxis__custom--MilestoneTwoMember_zpII7QNCRnh4" style="text-align: right" title="Contractual Value">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230930__us-gaap--BusinessAcquisitionAxis__custom--MilestoneTwoMember_zQVltBM0DoV1" style="text-align: right" title="Fair Value on the Merger Date">1,830</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestone 3 <span id="xdx_F27_z3lUnlCOaCx"><sup>(</sup></span></span><sup><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230930__us-gaap--BusinessAcquisitionAxis__custom--MilestoneThreeMember_fKGEp_zHACNEHzUwm6" style="text-align: right" title="Contractual Value">1,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230930__us-gaap--BusinessAcquisitionAxis__custom--MilestoneThreeMember_fKGEp_zuRnx4lhuNpf" style="text-align: right" title="Fair Value on the Merger Date">770</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalty 1 <span id="xdx_F2F_zv3vSG7QD8Kl"><sup>(</sup></span></span><sup><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></sup></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See(b)</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230930__us-gaap--BusinessAcquisitionAxis__custom--RoyaltyOneMember_fKGIp_z1GmABug8oAa" style="text-align: right" title="Fair Value on the Merger Date">5,980</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalty 2 <span id="xdx_F2D_z2Jkchv2aDe5"><sup>(</sup></span></span><sup><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></sup></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See(b)</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230930__us-gaap--BusinessAcquisitionAxis__custom--RoyaltyTwoMember_fKGIp_z2IUauoDMfBg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value on the Merger Date">1,210</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230930_zfgVDCumL1u5" style="border-bottom: Black 2.5pt double; text-align: right" title="Contractual Value">6,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230930_zq4a4GS2FUee" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value on the Merger Date">11,130</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0D_z7QJbvyQQp6c">(a)</sup></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zGA2w3bK0IHe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates the maximum payable if the Milestone is achieved.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F05_zy1Ybnsgayz8">(b)</sup></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_z4dZMwKzWyM6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration.</span></td></tr> </table> 1500000 1340000 3000000 1830000 1500000 770000 5980000 1210000 6000000 11130000 3100000 The significant unobservable inputs used in Insight’s contingent consideration valuation on September 30, 2023, included: (i) a discount period, based on the expected milestone payment dates, ranging from 0.5 years to 1.5 years, (ii) a discount rate of 15.2% to 15.4%, and (iii) a management probability estimate of 15% to 50%. <p id="xdx_899_ecustom--ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zIQpQJNTRL4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables reflect the activity for the Insight Contingent Consideration measured at fair value using Level 3 inputs:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zkc2rApGcaP7" style="display: none">Schedule of Contingent Consideration, Measured at Fair Value</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">(In thousands)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%">Balance at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zsyLmu3mBER6" style="width: 14%; text-align: right" title="Beginning balance">7,060</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in estimated fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zBUi6C6mo8Bh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in estimated fair value">420</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zLmYPTxJ4H0h" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance">7,480</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20230101__20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zmJEZwh8Dzdg" style="text-align: right" title="Beginning balance">5,370</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in estimated fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20230101__20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zUp2nJ0YU7l6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in estimated fair value">(3,080</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20230101__20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_z8VnrN3Df4Lb" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance">2,290</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> 7060000 420000 7480000 5370000 -3080000 2290000 14000000 0.15 0.75 0.10 0.05 0.15 13900000 The significant unobservable inputs used in Chronix’s contingent consideration valuation on September 30, 2023, included: (i) a discount period, based on the related patent expiration dates, ranging from 0.4 years to 12.2 years, (ii) a discount rate of 15.5% to 16.4%, and (iii) a payout percentage of 10% based on the earnout provision. <p id="xdx_892_ecustom--ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zYB2eBRZd1pk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables reflect the activity for the Chronix Contingent Consideration measured at fair value using Level 3 inputs:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zW5YngkfAFb2" style="display: none">Schedule of Contingent Consideration, Measured at Fair Value</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">(In thousands)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%">Balance at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zdtk6KNqPPr7" style="width: 14%; text-align: right" title="Beginning balance">69,621</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in estimated fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zRo9jDOPWNXj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in estimated fair value">(17,577</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zZP8JbYdr26d" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">52,044</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20230101__20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zRyNYOlNtRG6" style="text-align: right" title="Beginning balance">40,292</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in estimated fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20230101__20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zWHHShVlC5a3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in estimated fair value">(13,867</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20230101__20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zQNx4cDmoai2" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">26,425</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> 69621000 -17577000 52044000 40292000 -13867000 26425000 2200000 9500000 <p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zmxefXm06V99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4. <span id="xdx_821_zQ0gU2DvL9a9">Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--PropertyPlantAndEquipmentTextBlock_zuarPUSMYap1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use and financing lease assets, machinery and equipment, net, and construction in progress were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zv962Iwk67K3" style="display: none">Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230930_zZRbGlmFjFv" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231_zADz8kNuGAd1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">(In thousands)</td><td> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_maPPAENzQNB_zoCG6EitKnuc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span id="xdx_909_eus-gaap--OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_iI_dxL_c20221231_zTAphOx4qz31" title="::XDX::http%3A%2F%2Foncocyte.com%2F20230930%23MachineryAndEquipmentNetAndConstructionInProgress"><span id="xdx_90C_eus-gaap--OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_iI_dxL_c20230930_ztNzDZrwmDKh" title="::XDX::http%3A%2F%2Foncocyte.com%2F20230930%23MachineryAndEquipmentNetAndConstructionInProgress"><span style="-sec-ix-hidden: xdx2ixbrl1280"><span style="-sec-ix-hidden: xdx2ixbrl1281">Right-of-use assets</span></span></span></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,036</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,499</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAENzQNB_zHZLEFzPXpFl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Machinery and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,908</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,408</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzQNB_z9UTXYL0Jtok" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,819</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,196</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzQNB_maRAMAEzjhF_z4uR4kM7feP3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right-of-use assets and machinery and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,125</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,711</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ConstructionInProgressGross_iI_pn3n3_maRAMAEzjhF_z55H6MypVOn1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">708</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,140</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--RightofuseAssetsMachineryAndEquipmentContinuingOperations_iTI_pn3n3_mtRAMAEzjhF_zp3f1DW3GEd7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Right-of-use and financing lease assets, machinery and equipment, net, and construction in progress</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,833</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,851</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_z7CsfhZKGT3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed asset depreciation and amortization expense amounted to $<span id="xdx_908_eus-gaap--DepreciationAndAmortization_c20230701__20230930_zgBjIawRjyal" title="Depreciation expense">404,000</span> and $<span id="xdx_905_eus-gaap--DepreciationAndAmortization_c20220701__20220930_zs9Io0u69HGl" title="Depreciation expense">391,000</span> for the three months ended September 30, 2023 and 2022, respectively, and $<span id="xdx_906_eus-gaap--DepreciationAndAmortization_pn5n6_c20230101__20230930_zzkuQKWeM908" title="Depreciation expense">1.3</span> million and $<span id="xdx_901_eus-gaap--DepreciationAndAmortization_pn5n6_c20220101__20220930_z494k1KCW6Mf" title="Depreciation expense">1.1</span> million for the nine months ended September 30, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the third quarter of 2023, in connection with a new sublease arrangement (see Note 7), the Company identified circumstances that indicated a potential impairment of certain leasehold improvements (included in construction in progress) and after a valuation was performed, management concluded that such leasehold improvements were impaired. Accordingly, the Company recorded an impairment of approximately $<span id="xdx_905_eus-gaap--ImpairmentOfLeasehold_pn5n6_c20230701__20230930_zQbs1MD7Oec8" title="Asset impairment charges">1.8</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_892_eus-gaap--PropertyPlantAndEquipmentTextBlock_zuarPUSMYap1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use and financing lease assets, machinery and equipment, net, and construction in progress were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zv962Iwk67K3" style="display: none">Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230930_zZRbGlmFjFv" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231_zADz8kNuGAd1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">(In thousands)</td><td> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_maPPAENzQNB_zoCG6EitKnuc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span id="xdx_909_eus-gaap--OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_iI_dxL_c20221231_zTAphOx4qz31" title="::XDX::http%3A%2F%2Foncocyte.com%2F20230930%23MachineryAndEquipmentNetAndConstructionInProgress"><span id="xdx_90C_eus-gaap--OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_iI_dxL_c20230930_ztNzDZrwmDKh" title="::XDX::http%3A%2F%2Foncocyte.com%2F20230930%23MachineryAndEquipmentNetAndConstructionInProgress"><span style="-sec-ix-hidden: xdx2ixbrl1280"><span style="-sec-ix-hidden: xdx2ixbrl1281">Right-of-use assets</span></span></span></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,036</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,499</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAENzQNB_zHZLEFzPXpFl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Machinery and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,908</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,408</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzQNB_z9UTXYL0Jtok" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,819</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,196</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzQNB_maRAMAEzjhF_z4uR4kM7feP3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right-of-use assets and machinery and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,125</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,711</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ConstructionInProgressGross_iI_pn3n3_maRAMAEzjhF_z55H6MypVOn1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">708</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,140</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--RightofuseAssetsMachineryAndEquipmentContinuingOperations_iTI_pn3n3_mtRAMAEzjhF_zp3f1DW3GEd7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Right-of-use and financing lease assets, machinery and equipment, net, and construction in progress</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,833</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,851</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4036000 3499000 6908000 9408000 5819000 4196000 5125000 8711000 708000 2140000 5833000 10851000 404000 391000 1300000 1100000 1800000 <p id="xdx_807_eus-gaap--IntangibleAssetsDisclosureTextBlock_ztVGt0i8J4af" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5. <span id="xdx_825_zMS5DtC05iuf">Intangible Assets, Net</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the Insight and Chronix acquisitions completed on January 31, 2020, and April 15, 2021, respectively, the Company has acquired IPR&amp;D and customer relationships.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the first quarter of 2023, due to changes in management and the economic condition of the Company, management shifted the Company’s business strategy to direct efforts on fewer studies and to transition from tests that are laboratory developed tests to research use only sales. Due to the change in strategy, the Company’s long range plan forecasts were updated and anticipated future benefits derived from the Company’s assets. The change in strategy represent a significant indicator for change in value of the Company’s long-lived assets. The original IPR&amp;D balance was reassessed based on the updated long range plan, using the multi-period excess earnings method (“MPEEM”) approach, the results of the valuation noted that the carrying value of the DetermaIO related IPR&amp;D intangible assets was greater than the fair market value, whereas the CNI and VitaGraft related IPR&amp;D intangible assets carrying value was lower than the fair market value. Accordingly, the Company recorded an impairment of approximately $<span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pn5n6_c20230101__20230930_zAG8yfZvWdF6" title="Impairment of intangible">5.0</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The MPEEM valuation approach is a discounted cash flow valuation technique and was used to determine the Level 3 fair value of Insight’s IPR&amp;D discussed above. <span id="xdx_904_eus-gaap--FairValueMeasurementsSensitivityAnalysisDescription_c20230101__20230331__us-gaap--ValuationTechniqueAxis__custom--MPEEMValuationApproachMember_zLf6PlslbDqf" title="Unobservable Measurement Input, Uncertainty, Description">The significant unobservable inputs used on March 31, 2023, included: (i) a discount period of 20.0 years, based on the expected life of patent, (ii) a royalty rate of 0.3%, (iii) a contributory asset rate of return of 30.0%, and (iv) a weighted average cost of capital rate of 30.0%. As market conditions change, the Company will re-evaluate assumptions used in the determination of fair value for IPR&amp;D and is uncertain to the extent of the volatility in the unobservable inputs in the foreseeable future.</span> Refer to Note 2, “Goodwill and Intangible Assets” for additional IPR&amp;D information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zIFthrFrDWbf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net, consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zo1Res37m5W7" style="display: none">Schedule of Goodwill and Intangible Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td> </td> <td colspan="6" style="text-align: center">(In thousands)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Intangible assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired IPR&amp;D - DetermaIO<sup>TM (1<span id="xdx_F29_zl3xrxcxnlmk">)</span></sup></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20230101__20230930__dei--LegalEntityAxis__custom--DetermaIOMember_fKDEp_zjmon8Sx93H3" style="width: 16%; text-align: right" title="Intangible assets acquired IPR&amp;D">9,700</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20220101__20221231__dei--LegalEntityAxis__custom--DetermaIOMember_fKDEp_zxyYocJqNUHg" style="width: 16%; text-align: right" title="Intangible assets acquired IPR&amp;D">14,650</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired IPR&amp;D - DetermaCNI™ and VitaGraft™ <span id="xdx_F2D_zizMa2sDybSi"><sup>(</sup></span></span><sup><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20230101__20230930__dei--LegalEntityAxis__custom--DetermaCNIAndVitaGraftMember_fKDIp_zJWK5eiR5NMa" style="text-align: right" title="Intangible assets acquired IPR&amp;D">46,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20220101__20221231__dei--LegalEntityAxis__custom--DetermaCNIAndVitaGraftMember_fKDIp_zrymYUhCuxla" style="text-align: right" title="Intangible assets acquired IPR&amp;D">46,800</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Intangible assets subject to amortization:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Acquired intangible assets - customer relationship</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AcquiredFiniteLivedIntangibleAssetResidualValue_iI_pn3n3_c20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z8dUr6ZLBiCc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Acquired intangible assets">440</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AcquiredFiniteLivedIntangibleAssetResidualValue_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zIsBUl0Mwar1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Acquired intangible assets">440</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total intangible assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20230930_z2IzkhhA4Hka" style="text-align: right" title="Total intangible assets">56,940</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20221231_zFMfIn9ABwd2" style="text-align: right" title="Total intangible assets">61,890</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated amortization - customer relationship<span id="xdx_F2F_zdbM4OX0WKM6"><sup>(</sup></span></span><sup><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></sup></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_fKDMp_zO7sl55ndBQ7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite-lived intangible assets, accumulated amortization">(323</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_fKDMp_zsvPxEjJhQlj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite-lived intangible assets, accumulated amortization">(257</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20230930_zfMRWCXDhyoh" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">56,617</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20221231_z3Q0dPlyec3f" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">61,633</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F07_zxvkTafYCqv3">(1)</sup></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zee5Hn9SJXc8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 3 for information on the Insight Merger.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0B_zRCU9l36aa76">(2)</sup></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zL7EPLEoVnud" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 3 for information on the Chronix Merger.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td id="xdx_F0E_zL5YJumbEzn8" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zIumVEq8tjMl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of intangible assets is included in “Cost of revenues – amortization of acquired intangibles” on the consolidated statements of operations because the intangible assets pertain directly to the revenues generated from the acquired intangibles.</span></td></tr> </table> <p id="xdx_8A6_z2TEFpkAkxi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible asset amortization expense amounted to $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20230701__20230930_zhesSDMB4kri" title="Intangible asset amortization expense">22,000</span> and $<span id="xdx_908_eus-gaap--AmortizationOfIntangibleAssets_c20220701__20220930_zv4HKMVwYvya" title="Intangible asset amortization expense">976,000</span> for the three months ended September 30, 2023 and 2022, respectively, and $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230930_z4Nx94OWy3E1" title="Intangible asset amortization expense">66,000</span> and $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_pn5n6_c20220101__20220930_zvXlOxdUPb55" title="Intangible asset amortization expense">2.9</span> million for the nine months ended September 30, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zWLCCuJ64PR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future amortization expense of intangible assets subject to amortization is expected to be the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zw9S9GOxGFZf" style="display: none">Schedule of Intangible Assets Future Amortization Expense</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230930_z0wJ5dGNZs6e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: center">(In thousands)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-weight: bold">Year ending December 31,</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzyWn_zLyRadXg8el" style="vertical-align: bottom; background-color: White"> <td style="width: 82%; text-align: left">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">22</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzyWn_zocl53P3Fctk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">88</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzyWn_zkvCebsMKIIi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzyWn_zAWfdyK5tXDi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">117</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zYJdPLiBAp7c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> 5000000.0 The significant unobservable inputs used on March 31, 2023, included: (i) a discount period of 20.0 years, based on the expected life of patent, (ii) a royalty rate of 0.3%, (iii) a contributory asset rate of return of 30.0%, and (iv) a weighted average cost of capital rate of 30.0%. As market conditions change, the Company will re-evaluate assumptions used in the determination of fair value for IPR&D and is uncertain to the extent of the volatility in the unobservable inputs in the foreseeable future. <p id="xdx_890_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zIFthrFrDWbf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net, consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zo1Res37m5W7" style="display: none">Schedule of Goodwill and Intangible Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td> </td> <td colspan="6" style="text-align: center">(In thousands)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Intangible assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired IPR&amp;D - DetermaIO<sup>TM (1<span id="xdx_F29_zl3xrxcxnlmk">)</span></sup></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20230101__20230930__dei--LegalEntityAxis__custom--DetermaIOMember_fKDEp_zjmon8Sx93H3" style="width: 16%; text-align: right" title="Intangible assets acquired IPR&amp;D">9,700</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20220101__20221231__dei--LegalEntityAxis__custom--DetermaIOMember_fKDEp_zxyYocJqNUHg" style="width: 16%; text-align: right" title="Intangible assets acquired IPR&amp;D">14,650</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired IPR&amp;D - DetermaCNI™ and VitaGraft™ <span id="xdx_F2D_zizMa2sDybSi"><sup>(</sup></span></span><sup><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20230101__20230930__dei--LegalEntityAxis__custom--DetermaCNIAndVitaGraftMember_fKDIp_zJWK5eiR5NMa" style="text-align: right" title="Intangible assets acquired IPR&amp;D">46,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20220101__20221231__dei--LegalEntityAxis__custom--DetermaCNIAndVitaGraftMember_fKDIp_zrymYUhCuxla" style="text-align: right" title="Intangible assets acquired IPR&amp;D">46,800</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Intangible assets subject to amortization:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Acquired intangible assets - customer relationship</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AcquiredFiniteLivedIntangibleAssetResidualValue_iI_pn3n3_c20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z8dUr6ZLBiCc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Acquired intangible assets">440</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AcquiredFiniteLivedIntangibleAssetResidualValue_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zIsBUl0Mwar1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Acquired intangible assets">440</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total intangible assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20230930_z2IzkhhA4Hka" style="text-align: right" title="Total intangible assets">56,940</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20221231_zFMfIn9ABwd2" style="text-align: right" title="Total intangible assets">61,890</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated amortization - customer relationship<span id="xdx_F2F_zdbM4OX0WKM6"><sup>(</sup></span></span><sup><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></sup></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_fKDMp_zO7sl55ndBQ7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite-lived intangible assets, accumulated amortization">(323</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_fKDMp_zsvPxEjJhQlj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite-lived intangible assets, accumulated amortization">(257</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20230930_zfMRWCXDhyoh" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">56,617</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20221231_z3Q0dPlyec3f" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">61,633</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F07_zxvkTafYCqv3">(1)</sup></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zee5Hn9SJXc8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 3 for information on the Insight Merger.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0B_zRCU9l36aa76">(2)</sup></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zL7EPLEoVnud" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 3 for information on the Chronix Merger.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td id="xdx_F0E_zL5YJumbEzn8" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zIumVEq8tjMl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of intangible assets is included in “Cost of revenues – amortization of acquired intangibles” on the consolidated statements of operations because the intangible assets pertain directly to the revenues generated from the acquired intangibles.</span></td></tr> </table> 9700000 14650000 46800000 46800000 440000 440000 56940000 61890000 -323000 -257000 56617000 61633000 22000 976000 66000 2900000 <p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zWLCCuJ64PR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future amortization expense of intangible assets subject to amortization is expected to be the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zw9S9GOxGFZf" style="display: none">Schedule of Intangible Assets Future Amortization Expense</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230930_z0wJ5dGNZs6e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: center">(In thousands)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-weight: bold">Year ending December 31,</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzyWn_zLyRadXg8el" style="vertical-align: bottom; background-color: White"> <td style="width: 82%; text-align: left">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">22</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzyWn_zocl53P3Fctk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">88</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzyWn_zkvCebsMKIIi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzyWn_zAWfdyK5tXDi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">117</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 22000 88000 7000 117000 <p id="xdx_807_eus-gaap--LongTermDebtTextBlock_zs73EAVb48ah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6. <span id="xdx_82E_zP9BToOmZLq">Loan Payable to Silicon Valley Bank</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amended Loan Agreement</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 17, 2019, Oncocyte entered into a First Amendment to Loan and Security Agreement (the “Amended Loan Agreement”) with Silicon Valley Bank (“the Bank”) pursuant to which Oncocyte obtained a new $<span id="xdx_905_eus-gaap--LinesOfCreditCurrent_iI_pn6n6_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zWF6sQIxDOji" title="Line of credit, current">3</span> million secured credit facility (“Tranche 1”), a portion of which was used to repay the remaining balance of approximately $<span id="xdx_903_eus-gaap--RepaymentsOfLinesOfCredit_c20191016__20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zw5y41T74vr9" title="Repayments of lines of credit">400,000</span> on outstanding loans from the Bank, plus a final payment of $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_iI_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zIMqkKMz2B44" title="Debt instrument, final payment">116,000</span>, under the February 21, 2017 Loan Agreement. The credit line under the Amended Loan Agreement may be increased by an additional $<span id="xdx_908_eus-gaap--LinesOfCreditCurrent_iI_pn6n6_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_z5WEszvWiewe" title="Line of credit, current">2</span> million (“Tranche 2”) if Oncocyte obtains at least $<span id="xdx_909_eus-gaap--AdditionalPaidInCapital_iI_pn6n6_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zdBcM5iYcVai" title="Additional paid in capital">20</span> million of additional equity capital, as was the case with the original Loan Agreement, and a positive final coverage determination is received from CMS for DetermaRx at a specified minimum price point per test (the “Tranche 2 Milestone”), and Oncocyte is not in default under the Amended Loan Agreement. As of September 30, 2023, Oncocyte had satisfied the Tranche 2 Milestone and was eligible to borrow the $<span id="xdx_907_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_do_c20230930__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zmTgR46SGeAc" title="Line of credit facility, maximum borrowing capacity">2</span> million Tranche 2 funds. However, Oncocyte has not yet borrowed any funds under Tranche 2.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments of interest only on the principal balance were due monthly from the draw date through March 31, 2020, followed by 24 monthly payments of principal and interest, but the Bank has agreed to a deferral of principal payments, as discussed below. The outstanding principal balance of the loan will bear interest at a stated floating annual interest equal to the greater of (a) the prime rate or (b)<span id="xdx_90C_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zHdJ1U75z4Q5" title="Interest rate"> 5</span>% per annum. During August 2022, period in which the loan was paid off, the published prime rate was<span id="xdx_908_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20230930_zgMyy25UlRY5" title="Interest rate"> 5.5</span>% per annum.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 2, 2020, as part of the Bank’s COVID-19 pandemic relief program, Oncocyte and the Bank entered into a Loan Deferral Agreement (“Loan Deferral”) with respect to the Amended Loan Agreement. <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20200401__20200402__us-gaap--TypeOfArrangementAxis__custom--LoanDeferralAgreementMember_zsnl2sNWblcg" title="Debt instrument maturity date description">Under the Loan Deferral Agreement, the Bank agreed to (i) extend the scheduled maturity date of the Amended Loan Agreement from March 31, 2022 to September 30, 2022, and (ii) deferred the principal payments by an additional 6 months whereby payments of interest only on the Bank loan principal balance will be due monthly from May 1, 2020 through October 1, 2020, followed by 23 monthly payments of principal and interest beginning on November 1, 2020, all provided at no additional fees to Oncocyte.</span> No other terms of the Amended Loan Agreement were changed or modified. The Loan Deferral was accounted for as a modification of debt in accordance with ASC 470-50, <i>Debt – Modifications and Extinguishments</i>, thus there was no gain or loss recognized on the transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At maturity of the loan, Oncocyte agreed to pay the Bank an additional final payment fee of $<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_iI_c20191031__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zsBvaMguibze" title="Debt instrument, final payment">200,000</span>, which was recorded as a deferred financing charge in October 2019 and is being amortized to interest expense over the term of the loan using the effective interest method. Since August 2022, there is no remaining unamortized deferred financing cost and the full principal balance of the loan in addition to the final payment fee have been paid off.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bank Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2017, in connection with the Loan Agreement, Oncocyte issued common stock purchase warrants to the Bank (the “2017 Bank Warrants”) entitling the Bank to purchase shares of Oncocyte common stock in tranches related to the loan tranches under the Loan Agreement. In conjunction with the availability of the loan, the Bank was issued warrants to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zCvBfBDnykPl" title="Warrants to purchase, shares">412</span> shares of Oncocyte common stock at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z8evE7mrhBzf" title="Warrant exercise price, per share">97.00</span> per share, through February 21, 2027. On March 23, 2017, the Bank was issued warrants to purchase an additional <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20170323__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlQQxjVpnDi6" title="Warrants to purchase, shares">366</span> shares at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20170323__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zAzKFSVaGZ79" title="Warrant exercise price, per share">109.20</span> per share, through March 23, 2027. The Bank may elect to exercise the 2017 Bank Warrants on a “cashless exercise” basis and receive a number of shares determined by multiplying the number of shares for which the applicable tranche is being exercised by (A) the excess of the fair market value of the common stock over the applicable exercise price, divided by (B) the fair market value of the common stock. The fair market value of the common stock will be the last closing or sale price on a national securities exchange, inter-dealer quotation system, or over-the-counter market. These warrants meet the equity classification criteria and have been classified as equity, refer to Note 2 “Accounting for Warrants” for additional information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 17, 2019, in conjunction with Tranche 1 becoming available under the Amended Loan Agreement, Oncocyte issued a common stock purchase warrant to the Bank (the “2019 Bank Warrant”) entitling the Bank to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20191017__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_z5gZvAIAExB1" title="Warrants to purchase, shares">4,928</span> shares of Oncocyte common stock at the initial “Warrant Price” of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20191017__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zYOR9amsI0A5" title="Warrant exercise price, per share">33.80</span> per share through October 17, 2029. The number of shares of common stock issuable upon the exercise of the 2019 Bank Warrant will increase on the date of each draw, if any, on Tranche 2. The number of additional shares of common stock issuable upon the exercise of the 2019 Bank Warrant will be equal to<span id="xdx_906_ecustom--PercentageForWarrantExercisePricePerShare_pid_dp_uPure_c20191016__20191017__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_z01llAHGIpEk" title="Percentage for warrant exercise price per share"> 0.02</span>% of Oncocyte’s fully diluted equity outstanding for each $<span id="xdx_908_ecustom--DilutedEquityOutstanding_pn6n6_c20191016__20191017__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zPDv20I1xWme" title="Diluted equity outstanding">1</span> million draw under Tranche 2. The Warrant Price for Tranche 2 warrant shares will be determined upon each draw of Tranche 2 funds and will be closing price of Oncocyte common stock on the date immediately before the applicable date on which Oncocyte borrows funds under Tranche 2. The Bank may elect to exercise the 2019 Bank Warrant on a “cashless exercise” basis and receive a number of shares determined by multiplying the number of shares for which the 2019 Bank Warrant is being exercised by (A) the excess of the fair market value of the common stock over the applicable Warrant Price, divided by (B) the fair market value of the common stock. The fair market value of the common stock will be last closing or sale price on a national securities exchange, interdealer quotation system, or over-the-counter market. These warrants meet the equity classification criteria and have been classified as equity, refer to Note 2 “Accounting for Warrants” for additional information. As of September 30, 2023, Oncocyte has not borrowed any funds under Tranche 2.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3000000 400000 116000 2000000 20000000 2 0.05 0.055 Under the Loan Deferral Agreement, the Bank agreed to (i) extend the scheduled maturity date of the Amended Loan Agreement from March 31, 2022 to September 30, 2022, and (ii) deferred the principal payments by an additional 6 months whereby payments of interest only on the Bank loan principal balance will be due monthly from May 1, 2020 through October 1, 2020, followed by 23 monthly payments of principal and interest beginning on November 1, 2020, all provided at no additional fees to Oncocyte. 200000 412 97.00 366 109.20 4928 33.80 0.0002 1000000 <p id="xdx_80B_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zbDgNZFrn90k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7. <span id="xdx_827_zXa5mv2Q7Xb6">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Office and Facilities Leases</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Irvine Office Lease</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 23, 2019, Oncocyte and Cushing Ventures, LLC (“Landlord”) entered into an Office Lease Agreement (the “Irvine Lease”) of a building containing approximately <span id="xdx_90B_eus-gaap--AreaOfLand_iI_usqft_c20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zphKJUCE7dsb" title="Area of Land">26,800</span> square feet of rentable space located at 15 Cushing in Irvine, California (the “Premises”) that serves as Oncocyte’s principal executive and administrative offices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Irvine Lease has an initial term of 89 calendar months (the “Term”), which commenced on June 1, 2020 (the “Commencement Date”). Oncocyte has an option to extend the Term for a period of five years (the “Extended Term”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte agreed to pay base monthly rent in the amount of $<span id="xdx_904_eus-gaap--PaymentsForRent_c20191222__20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zmbn8rOnOIad" title="Payments for rent">61,640</span> during the first 12 months of the Term. Base monthly rent increases annually, over the base monthly rent then in effect, by <span id="xdx_90E_ecustom--CapitalLeaseAgreementImputedAnnualInterestRate_pid_dp_uPure_c20191222__20191223__srt--StatementScenarioAxis__custom--MonthlyRentMember__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zSiJ70XegPSk" title="Interest rate on lease agreement">3.5</span>%. Oncocyte was entitled to an abatement of <span id="xdx_905_ecustom--CapitalLeaseAgreementImputedAnnualInterestRate_pid_dp_uPure_c20191222__20191223__srt--StatementScenarioAxis__custom--FirstTenCalendarMember__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zGCiwpKtduVc" title="Interest rate on lease agreement">50</span>% of the base monthly rent during the first ten calendar months of the Term. If the Irvine Lease is terminated based on the occurrence of an “event of default,” Oncocyte will be obligated to pay the abated rent to the lessor.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If Oncocyte exercises its option to extend the Term, the initial base monthly rent during the Extended Term will be the greater of the base monthly rent in effect during the last year of the Term or the prevailing market rate. The prevailing market rate will be determined based on annual rental rates per square foot for comparable space in the area where the Premises are located. If Oncocyte does not agree with the prevailing market rate proposed by the lessor, the rate may be determined through an appraisal process. The base monthly rent during the Extended Term shall be subject to the same annual rent adjustment as applicable for base monthly rent during the Term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to base monthly rent, Oncocyte agreed to pay in monthly installments (a) all costs and expenses, other than certain excluded expenses, incurred by the lessor in each calendar year in connection with operating, maintaining, repairing (including replacements if repairs are not feasible or would not be effective) and managing the Premises and the building in which the Premises are located (“Expenses”), and (b) all real estate taxes and assessments on the Premises and the building in which the Premises are located, all personal property taxes for property that is owned by lessor and used in connection with the operation, maintenance and repair of the Premises, and costs and fees incurred in connection with seeking reductions in such tax liabilities (“Taxes”). Subject to certain exceptions, Expenses shall not be increased by more than 4% annually on a cumulative, compounded basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte was entitled to an abatement of its obligations to pay Expenses and Taxes while constructing improvements to the Premises constituting “Tenant’s Work” under the Irvine Lease prior to the Commencement Date, except that Oncocyte was obligated to pay <span id="xdx_905_ecustom--ObligatedToPayExpensesAndTaxesPercentage_pid_dp_uPure_c20191222__20191223__srt--StatementScenarioAxis__custom--MonthlyRentMember__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zEqAoJDhTXOe" title="Obligated to pay expenses and taxes percentage">43.7</span>% of Expenses and Taxes during the period prior to the Commencement Date for its use of the second floor of the Premises, which was already built out as office space.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The lessor provided Oncocyte with a “Tenant Improvement Allowance” in the amount of $<span id="xdx_905_eus-gaap--PaymentsForProceedsFromTenantAllowance_pn5n6_c20191222__20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zKp362avTdHb" title="Payments for (Proceeds from) Tenant Allowance">1.3</span> million to pay for the plan, design, permitting, and construction of the improvements constituting Tenant’s Work. The lessor retained<span id="xdx_908_ecustom--PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment_pid_dp_uPure_c20191222__20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zG0KcpKtxh3c" title="Percentage of administrative fee paid on original cost of equipment"> 1.5</span>% of the Tenant Improvement Allowance as an administrative fee as provided in the Irvine Lease. As of June 2021, the lessor had provided $<span id="xdx_900_eus-gaap--PaymentsForProceedsFromTenantAllowance_pn5n6_c20230101__20230930__srt--TitleOfIndividualAxis__custom--LandlordMember__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zsZSu8sFgkxk" title="Total tenant improvement allowance">1.3</span> million of the total Tenant Improvement Allowance, which is being amortized over the Term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte has provided the lessor with a security deposit in the amount of $<span id="xdx_905_eus-gaap--SecurityDeposit_iI_c20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zMOAqS5Q6Re5" title="Security Deposit">150,000</span> and a letter of credit in the amount of $<span id="xdx_90D_eus-gaap--LinesOfCreditCurrent_iI_pn5n6_c20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zWaZ5qAbu1eh" title="Line of Credit, Current">1.7</span> million. The lessor may apply the security deposit, in whole or in part, for the payment of rent and any other amount that Oncocyte is or becomes obligated to pay under the Irvine Lease but fails to pay when due and beyond any cure period. The lessor may draw on the letter of credit from time to time to pay any amount that is unpaid and due, or if the original issuing bank notifies the lessor that the letter of credit will not be renewed or extended for the period required under the Irvine Lease and Oncocyte fails to timely provide a replacement letter of credit, or an event of default under the Irvine Lease occurs and continues beyond the applicable cure period, or if certain insolvency or bankruptcy or insolvency with respect to Oncocyte occur. Oncocyte is required to restore any portion of the security deposit that is applied by the lessor to payments due under the Irvine Lease, and Oncocyte is required to restore the amount available under the letter of credit to the required amount if any portion of the letter of credit is drawn by the lessor. The Irvine Lease provides that commencing on the 34th month of the Term, (a) the amount of the letter of credit that Oncocyte is required to maintain shall be reduced on a monthly basis, in equal installments, to amortize the required amount to zero at the end of the Term, and (b) Oncocyte has the right to cancel the letter of credit at any time if it meets certain market capitalization and balance sheets thresholds; provided, in each case, that Oncocyte is not in then default under the Irvine Lease beyond any applicable notice and cure period and the lessor has not determined that an event exists that would lead to an event of default.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To obtain the letter of credit, Oncocyte has provided the issuing bank with a restricted cash deposit that the bank will hold to cover its obligation to pay any draws on the letter of credit by the lessor. The restricted cash may not be used for any other purpose, accordingly, Oncocyte has reflected $<span id="xdx_90E_eus-gaap--RestrictedCash_iI_pn5n6_c20230930_zjdeQXf08C4c" title="Restricted cash">1.7</span> million as restricted cash in the accompanying consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Irvine Office Sublease</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 8, 2023, Oncocyte and Induce Biologics USA, Inc. (“Subtenant”) entered into a Sublease Agreement (the “Sublease Agreement”), which subsequently became effective as of September 14, 2023, upon the execution and delivery by the Company, Subtenant, and Landlord, of that certain Landlord’s Consent to Sublease dated September 12, 2023 (the “Consent Agreement”), under which Landlord consented to the Sublease Agreement, on the terms and subject to the conditions set forth therein. The Sublease Agreement is subject and subordinate to the Irvine Lease.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Sublease Agreement, the Company agreed to initially sublet to Subtenant a portion of the Premises consisting of approximately <span id="xdx_908_eus-gaap--AreaOfLand_iI_usqft_c20230808__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zwiyIqSNyhg1" title="Area of land">13,400</span> square feet of rentable space for a term (the “Initial Period”) commencing on the date that is 120 days after the effective date of the Consent Agreement (the “Commencement Date”) and ending on the date that is 18 months following the Commencement Date or such earlier date as Subtenant may elect upon the exercise of its one-time option to accelerate such date upon 90 days prior written notice to the Company (the date on which the Initial Period ends, the “Expansion Date”). On the Expansion Date, the portion of the Premises that is subleased to Subtenant under the Sublease Agreement will automatically increase to include the remaining portion of the Premises, which consists of approximately <span id="xdx_908_eus-gaap--AreaOfLand_iI_usqft_c20230808__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zjv3w0X8LMTc" title="Area of land">13,400</span> square feet of additional rentable space for a term (the “Expansion Period”) beginning on the Expansion Date through the expiration of the Irvine Lease on October 31, 2027, unless earlier terminated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--LesseeOperatingSubleaseResidualValueGuaranteeDescription_c20230101__20230930_zOa9w1wVuUeh" title="lessee, operating sublease, residual value guarantee, description">The Sublease Agreement provides that, from and after the Commencement Date, Subtenant will pay to the Company monthly base rent in the following amounts: (i) $36,850.00 for rental periods beginning on the Commencement Date and ending on or before December 31, 2024 (subject to adjustment in the event that Subtenant exercises its option to accelerate the Expansion Date, such that the Expansion Period begins prior to December 31, 2024); (ii) $37,955.50 for rental periods beginning on or after January 1, 2025 and ending on or before June 20, 2025 (subject to adjustment in the event that Subtenant exercises its option to accelerate the Expansion Date, such that the Expansion Period begins prior to June 20, 2025); (iii) $75,844.00 for rental periods beginning on or after July 1, 2025 and ending on or before December 31, 2025; (iv) $78,188.33 for rental periods beginning on or after January 1, 2026 and ending on or before December 31, 2026; and (v) $80,533.98 for rental periods beginning on or after January 1, 2027 and ending on or before October 31, 2027</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the Commencement Date, Subtenant will be responsible for the payment of Additional Rent, including Expenses and Taxes (as each such term is defined in the Irvine Lease), provided that, with respect to the Initial Period, Subtenant will be responsible for only <span id="xdx_900_ecustom--ObligatedToPayExpensesAndTaxesPercentage_pid_dp_uPure_c20230101__20230930__srt--StatementScenarioAxis__custom--MonthlyRentMember__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zI6D0DMonesc" title="Obligated to pay expenses and taxes percentage">50</span>% of the Expenses and Taxes due. In addition, Subtenant will pay the Company a security deposit in the amount of $<span id="xdx_90C_eus-gaap--SecurityDeposit_iI_pp2d_c20230930__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zlnlJdXuI305" title="Security Deposit">101,987.38</span> in connection with the transactions contemplated by the Sublease Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Sublease Agreement contains customary provisions with respect to, among other things, Subtenant’s obligation to comply with the Irvine Lease and applicable laws, the payment of utilities and similar services utilized by Subtenant with respect its use of the Premises, the indemnification of the Company by Subtenant, and the right of the Company to terminate the Sublease Agreement in its entirety and retake the Premises if Subtenant fails to remedy certain defaults of its obligations under the Sublease Agreement within specified time periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nashville Office Lease</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 27, 2021, Oncocyte entered into a lease agreement to add an additional suite to its Nashville office space, containing approximately <span id="xdx_90A_eus-gaap--AreaOfLand_iI_usqft_c20210827__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zkg6bI41GDAl" title="Area of Land">1,928</span> square feet of rentable space located at 2 International Plaza, Suite 103, Nashville TN. The term of the lease commenced on October 1, 2021 and extends through April 9, 2024 and will serve as additional office space for Insight’s operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Embedded Operating Lease</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 31, 2019, in connection with Oncocyte’s purchase of 25% of the outstanding equity of Razor, Oncocyte entered into a Laboratory Services Agreement with Razor and Encore Clinical, Inc. (“Encore”), a former stockholder of Razor (the “Laboratory Agreement”). Under the Laboratory Agreement (which expired on September 29, 2021), Oncocyte assumed all of Razor’s Laboratory Agreement payment obligations. Although Oncocyte is not a party to any lease agreement with Razor or Encore, under the terms of the Laboratory Agreement, Oncocyte received the landlord’s consent for the use of the laboratory at Razor’s Brisbane, California location (the “Brisbane Facility”) under the terms of a sublease to which Encore is the sublessee. The sublease expired on March 31, 2023 (the “Brisbane Lease”). The laboratory fee payments to Encore include both laboratory services and the use of the Brisbane Facility. Under the provisions of the Laboratory Agreement, if Oncocyte terminates the Laboratory Agreement prior to the expiration of the Brisbane Lease, Oncocyte shall assume the costs related to the subletting or early termination of the Brisbane Lease. The Laboratory Agreement terminated on March 31, 2023. Oncocyte determined that the Laboratory Agreement contains an embedded operating lease for the Brisbane Facility and Oncocyte allocated the aggregate payments to this lease component for purposes of calculating the net present value of the right-of-use asset and liability as of the inception of the Laboratory Agreement in accordance with ASC 842, as shown in the table below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our office leases are operating leases under ASC 842 and are included in the tables below. The tables below provide the amounts recorded in connection with the application of ASC 842 for Oncocyte’s operating and financing leases (see Note 2 for additional policy information).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financing Lease</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, Oncocyte has one financing lease remaining through December 2023 for certain laboratory equipment with aggregate remaining payments of approximately $<span id="xdx_900_ecustom--PaymentObligationAmount_iI_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zvo4yKkVfcie" title="Payment obligation amount.">30,000</span> shown in the table below. Oncocyte’s lease obligations are collateralized by the equipment financed under the lease schedule.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating and Financing Leases</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_ecustom--ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock_zmO4P8S0A2D5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents supplemental balance sheet information related to operating and financing leases:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z3HvDEzn3qF9" style="display: none">Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20230930__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zzGgjK5twiK7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September 30, 2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_497_20221231__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zOdsVe4nSL2l" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">(In thousands)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_z3bKkcZ8w2i7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; width: 60%; text-align: left">Right-of-use assets, net</td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">1,748</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">2,088</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iI_ztJmKRl0xSUj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right-of-use lease liabilities, current</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">653</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">698</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zm2nY8elRo9f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Right-of-use lease liabilities, noncurrent</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,252</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,730</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zGtoxgIUyxB7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,905</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,428</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Financing lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Machinery and equipment</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">537</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">537</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FinanceLeaseRightOfUseAssetAccumulatedAmortization_iNI_pn3n3_di_zQjsIHnbWYz2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(528</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(446</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--FinanceLeaseRightOfUseAsset_iTI_pn3n3_zauDRQ1R7Mm4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Machinery and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">91</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pn3n3_zvXPhZdU2E2i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">117</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_zvL6chy49ipb" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Noncurrent liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1463">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1464">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_zd6ol4I9Rl5l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Total financing lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">30</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">117</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Weighted average remaining lease term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230930__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_z288hxQQ1bjk" title="Weighted average remaining lease term, Operating lease">3.9</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zVc9iHm3ZrSf" title="Weighted average remaining lease term, Operating lease">4.5</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Financing lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230930__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zJqpRVvaFJX8" title="Weighted average remaining lease term, Financing lease">0.3</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zRLFqpXt42mk" title="Weighted average remaining lease term, Financing lease">1.0</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zOxTNfZa9OFj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.29</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.24</td><td style="text-align: left">%</td></tr> <tr id="xdx_404_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zI9IdrsF0n75" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Financing lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.55</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.55</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AE_z6mf867yx9sl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_ecustom--ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock_zqEW0kIpqrl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum lease commitments are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zYHRZ2pRSer7" style="display: none">Schedule of Future Minimum Lease Commitments for Operating and Financing Leases</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Operating</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Financing</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Leases</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Leases</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">(In thousands)</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-weight: bold">Year Ending December 31,</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zLJJW4sZkOxc" style="width: 14%; text-align: right" title="2023">255</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_z01nCBEH0omd" style="width: 14%; text-align: right" title="2023">31</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zSjbLJebI4Sl" style="text-align: right" title="2024">903</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zlYBk5N7ZxE9" style="text-align: right" title="2024"><span style="-sec-ix-hidden: xdx2ixbrl1491">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zvcShZndYdIe" style="text-align: right" title="2025">869</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zFo4SFNcWIB3" style="text-align: right" title="2025"><span style="-sec-ix-hidden: xdx2ixbrl1495">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zgcvy0qzwFs5" style="text-align: right" title="2026">899</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zlzMvrwVVxGd" style="text-align: right" title="2025"><span style="-sec-ix-hidden: xdx2ixbrl1499">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">2027</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zPYBKISfRa3g" style="border-bottom: Black 1.5pt solid; text-align: right" title="2027">695</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pdn3_c20230930_zcWAZ5CJfAea" style="border-bottom: Black 1.5pt solid; text-align: right" title="2026"><span style="-sec-ix-hidden: xdx2ixbrl1503">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_z6IqkasqOra1" style="text-align: right" title="Total minimum lease payments">3,621</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zGROvMXbKrJh" style="text-align: right" title="Total minimum lease payments">31</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Less amounts representing interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_di_c20230930_zvqSd5NlK4fd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less amounts representing interest">(716</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20230930_zodNUevamisd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less amounts representing interest">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Present value of net minimum lease payments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--PresentValueOfNetMinimumLeasePayments_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zzIK5LgwFqGl" style="border-bottom: Black 2.5pt double; text-align: right" title="Present value of net minimum lease payments">2,905</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_c20230930_zRNGWPGLefd" style="border-bottom: Black 2.5pt double; text-align: right" title="Present value of net minimum lease payments">30</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zKCrW0oAqr93" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_ecustom--ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock_zIFv5hjFCkMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents supplemental cash flow information related to operating and financing leases:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zT6USz2fPhga" style="display: none">Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_494_20230101__20230930_zaAKlqYs1un" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_494_20220101__20220930_zStmCaxpZwha" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">Nine Months Ended</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, </b></span></td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">(In thousands)</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Cash paid for amounts included in the measurement of financing lease liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeasePayments_pn3n3_zGRSLkVYzEk2" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">Operating cash flows from operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">793</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">854</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_zOl1uEWR1qX7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating cash flows from financing leases</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">77</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FinanceLeasePrincipalPayments_pn3n3_zYENkpcXM4th" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Financing cash flows from financing leases</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">86</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A8_zSqN2ljeVcCk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Litigation – General</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte may be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and other matters. When Oncocyte is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, Oncocyte will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, Oncocyte discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tax Filings</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes Oncocyte has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could be significantly different than the amounts recorded in the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment Contracts</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte has entered into employment and severance benefit contracts with certain executive officers. Under the provisions of the contracts, Oncocyte may be required to incur severance obligations for matters relating to changes in control, as defined, and certain terminations of executives. As of September 30, 2023, Oncocyte accrued approximately $<span id="xdx_90E_eus-gaap--SeveranceCosts1_pn5n6_c20230101__20230930__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersMember_zDcbLU9MIup6" title="Severance Costs">2.7</span> million in severance obligations for certain executive officers, in accordance with the severance benefit provisions of their respective employment and severance benefit agreements, primarily related to Oncocyte’s acquisition of Chronix in 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the normal course of business, Oncocyte may provide indemnification of varying scope under Oncocyte’s agreements with other companies or consultants, typically Oncocyte’s clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, Oncocyte will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with the use or testing of Oncocyte’s diagnostic tests. Indemnification provisions could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to Oncocyte’s diagnostic tests. Oncocyte’s office and laboratory facility leases also will generally contain indemnification obligations, including obligations for indemnification of the lessor for environmental law matters and injuries to persons or property of others, arising from Oncocyte’s use or occupancy of the leased property. The term of these indemnification agreements will generally continue in effect after the termination or expiration of the particular research, development, services, lease, or license agreement to which they relate. The Razor Stock Purchase Agreement also contains provisions under which Oncocyte has agreed to indemnify Razor and Encore from losses and expenses resulting from breaches or inaccuracy of Oncocyte’s representations and warranties and breaches or nonfulfillment of Oncocyte’s covenants, agreements, and obligations under the Razor Stock Purchase Agreement. Oncocyte periodically enters into underwriting and securities sales agreements with broker-dealers in connection with the offer and sale of Oncocyte securities. The terms of those underwriting and securities sales agreements include indemnification provisions pursuant to which Oncocyte agrees to indemnify the broker-dealers from certain liabilities, including liabilities arising under the Securities Act, in connection with the offer and sale of Oncocyte securities. The potential future payments Oncocyte could be required to make under these indemnification agreements will generally not be subject to any specified maximum amounts. Historically, Oncocyte has not been subject to any claims or demands for indemnification. Oncocyte also maintains various liability insurance policies that limit Oncocyte’s financial exposure. As a result, Oncocyte management believes that the fair value of these indemnification agreements is minimal. Accordingly, Oncocyte has not recorded any liabilities for these agreements as of September 30, 2023 and December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 26800 61640 0.035 0.50 0.437 1300000 0.015 1300000 150000 1700000 1700000 13400 13400 The Sublease Agreement provides that, from and after the Commencement Date, Subtenant will pay to the Company monthly base rent in the following amounts: (i) $36,850.00 for rental periods beginning on the Commencement Date and ending on or before December 31, 2024 (subject to adjustment in the event that Subtenant exercises its option to accelerate the Expansion Date, such that the Expansion Period begins prior to December 31, 2024); (ii) $37,955.50 for rental periods beginning on or after January 1, 2025 and ending on or before June 20, 2025 (subject to adjustment in the event that Subtenant exercises its option to accelerate the Expansion Date, such that the Expansion Period begins prior to June 20, 2025); (iii) $75,844.00 for rental periods beginning on or after July 1, 2025 and ending on or before December 31, 2025; (iv) $78,188.33 for rental periods beginning on or after January 1, 2026 and ending on or before December 31, 2026; and (v) $80,533.98 for rental periods beginning on or after January 1, 2027 and ending on or before October 31, 2027 0.50 101987.38 1928 30000 <p id="xdx_89B_ecustom--ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock_zmO4P8S0A2D5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents supplemental balance sheet information related to operating and financing leases:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z3HvDEzn3qF9" style="display: none">Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20230930__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zzGgjK5twiK7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September 30, 2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_497_20221231__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zOdsVe4nSL2l" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">(In thousands)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_z3bKkcZ8w2i7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; width: 60%; text-align: left">Right-of-use assets, net</td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">1,748</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">2,088</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iI_ztJmKRl0xSUj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right-of-use lease liabilities, current</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">653</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">698</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zm2nY8elRo9f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Right-of-use lease liabilities, noncurrent</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,252</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,730</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zGtoxgIUyxB7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,905</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,428</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Financing lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Machinery and equipment</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">537</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">537</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FinanceLeaseRightOfUseAssetAccumulatedAmortization_iNI_pn3n3_di_zQjsIHnbWYz2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(528</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(446</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--FinanceLeaseRightOfUseAsset_iTI_pn3n3_zauDRQ1R7Mm4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Machinery and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">91</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pn3n3_zvXPhZdU2E2i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">117</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_zvL6chy49ipb" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Noncurrent liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1463">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1464">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_zd6ol4I9Rl5l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Total financing lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">30</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">117</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Weighted average remaining lease term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230930__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_z288hxQQ1bjk" title="Weighted average remaining lease term, Operating lease">3.9</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zVc9iHm3ZrSf" title="Weighted average remaining lease term, Operating lease">4.5</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Financing lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230930__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zJqpRVvaFJX8" title="Weighted average remaining lease term, Financing lease">0.3</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zRLFqpXt42mk" title="Weighted average remaining lease term, Financing lease">1.0</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zOxTNfZa9OFj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.29</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.24</td><td style="text-align: left">%</td></tr> <tr id="xdx_404_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zI9IdrsF0n75" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Financing lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.55</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.55</td><td style="text-align: left">%</td></tr> </table> 1748000 2088000 653000 698000 2252000 2730000 2905000 3428000 537000 537000 528000 446000 9000 91000 30000 117000 30000 117000 P3Y10M24D P4Y6M P0Y3M18D P1Y 0.1129 0.1124 0.1155 0.1155 <p id="xdx_891_ecustom--ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock_zqEW0kIpqrl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum lease commitments are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zYHRZ2pRSer7" style="display: none">Schedule of Future Minimum Lease Commitments for Operating and Financing Leases</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Operating</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Financing</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Leases</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Leases</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">(In thousands)</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-weight: bold">Year Ending December 31,</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zLJJW4sZkOxc" style="width: 14%; text-align: right" title="2023">255</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_z01nCBEH0omd" style="width: 14%; text-align: right" title="2023">31</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zSjbLJebI4Sl" style="text-align: right" title="2024">903</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zlYBk5N7ZxE9" style="text-align: right" title="2024"><span style="-sec-ix-hidden: xdx2ixbrl1491">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zvcShZndYdIe" style="text-align: right" title="2025">869</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zFo4SFNcWIB3" style="text-align: right" title="2025"><span style="-sec-ix-hidden: xdx2ixbrl1495">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zgcvy0qzwFs5" style="text-align: right" title="2026">899</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zlzMvrwVVxGd" style="text-align: right" title="2025"><span style="-sec-ix-hidden: xdx2ixbrl1499">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">2027</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zPYBKISfRa3g" style="border-bottom: Black 1.5pt solid; text-align: right" title="2027">695</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pdn3_c20230930_zcWAZ5CJfAea" style="border-bottom: Black 1.5pt solid; text-align: right" title="2026"><span style="-sec-ix-hidden: xdx2ixbrl1503">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_z6IqkasqOra1" style="text-align: right" title="Total minimum lease payments">3,621</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zGROvMXbKrJh" style="text-align: right" title="Total minimum lease payments">31</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Less amounts representing interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_di_c20230930_zvqSd5NlK4fd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less amounts representing interest">(716</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20230930_zodNUevamisd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less amounts representing interest">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Present value of net minimum lease payments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--PresentValueOfNetMinimumLeasePayments_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230930_zzIK5LgwFqGl" style="border-bottom: Black 2.5pt double; text-align: right" title="Present value of net minimum lease payments">2,905</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_c20230930_zRNGWPGLefd" style="border-bottom: Black 2.5pt double; text-align: right" title="Present value of net minimum lease payments">30</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 255000 31000 903000 869000 899000 695000 3621000 31000 716000 1000 2905000 30000 <p id="xdx_898_ecustom--ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock_zIFv5hjFCkMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents supplemental cash flow information related to operating and financing leases:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zT6USz2fPhga" style="display: none">Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_494_20230101__20230930_zaAKlqYs1un" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_494_20220101__20220930_zStmCaxpZwha" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">Nine Months Ended</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, </b></span></td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">(In thousands)</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Cash paid for amounts included in the measurement of financing lease liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeasePayments_pn3n3_zGRSLkVYzEk2" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">Operating cash flows from operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">793</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">854</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_zOl1uEWR1qX7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating cash flows from financing leases</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">77</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FinanceLeasePrincipalPayments_pn3n3_zYENkpcXM4th" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Financing cash flows from financing leases</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">86</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4</td><td style="text-align: left"> </td></tr> </table> 793000 854000 7000 77000 86000 4000 2700000 <p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zH81B2dmcpP3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8. <span id="xdx_820_zjARtdONfze6">Shareholders’ Equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series A Redeemable Convertible Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 13, 2022, the Company entered into the Securities Purchase Agreement with the Investors in a registered direct offering of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zEyIz3Uckuz5" title="Offering shares">11,765</span> shares of the Company’s Series A Preferred Stock, which shares of Series A Preferred Stock are convertible into a total of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zW0E0SKlHigh" title="Convertible preferred shares">384,477</span> shares of common stock, at a conversion price of $<span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zHEfc27wBQW5" title="Conversion price">30.60</span>. The purchase price of each share of Series A Preferred Stock was $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zdEIJ9NGM8Nf" title="Preferred stock offering">850</span>, which included an original issue discount to the stated value of $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zknjaXAdqiP4" title="Stated value per share">1,000</span> per share. The rights, preferences and privileges of the Series A Preferred Stock are set forth in the Company’s Certificate of Determination, which the Company filed with the Secretary of State of the State of California. The Securities Purchase Agreement provides that the closing of the Series A Preferred Stock Offering will occur, subject to the satisfaction of certain closing conditions, in two equal tranches of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zCLgzxi4A1u2" title="Preferred stock offering">5,000,000</span> each for aggregate gross proceeds from both closings of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zOyIbmgCMsk5" title="Gross proceeds, closing">10,000,000</span>. The first closing occurred on June 1, 2022, and Oncocyte received net proceeds of approximately $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zN4pWEUwAzr7" title="Net proceeds">4.9</span> million from the Series A Preferred Stock issued from the first tranche. The second closing would occur, subject to the satisfaction of certain closing conditions (including but not limited to a requirement that the Company has not received, in the 12 months preceding the second closing, a notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the listing and maintenance and listing requirements of Nasdaq), on the earlier of (a) the second trading day following the date that Oncocyte receives notice from an Investor to accelerate the second closing and (b) a date selected by Oncocyte on or after October 8, 2022 and on or prior to March 8, 2023. On August 9, 2022, Oncocyte received a letter from Nasdaq indicating that the Company no longer met the minimum bid price requirement of the Nasdaq continued listing requirements. Accordingly, the second closing did not occur and no additional proceeds were received under the Securities Purchase Agreement. On August 8, 2023, the Company received a letter from Nasdaq indicating that the Company had regained compliance with the minimum bid price requirement of the Nasdaq continued listing requirements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series A Preferred Stock is convertible into shares of the Company’s common stock at any time at the holder’s option. The conversion price will be subject to customary anti-dilution adjustments for matters such as stock splits, stock dividends and other distributions on our common stock, and recapitalizations. <span id="xdx_90B_eus-gaap--ConversionOfStockDescription_c20230101__20230930_z7HTPswMfia9" title="Conversion of stock, description">A holder is prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of our common stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership limitation solely as to itself up to 19.99% of the number of shares of our common stock outstanding immediately after giving effect to the conversion, provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect to the issuance of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer apply to the holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval).</span> On July 15, 2022, the Company received such shareholder approval to remove the beneficial ownership limitation with respect to the Series A Preferred Stock held by Broadwood. The Company may force the conversion of up to one-third of the shares of Series A Preferred Stock originally issued, subject to customary equity conditions,<span id="xdx_908_eus-gaap--EquityMethodInvestmentDescriptionOfPrincipalActivities_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_z4giUQZQgNT4" title="Equity method investment, description of principal activities"> if the daily volume weighted average price of our common stock for 20 out of 30 trading days exceeds <span id="xdx_90E_ecustom--ConversionPricePercentage_dp_uPure_c20220714__20220715_ziMLR02jGNul">140</span>% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or exceeds 20,000 shares of our common stock</span>. The Company may only effect one forced conversion during any 30-trading day period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event of the Company’s liquidation, dissolution, or winding up, holders of Series A Preferred Stock will receive a payment equal to the stated value of the Series A Preferred Stock plus accrued but unpaid dividends and any other amounts that may have become payable on the Series A Preferred Stock due to any failure or delay that may have occurred in issuing shares of common stock upon conversion of a portion of the Series A Preferred Stock, before any distribution or payment to the holders of common stock or any of our other junior equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of Series A Preferred Stock generally have no voting rights, except as required by law and except that the consent of holders of a majority of the outstanding Series A Preferred Stock will be required to amend any provision of our certificate of incorporation that would have a materially adverse effect on the rights of the holders of the Series A Preferred Stock. Additionally, as long as any shares of Series A Preferred Stock remain outstanding, unless the holders of at least <span id="xdx_90D_ecustom--PreferredStockRemainsOutstandingPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zEg2ddQQZUj8" title="Preferred stock outstanding percentage">51</span>% of the then outstanding shares of Series A Preferred Stock shall have otherwise given prior written consent, we, on a consolidated basis with our subsidiaries, are not permitted to (1) have less than $<span id="xdx_900_eus-gaap--Cash_iI_pn6n6_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zC259k0GsKE" title="Cash in hand">8</span> million of unrestricted, unencumbered cash on hand (“Cash Minimum Requirement”); (2) other than certain permitted indebtedness, incur indebtedness to the extent that our aggregate indebtedness exceeds $<span id="xdx_90B_ecustom--IndebtednessExpenses_iI_pn6n6_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_z23ynQViyfx3" title="Indebtedness expenses">15</span> million; (3) enter into any agreement (including any indenture, credit agreement or other debt instrument) that by its terms prohibits, prevents, or otherwise limits our ability to pay dividends on, or redeem, the Series A Preferred Stock in accordance with the terms of the Certificate of Determination; or (4) authorize or issue any class or series of preferred stock or other capital stock of the Company that ranks senior or pari passu with the Series A Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of Series A Preferred Stock are entitled to receive cumulative dividends at a rate per share (as a percentage of stated value) of <span id="xdx_907_ecustom--DividendsRatePerPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zl63miNlz3tl" title="Dividends rate">6</span>% per annum, payable quarterly in cash or, at our option, by accreting such dividends to the stated value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is required to redeem, for cash, the shares of Series A Preferred Stock on the earlier to occur of (1) April 8, 2024, (2) the commencement of certain a voluntary or involuntary bankruptcy, receivership, or similar proceedings against the Company or its assets, (3) a Change of Control Transaction (as defined herein) and (4) at the election and upon notice of <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--InterestMember_z9DZJwwgOnu3" title="Ownership percentage">51</span>% in interest of the holders, if the Company fails to meet the Cash Minimum Requirement. A “Change of Control Transaction” means the occurrence of any of (a) an acquisition by an individual or legal entity or “group” (as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective control (whether through legal or beneficial ownership of capital stock of the Company, by contract or otherwise) of in excess of <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_z9ubDoAky2ch" title="Ownership percentage">50</span>% of the voting securities of the Company (other than by means of conversion of Series A Preferred Stock), (b) the Company merges into or consolidates with any other person, or any person merges into or consolidates with the Company and, after giving effect to such transaction, the stockholders of the Company immediately prior to such transaction own less than <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SecurityMember_zWd4IqOnGey7" title="Ownership percentage">50</span>% of the aggregate voting power of the Company or the successor entity of such transaction, or (c) the Company sells or transfers all or substantially all of its assets to another person. Additionally, the Company has the right to redeem the Series A Preferred Stock for cash upon 30 days prior notice to the holders; provided if the Company undertakes a capital raise in connection with such redemption, the Investors will have the right to participate in such financing. On April 5, 2023, the Company redeemed <span id="xdx_901_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20230404__20230405__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zI0ahQQC7Z4f" title="Number of stock redeem">1,064</span> shares of the Series A Preferred Stock for approximately $<span id="xdx_908_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_pn5n6_c20230404__20230405__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zDRE5eeoUk4d" title="Number of stock redeem value">1.1</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The issuance and sale of the Series A Preferred Stock was completed pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-256650), filed with the SEC on May 28, 2021 and declared effective by the SEC on June 8, 2021, and an accompanying prospectus dated June 8, 2021 as supplemented by a prospectus supplement dated April 13, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series A Preferred Stock dividend for all issued and outstanding shares is set at<span id="xdx_909_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0Y0hibvAb6e" title="Preferred stock, dividend rate, percentage"> 6%</span> per annum per share. As of September 30, 2023, the Company elected to accrete dividends of $<span id="xdx_90B_eus-gaap--DividendsPreferredStock_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zgPlrlJC0zqk" title="Dividends, preferred stock">399,000</span>, net of the April 2023 redemption, with respect to shares of Series A Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023 and December 31, 2022, Oncocyte had<span id="xdx_90B_eus-gaap--TemporaryEquitySharesIssued_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zrPsUMinI3aj" title="Temporary equity, shares issued"> <span id="xdx_90C_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zywmzkLt3bMl" title="Temporary equity, shares outstanding">4,818</span></span> and<span id="xdx_909_eus-gaap--TemporaryEquitySharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zzjVIMc2umb6" title="Temporary equity, shares issued"> <span id="xdx_90F_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zbMQerzQEN72" title="Temporary equity, shares oustanding">5,882</span></span>, shares issued and outstanding, respectively. The future right or obligation associated with the Series A Preferred Stock to be issued in the second closing was written off in the prior year since the second closing was not completed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023 and December 31, 2022, Oncocyte has <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230930_zyf98tUpbPxc" title="Common stock, shares authorized"><span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zvQmwYcdiN3i" title="Common stock, shares authorized">230,000,000</span></span> shares of common stock, <span id="xdx_905_eus-gaap--CommonStockNoParValue_iI_pid_do_c20230930_zgfR2RR1CLf5" title="Common stock no par value"><span id="xdx_90F_eus-gaap--CommonStockNoParValue_iI_pid_do_c20221231_zhMMDg12Pe1i" title="Common stock no par value">no</span></span>-par value, authorized. As of September 30, 2023 and December 31, 2022, Oncocyte had<span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_pid_c20230930_z2AhX096qUT7" title="Common stock, shares issued"> <span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230930_z6vlnyVyM7t7" title="Common stock, shares outstanding">8,260,762</span></span> and <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_znycOU8pvnkg" title="Common stock, shares issued"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zInuESRMqbHd" title="Common stock, shares outstanding">5,932,191</span></span> shares of common stock issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Underwritten Offering</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 13, 2022, Oncocyte entered into the Underwriting Agreement with the Underwriters, pursuant to which the Company agreed to issue and sell to the Underwriters an aggregate of<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyTwoWarrantsMember_z6SCdDjA7aFk" title="Stock issued during period, shares, new issues"> 1,313,320</span> shares of common stock and <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyTwoWarrantsMember_z1Ea6srrL9hc" title="Number of warrants">1,313,320</span> April 2022 Warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjoIU3hXDVG2" title="Number of warrants">656,660</span> shares of common stock. Each share of common stock and the accompanying April 2022 Warrant was sold at a combined offering price of $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyTwoWarrantsMember_zIjPzmxd0reg" title="Sale of stock, price per share">26.65</span>, representing an offering price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSbDgGIULhS9" title="Sale of stock, price per share">26.45 </span>per share of common stock and $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMqXK26DE0Od" title="Exercise price">0.20</span> per accompanying April 2022 Warrant, before underwriting discounts and commissions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the terms of the Underwriting Agreement, the Company also granted to the Underwriters an over-allotment option, exercisable in whole or in part at any time for a period of 30 days from the date of the Underwriting Agreement, to purchase up to an additional <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyTwoWarrantsMember_ztjYAVjtFHi" title="Stock issued during period, shares, new issues">196,998</span> shares of common stock and <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZaC1LaoA3y" title="Number of warrants">196,998</span> April 2022 Warrants to purchase<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeYnBs6KqGD3" title="Number of warrants"> 98,499</span> shares of common stock to cover over-allotments, if any. The over-allotment option may be exercised separately for shares of common stock at a price to the underwriters of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zdCfhoFGVix4" title="Shares issued, price per share">24.85</span> per share, and April 2022 Warrants at a price of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220413__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBNawVVbnSq7" title="Shares issued, price per share">0.20</span> per April 2022 Warrant. On April 14, 2022, the Underwriters exercised their option to purchase the <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zYFsdw5rbaQg" title="Stock issued during period, shares, new issues">196,998</span> April 2022 Warrants pursuant to the over-allotment option but did not exercise their option to purchase the additional <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_znRb64EEYhu9" title="Stock issued during period, shares, new issues">196,998</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company received net proceeds of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20220418__20220419__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z1QB6j3E1yOe" title="Net proceeds">32.8</span> million from the Underwritten Offering, which includes the April 2022 Warrants sold upon the exercise of the Underwriters’ overallotment option. The Underwritten Offering closed on April 19, 2022. Refer to Note 11 for additional information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Underwritten Offering was made pursuant to the Company’s effective “shelf” registration statement on Form S-3 (Registration No. 333-256650) filed with the SEC Commission on May 28, 2021 and declared effective by the SEC on June 8, 2021, and an accompanying prospectus dated June 8, 2021 as supplemented by a prospectus supplement dated April 13, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>April 2023 Offering</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 3, 2023, Oncocyte entered into an agreement with certain members of the Company’s board of directors, and several institutional and accredited investors, including Broadwood, the Company’s largest shareholder, and certain members of the Company’s board of directors (and certain of their affiliated parties), relating to their purchase of an aggregate of up to <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--RangeAxis__srt--MaximumMember_zV2wrCMi5AY1" title="Number of shares issued">2,278,121 </span>shares of its common stock at an offering price of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--BoardMembersMember_zEMuaJVpEVj9" title="Shares issued price per share">7.08</span> per share to board members and $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--OtherInvestorsMember_zwJr0O9DQzgi" title="Shares issued price per share">6.03</span> per share to the other investors participating in the April 2023 Offering. The April 2023 Offering was intended to be priced at-the-market for purposes of complying with applicable Nasdaq Listing Rules. The Company issued an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z1PARUTXCAPi" title="Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares">2,274,709</span> shares of common stock from this offering, as further discussed in Note 11. The aggregate gross proceeds from the offering were approximately $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember_zM74fTeRzy8e" title="Proceeds from issuance of common stock">13.9</span> million. The Company used approximately $<span id="xdx_90C_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_pn5n6_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zEtZMyE1Cb68" title="Net proceeds to immediately redeem">1.1</span> million of the net proceeds to immediately redeem an aggregate of <span id="xdx_906_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zd1gbz9MVIEf" title="Number of stock redeem, shares">1,064</span> shares of its Series A Preferred Stock and may thereafter elect to redeem additional shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock Purchase Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, Oncocyte had an aggregate of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230930_zGAzupPQZ2lg" title="Number of common stock purchase warrants">819,767</span> common stock purchase warrants issued and outstanding with exercise prices ranging from $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__srt--RangeAxis__srt--MinimumMember_zpstaYeYPick" title="Warrant exercise price per share">30.60</span> to $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__srt--RangeAxis__srt--MaximumMember_z6S8l1iW7wf7" title="Warrant exercise price per share">109.20</span> per warrant. The warrants will expire on various dates ranging from February 2024 to October 2029. Certain warrants have “cashless exercise” provisions meaning that the value of a portion of warrant shares may be used to pay the exercise price rather than payment in cash, which may be exercised under any circumstances in the case of the 2017 Bank Warrants and 2019 Bank Warrants (see Note 6) or, in the case of certain other warrants, only if a registration statement for the warrants and underlying shares of common stock is not effective under the Securities Act or a prospectus in the registration statement is not available for the issuance of shares upon the exercise of the warrants. All of the outstanding warrants meet the equity classification criteria and have been classified as equity, refer to Note 2 for additional information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 11765 384477 30.60 850 1000 5000000 10000000 4900000 A holder is prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of our common stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership limitation solely as to itself up to 19.99% of the number of shares of our common stock outstanding immediately after giving effect to the conversion, provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect to the issuance of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer apply to the holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval). if the daily volume weighted average price of our common stock for 20 out of 30 trading days exceeds 140% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or exceeds 20,000 shares of our common stock 1.40 0.51 8000000 15000000 0.06 0.51 0.50 0.50 1064 1100000 0.06 399000 4818 4818 5882 5882 230000000 230000000 0 0 8260762 8260762 5932191 5932191 1313320 1313320 656660 26.65 26.45 0.20 196998 196998 98499 24.85 0.20 196998 196998 32800000 2278121 7.08 6.03 2274709 13900000 1100000 1064 819767 30.60 109.20 <p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zh62tnIaOFtj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9. <span id="xdx_821_zPSHrGA0wKte">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity Incentive Plans</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte had a 2010 Stock Option Plan (the “2010 Plan”) under which <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenStockOptionPlanMember_zpcyWcEL4m3h" title="Number of shares authorized">260,000</span> shares of common stock were authorized for the grant of stock options or the sale of restricted stock. On August 27, 2018, Oncocyte shareholders approved a new Equity Incentive Plan (the “2018 Incentive Plan”) to replace the 2010 Plan. In adopting the 2018 Incentive Plan, Oncocyte terminated the 2010 Plan and will not grant any additional stock options or sell any stock under restricted stock purchase agreements under the 2010 Plan; however, stock options issued under the 2010 Plan will continue in effect in accordance with their terms and the terms of the 2010 Plan until the exercise or expiration of the individual options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenIncentivePlanMember_zfxqkURKnszj" title="Number of shares authorized">1,050,000</span> shares of common stock were reserved under the 2018 Incentive Plan for the grant of stock options or the sale of restricted stock or for the settlement of RSUs. Oncocyte may also grant stock appreciation rights under the 2018 Incentive Plan. As of September 30, 2023, <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenIncentivePlanMember_zr22Cd2k46v2" title="Number of shares available for grant">387,000</span> shares are available for grant under the 2018 Incentive Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022 Equity Awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company awarded executive share-based payment awards under the 2018 Plan to certain executive officers and employees with time-based, market-based and performance-based vesting conditions (“2022 equity awards”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the RSU 2022 equity awards with performance-based vesting condition was estimated using the Black-Scholes option-pricing model assuming that performance goals will be achieved. If such performance conditions are not met, no compensation cost is recognized and any recognized compensation cost is reversed. The probability of 2022 equity awards performance-based vesting conditions will be evaluated each reporting period and the Company will true-up the amount of cumulative cost recognized for the 2022 performance-based awards at each reporting period based on the most up-to-date probability estimates. The Company will recognize the compensation expense for 2022 performance-based awards expected to vest on a straight-line basis over the respective service period for each separately vesting tranche.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the RSU 2022 equity awards with market-based and time-based vesting conditions were estimated using the Monte Carlo simulation model. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated period to achievement of the performance and market conditions, which are subject to the achievement of the market-based goals established by the Company and the continued employment of the participant. These awards vest only to the extent that the market-based conditions are satisfied as specified in the vesting conditions. Unlike the performance-based awards, the grant date fair value and associated compensation cost of the market-based awards reflect the probability of the market condition being achieved, and the Company will recognize this compensation cost regardless of the actual achievement of the market condition. Assumptions utilized in connection with the Monte Carlo valuation technique included: estimated risk-free interest rate of<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_zCUXtLECyw9i" title="Risk-free interest rates"> 2.0</span> percent; term of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_z8GSXuDmiNSg" title="Expected life (in years)">2.8</span> years; expected volatility of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_zA5l0oa40hGi" title="Expected Volatility">100</span> percent; and expected dividend yield of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_zvtUGq2fXLu8" title="Dividend yield">0</span> percent. The risk-free interest rate was determined based on the yields available on U.S. Treasury zero-coupon issues. The expected stock price volatility was determined using historical volatility. The expected dividend yield was based on expectations regarding dividend payments. The total grant date fair value of the market-based awards was $<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_c20220101__20221231__us-gaap--PlanNameAxis__custom--PerformanceBasedOptionsMember_zvvfPeVg6bXb" title="Grant date fair value">117,625</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022 Modifications</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2022, the Company approved amendments to vesting conditions of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220501__20220531__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersAndEmployeesMember_z1fZ9D4bgURd">61,875</span> performance-based and <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220501__20220531__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersAndEmployeesMember_zOzDwscK5X6k">12,500</span> market-based awards of certain executive officers and employees. The performance-based awards were modified such that the stock awards will be eligible to vest as follows: (i) <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_c20220501__20220531__dei--LegalEntityAxis__custom--VitaGraftMember_zw3eLydDhw3i">50</span>% will vest on December 31, 2023 if the Company achieves LCD reimbursement for VitaGraft (formerly TheraSure Transplant Monitor) for one organ no later than December 31, 2022 and (ii) <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_c20220501__20220531__dei--LegalEntityAxis__custom--DetermalOMember_zu16xApKzOPf">50</span>% will vest on December 31, 2023 if DetermaIO or DetermaCNI (formerly TheraSure - CNI Monitor) submission for LCD is completed no later than December 31, 2022. Additional performance-based RSU awards were modified to be eligible to vest upon the achievement by <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220501__20220531_zdmYnBRr9iT3">the Company of average market capitalization minimum, target, and maximum goals of (i) $300 million; (ii) $400 million; and (iii) $500 million, respectively, during the period beginning on January 1, 2022 and ending on December 31, 2024</span>. The market-based RSU awards were modified such that the awards will be eligible to vest upon the achievement of product commercial launch minimum, target, and maximum goals as follows: (i) one laboratory test product in the US; (ii) two laboratory test products in US, and (iii) three laboratory test products in the US, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 718, the Company calculated the fair value of the market-based awards on the date of modification, noting an increase in the fair value of approximately $<span id="xdx_904_eus-gaap--IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_c20230101__20230930_zJkI6bnfpaG5" title="Increase in fair value">58,500</span>, with the incremental increase in fair value representing additional stock-based compensation expense. The following assumptions were used in calculating the fair value of the market-based options on the date of modification: estimated risk-free interest rate of<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zHlwFOI7njue" title="Risk-free interest rates"> 2.72</span> percent, term of<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_z7WP0S7XUiqc" title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"> 2.6</span> years, expected volatility of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zzdhYlEyOzv8" title="Volatility">95.0</span> percent and expected dividend yield of<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230930__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zWNT4ZzZN7K9" title="Grant date fair value of awards granted during the period"> 0</span> percent.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2022, the Company approved amendments to vesting conditions of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220701__20220731__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersAndEmployeesMember_zvSSEmoaiHg8" title="Share based awards vesting">23,750</span> performance-based awards of certain executive officers and employees. Certain performance-based awards were modified such that the stock awards will be eligible to vest as follows: (i) fifty percent (<span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20220701__20220731__dei--LegalEntityAxis__custom--VitaGraftMember_zY4ffv4PI697" title="Vested percentage">50</span>%) of the options will vest on December 31, 2023 (the “Vesting Date”), subject to Continuous Service through the Vesting Date, if local coverage determination is issued and priced for VitaGraft (Transplant) with respect to one organ no later than December 31, 2022; and (ii) fifty percent (<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_c20220701__20220731__dei--LegalEntityAxis__custom--DetermalOMember_zMuK6scGdnO1" title="Vested percentage">50</span>%) of the options will vest on the Vesting Date, subject to Continuous Service through the Vesting Date, if the Company submits a local coverage determination request for DetermaIO or DetermaCNI no later than December 31, 2022. Additional performance-based stock awards were modified to be eligible to vest upon <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220701__20220731_zU7OCJuNFYs" title="Share based payment award description">the achievement of performance minimum, target, and maximum goals of (i) 90% of revenue goal; (ii) 100% of revenue goal; and (iii) exceed revenue goal by up to 150%, respectively, during fiscal year 2022</span>. These same awards contained budget performance goals which were modified to be eligible to vest upon the achievement of performance minimum, target, and maximum goals of (i) complete fiscal year 2022 with sufficient cash to continue operations for 12 months; (ii) complete fiscal year 2022 with sufficient cash to continue operations for 15 months; and (iii) complete fiscal year 2022 with sufficient cash to continue operations for 16 months, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zoGtMP4OCHV8" title="Share based payment award description">50</span>% of the performance-based were forfeited since the Company did not achieve LCD reimbursement for VitaGraft.<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20221214__20221216__dei--LegalEntityAxis__custom--DetermaCNIMember_z3ir1TXxnyl" title="Share based payment award vesting rights description"> The remaining 50% is eligible to vest on December 31, 2023, since the Company completed the LCD submission for DetermaCNI on December 16, 2022</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company accelerated the vesting of certain equity awards in accordance with the 2018 Incentive Plan after the departure of officers of the Company and the adoption of the workforce reduction plan. Due to the acceleration of such awards all associated unrecognized compensation was accelerated and recognized in full.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2010 Plan Activity</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zVZDz99EJJz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of Oncocyte’s 2010 Plan activity and related information follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_znSnSA8bGEW5" style="display: none">Summary of Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Available</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of Options</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Options</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">for Grant</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="10" style="text-align: center">(In thousands, except weighted average exercise price)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zCpG7KBQtjt8" style="width: 14%; text-align: right" title="Shares available for grant options, beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1694">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zZj1YFNug3zd" style="width: 14%; text-align: right" title="Number of options outstanding, beginning of period">30</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_z9UML6Muyaji" style="width: 14%; text-align: right" title="Weighted average exercise price, options outstanding, beginning of period">80.78</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zvG1hK2QmQ0i" style="text-align: right" title="Shares available for grant options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1700">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zGdPACU7QrNk" style="text-align: right" title="Number of options outstanding, option exercised"><span style="-sec-ix-hidden: xdx2ixbrl1702">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zbRMb5QusH7h" style="text-align: right" title="Weighted average exercise price, options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1704">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zHFYavdjqa2b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares available for grant options forfeited, cancelled and expired"><span style="-sec-ix-hidden: xdx2ixbrl1706">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zaGm4BQli1ph" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, options forfeited, cancelled and expired">(20</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zRL2rBI09lNj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, options forfeited, cancelled and expired"><span style="-sec-ix-hidden: xdx2ixbrl1710">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zhBUnCzoB7fc" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares available for grant outstanding, end of period"><span style="-sec-ix-hidden: xdx2ixbrl1712">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zXdlCtrg2Kn6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, end of period">10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zvuEwkRoWGwh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding end of period">73.22</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zoTso7WxZtW" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, exercisable, end of period">10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zSyCQ2ln0xSb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, end of period">73.22</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zpMUEgZEfkvd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2018 Plan Activity</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z1tZ4cClLj52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of Oncocyte’s 2018 Incentive Plan activity and related information follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_z4eXZgafUv43" style="display: none">Summary of Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Shares</p> <p style="margin-top: 0; margin-bottom: 0">Available</p> <p style="margin-top: 0; margin-bottom: 0">for Grant</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number</p> <p style="margin-top: 0; margin-bottom: 0">of Options</p> <p style="margin-top: 0; margin-bottom: 0">Outstanding</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number</p> <p style="margin-top: 0; margin-bottom: 0">of RSUs</p> <p style="margin-top: 0; margin-bottom: 0">Outstanding</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p> <p style="margin-top: 0; margin-bottom: 0">Average</p> <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="14" style="text-align: center">(In thousands, except weighted average exercise price)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Balance at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z2DNlTKpk85l" style="width: 10%; text-align: right" title="Shares available for grant options, beginning of period">442</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zoqy3LCanFs7" style="width: 10%; text-align: right" title="Number of options outstanding, beginning of period">428</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zxmQeBDsj1Cg" style="width: 10%; text-align: right" title="Number of RSUs Outstanding, beginning of period">22</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zkyLexTFpVT6" style="width: 10%; text-align: right" title="Weighted average exercise price, options outstanding, beginning of period">59.23</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">RSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zSjqu7RwrUB" style="text-align: right" title="Shares available for grant options RSUs vested"><span style="-sec-ix-hidden: xdx2ixbrl1732">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zUJ1yMvqLNA8" style="text-align: right" title="Number of options outstanding, option RSUs vested"><span style="-sec-ix-hidden: xdx2ixbrl1734">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zZb87k7ugaLa" style="text-align: right" title="Number of RSUs Outstanding, option RSUs vested">(14</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zeY5CEA8Kyn7" style="text-align: right" title="Weighted average exercise price, options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1738">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_ztrPnb1hHowk" style="text-align: right" title="Shares available for grant options RSUs granted">(9</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zflKXdTfzkV3" style="text-align: right" title="Number of options outstanding, option RSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl1742">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zWrJ2t3Eomlj" style="text-align: right" title="Number of RSUs Outstanding, option RSUs granted">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zGFEUcFNliUi" style="text-align: right" title="Weighted average exercise price, option RSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl1746">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zEjsFZcVmpwk" style="text-align: right" title="Shares available for grant options granted">(298</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zyrOPYvkUqV3" style="text-align: right" title="Number of options outstanding, option granted">298</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zRIPcdNmOFvk" style="text-align: right" title="Number of RSUs Outstanding, option granted"><span style="-sec-ix-hidden: xdx2ixbrl1752">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zhe7I6PavfG6" style="text-align: right" title="Weighted average exercise price, option granted">5.96</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options forfeited/expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zIcKbZV3tKnd" style="text-align: right" title="Shares available for grant options forfeited/expired">235</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z9WkSho4b1Me" style="text-align: right" title="Number of options outstanding, options forfeited/expired">(235</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zxqx6QdhjZtl" style="text-align: right" title="Number of RSUs Outstanding, options forfeited/expired"><span style="-sec-ix-hidden: xdx2ixbrl1760">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zrW7Fw9c6iYf" style="text-align: right" title="Weighted average exercise price, options forfeited/expired"><span style="-sec-ix-hidden: xdx2ixbrl1762">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">RSUs forfeited/expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z3Zt0bgT0anb" style="text-align: right" title="Shares available for grant RSUs forfeited/expired">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zJFfjnjEeUz4" style="text-align: right" title="Number of options outstanding, RSUs forfeited/expired"><span style="-sec-ix-hidden: xdx2ixbrl1766">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited_iN_pn3n3_di_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zF2tf4KDUIN5" style="text-align: right" title="Number of RSUs Outstanding, RSUs forfeited/expired">(1</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z1Cn1msD6Ljb" style="text-align: right" title="Weighted average exercise price, RSUs forfeited/expired"><span style="-sec-ix-hidden: xdx2ixbrl1770">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Performance RSUs forfeited/expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zf8CvRoiX4sg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares available for grant performance RSUs forfeited/expired">15</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zK6lofStwKB3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, performance RSUs forfeited/expired"><span style="-sec-ix-hidden: xdx2ixbrl1774">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited_iN_pn3n3_di_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zj40Dv3lwRM5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Performance RSUs Outstanding, performance RSUs forfeited/expired">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zmhdnM33p0vl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, performance RSUs forfeited/expired"><span style="-sec-ix-hidden: xdx2ixbrl1778">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zUWzK6PWdNK5" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares available for grant outstanding, end of period">387</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zD3UETXoGIwe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, end of period">491</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zxlyaxF4KTOf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs Outstanding, end of period">5</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zIGfZv6iv3O2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding end of period">27.31</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Options exercisable at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zeVfE98c7y8d" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, exercisable, end of period">140</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zuiwNdIvFSLd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, end of period">98.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zaES5w7nTDke" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z6SiVo1n1x83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2023, the Company granted <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930__srt--TitleOfIndividualAxis__custom--EmployeeAndNonEmployeeMember_z9Bq9l6SCo52" title="Grants shares">178,000</span> employee and non-employee stock option awards. The assumptions used to calculate the Black-Scholes grant date fair value of such awards were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zw3q5YRxetqc" style="display: none">Schedule of Assumptions Used to Calculate Fair Value of Stock Options</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">Nine Months Ended</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Expected life (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930_zhxWyU7zPYGc" title="Expected life (in years)">6.25</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930_zgIZfzGu0G25" title="Expected life (in years)">5.98</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rates</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930_zUH3K3QgxjWh" style="text-align: right" title="Risk-free interest rates">3.76</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930_zThqNlRuMiri" style="text-align: right" title="Risk-free interest rates">2.29</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930_zYM0Bm5SI7Aa" style="text-align: right" title="Volatility">105.99</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930_zJyqi5n2Y3sh" style="text-align: right" title="Volatility">106.85</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20230101__20230930_z4bI3QnycGJe" title="Dividend yield">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d0_c20220101__20220930_znX2ndM8Bxg" title="Dividend yield">0</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A8_zyLCZSReCycj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2023, the Company awarded <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230801__20230831__us-gaap--PlanNameAxis__custom--PerformanceBasedOptionsMember_zq8GVU6MVIOk" title="Stock option grant">120,000</span> stock option grants with market-based and time-based vesting conditions to certain executives. The fair value of such awards was estimated using the Monte Carlo simulation model. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated period to achievement of the performance and market conditions, which are subject to the achievement of the market-based goals established by the Company and the continued employment of the executives through December 31, 2025. These awards vest only to the extent that the market-based conditions are satisfied as specified in the vesting conditions. The grant date fair value and associated compensation cost of the market-based awards reflect the probability of the market condition being achieved, and the Company will recognize this compensation cost regardless of the actual achievement of the market condition. Assumptions utilized in connection with the Monte Carlo valuation technique included: estimated risk-free interest rate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_zRmdlWwwOBth" title="Risk-free interest rates">4.81</span> percent; term of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_zWBcRRUNjdZ6" title="Expected life (in years)">6.19</span> years; expected volatility of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_zvPQbwJ2l0h7" title="Expected Volatility">91.0</span> percent; and expected dividend yield of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_ze3ZsRhxgoBi" title="Dividend yield">0</span> percent. The risk-free interest rate was determined based on the yields available on U.S. Treasury zero-coupon issues. The expected stock price volatility was determined using historical volatility. The expected dividend yield was based on expectations regarding dividend payments. Based on the market-based conditions, the grant date fair values of these awards ranged from $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember__srt--RangeAxis__srt--MinimumMember_zz0kfmK6aAmb" title="Fair value grants">1.09</span> to $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember__srt--RangeAxis__srt--MaximumMember_zRnwk3Lhyhnk" title="Fair value grants">1.74</span>, amounting to a total fair value of approximately $<span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_c20230101__20230930__us-gaap--PlanNameAxis__custom--PerformanceBasedOptionsMember_zq5SOS0UOSlf" title="Grant date fair value">156,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zlJt6WwCpdP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zRuuFJ6pLkkg" style="display: none">Summary of Stock-based Compensation Expense</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_494_20230701__20230930_zDIKKI3cUbug" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_496_20220701__20220930_z8Wof0wyl66j" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_490_20230101__20230930_zwX03iOHIrXi" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_490_20220101__20220930_zhJxGs1whVna" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">Three Months Ended</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">Nine Months Ended</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="14" style="text-align: center">(In thousands)</td><td style="text-align: center"> </td></tr> <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--CostOfRevenuesMember_zBo1Vt3LjIL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Cost of revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(2</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">94</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">10</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">239</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zw2T1LWjmAQ1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">294</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">521</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">931</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,416</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zBD1kgxlQiBd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Sales and marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">942</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">216</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,681</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zVVUYEkeSEu7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">252</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,624</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,119</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,087</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zIfeQKDdbMK9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">608</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,181</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,276</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,423</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_z6Jhq3dTQ79f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2023, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20230801__20230831_zRi6iiEZRKTk" title="Number of restricted stock awards, shares">9,091</span> restricted stock awards in connection with a consulting service arrangement for a total fair value of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20230801__20230831_znUdmY9Zl8Ye" title="Number of restricted stock awards, value">36,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If Oncocyte had made different assumptions, its stock-based compensation expense and net loss for the three and nine months ended September 30, 2023, and 2022 may have been significantly different. Refer to Note 2 for additional information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when a disqualified disposition has occurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 260000 1050000 387000 0.020 P2Y9M18D 1 0 117625 61875 12500 0.50 0.50 the Company of average market capitalization minimum, target, and maximum goals of (i) $300 million; (ii) $400 million; and (iii) $500 million, respectively, during the period beginning on January 1, 2022 and ending on December 31, 2024 58500 0.0272 P2Y7M6D 0.950 0 23750 0.50 0.50 the achievement of performance minimum, target, and maximum goals of (i) 90% of revenue goal; (ii) 100% of revenue goal; and (iii) exceed revenue goal by up to 150%, respectively, during fiscal year 2022 50 The remaining 50% is eligible to vest on December 31, 2023, since the Company completed the LCD submission for DetermaCNI on December 16, 2022 <p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zVZDz99EJJz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of Oncocyte’s 2010 Plan activity and related information follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_znSnSA8bGEW5" style="display: none">Summary of Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Available</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of Options</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Options</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">for Grant</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="10" style="text-align: center">(In thousands, except weighted average exercise price)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zCpG7KBQtjt8" style="width: 14%; text-align: right" title="Shares available for grant options, beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1694">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zZj1YFNug3zd" style="width: 14%; text-align: right" title="Number of options outstanding, beginning of period">30</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_z9UML6Muyaji" style="width: 14%; text-align: right" title="Weighted average exercise price, options outstanding, beginning of period">80.78</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zvG1hK2QmQ0i" style="text-align: right" title="Shares available for grant options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1700">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zGdPACU7QrNk" style="text-align: right" title="Number of options outstanding, option exercised"><span style="-sec-ix-hidden: xdx2ixbrl1702">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zbRMb5QusH7h" style="text-align: right" title="Weighted average exercise price, options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1704">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zHFYavdjqa2b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares available for grant options forfeited, cancelled and expired"><span style="-sec-ix-hidden: xdx2ixbrl1706">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zaGm4BQli1ph" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, options forfeited, cancelled and expired">(20</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zRL2rBI09lNj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, options forfeited, cancelled and expired"><span style="-sec-ix-hidden: xdx2ixbrl1710">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zhBUnCzoB7fc" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares available for grant outstanding, end of period"><span style="-sec-ix-hidden: xdx2ixbrl1712">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zXdlCtrg2Kn6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, end of period">10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zvuEwkRoWGwh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding end of period">73.22</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zoTso7WxZtW" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, exercisable, end of period">10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zSyCQ2ln0xSb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, end of period">73.22</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 30000 80.78 20000 10000 73.22 10000 73.22 <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z1tZ4cClLj52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of Oncocyte’s 2018 Incentive Plan activity and related information follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_z4eXZgafUv43" style="display: none">Summary of Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Shares</p> <p style="margin-top: 0; margin-bottom: 0">Available</p> <p style="margin-top: 0; margin-bottom: 0">for Grant</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number</p> <p style="margin-top: 0; margin-bottom: 0">of Options</p> <p style="margin-top: 0; margin-bottom: 0">Outstanding</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number</p> <p style="margin-top: 0; margin-bottom: 0">of RSUs</p> <p style="margin-top: 0; margin-bottom: 0">Outstanding</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p> <p style="margin-top: 0; margin-bottom: 0">Average</p> <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="14" style="text-align: center">(In thousands, except weighted average exercise price)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Balance at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z2DNlTKpk85l" style="width: 10%; text-align: right" title="Shares available for grant options, beginning of period">442</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zoqy3LCanFs7" style="width: 10%; text-align: right" title="Number of options outstanding, beginning of period">428</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zxmQeBDsj1Cg" style="width: 10%; text-align: right" title="Number of RSUs Outstanding, beginning of period">22</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zkyLexTFpVT6" style="width: 10%; text-align: right" title="Weighted average exercise price, options outstanding, beginning of period">59.23</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">RSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zSjqu7RwrUB" style="text-align: right" title="Shares available for grant options RSUs vested"><span style="-sec-ix-hidden: xdx2ixbrl1732">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zUJ1yMvqLNA8" style="text-align: right" title="Number of options outstanding, option RSUs vested"><span style="-sec-ix-hidden: xdx2ixbrl1734">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zZb87k7ugaLa" style="text-align: right" title="Number of RSUs Outstanding, option RSUs vested">(14</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zeY5CEA8Kyn7" style="text-align: right" title="Weighted average exercise price, options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1738">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_ztrPnb1hHowk" style="text-align: right" title="Shares available for grant options RSUs granted">(9</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zflKXdTfzkV3" style="text-align: right" title="Number of options outstanding, option RSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl1742">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zWrJ2t3Eomlj" style="text-align: right" title="Number of RSUs Outstanding, option RSUs granted">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zGFEUcFNliUi" style="text-align: right" title="Weighted average exercise price, option RSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl1746">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zEjsFZcVmpwk" style="text-align: right" title="Shares available for grant options granted">(298</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zyrOPYvkUqV3" style="text-align: right" title="Number of options outstanding, option granted">298</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zRIPcdNmOFvk" style="text-align: right" title="Number of RSUs Outstanding, option granted"><span style="-sec-ix-hidden: xdx2ixbrl1752">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zhe7I6PavfG6" style="text-align: right" title="Weighted average exercise price, option granted">5.96</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options forfeited/expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zIcKbZV3tKnd" style="text-align: right" title="Shares available for grant options forfeited/expired">235</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z9WkSho4b1Me" style="text-align: right" title="Number of options outstanding, options forfeited/expired">(235</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zxqx6QdhjZtl" style="text-align: right" title="Number of RSUs Outstanding, options forfeited/expired"><span style="-sec-ix-hidden: xdx2ixbrl1760">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zrW7Fw9c6iYf" style="text-align: right" title="Weighted average exercise price, options forfeited/expired"><span style="-sec-ix-hidden: xdx2ixbrl1762">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">RSUs forfeited/expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z3Zt0bgT0anb" style="text-align: right" title="Shares available for grant RSUs forfeited/expired">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zJFfjnjEeUz4" style="text-align: right" title="Number of options outstanding, RSUs forfeited/expired"><span style="-sec-ix-hidden: xdx2ixbrl1766">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited_iN_pn3n3_di_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zF2tf4KDUIN5" style="text-align: right" title="Number of RSUs Outstanding, RSUs forfeited/expired">(1</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z1Cn1msD6Ljb" style="text-align: right" title="Weighted average exercise price, RSUs forfeited/expired"><span style="-sec-ix-hidden: xdx2ixbrl1770">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Performance RSUs forfeited/expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zf8CvRoiX4sg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares available for grant performance RSUs forfeited/expired">15</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zK6lofStwKB3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, performance RSUs forfeited/expired"><span style="-sec-ix-hidden: xdx2ixbrl1774">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited_iN_pn3n3_di_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zj40Dv3lwRM5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Performance RSUs Outstanding, performance RSUs forfeited/expired">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zmhdnM33p0vl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, performance RSUs forfeited/expired"><span style="-sec-ix-hidden: xdx2ixbrl1778">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zUWzK6PWdNK5" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares available for grant outstanding, end of period">387</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zD3UETXoGIwe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, end of period">491</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zxlyaxF4KTOf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs Outstanding, end of period">5</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zIGfZv6iv3O2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding end of period">27.31</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Options exercisable at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pn3n3_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zeVfE98c7y8d" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, exercisable, end of period">140</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zuiwNdIvFSLd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, end of period">98.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 442000 428000 22000 59.23 -14000 -9000 5000 -298000 298000 5.96 235000 235000 2000 1000 15000 7000 387000 491000 5000 27.31 140000 98.80 <p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z6SiVo1n1x83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2023, the Company granted <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930__srt--TitleOfIndividualAxis__custom--EmployeeAndNonEmployeeMember_z9Bq9l6SCo52" title="Grants shares">178,000</span> employee and non-employee stock option awards. The assumptions used to calculate the Black-Scholes grant date fair value of such awards were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zw3q5YRxetqc" style="display: none">Schedule of Assumptions Used to Calculate Fair Value of Stock Options</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">Nine Months Ended</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Expected life (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930_zhxWyU7zPYGc" title="Expected life (in years)">6.25</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930_zgIZfzGu0G25" title="Expected life (in years)">5.98</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rates</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930_zUH3K3QgxjWh" style="text-align: right" title="Risk-free interest rates">3.76</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930_zThqNlRuMiri" style="text-align: right" title="Risk-free interest rates">2.29</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930_zYM0Bm5SI7Aa" style="text-align: right" title="Volatility">105.99</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930_zJyqi5n2Y3sh" style="text-align: right" title="Volatility">106.85</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20230101__20230930_z4bI3QnycGJe" title="Dividend yield">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d0_c20220101__20220930_znX2ndM8Bxg" title="Dividend yield">0</span></td><td style="text-align: left">%</td></tr> </table> 178000 P6Y3M P5Y11M23D 0.0376 0.0229 1.0599 1.0685 0 0 120000 0.0481 P6Y2M8D 0.910 0 1.09 1.74 156000 <p id="xdx_89B_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zlJt6WwCpdP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zRuuFJ6pLkkg" style="display: none">Summary of Stock-based Compensation Expense</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_494_20230701__20230930_zDIKKI3cUbug" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_496_20220701__20220930_z8Wof0wyl66j" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_490_20230101__20230930_zwX03iOHIrXi" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_490_20220101__20220930_zhJxGs1whVna" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">Three Months Ended</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">Nine Months Ended</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="14" style="text-align: center">(In thousands)</td><td style="text-align: center"> </td></tr> <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--CostOfRevenuesMember_zBo1Vt3LjIL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Cost of revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(2</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">94</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">10</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">239</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zw2T1LWjmAQ1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">294</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">521</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">931</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,416</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zBD1kgxlQiBd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Sales and marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">942</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">216</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,681</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zVVUYEkeSEu7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">252</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,624</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,119</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,087</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zIfeQKDdbMK9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">608</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,181</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,276</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,423</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> -2000 94000 10000 239000 294000 521000 931000 1416000 64000 942000 216000 1681000 252000 1624000 1119000 4087000 608000 3181000 2276000 7423000 9091 36000 <p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zOFWvW4LyN92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10. <span id="xdx_82B_zzxB6FyJ5WGc">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270, <i>Income Taxes, Interim Reporting</i>. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where Oncocyte conducts business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte did not record any provision or benefit for income taxes for the nine months ended September 30, 2023 and 2022, as Oncocyte had a full valuation allowance for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. Oncocyte established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carry-forwards and other deferred tax assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zsDXwxAqmGBi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11. <span id="xdx_82F_z6msc3BmI25h">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financing Transactions</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 13, 2022, Oncocyte entered into the Securities Purchase Agreement with the Investors, including Broadwood and John Peter Gutfreund, a former director of Oncocyte, for the Series A Preferred Stock Offering. Each of Broadwood and Mr. Gutfreund has a direct material interest in the Series A Preferred Stock Offering and agreed to purchase <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp2d_c20220412__20220412__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zFPECQemd5Rl" title="Offering shares">5,882.35</span> and <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp2d_c20220413__20220413__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zHDu0vxZEF19" title="Offering shares">1,176.48</span> shares, respectively, in the Series A Preferred Stock Offering and on the same terms as other investors. Additionally, Halle Capital Management, L.P. received $<span id="xdx_900_eus-gaap--LegalFees_c20220413__20220413__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zvFjju7HSRt2" title="Legal fees">85,000</span> from the Company as reimbursement for its legal fees and expenses. Mr. Gutfreund is the Managing Partner of Halle Capital Management, L.P. See Note 8 for additional information about the Series A Preferred Stock Offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further, on April 13, 2022, Oncocyte entered into the Underwriting Agreement with the Underwriters for the Underwritten Offering. Pursuant to the Underwritten Offering, Broadwood acquired from us (i) <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zOKx2WKuLdm7" title="Sale of stock, shares">261,032</span> shares of common stock, and (ii) <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zTStrUhM4A8l" title="Warrant to purchase common stock">300,187</span> April 2022 Warrants to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember__srt--RangeAxis__srt--MaximumMember_zzaRfGgwZoL2" title="Warrant to purchase common stock">150,093</span> shares of common stock at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zyyxkIlwABw4" title="Warrant exercise price">30.60</span> per share. However, the total number of shares of common stock that Broadwood purchased in the Underwritten Offering was <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zXZlvL6ZF9ef" title="Warrant to purchase common stock">300,187</span>, of which <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_znCSEooRDhgj" title="Warrant to purchase common stock">39,154</span> existing shares were acquired by the underwriters in the open market and re-sold to Broadwood. Pura Vida acquired from us (i) <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember_zth1JUe2sIMb" title="Sale of stock, shares">249,204</span> shares of common stock, and (ii) <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember_zUXjgJ5x22zd" title="Warrant to purchase common stock">286,585</span> April 2022 Warrants to purchase up to <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember__srt--RangeAxis__srt--MaximumMember_zJkQCdH7WBA9" title="Sale of stock, shares">143,292</span> shares of common stock. However, the total number of shares of common stock that Pura Vida purchased in the Underwritten Offering was <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember_zH74U7nKFSO3" title="Issuance of shares">286,585</span>, of which <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zcEGwMomjJEg" title="Issuance of shares">37,380</span> existing shares were acquired by the underwriters in the open market and re-sold to Pura Vida. Halle Special Situations Fund LLC purchased from us (i) <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember_zJjE5lOj3PK3" title="Sale of stock, shares">309,976</span> shares of common stock, and (ii) <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember_zwTznSPWYdR1" title="Warrant to purchase common stock">356,472</span> 2022 Warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember__srt--RangeAxis__srt--MaximumMember_zlANuBD9oha5" title="Warrant to purchase common stock">178,236</span> shares of common stock. Mr. Gutfreund is the investment manager and a control person of Halle Capital Partners GP LLC, the managing member of Halle Special Situations Fund LLC. However, the total number of shares of common stock that Halle Special Situations Fund LLC purchased in the Underwritten was <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember_zPC29UjVTb05" title="Warrant to purchase common stock">356,472</span>, of which <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zlZ4isMVNmm9" title="Issuance of shares">46,496</span> existing shares were acquired by the underwriters in the open market and re-sold to Halle Special Situations Fund LLC. See Note 8 for additional information about the Underwritten Offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 3, 2023, Oncocyte entered into a securities purchase agreement (the “2023 Securities Purchase Agreement”) with certain investors, including Broadwood, Pura Vida and entities affiliated with AWM, and certain individuals, including our Chairman Andrew Arno and former director John Peter Gutfreund (and certain of their affiliated parties), which provides for the sale and issuance by the Company of an aggregate of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zgPFcG5bq4Sd" title="Offering shares">2,274,709</span> shares of common stock at an offering price of: <span id="xdx_90E_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z85KnLvPQyN6" title="Related party transaction, description">(i) $6.03 to investors who are not considered to be “insiders” of the Company pursuant to Nasdaq Listing Rules (“Insiders”), which amount reflects the average closing price of the Common Stock on Nasdaq during the five trading day period immediately prior to pricing, and (ii) $7.08 to Insiders, which amount reflects the final closing price of the Common Stock on Nasdaq on the last trading day immediately prior to pricing (the “2023 Registered Direct Offering”)</span>. Broadwood purchased <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--BroadwoodPartnersLPMember_zPQNBqnD0zAc" title="Offering shares">1,341,381</span> shares of common stock for $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--BroadwoodPartnersLPMember_zf6wfnPna0t8" title="Proceeds from issuance of stock">8,093,361.84</span>, Pura Vida purchased <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--PuraVidaMember_zy10aWqpYn1f" title="Offering shares">33,150</span> shares of common stock for $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--PuraVidaMember_zz2eI01tCUZ9" title="Proceeds from issuance of stock">200,013.84</span> and entities affiliated with AVM purchased <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--AVMMember_z1PytHK3zsM4" title="Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares">472,354</span> shares of common stock for $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--AVMMember_zgbtbH3WlcW6" title="Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts">2,849,999.92</span>. Mr. Arno and his affiliated parties purchased <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--ArnoMember_z94gLShJL5d3" title="Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares">21,162</span> shares of common stock for $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--ArnoMember_z4Edu7rTvzcd" title="Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts">150,000.51</span>, and Mr. Gutfreund and his affiliated parties purchased <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--MrGutfreundMember_z76tBuzfCvW6" title="Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares">85,250</span> for $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--MrGutfreundMember_zIErbLAp7Wbe" title="Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts">604,252.00</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 5, 2023, Oncocyte redeemed all of the <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pp5d_c20230405__20230405__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_znBeoWVxJmX2" title="Issuance of Series A redeemable convertible preferred stock, net of financing costs, shares">588.23529</span> shares of Series A Preferred Stock held by Mr. Gutfreund for $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_pp2d_c20230405__20230405__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGBw6Rj82w9e" title="Issuance of Series A redeemable convertible preferred stock, net of financing costs">618,672.34</span>. Mr. Gutfreund is no longer a related party as of June 23, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company Employee</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company previously employed the son of Andrew Arno, Chairman of the Board as its Senior Manager, Investor Relations, Corporate Planning &amp; Development. The total compensation paid by the Company to Mr. Arno’s son since January 1, 2022 is approximately $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionAxis__custom--ArnoMember_zKD4KBsuFk3f" title="Total compensation paid">200,000</span>. Mr. Arno’s son is no longer an employee of the Company as of July 28, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 5882.35 1176.48 85000 261032 300187 150093 30.60 300187 39154 249204 286585 143292 286585 37380 309976 356472 178236 356472 46496 2274709 (i) $6.03 to investors who are not considered to be “insiders” of the Company pursuant to Nasdaq Listing Rules (“Insiders”), which amount reflects the average closing price of the Common Stock on Nasdaq during the five trading day period immediately prior to pricing, and (ii) $7.08 to Insiders, which amount reflects the final closing price of the Common Stock on Nasdaq on the last trading day immediately prior to pricing (the “2023 Registered Direct Offering”) 1341381 8093361.84 33150 200013.84 472354 2849999.92 21162 150000.51 85250 604252.00 588.23529 618672.34 200000 <p id="xdx_80F_ecustom--CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock_zt5FLu11iJ86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12. <span id="xdx_821_zpInfqLpSUSe">Co-Development Agreement with Life Technologies Corporation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 13, 2022, Oncocyte entered into a Collaboration Agreement (the “LTC Agreement”) with Life Technologies Corporation, a Delaware corporation and subsidiary of Thermo Fisher Scientific (“LTC” and together with Oncocyte, the “Parties” or individually, a “Party”), in order to partner in the development and collaborate in the commercialization of Thermo Fisher Scientific’s existing Oncomine Comprehensive Assay Plus and Oncocyte’s DetermaIO assay for use with LTC’s Ion Torrent<sup>TM </sup>Genexus<sup>TM</sup> Integrated Sequencer and LTC’s Ion Torrent<sup>TM</sup> Genexus<sup>TM </sup>Purification System (“Genexus system”) in order to obtain <i>in vitro </i>diagnostic regulatory approval. On February 7, 2023, Oncocyte entered into a Termination Agreement with LTC, pursuant to which the parties terminated the LTC Agreement. As of the termination date, Oncocyte was responsible for reimbursing LTC for $<span id="xdx_901_eus-gaap--DevelopmentCosts_c20230101__20230930__dei--LegalEntityAxis__custom--LifeTechnologiesCorporationMember_zbrao5O1qjsf" title="Development costs">749,000</span> of certain development costs under the terms of the LTC Agreement, which have been fully paid.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 749000 <p id="xdx_800_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_z3v2ioizRP93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13. <span id="xdx_827_z7unIyWVG5ef">Discontinued Operations of Razor</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 15, 2022, the Company entered into the Razor Stock Purchase Agreement with Dragon and Razor. Pursuant to the Razor Stock Purchase Agreement, Oncocyte agreed to sell, and Dragon agreed to purchase, <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221214__20221215__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--DragonMember_zLAFgK7rOva6" title="Number of shares issued">3,188,181</span> shares of common stock of Razor, which constitutes approximately <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221215__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__srt--TitleOfIndividualAxis__custom--DragonMember_z0f3QUHPFMWj" title="Equity method investment ownership percentage">70</span>% of the issued and outstanding equity interests of Razor on a fully-diluted basis. On February 16, 2023, Oncocyte completed the Razor Sale Transaction. In connection with the Razor Closing, Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx. While <span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_dp_c20230216__20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__srt--TitleOfIndividualAxis__custom--DragonMember_zAuqDHvIkEoe" title="Cash received on stock transaction">no</span> monetary consideration was received for the sale of <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__srt--TitleOfIndividualAxis__custom--DragonMember_zj9D1e8iUBue" title="Equity method investment ownership percentage">70</span>% of the equity interests of Razor, the transaction allows the Company to eliminate all development and commercialization costs with respect to DetermaRx. Following the Razor Closing, Oncocyte continues to own <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230216__20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zoOkntvXlp94" title="Number of shares issued">1,366,364</span> shares of common stock of Razor, which constitutes approximately <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zOdwNaxTte37" title="Equity method investment ownership percentage">30</span>% of the issued and outstanding equity interests of Razor on a fully-diluted basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to the transfer of <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__srt--TitleOfIndividualAxis__custom--DragonMember_zbBt1Xty2Mhl" title="Equity method investment ownership percentage">70</span>% of the equity interests of Razor, the Razor Stock Purchase Agreement provided that Dragon would purchase furniture, fixtures, and equipment from the Company for a cash consideration of $<span id="xdx_90A_eus-gaap--BusinessCombinationConsiderationTransferred1_c20230216__20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--BusinessAcquisitionAxis__custom--RazorMember_zTUyLqCZtNk6" title="Consideration transferred">115,660</span>. Upon the Razor Closing, the Company deconsolidated the assets and liabilities of Razor as control of Razor has transferred to Dragon.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded the final adjustment related to the disposal, including final working capital adjustments, and recognized a loss of $<span id="xdx_90A_eus-gaap--EquityMethodInvestmentRealizedGainLossOnDisposal_iN_pn5n6_di_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zikyhvKdhttc" title="Loss on disposal">1.3</span> million during the first quarter of 2023. Including the impairment losses we recognized as of December 31, 2022 related to this transaction, we recorded an overall loss of $<span id="xdx_902_eus-gaap--EquityMethodInvestmentRealizedGainLossOnDisposal_iN_pn5n6_di_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zixRwyraFNs2" title="Loss on disposal">27.2</span> million. The operating results for Razor have been recorded in discontinued operations of the accompanying consolidated statements of operations for all periods presented, and we have reclassified their assets and liabilities as discontinued operations in the accompanying balance sheets. We have retrospectively adjusted the amounts reported for the period ended September 30, 2022, in the following table to give effect to such reporting of discontinued operations. For the period ended September 30, 2023, discontinued operations reflect operating results of Razor up to the closing of the sale.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated balance sheets and consolidated statements of operations report discontinued operations separate from continuing operations. Our consolidated statements of comprehensive loss, statements of shareholders’ equity and statements of cash flows combined continuing and discontinued operations. A summary of financial information related to the Company’s discontinued operations is as follows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zULGooCk6SCf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table represents the results of the discontinued operations of Razor:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zfX1Cpaf9nbg" style="display: none">Schedule of Discontinued Operations</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20230701__20230930_zYfcrXcErerk" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_492_20220701__20220930_zEiM8d83Tzu2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_490_20230101__20230930_zv83ICgKiwdi" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20220101__20220930_z4lI5N6oHqAk" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">Three Months Ended</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">Nine Months Ended</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="14" style="text-align: center">(In thousands)</td><td style="text-align: center"> </td></tr> <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_maILFDOz7EG_zdL4wfFQ1m2j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; font-weight: bold; text-align: left">Net revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1959">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">950</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">421</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,824</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_pn3n3_msILFDOz7EG_zmIDBv06Ingf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cost of revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1964">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,855</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">507</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,854</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_pn3n3_msILFDOz7EG_ziTl9kY67oN3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1969">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,949</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">702</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,200</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing_pn3n3_msILFDOz7EG_zVqbUfPtlGq8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Sales and marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1974">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">498</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,966</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_pn3n3_msILFDOz7EG_zn0JgTBsNoJ6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1979">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">61</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">329</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax_pn3n3_msILFDOz7EG_zAmP4YHF8evi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Loss from impairment of held for sale assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1984">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1985">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,311</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1987">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_pn3n3_maNILziQi_mtILFDOz7EG_zSucV0xek7Jf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Net loss from discontinued operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1989">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(7,515</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,926</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(21,329</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A1_zvX7v3a8Flv2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_hus-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_zWs41YwSDSNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table represents the carrying amounts of the assets and liabilities of the discontinued operations of Razor:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B6_zhTo33y86vj4" style="display: none">Schedule of Assets and Liabilities Discontinued Operations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20230930__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_zmesD9x3mrt" style="text-align: center; font-weight: bold">September 30,</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20221231__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_z2CCBH7x3s8h" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">(In thousands)</td><td style="text-align: center"> </td></tr> <tr id="xdx_403_eus-gaap--AssetsAbstract_iB_zxZ6UmbAF43b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">ASSETS</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_iB_zVWfdk7wy0ml" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">CURRENT ASSETS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_zljnrxEAz3w6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 64%; text-align: left">Cash and cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2002">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,510</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_zM5Fz6L06h67" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2005">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">346</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment_iI_z6Z4JIDiheL1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Machinery and equipment, net, and construction in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2008">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">211</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_iI_zg7czovm2eX4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Intangible assets, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2011">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,920</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales_iI_z3inGdKQJTTg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Impairment of held for sale assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2014">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,866</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--Assets_iTI_zWyyxVjzhJS6" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2017">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,121</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zvcjQGujEmi1" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">LIABILITIES AND SHAREHOLDERS’ EQUITY</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_z0JNM97S1kF6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">90</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">492</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DisposalGroupIncludingDiscontinuedOperationAccruedCompensation_iI_pn3n3_zquu8234rHVa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Accrued compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2026">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">248</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities_iI_zYZ8vbNScCP6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2029">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,265</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LiabilitiesCurrent_iI_zGsCKJaf9IY9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Total current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">90</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,005</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Liabilities_iTI_zJGADw7emao3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">TOTAL LIABILITIES</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">90</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,005</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes cash used related to the discontinued operations of Razor:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20230101__20230930_zBlZsNReOQ5c" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_498_20220101__20220930_zl9rjzx6hARf" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">Nine Months Ended</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">(In thousands)</td><td style="text-align: center"> </td></tr> <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInDiscontinuedOperationsAbstract_iB_zzFtaPVqVS3i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_i01_z1KnjzC3Q4Wh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; width: 64%; text-align: left">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">(4,357</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">(15,744</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zUk0VdOb4uqk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_i01_zHT2hatV4jXj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2047">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(96</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A1_zgspnOKodmzj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3188181 0.70 0.70 1366364 0.30 0.70 115660 -1300000 -27200000 <p id="xdx_897_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zULGooCk6SCf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table represents the results of the discontinued operations of Razor:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zfX1Cpaf9nbg" style="display: none">Schedule of Discontinued Operations</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20230701__20230930_zYfcrXcErerk" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_492_20220701__20220930_zEiM8d83Tzu2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_490_20230101__20230930_zv83ICgKiwdi" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20220101__20220930_z4lI5N6oHqAk" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">Three Months Ended</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">Nine Months Ended</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="14" style="text-align: center">(In thousands)</td><td style="text-align: center"> </td></tr> <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_maILFDOz7EG_zdL4wfFQ1m2j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; font-weight: bold; text-align: left">Net revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1959">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">950</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">421</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,824</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_pn3n3_msILFDOz7EG_zmIDBv06Ingf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cost of revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1964">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,855</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">507</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,854</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_pn3n3_msILFDOz7EG_ziTl9kY67oN3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1969">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,949</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">702</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,200</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing_pn3n3_msILFDOz7EG_zVqbUfPtlGq8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Sales and marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1974">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">498</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,966</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_pn3n3_msILFDOz7EG_zn0JgTBsNoJ6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1979">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">61</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">329</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax_pn3n3_msILFDOz7EG_zAmP4YHF8evi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Loss from impairment of held for sale assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1984">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1985">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,311</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1987">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_pn3n3_maNILziQi_mtILFDOz7EG_zSucV0xek7Jf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Net loss from discontinued operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1989">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(7,515</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,926</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(21,329</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 950000 421000 3824000 1855000 507000 5854000 2949000 702000 9200000 3600000 498000 9966000 61000 329000 133000 1311000 -7515000 -2926000 -21329000 <p id="xdx_899_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_hus-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_zWs41YwSDSNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table represents the carrying amounts of the assets and liabilities of the discontinued operations of Razor:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B6_zhTo33y86vj4" style="display: none">Schedule of Assets and Liabilities Discontinued Operations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20230930__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_zmesD9x3mrt" style="text-align: center; font-weight: bold">September 30,</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20221231__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_z2CCBH7x3s8h" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">(In thousands)</td><td style="text-align: center"> </td></tr> <tr id="xdx_403_eus-gaap--AssetsAbstract_iB_zxZ6UmbAF43b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">ASSETS</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_iB_zVWfdk7wy0ml" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">CURRENT ASSETS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_zljnrxEAz3w6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 64%; text-align: left">Cash and cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2002">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,510</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_zM5Fz6L06h67" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2005">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">346</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment_iI_z6Z4JIDiheL1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Machinery and equipment, net, and construction in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2008">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">211</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_iI_zg7czovm2eX4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Intangible assets, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2011">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,920</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales_iI_z3inGdKQJTTg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Impairment of held for sale assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2014">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,866</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--Assets_iTI_zWyyxVjzhJS6" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2017">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,121</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zvcjQGujEmi1" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">LIABILITIES AND SHAREHOLDERS’ EQUITY</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_z0JNM97S1kF6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">90</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">492</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DisposalGroupIncludingDiscontinuedOperationAccruedCompensation_iI_pn3n3_zquu8234rHVa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Accrued compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2026">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">248</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities_iI_zYZ8vbNScCP6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2029">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,265</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LiabilitiesCurrent_iI_zGsCKJaf9IY9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Total current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">90</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,005</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Liabilities_iTI_zJGADw7emao3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">TOTAL LIABILITIES</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">90</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,005</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes cash used related to the discontinued operations of Razor:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20230101__20230930_zBlZsNReOQ5c" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_498_20220101__20220930_zl9rjzx6hARf" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">Nine Months Ended</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">(In thousands)</td><td style="text-align: center"> </td></tr> <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInDiscontinuedOperationsAbstract_iB_zzFtaPVqVS3i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_i01_z1KnjzC3Q4Wh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; width: 64%; text-align: left">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">(4,357</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">(15,744</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zUk0VdOb4uqk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_i01_zHT2hatV4jXj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2047">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(96</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> </table> 1510000 346000 211000 25920000 -25866000 2121000 90000 492000 248000 1265000 90000 2005000 90000 2005000 -4357000 -15744000 -96000 Less than 10% Indicates the maximum payable if the Milestone is achieved. As defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration. See Note 3 for information on the Insight Merger. See Note 3 for information on the Chronix Merger. Amortization of intangible assets is included in “Cost of revenues – amortization of acquired intangibles” on the consolidated statements of operations because the intangible assets pertain directly to the revenues generated from the acquired intangibles. EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end
XML 72 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 336 398 1 true 125 0 false 7 false false R1.htm 00000001 - Document - Cover Sheet http://oncocyte.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://oncocyte.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://oncocyte.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://oncocyte.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://oncocyte.com/role/StatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Sheet http://oncocyte.com/role/StatementsOfShareholdersEquity Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://oncocyte.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - Organization, Description of the Business and Liquidity Sheet http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity Organization, Description of the Business and Liquidity Notes 8 false false R9.htm 00000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://oncocyte.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Business Combinations Sheet http://oncocyte.com/role/BusinessCombinations Business Combinations Notes 10 false false R11.htm 00000011 - Disclosure - Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress Sheet http://oncocyte.com/role/Right-of-useAndFinancingLeaseAssetsMachineryAndEquipmentNetAndConstructionInProgress Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress Notes 11 false false R12.htm 00000012 - Disclosure - Intangible Assets, Net Sheet http://oncocyte.com/role/IntangibleAssetsNet Intangible Assets, Net Notes 12 false false R13.htm 00000013 - Disclosure - Loan Payable to Silicon Valley Bank Sheet http://oncocyte.com/role/LoanPayableToSiliconValleyBank Loan Payable to Silicon Valley Bank Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingencies Sheet http://oncocyte.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Shareholders??? Equity Sheet http://oncocyte.com/role/ShareholdersEquity Shareholders??? Equity Notes 15 false false R16.htm 00000016 - Disclosure - Stock-Based Compensation Sheet http://oncocyte.com/role/Stock-basedCompensation Stock-Based Compensation Notes 16 false false R17.htm 00000017 - Disclosure - Income Taxes Sheet http://oncocyte.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 00000018 - Disclosure - Related Party Transactions Sheet http://oncocyte.com/role/RelatedPartyTransactions Related Party Transactions Notes 18 false false R19.htm 00000019 - Disclosure - Co-Development Agreement with Life Technologies Corporation Sheet http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporation Co-Development Agreement with Life Technologies Corporation Notes 19 false false R20.htm 00000020 - Disclosure - Discontinued Operations of Razor Sheet http://oncocyte.com/role/DiscontinuedOperationsOfRazor Discontinued Operations of Razor Notes 20 false false R21.htm 00000021 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://oncocyte.com/role/SummaryOfSignificantAccountingPolicies 21 false false R22.htm 00000022 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://oncocyte.com/role/SummaryOfSignificantAccountingPolicies 22 false false R23.htm 00000023 - Disclosure - Business Combinations (Tables) Sheet http://oncocyte.com/role/BusinessCombinationsTables Business Combinations (Tables) Tables http://oncocyte.com/role/BusinessCombinations 23 false false R24.htm 00000024 - Disclosure - Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress (Tables) Sheet http://oncocyte.com/role/Right-of-useAndFinancingLeaseAssetsMachineryAndEquipmentNetAndConstructionInProgressTables Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress (Tables) Tables http://oncocyte.com/role/Right-of-useAndFinancingLeaseAssetsMachineryAndEquipmentNetAndConstructionInProgress 24 false false R25.htm 00000025 - Disclosure - Intangible Assets, Net (Tables) Sheet http://oncocyte.com/role/IntangibleAssetsNetTables Intangible Assets, Net (Tables) Tables http://oncocyte.com/role/IntangibleAssetsNet 25 false false R26.htm 00000026 - Disclosure - Commitments and Contingencies (Tables) Sheet http://oncocyte.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://oncocyte.com/role/CommitmentsAndContingencies 26 false false R27.htm 00000027 - Disclosure - Stock-Based Compensation (Tables) Sheet http://oncocyte.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://oncocyte.com/role/Stock-basedCompensation 27 false false R28.htm 00000028 - Disclosure - Discontinued Operations of Razor (Tables) Sheet http://oncocyte.com/role/DiscontinuedOperationsOfRazorTables Discontinued Operations of Razor (Tables) Tables http://oncocyte.com/role/DiscontinuedOperationsOfRazor 28 false false R29.htm 00000029 - Disclosure - Organization, Description of the Business and Liquidity (Details Narrative) Sheet http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative Organization, Description of the Business and Liquidity (Details Narrative) Details http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity 29 false false R30.htm 00000030 - Disclosure - Schedule of Fair Value Measurement of Financial Assets and Liabilities (Details) Sheet http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails Schedule of Fair Value Measurement of Financial Assets and Liabilities (Details) Details 30 false false R31.htm 00000031 - Disclosure - Schedule of Disaggregation Of Revenue (Details) Sheet http://oncocyte.com/role/ScheduleOfDisaggregationOfRevenueDetails Schedule of Disaggregation Of Revenue (Details) Details 31 false false R32.htm 00000032 - Disclosure - Schedule of Concentration Of Risk (Details) Sheet http://oncocyte.com/role/ScheduleOfConcentrationOfRiskDetails Schedule of Concentration Of Risk (Details) Details 32 false false R33.htm 00000033 - Disclosure - Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details) Sheet http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details) Details 33 false false R34.htm 00000034 - Disclosure - Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details) Sheet http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details) Details 34 false false R35.htm 00000035 - Disclosure - Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details) Sheet http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details) Details 35 false false R36.htm 00000036 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesTables 36 false false R37.htm 00000037 - Disclosure - Schedule of Fair Value of Contingent Consideration Liability (Details) Sheet http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails Schedule of Fair Value of Contingent Consideration Liability (Details) Details 37 false false R38.htm 00000038 - Disclosure - Schedule of Contingent Consideration, Measured at Fair Value (Details) Sheet http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails Schedule of Contingent Consideration, Measured at Fair Value (Details) Details 38 false false R39.htm 00000039 - Disclosure - Business Combinations (Details Narrative) Sheet http://oncocyte.com/role/BusinessCombinationsDetailsNarrative Business Combinations (Details Narrative) Details http://oncocyte.com/role/BusinessCombinationsTables 39 false false R40.htm 00000040 - Disclosure - Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress (Details) Sheet http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress (Details) Details 40 false false R41.htm 00000041 - Disclosure - Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress (Details Narrative) Sheet http://oncocyte.com/role/Right-of-useAndFinancingLeaseAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress (Details Narrative) Details http://oncocyte.com/role/Right-of-useAndFinancingLeaseAssetsMachineryAndEquipmentNetAndConstructionInProgressTables 41 false false R42.htm 00000042 - Disclosure - Schedule of Goodwill and Intangible Assets (Details) Sheet http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails Schedule of Goodwill and Intangible Assets (Details) Details 42 false false R43.htm 00000043 - Disclosure - Schedule of Intangible Assets Future Amortization Expense (Details) Sheet http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails Schedule of Intangible Assets Future Amortization Expense (Details) Details 43 false false R44.htm 00000044 - Disclosure - Intangible Assets, Net (Details Narrative) Sheet http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative Intangible Assets, Net (Details Narrative) Details http://oncocyte.com/role/IntangibleAssetsNetTables 44 false false R45.htm 00000045 - Disclosure - Loan Payable to Silicon Valley Bank (Details Narrative) Sheet http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative Loan Payable to Silicon Valley Bank (Details Narrative) Details http://oncocyte.com/role/LoanPayableToSiliconValleyBank 45 false false R46.htm 00000046 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details) Sheet http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details) Details 46 false false R47.htm 00000047 - Disclosure - Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details) Sheet http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details) Details 47 false false R48.htm 00000048 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details) Sheet http://oncocyte.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details) Details 48 false false R49.htm 00000049 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://oncocyte.com/role/CommitmentsAndContingenciesTables 49 false false R50.htm 00000050 - Disclosure - Shareholders??? Equity (Details Narrative) Sheet http://oncocyte.com/role/ShareholdersEquityDetailsNarrative Shareholders??? Equity (Details Narrative) Details http://oncocyte.com/role/ShareholdersEquity 50 false false R51.htm 00000051 - Disclosure - Summary of Stock Option Activity (Details) Sheet http://oncocyte.com/role/SummaryOfStockOptionActivityDetails Summary of Stock Option Activity (Details) Details 51 false false R52.htm 00000052 - Disclosure - Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details) Sheet http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details) Details 52 false false R53.htm 00000053 - Disclosure - Summary of Stock-based Compensation Expense (Details) Sheet http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails Summary of Stock-based Compensation Expense (Details) Details 53 false false R54.htm 00000054 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://oncocyte.com/role/Stock-basedCompensationTables 54 false false R55.htm 00000055 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://oncocyte.com/role/RelatedPartyTransactions 55 false false R56.htm 00000056 - Disclosure - Co-Development Agreement with Life Technologies Corporation (Details Narrative) Sheet http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative Co-Development Agreement with Life Technologies Corporation (Details Narrative) Details http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporation 56 false false R57.htm 00000057 - Disclosure - Schedule of Discontinued Operations (Details) Sheet http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails Schedule of Discontinued Operations (Details) Details 57 false false R58.htm 00000058 - Disclosure - Schedule of Assets and Liabilities Discontinued Operations (Details) Sheet http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails Schedule of Assets and Liabilities Discontinued Operations (Details) Details 58 false false R59.htm 00000059 - Disclosure - Discontinued Operations of Razor (Details Narrative) Sheet http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative Discontinued Operations of Razor (Details Narrative) Details http://oncocyte.com/role/DiscontinuedOperationsOfRazorTables 59 false false All Reports Book All Reports form10-q.htm ocx-20230930.xsd ocx-20230930_cal.xml ocx-20230930_def.xml ocx-20230930_lab.xml ocx-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 76 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-q.htm": { "nsprefix": "OCX", "nsuri": "http://oncocyte.com/20230930", "dts": { "inline": { "local": [ "form10-q.htm" ] }, "schema": { "local": [ "ocx-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "ocx-20230930_cal.xml" ] }, "definitionLink": { "local": [ "ocx-20230930_def.xml" ] }, "labelLink": { "local": [ "ocx-20230930_lab.xml" ] }, "presentationLink": { "local": [ "ocx-20230930_pre.xml" ] } }, "keyStandard": 322, "keyCustom": 76, "axisStandard": 30, "axisCustom": 0, "memberStandard": 33, "memberCustom": 83, "hidden": { "total": 203, "http://oncocyte.com/20230930": 41, "http://fasb.org/us-gaap/2023": 158, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 336, "entityCount": 1, "segmentCount": 125, "elementCount": 667, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1051, "http://xbrl.sec.gov/dei/2023": 29 }, "report": { "R1": { "role": "http://oncocyte.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R2": { "role": "http://oncocyte.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R3": { "role": "http://oncocyte.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:PreferredStockNoParValue", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R4": { "role": "http://oncocyte.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:CostOfRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R5": { "role": "http://oncocyte.com/role/StatementsOfComprehensiveLoss", "longName": "00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R6": { "role": "http://oncocyte.com/role/StatementsOfShareholdersEquity", "longName": "00000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R7": { "role": "http://oncocyte.com/role/StatementsOfCashFlows", "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R8": { "role": "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity", "longName": "00000008 - Disclosure - Organization, Description of the Business and Liquidity", "shortName": "Organization, Description of the Business and Liquidity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R9": { "role": "http://oncocyte.com/role/SummaryOfSignificantAccountingPolicies", "longName": "00000009 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R10": { "role": "http://oncocyte.com/role/BusinessCombinations", "longName": "00000010 - Disclosure - Business Combinations", "shortName": "Business Combinations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R11": { "role": "http://oncocyte.com/role/Right-of-useAndFinancingLeaseAssetsMachineryAndEquipmentNetAndConstructionInProgress", "longName": "00000011 - Disclosure - Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress", "shortName": "Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R12": { "role": "http://oncocyte.com/role/IntangibleAssetsNet", "longName": "00000012 - Disclosure - Intangible Assets, Net", "shortName": "Intangible Assets, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R13": { "role": "http://oncocyte.com/role/LoanPayableToSiliconValleyBank", "longName": "00000013 - Disclosure - Loan Payable to Silicon Valley Bank", "shortName": "Loan Payable to Silicon Valley Bank", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R14": { "role": "http://oncocyte.com/role/CommitmentsAndContingencies", "longName": "00000014 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R15": { "role": "http://oncocyte.com/role/ShareholdersEquity", "longName": "00000015 - Disclosure - Shareholders\u2019 Equity", "shortName": "Shareholders\u2019 Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R16": { "role": "http://oncocyte.com/role/Stock-basedCompensation", "longName": "00000016 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R17": { "role": "http://oncocyte.com/role/IncomeTaxes", "longName": "00000017 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R18": { "role": "http://oncocyte.com/role/RelatedPartyTransactions", "longName": "00000018 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R19": { "role": "http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporation", "longName": "00000019 - Disclosure - Co-Development Agreement with Life Technologies Corporation", "shortName": "Co-Development Agreement with Life Technologies Corporation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "OCX:CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "OCX:CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R20": { "role": "http://oncocyte.com/role/DiscontinuedOperationsOfRazor", "longName": "00000020 - Disclosure - Discontinued Operations of Razor", "shortName": "Discontinued Operations of Razor", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R21": { "role": "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000021 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "OCX:AccountingPrinciplesPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "OCX:AccountingPrinciplesPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R22": { "role": "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "00000022 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "OCX:BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "OCX:BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R23": { "role": "http://oncocyte.com/role/BusinessCombinationsTables", "longName": "00000023 - Disclosure - Business Combinations (Tables)", "shortName": "Business Combinations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R24": { "role": "http://oncocyte.com/role/Right-of-useAndFinancingLeaseAssetsMachineryAndEquipmentNetAndConstructionInProgressTables", "longName": "00000024 - Disclosure - Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress (Tables)", "shortName": "Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R25": { "role": "http://oncocyte.com/role/IntangibleAssetsNetTables", "longName": "00000025 - Disclosure - Intangible Assets, Net (Tables)", "shortName": "Intangible Assets, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R26": { "role": "http://oncocyte.com/role/CommitmentsAndContingenciesTables", "longName": "00000026 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "OCX:ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "OCX:ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R27": { "role": "http://oncocyte.com/role/Stock-basedCompensationTables", "longName": "00000027 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R28": { "role": "http://oncocyte.com/role/DiscontinuedOperationsOfRazorTables", "longName": "00000028 - Disclosure - Discontinued Operations of Razor (Tables)", "shortName": "Discontinued Operations of Razor (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R29": { "role": "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "longName": "00000029 - Disclosure - Organization, Description of the Business and Liquidity (Details Narrative)", "shortName": "Organization, Description of the Business and Liquidity (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2021-07-012023-09-30_custom_BTIGLLCMember", "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R30": { "role": "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails", "longName": "00000030 - Disclosure - Schedule of Fair Value Measurement of Financial Assets and Liabilities (Details)", "shortName": "Schedule of Fair Value Measurement of Financial Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "OCX:BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "OCX:BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R31": { "role": "http://oncocyte.com/role/ScheduleOfDisaggregationOfRevenueDetails", "longName": "00000031 - Disclosure - Schedule of Disaggregation Of Revenue (Details)", "shortName": "Schedule of Disaggregation Of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30_custom_PharmaServicesMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "OCX:DisaggregationOfConsolidatedRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R32": { "role": "http://oncocyte.com/role/ScheduleOfConcentrationOfRiskDetails", "longName": "00000032 - Disclosure - Schedule of Concentration Of Risk (Details)", "shortName": "Schedule of Concentration Of Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_PharmaServicesMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R33": { "role": "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails", "longName": "00000033 - Disclosure - Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details)", "shortName": "Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_PharmaServicesCompanyAMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_PharmaServicesCompanyAMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R34": { "role": "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails", "longName": "00000034 - Disclosure - Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details)", "shortName": "Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30_country_US_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R35": { "role": "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails", "longName": "00000035 - Disclosure - Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details)", "shortName": "Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R36": { "role": "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000036 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "From2023-07-232023-07-24", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-232023-07-24", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R37": { "role": "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails", "longName": "00000037 - Disclosure - Schedule of Fair Value of Contingent Consideration Liability (Details)", "shortName": "Schedule of Fair Value of Contingent Consideration Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "OCX:ContingentConsiderationLiabilityContractualValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "OCX:ContingentConsiderationLiabilityContractualValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R38": { "role": "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails", "longName": "00000038 - Disclosure - Schedule of Contingent Consideration, Measured at Fair Value (Details)", "shortName": "Schedule of Contingent Consideration, Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "OCX:ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R39": { "role": "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative", "longName": "00000039 - Disclosure - Business Combinations (Details Narrative)", "shortName": "Business Combinations (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "OCX:FairValueOfContingentConsideration", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "OCX:FairValueOfContingentConsideration", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R40": { "role": "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails", "longName": "00000040 - Disclosure - Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress (Details)", "shortName": "Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:MachineryAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R41": { "role": "http://oncocyte.com/role/Right-of-useAndFinancingLeaseAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative", "longName": "00000041 - Disclosure - Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress (Details Narrative)", "shortName": "Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R42": { "role": "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails", "longName": "00000042 - Disclosure - Schedule of Goodwill and Intangible Assets (Details)", "shortName": "Schedule of Goodwill and Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R43": { "role": "http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails", "longName": "00000043 - Disclosure - Schedule of Intangible Assets Future Amortization Expense (Details)", "shortName": "Schedule of Intangible Assets Future Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R44": { "role": "http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative", "longName": "00000044 - Disclosure - Intangible Assets, Net (Details Narrative)", "shortName": "Intangible Assets, Net (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R45": { "role": "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative", "longName": "00000045 - Disclosure - Loan Payable to Silicon Valley Bank (Details Narrative)", "shortName": "Loan Payable to Silicon Valley Bank (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R46": { "role": "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails", "longName": "00000046 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)", "shortName": "Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30_custom_OperatingAndFinancingLeasesMember", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "OCX:ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R47": { "role": "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails", "longName": "00000047 - Disclosure - Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details)", "shortName": "Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "OCX:ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "OCX:ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R48": { "role": "http://oncocyte.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails", "longName": "00000048 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details)", "shortName": "Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "OCX:ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "OCX:ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R49": { "role": "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "00000049 - Disclosure - Commitments and Contingencies (Details Narrative)", "shortName": "Commitments and Contingencies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:RestrictedCash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:RestrictedCash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R50": { "role": "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "longName": "00000050 - Disclosure - Shareholders\u2019 Equity (Details Narrative)", "shortName": "Shareholders\u2019 Equity (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "From2022-01-012022-09-30", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ConversionOfStockDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R51": { "role": "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails", "longName": "00000051 - Disclosure - Summary of Stock Option Activity (Details)", "shortName": "Summary of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "AsOf2022-12-31_custom_TwoThousandTenPlanActivityMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_custom_TwoThousandTenPlanActivityMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R52": { "role": "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails", "longName": "00000052 - Disclosure - Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details)", "shortName": "Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-09-30_custom_EmployeeAndNonEmployeeMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R53": { "role": "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails", "longName": "00000053 - Disclosure - Summary of Stock-based Compensation Expense (Details)", "shortName": "Summary of Stock-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30_us-gaap_EmployeeStockOptionMember_custom_CostOfRevenuesMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R54": { "role": "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative", "longName": "00000054 - Disclosure - Stock-Based Compensation (Details Narrative)", "shortName": "Stock-Based Compensation (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-07-012022-07-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R55": { "role": "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "00000055 - Disclosure - Related Party Transactions (Details Narrative)", "shortName": "Related Party Transactions (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-09-30_custom_ArnoMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R56": { "role": "http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative", "longName": "00000056 - Disclosure - Co-Development Agreement with Life Technologies Corporation (Details Narrative)", "shortName": "Co-Development Agreement with Life Technologies Corporation (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "From2023-01-012023-09-30_custom_LifeTechnologiesCorporationMember", "name": "us-gaap:DevelopmentCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "OCX:CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-09-30_custom_LifeTechnologiesCorporationMember", "name": "us-gaap:DevelopmentCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "OCX:CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R57": { "role": "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails", "longName": "00000057 - Disclosure - Schedule of Discontinued Operations (Details)", "shortName": "Schedule of Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "From2022-07-012022-09-30", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-012022-09-30", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R58": { "role": "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails", "longName": "00000058 - Disclosure - Schedule of Assets and Liabilities Discontinued Operations (Details)", "shortName": "Schedule of Assets and Liabilities Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:Assets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R59": { "role": "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "longName": "00000059 - Disclosure - Discontinued Operations of Razor (Details Narrative)", "shortName": "Discontinued Operations of Razor (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "From2022-01-012022-09-30_us-gaap_CommonStockMember", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-02-162023-02-16_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember18928984", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } } }, "tag": { "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r730" ] }, "OCX_BankWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "BankWarrantMember", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Bank Warrant [Member]", "documentation": "Bank Warrant [Member]" } } }, "auth_ref": [] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r309", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r343", "r344", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r698", "r758", "r851" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails", "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of options outstanding, option granted", "verboseLabel": "Grants shares", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r411" ] }, "OCX_PercentageForWarrantExercisePricePerShare": { "xbrltype": "percentItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "PercentageForWarrantExercisePricePerShare", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage for warrant exercise price per share", "documentation": "Percentage for warrant exercise price per share." } } }, "auth_ref": [] }, "OCX_RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "RegisteredDirectOfferingMember", "presentation": [ "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Registered Direct Offering [Member]", "documentation": "Registered Direct Offering [Member]" } } }, "auth_ref": [] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cost of Revenues", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r759" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value Measurement of Financial Assets and Liabilities", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r471", "r472" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r307", "r308", "r590", "r591", "r592", "r654", "r657", "r661", "r664", "r671", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r688", "r703", "r719", "r802", "r851" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://oncocyte.com/role/ScheduleOfConcentrationOfRiskDetails", "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails", "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r59", "r62", "r107", "r108", "r309", "r672" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r747" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r55" ] }, "us-gaap_DevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DevelopmentCosts", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Development costs", "documentation": "The capitalized costs incurred during the period (excluded from amortization) to obtain access to proved reserves and to provide facilities for extracting, treating, gathering and storing the oil and gas." } } }, "auth_ref": [ "r517" ] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued expenses and other current liabilities", "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "OCX_DilutedEquityOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "DilutedEquityOutstanding", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Diluted equity outstanding", "documentation": "Diluted equity outstanding." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity" ], "lang": { "en-us": { "role": { "label": "Organization, Description of the Business and Liquidity", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r113", "r186", "r565", "r566" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r164", "r245" ] }, "OCX_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accretion of Series A convertible preferred stock to redemption value", "documentation": "Accretion of Series A convertible preferred stock to redemption value." } } }, "auth_ref": [] }, "OCX_PresentValueOfNetMinimumLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "PresentValueOfNetMinimumLeasePayments", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Present value of net minimum lease payments", "documentation": "Present value of net minimum lease payments.", "label": "Present value of net minimum lease payments" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "OCX_CapitalLeaseAgreementImputedAnnualInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "CapitalLeaseAgreementImputedAnnualInterestRate", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate on lease agreement", "documentation": "Refers to annual interest rate on capital lease agreement." } } }, "auth_ref": [] }, "OCX_CostOfRevenuesAmortizationOfAcquiredIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "CostOfRevenuesAmortizationOfAcquiredIntangibles", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of revenues \u2013 amortization of acquired intangibles", "documentation": "Cost of revenues &#8211; amortization of acquired intangibles." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "OCX_ObligatedToPayExpensesAndTaxesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ObligatedToPayExpensesAndTaxesPercentage", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Obligated to pay expenses and taxes percentage", "documentation": "Obligated to pay expenses and taxes percentage." } } }, "auth_ref": [] }, "OCX_DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Less: dividends and accretion of Series A redeemable convertible preferred stock", "documentation": "Dividends and Accretion of Series A Redeemable Convertible Preferred Stock." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://oncocyte.com/role/IntangibleAssetsNet" ], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r334" ] }, "OCX_RoyaltyOneMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "RoyaltyOneMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Royalty 1 [Member]", "documentation": "Royalty 1 [Member]" } } }, "auth_ref": [] }, "OCX_StockIssuedDuringPeriodValueVestingOfBonusAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "StockIssuedDuringPeriodValueVestingOfBonusAwards", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Vesting of bonus awards", "documentation": "Stock issued during period value vesting of bonus awards." } } }, "auth_ref": [] }, "OCX_DeemedDividendOnSeriesRedeemableConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "DeemedDividendOnSeriesRedeemableConvertiblePreferredStock", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Deemed dividend on Series A redeemable convertible preferred stock", "documentation": "Deemed dividend on Series A redeemable convertible preferred stock." } } }, "auth_ref": [] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" ], "auth_ref": [ "r307", "r308", "r590", "r591", "r592", "r654", "r657", "r661", "r664", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r688", "r703", "r719", "r802", "r851" ] }, "OCX_EquityCompensationForBonusAwardsAndConsultingServices": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "EquityCompensationForBonusAwardsAndConsultingServices", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Equity compensation for bonus awards and consulting services", "documentation": "Equity compensation for bonus awards and consulting services." } } }, "auth_ref": [] }, "OCX_DividendsRatePerPercentage": { "xbrltype": "percentItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "DividendsRatePerPercentage", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividends rate", "documentation": "Dividends rate per percentage." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows", "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Unrealized (loss) gain on marketable equity securities", "negatedLabel": "Unrealized (gain) loss on marketable equity securities", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": [ "r148" ] }, "OCX_ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Change in fair value of Series A redeemable convertible preferred stock second tranche obligation", "documentation": "Change in fair value of Series A redeemable convertible preferred stock second tranche obligation." } } }, "auth_ref": [] }, "OCX_RoyaltyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "RoyaltyTwoMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Royalty 2 [Member]", "documentation": "Royalty 2 [Member]" } } }, "auth_ref": [] }, "OCX_AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accrued severance and liabilities from Chronix Biomedical acquisition", "documentation": "Accrued Severance And Liabilities From Chronix Biomedical Acquisition." } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES" } } }, "auth_ref": [] }, "OCX_PaymentForCashSoldInDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "PaymentForCashSoldInDiscontinuedOperations", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash sold in discontinued operations (Note 13)", "documentation": "Cash sold in discontinued operations." } } }, "auth_ref": [] }, "OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice": { "xbrltype": "perShareItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average exercise price, options exercised", "documentation": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Vesting Price.", "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice" } } }, "auth_ref": [] }, "OCX_FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Financing costs to issue redeemable convertible Series A preferred shares", "documentation": "Change in fair value of Series A redeemable convertible preferred stock second tranche obligation.", "label": "FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares" } } }, "auth_ref": [] }, "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Shares available for grant options RSUs vested", "documentation": "Share based compensation arrangement by share based payment award options available restricted stock options vested in period." } } }, "auth_ref": [] }, "OCX_ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of common shares under at-the-market transactions", "documentation": "Proceeds from sale of common shares under At the market transactions." } } }, "auth_ref": [] }, "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of options outstanding, option RSUs vested", "documentation": "Share Based CompensationArrangement By Share Based Payment Award Restricted Stock Options Vested In Period" } } }, "auth_ref": [] }, "OCX_MergerAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "MergerAgreementMember", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Merger Agreement [Member]", "documentation": "Merger Agreement [Member]" } } }, "auth_ref": [] }, "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of RSUs Outstanding, option RSUs vested", "documentation": "Number of RSUs Outstanding, option RSUs vested." } } }, "auth_ref": [] }, "us-gaap_ConstructionInProgressGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressGross", "crdr": "debit", "calculation": { "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails": { "parentTag": "OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails" ], "lang": { "en-us": { "role": { "label": "Construction in progress", "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [ "r171" ] }, "OCX_PaymentForFinancingCostsForAtthemarketSales": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "PaymentForFinancingCostsForAtthemarketSales", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Financing costs for at-the-market sales", "documentation": "Payment For Financing Costs For Atthemarket Sales.", "label": "PaymentForFinancingCostsForAtthemarketSales" } } }, "auth_ref": [] }, "OCX_RepaymentOfFinancingLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "RepaymentOfFinancingLeaseObligations", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of financing lease obligations", "documentation": "Repayment Of Financing Lease Obligations.", "label": "RepaymentOfFinancingLeaseObligations" } } }, "auth_ref": [] }, "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Shares available for grant options RSUs granted", "documentation": "Share based compensation arrangement by share based payment award options available restricted stock options grants in period gross." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r80", "r81", "r82", "r83", "r84", "r85", "r86", "r179", "r180", "r181", "r224", "r225", "r226", "r281", "r363", "r364", "r366", "r368", "r371", "r376", "r378", "r568", "r569", "r570", "r571", "r701", "r748", "r775" ] }, "OCX_ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Construction in progress, machinery and equipment purchases included in accounts payable and accrued liabilities", "documentation": "Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability." } } }, "auth_ref": [] }, "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of options outstanding, option RSUs granted", "documentation": "Number of Options Outstanding, Option RSUs Granted." } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r224", "r225", "r226", "r281", "r363", "r364", "r366", "r368", "r371", "r376", "r378", "r568", "r569", "r570", "r571", "r701", "r748", "r775" ] }, "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of RSUs Outstanding, option RSUs granted", "documentation": "Number of RSUs Outstanding, option RSUs granted." } } }, "auth_ref": [] }, "OCX_ChronixBiomedicalIncMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ChronixBiomedicalIncMember", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chronix Biomedical Inc [Member]", "documentation": "Chronix Biomedical Inc [Member]" } } }, "auth_ref": [] }, "OCX_DisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "DisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract", "lang": { "en-us": { "role": { "label": "Co-development Agreement With Life Technologies Corporation" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfMachineryAndEquipment", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of equipment", "documentation": "The cash inflow from sale of machinery and equipment." } } }, "auth_ref": [ "r158" ] }, "OCX_CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock", "presentation": [ "http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporation" ], "lang": { "en-us": { "role": { "label": "Co-Development Agreement with Life Technologies Corporation", "documentation": "Co development agreementwith life technologies corporation [TextBlock]" } } }, "auth_ref": [] }, "OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, option RSUs granted", "documentation": "Share based compensation arrangements by share based payment award restricted stock grants in period weighted average exercise price." } } }, "auth_ref": [] }, "OCX_AccountingPrinciplesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "AccountingPrinciplesPolicyTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounting Principles", "documentation": "Accounting Principles [Policy Text Block]" } } }, "auth_ref": [] }, "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Shares available for grant options granted", "documentation": "Share Based Compensation Arrangement By Share based Payment Award Options Available Grants In Period Gross." } } }, "auth_ref": [] }, "OCX_SegmentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "SegmentsPolicyTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segments", "documentation": "Segments [Policy Text Block]" } } }, "auth_ref": [] }, "OCX_StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Shares available for grant options forfeited/expired", "documentation": "Stock issued during period shares stock options nonvested options forfeited." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r347", "r348", "r349", "r350", "r391", "r398", "r426", "r427", "r428", "r509", "r510", "r557", "r593", "r594", "r652", "r655", "r659", "r660", "r662", "r684", "r685", "r697", "r701", "r710", "r716", "r719", "r790", "r799", "r840", "r841", "r842", "r843", "r844" ] }, "OCX_UnderwriterMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "UnderwriterMember", "presentation": [ "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Underwriter [Member]", "documentation": "Underwriter [Member]" } } }, "auth_ref": [] }, "OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Shares available for grant RSUs forfeited/expired", "documentation": "Sharebased compensation arrangement by sharebased payment award options nonvested restricted stock options forfeited number of shares." } } }, "auth_ref": [] }, "OCX_ChronixEquityMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ChronixEquityMember", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chronix Equity [Member]", "documentation": "Chronix Equity [Member]" } } }, "auth_ref": [] }, "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of options outstanding, RSUs forfeited/expired", "documentation": "Sharebased compensation arrangement by sharebased payment award restricted stock units options forfeitures in period.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://oncocyte.com/role/BalanceSheetsParenthetical", "http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative", "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r250", "r251", "r252", "r280", "r514", "r567", "r589", "r595", "r596", "r597", "r598", "r599", "r600", "r603", "r606", "r607", "r608", "r609", "r610", "r612", "r613", "r614", "r615", "r617", "r618", "r619", "r620", "r621", "r623", "r626", "r627", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r645", "r720" ] }, "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of RSUs Outstanding, RSUs forfeited/expired", "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options restricted stock options forfeited.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited" } } }, "auth_ref": [] }, "OCX_DisaggregationOfConsolidatedRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "DisaggregationOfConsolidatedRevenueTableTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Disaggregation Of Revenue", "documentation": "Disaggregation Of Consolidated Revenue [Table Text Block]" } } }, "auth_ref": [] }, "OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, RSUs forfeited/expired", "documentation": "Sharebased compensation arrangements by sharebased payment award restricted stock units options forfeitures in period weighted average exercise price." } } }, "auth_ref": [] }, "OCX_BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements, Business Combinations and Contingent Consideration Liabilities", "documentation": "Business Combinations and Fair Value Measurements [Policy Text Block]" } } }, "auth_ref": [] }, "OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Shares available for grant performance RSUs forfeited/expired", "documentation": "Share based compensation arrangement by share based payment award options nonvested performance restricted stock options forfeited number of shares." } } }, "auth_ref": [] }, "OCX_ChronixMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ChronixMilestoneMember", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chronix Milestone [Member]", "documentation": "Chronix Milestone [Member]" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total", "label": "Total compensation paid", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r430", "r438" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r16" ] }, "OCX_SalesAndMarketingExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "SalesAndMarketingExpensesPolicyTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Sales and Marketing Expenses", "documentation": "Sales and Marketing Expenses [Policy Text Block]" } } }, "auth_ref": [] }, "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of options outstanding, performance RSUs forfeited/expired", "documentation": "Share based compensation arrangement by share based payment award performance restricted stock units options forfeitures in period.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r347", "r348", "r349", "r350", "r398", "r510", "r557", "r593", "r594", "r652", "r655", "r659", "r660", "r662", "r684", "r685", "r697", "r701", "r710", "r716", "r799", "r839", "r840", "r841", "r842", "r843", "r844" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r135", "r526", "r714" ] }, "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Performance RSUs Outstanding, performance RSUs forfeited/expired", "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options performance restricted stock options forfeited.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited" } } }, "auth_ref": [] }, "OCX_AccountingForWarrantsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "AccountingForWarrantsPolicyTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounting for Warrants", "documentation": "Accounting For Warrants [Policy Text Block]" } } }, "auth_ref": [] }, "OCX_PreferredStockRemainsOutstandingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "PreferredStockRemainsOutstandingPercentage", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock outstanding percentage", "documentation": "Preferred stock remains outstanding percentage." } } }, "auth_ref": [] }, "OCX_DetermaCNIAndVitaGraftMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "DetermaCNIAndVitaGraftMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "DetermaCNI and VitaGraft [Member]", "documentation": "DetermaCNI and VitaGraft [Member]" } } }, "auth_ref": [] }, "OCX_ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Contingent Consideration, Measured at Fair Value", "documentation": "Schedule of contingent consideration measured at fair value [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares issued price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentGross", "crdr": "debit", "calculation": { "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails" ], "lang": { "en-us": { "role": { "label": "Machinery and equipment", "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [ "r171" ] }, "OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, performance RSUs forfeited/expired", "documentation": "Share based compensation arrangements by share based payment award performance restricted stock units options forfeitures in period weighted average exercise price." } } }, "auth_ref": [] }, "OCX_MPEEMValuationApproachMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "MPEEMValuationApproachMember", "presentation": [ "http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "MPEEM Valuation Approach [Member]", "documentation": "MPEEM Valuation Approach [Member]" } } }, "auth_ref": [] }, "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Grant date fair value", "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value." } } }, "auth_ref": [] }, "OCX_ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases", "documentation": "Schedule of operating and finance lease balance sheet [TableTextBlock]" } } }, "auth_ref": [] }, "OCX_ChronixMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ChronixMember", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chronix [Member]", "documentation": "Chronix [Member]" } } }, "auth_ref": [] }, "OCX_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment", "crdr": "debit", "calculation": { "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development", "documentation": "Disposal group including discontinued operation research and development.", "label": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" } } }, "auth_ref": [] }, "OCX_ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Future Minimum Lease Commitments for Operating and Financing Leases", "documentation": "Schedule of future minimum lease commitments for operating and financing leases [Table Text Block]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r347", "r348", "r349", "r350", "r398", "r510", "r557", "r593", "r594", "r652", "r655", "r659", "r660", "r662", "r684", "r685", "r697", "r701", "r710", "r716", "r799", "r839", "r840", "r841", "r842", "r843", "r844" ] }, "OCX_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing", "crdr": "debit", "calculation": { "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Sales and marketing", "documentation": "Disposal group including discontinued operation sales and marketing.", "label": "DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing" } } }, "auth_ref": [] }, "OCX_ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease", "documentation": "Schedule of operating and finance lease cashflow [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Sale of common shares, net of financing costs", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "OCX_DeemedDividendOnPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "DeemedDividendOnPreferredStock", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Deemed dividend on Series A redeemable convertible preferred stock", "documentation": "Deemed dividend on preferred stock.", "label": "DeemedDividendOnPreferredStock" } } }, "auth_ref": [] }, "OCX_DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Machinery and equipment, net, and construction in progress", "documentation": "Disposal group including discontinued operation machinery and equipment.", "label": "DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment" } } }, "auth_ref": [] }, "OCX_DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Impairment of held for sale assets", "documentation": "Disposal group including discontinued operation impairment of held for sale assets." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Sale of common shares, net of financing costs, shares", "verboseLabel": "Issuance of shares", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "OCX_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedCompensation", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued compensation", "documentation": "Disposal group including discontinued operation accrued compensation.", "label": "DisposalGroupIncludingDiscontinuedOperationAccruedCompensation" } } }, "auth_ref": [] }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r127", "r161" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r16" ] }, "OCX_FairValueOfContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "FairValueOfContingentConsideration", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value", "documentation": "Fair value of contingent consideration." } } }, "auth_ref": [] }, "OCX_DetermaIOMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "DetermaIOMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "DetermaIO [Member]", "documentation": "DetermaI O [Member]" } } }, "auth_ref": [] }, "OCX_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses and other current liabilities", "documentation": "Disposal group including discontinued operation accrued expenses other current liabilities.", "label": "DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities" } } }, "auth_ref": [] }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r127", "r161" ] }, "OCX_CommonStockSharesHeldAsAvailableForSaleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "CommonStockSharesHeldAsAvailableForSaleSecurities", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares held as available for sale securities", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury) held by the entity as available for sale securities." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "OCX_OfficeLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "OfficeLeaseAgreementMember", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Office Lease Agreement [Member]", "documentation": "Office Lease Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "OCX_ContingentConsiderationLiabilityContractualValue": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ContingentConsiderationLiabilityContractualValue", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Contractual Value", "documentation": "Business Combination, Contingent Consideration, Liability Contractual value." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative", "http://oncocyte.com/role/BusinessCombinationsTables", "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails", "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r98", "r99", "r452", "r708", "r709" ] }, "OCX_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Change in estimated fair value", "documentation": "Change in estimated fair value." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r739", "r741", "r742" ] }, "OCX_EarnoutPercentageOnCollectionsForSales": { "xbrltype": "percentItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "EarnoutPercentageOnCollectionsForSales", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Earnout percentage on collections for sales", "documentation": "Earnout percentage on collections for sales." } } }, "auth_ref": [] }, "OCX_AmendedLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "AmendedLoanAgreementMember", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amended Loan Agreement [Member]", "documentation": "Amended Loan Agreement [Member]" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r309", "r704", "r802", "r851", "r852" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r740" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r39", "r110", "r524", "r602" ] }, "OCX_EarnoutPercentageOnCollectionsForSaleOrLicense": { "xbrltype": "percentItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "EarnoutPercentageOnCollectionsForSaleOrLicense", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Earnout percentage on collections for sale or license", "documentation": "Earnout percentage on collections for sale or license." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative", "http://oncocyte.com/role/BusinessCombinationsTables", "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails", "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r452", "r708", "r709" ] }, "OCX_EarnoutPercentageOnCollectionsForSale": { "xbrltype": "percentItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "EarnoutPercentageOnCollectionsForSale", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds percentage", "documentation": "Earnout percentage on collections for sale." } } }, "auth_ref": [] }, "OCX_RoyaltyPaymentsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "RoyaltyPaymentsPercentage", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Royalty payments", "documentation": "Royalty payments percentage." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "auth_ref": [ "r263", "r399", "r749", "r781" ] }, "OCX_LoanDeferralAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "LoanDeferralAgreementMember", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loan Deferral Agreement [Member]", "documentation": "Loan Deferral Agreement [Member]" } } }, "auth_ref": [] }, "OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "RightofuseAssetsMachineryAndEquipmentContinuingOperations", "crdr": "debit", "calculation": { "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Right-of-use and financing lease assets, machinery and equipment, net, and construction in progress", "documentation": "Right of use assets machinery and equipment continuing operations.", "label": "RightofuseAssetsMachineryAndEquipmentContinuingOperations" } } }, "auth_ref": [] }, "OCX_IndebtednessExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "IndebtednessExpenses", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Indebtedness expenses", "documentation": "Indebtedness expenses." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative", "http://oncocyte.com/role/BusinessCombinationsTables", "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails", "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r452" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative", "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r456" ] }, "us-gaap_AreaOfLand": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AreaOfLand", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Area of Land", "documentation": "Area of land held." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative", "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r456" ] }, "us-gaap_PaymentsForProceedsFromTenantAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromTenantAllowance", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total tenant improvement allowance", "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy." } } }, "auth_ref": [ "r44", "r159" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://oncocyte.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r340", "r342", "r630" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://oncocyte.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "auth_ref": [ "r342", "r630" ] }, "us-gaap_ImpairmentOfLeasehold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLeasehold", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/Right-of-useAndFinancingLeaseAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Asset impairment charges", "label": "Impairment of Leasehold", "documentation": "The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced." } } }, "auth_ref": [ "r17", "r76" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r138", "r181", "r530", "r561", "r563", "r572", "r604", "r714" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Asset impairment charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r17", "r76" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r493", "r713" ] }, "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposal", "label": "Equity Method Investment, Realized Gain (Loss) on Disposal", "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment." } } }, "auth_ref": [ "r769", "r770", "r773" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensation" ], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r400", "r403", "r431", "r432", "r433", "r711" ] }, "us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInDiscontinuedOperationsAbstract", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r241" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vested percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r803" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r241" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Financing lease", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r493", "r713" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails", "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r161", "r162", "r163" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current", "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r7", "r115", "r128", "r170", "r173" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r494" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-lived intangible assets, useful life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r494" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses and other current assets", "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current", "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r7", "r115", "r128", "r170", "r173" ] }, "us-gaap_AccountsReceivableSale": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableSale", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts receivable", "documentation": "Amount of decrease from sale of accounts receivable." } } }, "auth_ref": [ "r320" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r494" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r741" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r494" ] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Lease assets and liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r757", "r772" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r494" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828" ] }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRedeemedOrCalledDuringPeriodShares", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Redemption of SeriesA redeemable convertible preferred stock, shares", "verboseLabel": "Number of stock redeem, shares", "documentation": "Number of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": [ "r24" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2023", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r834" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r741" ] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 }, "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows", "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Impairment losses", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": [ "r773", "r788" ] }, "us-gaap_GainLossOnSaleOfOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfOtherAssets", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposal and held for sale assets", "label": "Gain (Loss) on Disposition of Other Assets", "documentation": "Amount of gain (loss) on sale or disposal of other assets." } } }, "auth_ref": [ "r773" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r742" ] }, "us-gaap_RedeemablePreferredStockDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemablePreferredStockDividends", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accretion of Series A redeemable convertible preferred stock", "label": "Redeemable Preferred Stock Dividends", "documentation": "Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r24", "r53", "r181" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r48", "r216", "r689" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Estimated useful life of plant and equipment", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r100" ] }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": [ "r484" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents and Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r49", "r189" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/Right-of-useAndFinancingLeaseAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Depreciation expense", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r17", "r77" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r211", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r309", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r341", "r343", "r344", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r698", "r758", "r851" ] }, "us-gaap_TemporaryEquitySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesIssued", "presentation": [ "http://oncocyte.com/role/BalanceSheetsParenthetical", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Temporary equity, shares issued", "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r134" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r71", "r74", "r515" ] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r106" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r284", "r297", "r303", "r305", "r696" ] }, "us-gaap_TemporaryEquityLiquidationPreference": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityLiquidationPreference", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Temporary equity, liquidation preference", "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r106" ] }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityParOrStatedValuePerShare", "presentation": [ "http://oncocyte.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Temporary equity, stated par value", "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable." } } }, "auth_ref": [ "r30", "r79" ] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesOutstanding", "presentation": [ "http://oncocyte.com/role/BalanceSheetsParenthetical", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Temporary equity, shares outstanding", "verboseLabel": "Temporary equity, shares oustanding", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r134" ] }, "OCX_DragonMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "DragonMember", "presentation": [ "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dragon [Member]", "documentation": "Dragon [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]", "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability." } } }, "auth_ref": [ "r87", "r183" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r208", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r686" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share based payment award description", "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance." } } }, "auth_ref": [ "r88", "r90" ] }, "OCX_MilestoneThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "MilestoneThreeMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Milestone 3 [Member]", "documentation": "Milestone 3 [Member]" } } }, "auth_ref": [] }, "OCX_MilestoneTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "MilestoneTwoMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Milestone 2 [Member]", "documentation": "Milestone 2 [Member]" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "OCX_RazorMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "RazorMember", "presentation": [ "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Razor [Member]", "documentation": "Razor [Member]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r214", "r229", "r247", "r316", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r457", "r459", "r474", "r714", "r795", "r796", "r837" ] }, "OCX_LineageAndAgeXMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "LineageAndAgeXMember", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lineage and AgeX [Member]", "documentation": "Lineage and AgeX [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecurityDeposit", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Security Deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": [ "r762" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r249", "r457", "r458", "r459", "r460", "r505", "r683", "r794", "r797", "r798" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r167" ] }, "OCX_PharmaServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "PharmaServicesMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfConcentrationOfRiskDetails", "http://oncocyte.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pharma Services [Member]", "documentation": "Pharma Services [Member]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r167" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r249", "r457", "r458", "r459", "r460", "r505", "r683", "r794", "r797", "r798" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets", "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r37", "r215", "r247", "r316", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r458", "r459", "r460", "r474", "r714", "r795", "r837", "r838" ] }, "OCX_MarketableEquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "MarketableEquitySecuritiesMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Marketable Equity Securities [Member]", "documentation": "Marketable Equity Securities [Member]" } } }, "auth_ref": [] }, "OCX_MedicareAndMedicareAdvantageMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "MedicareAndMedicareAdvantageMember", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Medicare And Medicare Advantage [Member]", "documentation": "Medicare And Medicare Advantage [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "OCX_PharmaServicesCustomersOneMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "PharmaServicesCustomersOneMember", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pharma Services Customers One [Member]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "2023", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "OCX_PharmaServicesCustomersTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "PharmaServicesCustomersTwoMember", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pharma Services Customers Two [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value of Contingent Consideration Liability", "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments." } } }, "auth_ref": [] }, "OCX_ContingentConsiderationLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ContingentConsiderationLiabilitiesMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Contingent Consideration Liabilities [Member]", "documentation": "Contingent Consideration Liabilities [Member]" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://oncocyte.com/role/ScheduleOfConcentrationOfRiskDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r306", "r514", "r551", "r552", "r553", "r554", "r555", "r556", "r687", "r702", "r715", "r758", "r792", "r793", "r802", "r851" ] }, "OCX_LaboratoryDevelopedTestServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "LaboratoryDevelopedTestServicesMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfConcentrationOfRiskDetails", "http://oncocyte.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Laboratory Developed Test Services [Member]", "documentation": "Laboratory Developed Test Services [Member]" } } }, "auth_ref": [] }, "OCX_PharmaServicesCompanyAMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "PharmaServicesCompanyAMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Pharma Services Company A [Member]", "documentation": "Pharma Services Company A [Member]" } } }, "auth_ref": [] }, "OCX_PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment": { "xbrltype": "percentItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of administrative fee paid on original cost of equipment", "documentation": "Percentage of administrative fee paid on original cost of equipment." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilities", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net deferred tax liabilities", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r97", "r829" ] }, "OCX_PharmaServicesCompanyBMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "PharmaServicesCompanyBMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Pharma Services Company B [Member]", "documentation": "Pharma Services Company B [Member]" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://oncocyte.com/role/ScheduleOfConcentrationOfRiskDetails" ], "auth_ref": [ "r306", "r514", "r551", "r552", "r553", "r554", "r555", "r556", "r687", "r702", "r715", "r758", "r792", "r793", "r802", "r851" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets", "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r35", "r247", "r316", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r458", "r459", "r460", "r474", "r601", "r695", "r727", "r795", "r837", "r838" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities of discontinuing operations", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r7", "r115", "r128", "r170", "r173", "r212", "r213" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r55" ] }, "OCX_PharmaServicesCompanyCMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "PharmaServicesCompanyCMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Pharma Services Company C [Member]", "documentation": "Pharma Services Company C [Member]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://oncocyte.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r135", "r363" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://oncocyte.com/role/BalanceSheets", "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "OCX_PharmaServicesCompanyDMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "PharmaServicesCompanyDMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Pharma Services Company D [Member]", "documentation": "Pharma Services Company D [Member]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r278" ] }, "OCX_OutsideUnitedStatesPharmaServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "OutsideUnitedStatesPharmaServicesMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" ], "lang": { "en-us": { "role": { "label": "Outside United States Pharma Services [Member]", "documentation": "Outside United States Pharma Services [Member]" } } }, "auth_ref": [] }, "OCX_UnitedStatesLaboratoryDevelopedTestServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "UnitedStatesLaboratoryDevelopedTestServicesMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" ], "lang": { "en-us": { "role": { "label": "United States Laboratory Developed Test Services [Member]", "documentation": "United States Laboratory Developed Test Services [Member]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "OCX_InsightMergerMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "InsightMergerMember", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative", "http://oncocyte.com/role/BusinessCombinationsTables", "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Insight Merger [Member]", "documentation": "Insight Merger [Member]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://oncocyte.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r135", "r603" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://oncocyte.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r135", "r603", "r622", "r855", "r856" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations", "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r67", "r150" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r16" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r16" ] }, "OCX_ChronixMergerMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ChronixMergerMember", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative", "http://oncocyte.com/role/BusinessCombinationsTables", "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Chronix Merger [Member]", "documentation": "Chronix Merger [Member]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r141", "r192", "r531", "r714", "r777", "r785", "r832" ] }, "us-gaap_IncreaseDecreaseInAssetsHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAssetsHeldForSale", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Assets held for sale", "label": "Increase (Decrease) in Asset, Held-for-Sale", "documentation": "The increase (decrease) during the period in book value of long-lived assets that the reporting entity plans to sell within one year (or one business cycle)." } } }, "auth_ref": [ "r16" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r784", "r835" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r735" ] }, "OCX_MilestoneOneMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "MilestoneOneMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Milestone 1 [Member]", "documentation": "Milestone 1 [Member]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Machinery and Equipment, Net, and Construction in Progress", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r18", "r203", "r206", "r532" ] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued royalties", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r36", "r691" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r17", "r77" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails", "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss attributable to common stockholders per share: basic", "verboseLabel": "Basic net loss per common share", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r238", "r255", "r256", "r257", "r258", "r259", "r264", "r267", "r275", "r276", "r277", "r279", "r469", "r470", "r520", "r539", "r694" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r515" ] }, "us-gaap_DebtInstrumentMaturityDateDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDateDescription", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument maturity date description", "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities." } } }, "auth_ref": [ "r38" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails", "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value on the Merger Date", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r4", "r101", "r454" ] }, "us-gaap_IndefinitelivedIntangibleAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefinitelivedIntangibleAssetsAcquired", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets acquired IPR&D", "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r335", "r336", "r337", "r338", "r515", "r516" ] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IPOMember", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r71", "r74" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "General and administrative", "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r126" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued liabilities from acquisition", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r5", "r101" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Contingent consideration liabilities", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r5", "r101" ] }, "OCX_VitaGraftMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "VitaGraftMember", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vita Graft [Member]", "documentation": "Vita Graft [Member]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r263", "r399", "r749", "r750", "r781" ] }, "OCX_MonthlyRentMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "MonthlyRentMember", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Monthly Rent [Member]", "documentation": "Monthly Rent [Member]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r746" ] }, "OCX_FirstTenCalendarMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "FirstTenCalendarMember", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "First Ten Calendar [Member]", "documentation": "First Ten Calendar [Member]" } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesBPreferredStockMember", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": [ "r763", "r764", "r801" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r487", "r491" ] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r147" ] }, "OCX_LeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "LeaseAgreementMember", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease Agreement [Member]", "documentation": "Lease Agreement [Member]" } } }, "auth_ref": [] }, "OCX_LandlordMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "LandlordMember", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Landlord [Member]", "documentation": "Landlord [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfComprehensiveLoss", "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Foreign currency translation adjustments", "verboseLabel": "Foreign currency translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r9" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Financing cash flows from financing leases", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r485", "r491" ] }, "OCX_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "LaboratoryEquipmentMember", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Laboratory Equipment [Member]", "documentation": "Laboratory Equipment [Member]" } } }, "auth_ref": [] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r313", "r314", "r315" ] }, "OCX_ExecutiveOfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ExecutiveOfficersMember", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Executive Officers [Member]", "documentation": "Executive Officers [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsSensitivityAnalysisDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsSensitivityAnalysisDescription", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative", "http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unobservable Measurement Input, Uncertainty, Description", "documentation": "Description of uncertainty of fair value measurement from use of unobservable input, including, but not limited to, inter-relationships among inputs used in fair value measurement." } } }, "auth_ref": [ "r28" ] }, "OCX_MarketBasedAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "MarketBasedAwardsMember", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Market Based Awards [Member]", "documentation": "Market Based Awards [Member]" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Marketable equity securities", "verboseLabel": "Marketable equity securities fair value", "terseLabel": "Fair value of equity securities", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r222", "r473", "r690" ] }, "OCX_OperatingAndFinancingLeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "OperatingAndFinancingLeasesMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating and Financing Leases [Member]", "documentation": "Operating and Financing Leases [Member]" } } }, "auth_ref": [] }, "OCX_InvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "InvestorsMember", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investors [Member]", "documentation": "Investors [Member]" } } }, "auth_ref": [] }, "OCX_BoardMembersMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "BoardMembersMember", "presentation": [ "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Board Members [Member]", "documentation": "Board Members [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "OCX_OncocyteCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "OncocyteCorpMember", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Oncocyte Corp [Member]", "documentation": "Oncocyte Corp [Member]" } } }, "auth_ref": [] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDomain", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative", "http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r25" ] }, "OCX_SecurityMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "SecurityMember", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Security [Member]", "documentation": "Security [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "OCX_InterestMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "InterestMember", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest [Member]", "documentation": "Interest [Member]" } } }, "auth_ref": [] }, "OCX_TwoThousandEighteenIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "TwoThousandEighteenIncentivePlanMember", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2018 Incentive Plan [Member]", "documentation": "2018 Incentive Plan [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://oncocyte.com/role/BalanceSheetsParenthetical", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r209", "r224", "r225", "r226", "r247", "r267", "r268", "r275", "r277", "r281", "r282", "r316", "r351", "r353", "r354", "r355", "r358", "r359", "r363", "r364", "r368", "r371", "r378", "r474", "r568", "r569", "r570", "r571", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r589", "r603", "r625", "r645", "r665", "r666", "r667", "r668", "r669", "r748", "r775", "r783" ] }, "OCX_AprilTwoThousandTwentyTwoWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "AprilTwoThousandTwentyTwoWarrantsMember", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "April 2022 Warrants [Member]", "documentation": "April 2022 Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueAxis", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative", "http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r25" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other (expenses) income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r157" ] }, "OCX_TwoThousandTenStockOptionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "TwoThousandTenStockOptionPlanMember", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2010 Stock Option Plan [Member]", "documentation": "2010 Stock Option Plan [Member]" } } }, "auth_ref": [] }, "OCX_MonteCarloValuationTechniqueMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "MonteCarloValuationTechniqueMember", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Monte Carlo Valuation Technique [Member]", "documentation": "Monte Carlo Valuation Technique [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "OCX_PerformanceBasedOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "PerformanceBasedOptionsMember", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Performance-Based Options [Member]", "documentation": "Performance-Based Options [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "OCX_ExecutiveOfficersAndEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ExecutiveOfficersAndEmployeesMember", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Executive Officers And Employees [Member]", "documentation": "Executive Officers And Employees [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r672" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails", "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expected life (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r425" ] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Series A Redeemable Convertible Preferred Stock, no par value; stated value $1,000 per share; 5 and 6 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively; aggregate liquidation preference of $5,217 and $6,091 as of September 30, 2023 and December 31, 2022, respectively", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r351", "r353", "r354", "r355", "r358", "r359", "r437", "r528" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r200", "r762", "r774" ] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r761", "r774", "r846", "r848" ] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://oncocyte.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r248", "r441", "r442", "r443", "r444", "r447", "r448", "r450", "r451", "r573" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, option granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r411" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "CURRENT ASSETS" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "NET CHANGE IN CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r6", "r161" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Consolidated Revenues Generated by Unaffiliated Customers", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r802" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, options exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r412" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH, BEGINNING", "periodEndLabel": "CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH, ENDING", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r48", "r161", "r244" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, options forfeited/expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r413" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of RSUs Outstanding, options forfeited/expired", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r420" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative", "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of RSUs Outstanding, option granted", "verboseLabel": "Stock option grant", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r418" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of RSUs Outstanding, beginning of period", "periodEndLabel": "Number of RSUs Outstanding, end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r415", "r416" ] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Number of options outstanding, exercisable, end of period", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": [ "r95" ] }, "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Net loss attributable to Oncocyte Corporation", "documentation": "Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments." } } }, "auth_ref": [ "r152", "r768" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share based payment award vesting rights description", "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r91" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://oncocyte.com/role/ScheduleOfConcentrationOfRiskDetails", "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails", "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r59", "r62", "r107", "r108", "r309", "r672", "r754" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional paid in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r137", "r714", "r854" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative", "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r456" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r742" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r712" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-lived intangible assets, accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r219", "r337" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares available for grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r89" ] }, "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument, final payment", "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r64", "r65", "r66", "r201", "r202", "r204", "r205" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails", "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding: diluted", "verboseLabel": "Weighted average number of shares outstanding, diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r266", "r277" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of options outstanding, options forfeited/expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r413" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r41", "r42", "r142", "r227", "r529", "r562", "r563" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value grants", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r421" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails", "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding: basic", "verboseLabel": "Weighted average number of shares outstanding, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r264", "r277" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r78", "r217", "r533" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of options outstanding, beginning of period", "periodEndLabel": "Number of options outstanding, end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r407", "r408" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetResidualValue", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Acquired intangible assets", "documentation": "The aggregate expected value at the end of their useful life of a major finite-lived intangible asset class acquired during the period either individually or as part of a group of assets (in either an asset acquisition or business combination). A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r72" ] }, "OCX_OtherInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "OtherInvestorsMember", "presentation": [ "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Other Investors [Member]", "documentation": "Other Investors [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price, options outstanding, beginning of period", "periodEndLabel": "Weighted average exercise price, outstanding end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r407", "r408" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails", "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r360", "r392", "r393", "r394", "r395", "r396", "r397", "r506", "r507", "r508", "r699", "r700", "r705", "r706", "r707" ] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Repayments of lines of credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r47", "r776" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails", "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r427" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails", "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Volatility", "verboseLabel": "Expected Volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r426" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails", "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rates", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r428" ] }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Machinery and equipment", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r751" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expenses", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r439" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated depreciation", "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization", "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease." } } }, "auth_ref": [ "r752", "r756" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative", "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative", "http://oncocyte.com/role/Stock-basedCompensationTables", "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails", "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r401", "r402", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative", "http://oncocyte.com/role/Stock-basedCompensationTables", "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails", "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r401", "r402", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://oncocyte.com/role/ScheduleOfConcentrationOfRiskDetails", "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails", "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Product Information [Table]", "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://oncocyte.com/role/BusinessCombinations" ], "lang": { "en-us": { "role": { "label": "Business Combinations", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r185", "r453" ] }, "OCX_PaymentObligationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "PaymentObligationAmount", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payment obligation amount.", "documentation": "Payment obligation amount." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r488" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r743" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Financing costs to issue common shares", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r45" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r102", "r692" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/BalanceSheetsParenthetical", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, allowance for credit loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r228", "r312", "r319", "r321", "r322", "r849" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r176", "r345", "r346", "r673", "r791" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "calculation": { "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cost of revenues", "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r126", "r213" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r741" ] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r719" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts", "verboseLabel": "Preferred stock offering", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r24", "r135", "r136", "r181", "r577", "r645", "r666", "r726" ] }, "OCX_RazorGenomicsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "RazorGenomicsIncMember", "presentation": [ "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Razor Genomics, Inc. [Member]", "documentation": "Razor Genomics, Inc. [Member]" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of restricted stock awards, value", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r24", "r135", "r136", "r181" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r18" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued upon vesting of RSU, net of shares retired to pay employees\u2019 taxes", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r24", "r181" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r60", "r309" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://oncocyte.com/role/ScheduleOfConcentrationOfRiskDetails", "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails", "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total", "verboseLabel": "Pharma services - Company D", "terseLabel": "Concentration risk percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r59", "r62", "r107", "r108", "r309" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "calculation": { "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net revenue", "label": "Disposal Group, Including Discontinued Operation, Revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r126", "r213" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://oncocyte.com/role/BalanceSheetsParenthetical", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r136" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "SHAREHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/StatementsOfShareholdersEquity", "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares", "verboseLabel": "Share based awards vesting", "terseLabel": "Number of shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r24", "r135", "r136", "r181", "r568", "r645", "r666" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Purchase of warrant", "verboseLabel": "Warrants to purchase, shares", "terseLabel": "Number of common stock purchase warrants", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r379" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r360", "r392", "r397", "r472", "r507", "r699", "r700", "r705", "r706", "r707" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease term", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r833" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://oncocyte.com/role/ShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r178", "r246", "r362", "r364", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r377", "r380", "r467", "r648", "r650", "r670" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r730" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, no par value, 230,000 shares authorized; 8,261 and 5,932 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r136", "r527", "r714" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r360", "r392", "r397", "r472", "r506", "r705", "r706", "r707" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets", "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r190", "r221", "r247", "r284", "r298", "r304", "r316", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r457", "r459", "r474", "r523", "r616", "r714", "r727", "r795", "r796", "r837" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://oncocyte.com/role/BalanceSheetsParenthetical", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r136", "r603" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining lease term, Operating lease", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r492", "r713" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative", "http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails", "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OverAllotmentOptionMember", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Over-Allotment Option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://oncocyte.com/role/DiscontinuedOperationsOfRazorTables", "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Reverse stock split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r182" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://oncocyte.com/role/BalanceSheetsParenthetical", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r24", "r136", "r603", "r622", "r855", "r856" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails", "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r360", "r392", "r393", "r394", "r395", "r396", "r397", "r472", "r508", "r699", "r700", "r705", "r706", "r707" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r24", "r40", "r210", "r234", "r235", "r236", "r250", "r251", "r252", "r254", "r260", "r262", "r280", "r317", "r318", "r380", "r434", "r435", "r436", "r445", "r446", "r461", "r462", "r463", "r464", "r465", "r466", "r468", "r475", "r476", "r477", "r478", "r479", "r480", "r498", "r558", "r559", "r560", "r577", "r645" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://oncocyte.com/role/DiscontinuedOperationsOfRazorTables", "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r19", "r29", "r31", "r115", "r121", "r122", "r123", "r124", "r125", "r129", "r131", "r132", "r174" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative", "http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails", "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of restricted stock awards, shares", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r24", "r181" ] }, "OCX_AtTheMarketSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "AtTheMarketSalesAgreementMember", "presentation": [ "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "At The Market Sales Agreement [Member]", "documentation": "At The Market Sales Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r210", "r250", "r251", "r252", "r254", "r260", "r262", "r317", "r318", "r434", "r435", "r436", "r445", "r446", "r461", "r463", "r464", "r466", "r468", "r558", "r560", "r577", "r855" ] }, "us-gaap_DiscontinuedOperationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsPolicyTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Assets Held for Sale", "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation." } } }, "auth_ref": [ "r19", "r32" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r24", "r210", "r234", "r235", "r236", "r250", "r251", "r252", "r254", "r260", "r262", "r280", "r317", "r318", "r380", "r434", "r435", "r436", "r445", "r446", "r461", "r462", "r463", "r464", "r465", "r466", "r468", "r475", "r476", "r477", "r478", "r479", "r480", "r498", "r558", "r559", "r560", "r577", "r645" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued upon vesting of RSU, shares", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r24", "r135", "r136", "r181" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r730" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of options outstanding, option exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r24", "r135", "r136", "r181", "r412" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued for consultant services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued for consultant services, shares", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r8", "r23", "r42", "r462", "r465", "r498", "r558", "r559", "r766", "r767", "r768", "r778", "r779", "r780" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of credit facility, maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r34" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total minimum lease payments", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r494" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r88" ] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRent", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payments for rent", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": [ "r15" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Inventory write down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r323" ] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://oncocyte.com/role/DiscontinuedOperationsOfRazorTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Assets and Liabilities Discontinued Operations", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r19", "r29", "r31", "r115", "r121", "r122", "r123", "r124", "r125", "r129", "r131", "r132", "r174" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2024", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r494" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Summary of Stock-based Compensation Expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r96" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r494" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r494" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r494" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2023", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r834" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r33", "r714" ] }, "us-gaap_ScheduleOfCreditDerivativesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCreditDerivativesTable", "presentation": [ "http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Credit Derivatives [Table]", "documentation": "Schedule of credit derivatives, including information about each credit derivative, or each group of similar credit derivatives, including (a) the nature of the credit derivative - its term, how it arose, the events or circumstances that would require the seller to perform under the credit derivative, and the current status of the payment/performance risk of the credit derivative; (b) the maximum potential amount of future payments (undiscounted) the seller could be required to make under the credit derivative; (c) the current fair value of the credit derivative; and (d) the nature of any recourse provisions under the credit derivative, and any assets held either as collateral or by third parties." } } }, "auth_ref": [ "r103", "r104", "r105" ] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Operating cash flows from financing leases", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r486", "r491" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails", "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss attributable to common stockholders per share: diluted", "verboseLabel": "Earnings Per Share, diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r238", "r255", "r256", "r257", "r258", "r259", "r267", "r275", "r276", "r277", "r279", "r469", "r470", "r520", "r539", "r694" ] }, "us-gaap_CreditDerivativesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditDerivativesLineItems", "presentation": [ "http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Credit Derivatives [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less amounts representing interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r494" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://oncocyte.com/role/DiscontinuedOperationsOfRazor" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations of Razor", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r114", "r168" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r483" ] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalFees", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal fees", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": [ "r154" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Concentration Of Risk", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r58", "r59", "r62", "r63", "r107", "r188" ] }, "OCX_BTIGLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "BTIGLLCMember", "presentation": [ "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "BTIG, LLC [Member]", "documentation": "BTIG, LLC [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-use lease liabilities, noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r483" ] }, "us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Increase in fair value", "documentation": "Amount of increase (decrease) in fair value adjustment on other assets (liabilities) carried at fair value under the fair value option on the statement of cash flows of Federal Home Loan Banks (FHLBanks)." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other noncurrent assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r220" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-use lease liabilities, current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r483" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued compensation", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative", "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r456" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r717", "r718", "r719", "r721", "r722", "r723", "r724", "r778", "r779", "r830", "r853", "r855" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining lease term, Financing lease", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r492", "r713" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://oncocyte.com/role/Right-of-useAndFinancingLeaseAssetsMachineryAndEquipmentNetAndConstructionInProgressTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r18" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of revenues", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r153", "r247", "r316", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r474", "r795" ] }, "OCX_RightOfUseAndFinancingLeaseLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "RightOfUseAndFinancingLeaseLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Right-of-use and financing lease liabilities, noncurrent", "documentation": "Right-of-use and financing lease liabilities, noncurrent." } } }, "auth_ref": [] }, "OCX_AccruedSeveranceFromAcquisitionCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "AccruedSeveranceFromAcquisitionCurrent", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued severance from acquisition", "documentation": "Accrued severance from acquisition current." } } }, "auth_ref": [] }, "OCX_DetermalOMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "DetermalOMember", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Determal O [Member]", "documentation": "Determal O [Member]" } } }, "auth_ref": [] }, "OCX_DetermaCNIMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "DetermaCNIMember", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Determa CNI [Member]", "documentation": "Determa CNI [Member]" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash in hand", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r199", "r525", "r588", "r611", "r714", "r727", "r761" ] }, "OCX_DragonScientificLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "DragonScientificLLCMember", "presentation": [ "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dragon Scientific LLC [Member]", "documentation": "Dragon Scientific LLC [Member]" } } }, "auth_ref": [] }, "OCX_TwoThousandTenPlanActivityMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "TwoThousandTenPlanActivityMember", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationTables", "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "2010 Plan Activity [Member]", "documentation": "2010 Plan Activity [Member]" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "OCX_TwoThousandEighteenPalnActivityMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "TwoThousandEighteenPalnActivityMember", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "2018 Paln Activity [Member]", "documentation": "2018 Paln Activity [Member]" } } }, "auth_ref": [] }, "OCX_EmployeeAndNonEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "EmployeeAndNonEmployeeMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Employee And Non Employee [Member]", "documentation": "Employee And Non Employee [Member]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r7", "r115", "r128", "r173" ] }, "OCX_CostOfRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "CostOfRevenuesMember", "presentation": [ "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Cost Of Revenues [Member]" } } }, "auth_ref": [] }, "OCX_BroadwoodCapitalLPMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "BroadwoodCapitalLPMember", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Broadwood Capital LP [Member]", "documentation": "Broadwood Capital LP [Member]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r489" ] }, "OCX_UnderwrittenOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "UnderwrittenOfferingMember", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Underwritten Offering [Member]", "documentation": "Underwritten Offering [Member]" } } }, "auth_ref": [] }, "OCX_RazorStockPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "RazorStockPurchaseAgreementMember", "presentation": [ "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Razor Stock Purchase Agreement [Member]", "documentation": "Razor Stock Purchase Agreement [Member]" } } }, "auth_ref": [] }, "OCX_TemporaryEquityNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "TemporaryEquityNoParValue", "presentation": [ "http://oncocyte.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Temporary equity, no par value", "documentation": "Temporary equity no par value." } } }, "auth_ref": [] }, "OCX_PuraVidaInvestmentsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "PuraVidaInvestmentsLLCMember", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pura Vida Investments LLC [Member]", "documentation": "Pura Vida Investments LLC [Member]" } } }, "auth_ref": [] }, "OCX_UnderwritersMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "UnderwritersMember", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Underwriters [Member]", "documentation": "Underwriters [Member]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets, net", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Current", "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r7", "r115", "r128", "r170", "r173" ] }, "OCX_RightOfUseAndFinancingLeaseLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "RightOfUseAndFinancingLeaseLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Right-of-use and financing lease liabilities, current", "documentation": "Right-of-use and financing lease liabilities, current." } } }, "auth_ref": [] }, "OCX_MrGutfreundMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "MrGutfreundMember", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mr Gutfreund [Member]", "documentation": "Mr Gutfreund [Member]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r717", "r718", "r721", "r722", "r723", "r724", "r853", "r855" ] }, "OCX_HalleSpecialSituationsFundLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "HalleSpecialSituationsFundLLCMember", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Halle Special Situations Fund LLC [Member]", "documentation": "Halle Special Situations Fund LLC [Member]" } } }, "auth_ref": [] }, "OCX_BroadwoodPartnersLPMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "BroadwoodPartnersLPMember", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Broadwood Partners LP [Member]", "documentation": "Broadwood Partners LP [Member]" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://oncocyte.com/role/BalanceSheetsParenthetical", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r209", "r224", "r225", "r226", "r247", "r267", "r268", "r275", "r277", "r281", "r282", "r316", "r351", "r353", "r354", "r355", "r358", "r359", "r363", "r364", "r368", "r371", "r378", "r474", "r568", "r569", "r570", "r571", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r589", "r603", "r625", "r645", "r665", "r666", "r667", "r668", "r669", "r748", "r775", "r783" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r489" ] }, "OCX_SeriesARedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "SeriesARedeemableConvertiblePreferredStockMember", "presentation": [ "http://oncocyte.com/role/BalanceSheetsParenthetical", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Series A Redeemable Convertible Preferred Stock [Member]", "documentation": "Series A Redeemable Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "OCX_AVMMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "AVMMember", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "AVM [Member]", "documentation": "AVM [Member]" } } }, "auth_ref": [] }, "OCX_PuraVidaMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "PuraVidaMember", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pura Vida [Member]", "documentation": "Pura Vida [Member]" } } }, "auth_ref": [] }, "OCX_ArnoMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ArnoMember", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Arno [Member]", "documentation": "Arno [Member]" } } }, "auth_ref": [] }, "OCX_MachineryAndEquipmentNetAndConstructionInProgress": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "MachineryAndEquipmentNetAndConstructionInProgress", "crdr": "debit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Machinery and equipment, net, and construction in progress", "documentation": "Machinery and equipment net and construction in progress." } } }, "auth_ref": [] }, "OCX_LifeTechnologiesCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "LifeTechnologiesCorporationMember", "presentation": [ "http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Life Technologies Corporation [Member]", "documentation": "Life Technologies Corporation [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock", "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share." } } }, "auth_ref": [ "r54", "r57", "r782" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative", "http://oncocyte.com/role/BusinessCombinationsTables", "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails", "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r98", "r99", "r452" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r742" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of Series A redeemable convertible preferred stock, net of financing costs", "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r24", "r40", "r181" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": [ "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of Series A redeemable convertible preferred stock, net of financing costs, shares", "verboseLabel": "Convertible preferred shares", "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r24", "r83", "r135", "r136", "r181" ] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductConcentrationRiskMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfConcentrationOfRiskDetails", "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" ], "lang": { "en-us": { "role": { "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": [ "r61" ] }, "us-gaap_LesseeOperatingSubleaseResidualValueGuaranteeDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingSubleaseResidualValueGuaranteeDescription", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "lessee, operating sublease, residual value guarantee, description", "documentation": "Description of terms and conditions of residual value guarantee provided by sublessee for operating sublease." } } }, "auth_ref": [ "r490" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Net loss attributable to common stockholders - diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r239", "r266", "r269", "r270", "r271", "r272", "r274", "r277" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r55" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r730" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Net Loss Per Common Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r55", "r56" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Summary of Stock Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r26", "r27", "r93" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, net of allowance for credit losses of $178 and $154, respectively", "verboseLabel": "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r310", "r311" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Assumptions Used to Calculate Fair Value of Stock Options", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r184" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRedeemedOrCalledDuringPeriodValue", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Redemption of Series A redeemable convertible preferred stock", "verboseLabel": "Net proceeds to immediately redeem", "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": [ "r24" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative", "http://oncocyte.com/role/Stock-basedCompensationTables", "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r151", "r247", "r284", "r297", "r303", "r305", "r316", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r474", "r696", "r795" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LinesOfCreditCurrent", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of credit, current", "verboseLabel": "Line of Credit, Current", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r133", "r191" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Long-Lived Intangible Assets", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r74", "r511", "r512", "r513", "r515", "r693" ] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r20", "r68" ] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendRatePercentage", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, dividend rate, percentage", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": [ "r364", "r653", "r656", "r658", "r663" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r745" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative", "http://oncocyte.com/role/Stock-basedCompensationTables", "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r729" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r730" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative", "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r728" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r730" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassifications", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r760" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r240", "r242", "r243" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from continuing operations", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r144", "r194", "r284", "r297", "r303", "r305", "r521", "r535", "r696" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r741" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r730" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r732" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r744" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails": { "parentTag": "OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Right-of-use assets and machinery and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r18", "r522", "r534", "r714" ] }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate", "documentation": "The effective interest rate at the end of the reporting period." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Valuation Technique, Discounted Cash Flow [Member]", "documentation": "Valuation technique calculating present value of future cash flows." } } }, "auth_ref": [ "r831" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r765" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative", "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of intangible assets", "verboseLabel": "Intangible asset amortization expense", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r17", "r70", "r75" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets", "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r69", "r73" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsPolicy", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Investments in Capital Stock of Privately Held Companies", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": [ "r14", "r109", "r314" ] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesPolicy", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Marketable Equity Securities", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r111" ] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of debt issuance costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r149", "r361", "r481", "r773" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r736" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r738" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r166", "r515" ] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r763", "r764", "r801" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r218", "r324", "r518", "r698", "r714", "r786", "r787" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant exercise price, per share", "verboseLabel": "Warrant exercise price per share", "terseLabel": "Warrant exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r379" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://oncocyte.com/role/DiscontinuedOperationsOfRazorTables", "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds from offering", "verboseLabel": "Cash received on stock transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of common stock sold", "verboseLabel": "Sale of stock, shares", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://oncocyte.com/role/DiscontinuedOperationsOfRazorTables", "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r212" ] }, "us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentDescriptionOfPrincipalActivities", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity method investment, description of principal activities", "documentation": "A description of the principal activities of an investee accounted for under the equity method." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of stock, price per share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://oncocyte.com/role/ScheduleOfConcentrationOfRiskDetails", "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails", "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r59", "r62", "r107", "r108", "r309", "r672" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity interest", "verboseLabel": "Ownership percentage", "terseLabel": "Equity method investment ownership percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r313" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://oncocyte.com/role/ScheduleOfConcentrationOfRiskDetails", "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails", "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r59", "r62", "r107", "r108", "r309", "r564", "r672" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted average exercise price, exercisable, end of period", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding." } } }, "auth_ref": [ "r94" ] }, "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax", "crdr": "debit", "calculation": { "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Loss from impairment of held for sale assets", "documentation": "Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale attributable to noncontrolling interest. Excludes discontinued operations." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "OCX_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "SecuritiesPurchaseAgreementMember", "presentation": [ "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement [Member]", "documentation": "Securities Purchase Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss from continuing operations per share: basic", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r143", "r193", "r195", "r238", "r253", "r255", "r256", "r257", "r258", "r267", "r275", "r276", "r470", "r520", "r850" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r347", "r348", "r349", "r350", "r391", "r398", "r426", "r427", "r428", "r509", "r510", "r557", "r593", "r594", "r652", "r655", "r659", "r660", "r662", "r684", "r685", "r697", "r701", "r710", "r716", "r719", "r790", "r799", "r840", "r841", "r842", "r843", "r844" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails", "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-use assets", "verboseLabel": "Right-of-use assets, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r482" ] }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds, closing", "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation." } } }, "auth_ref": [ "r10" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss from continuing operations per share: diluted", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r143", "r238", "r253", "r255", "r256", "r257", "r258", "r267", "r275", "r276", "r277", "r470", "r520", "r850" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r18" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 }, "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails", "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Loss from discontinuing operations", "totalLabel": "Net loss from discontinued operations", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r116", "r117", "r118", "r119", "r120", "r130", "r213", "r449", "r536" ] }, "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDescriptionOfTransaction", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related party transaction, description", "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates." } } }, "auth_ref": [ "r198", "r223", "r495", "r496", "r497", "r501" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://oncocyte.com/role/BalanceSheets", "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss from discontinuing operations per share: diluted", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": [ "r187", "r268", "r275", "r276" ] }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent", "crdr": "debit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets held for sale", "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r169", "r714" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets of discontinuing operations", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r7", "r115", "r128", "r170", "r173", "r212", "r213" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares available for grant options, beginning of period", "periodEndLabel": "Shares available for grant outstanding, end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-Based Compensation", "label": "Compensation Related Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": [ "r92" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss from discontinuing operations per share: basic", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": [ "r145", "r238", "r268", "r275", "r276", "r847", "r850" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Shares available for grant options exercised", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r734" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets", "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-use and financing lease assets, net", "totalLabel": "Machinery and equipment, net", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r482" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "presentation": [ "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Shares available for grant options forfeited, cancelled and expired", "documentation": "Number of non-vested options forfeited." } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://oncocyte.com/role/BalanceSheetsParenthetical", "http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative", "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r250", "r251", "r252", "r280", "r514", "r567", "r589", "r595", "r596", "r597", "r598", "r599", "r600", "r603", "r606", "r607", "r608", "r609", "r610", "r612", "r613", "r614", "r615", "r617", "r618", "r619", "r620", "r621", "r623", "r626", "r627", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r645", "r720" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfConcentrationOfRiskDetails", "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails", "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r309", "r753" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r499", "r500", "r501", "r503", "r504", "r574", "r575", "r576", "r628", "r629", "r630", "r649", "r651" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "OCX_UnderwritingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "UnderwritingAgreementMember", "presentation": [ "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Underwriting Agreement [Member]", "documentation": "Underwriting Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative", "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of common shares", "verboseLabel": "Proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r10" ] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative", "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Business combination consideration transferred", "verboseLabel": "Consideration transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r2", "r3", "r22" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net revenue", "verboseLabel": "Total", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r285", "r286", "r296", "r301", "r302", "r306", "r307", "r309", "r389", "r390", "r514" ] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Severance cost", "verboseLabel": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r17" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net proceeds", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r10", "r568" ] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposal and held for sale assets", "label": "Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r773" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://oncocyte.com/role/StatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r43", "r231", "r233", "r237", "r519", "r538" ] }, "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of redeemable convertible Series A preferred shares", "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stated value per share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r135", "r363" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Construction in progress and purchases of furniture and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r160" ] }, "OCX_ConversionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://oncocyte.com/20230930", "localname": "ConversionPricePercentage", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion price percentage", "documentation": "Conversion price percentage." } } }, "auth_ref": [] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://oncocyte.com/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "auth_ref": [ "r313", "r314", "r315" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other income (expenses):" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Impairment of intangible", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r17", "r76", "r172" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://oncocyte.com/role/Right-of-useAndFinancingLeaseAssetsMachineryAndEquipmentNetAndConstructionInProgress" ], "lang": { "en-us": { "role": { "label": "Right-Of-Use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r168", "r203", "r206", "r207" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expenses)", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r156" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r502", "r503", "r836" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r309", "r704", "r802", "r851", "r852" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBank" ], "lang": { "en-us": { "role": { "label": "Loan Payable to Silicon Valley Bank", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r177" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 }, "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows", "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Change in fair value of contingent consideration", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r455", "r772" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r171" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "NONCURRENT LIABILITIES" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment of Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r175" ] }, "us-gaap_DiscontinuedOperationsHeldforsaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsHeldforsaleMember", "presentation": [ "http://oncocyte.com/role/DiscontinuedOperationsOfRazorTables", "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations, Held-for-Sale [Member]", "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale." } } }, "auth_ref": [ "r11", "r12", "r212" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://oncocyte.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "NONCURRENT ASSETS" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Total intangible assets", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r218" ] }, "us-gaap_PreferredStockNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockNoParValue", "presentation": [ "http://oncocyte.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, no par value", "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r135", "r800" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Noncurrent liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r483" ] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails", "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total financing lease liabilities", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r483", "r494" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expenses", "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption." } } }, "auth_ref": [ "r21" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Current liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r483" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://oncocyte.com/role/IntangibleAssetsNetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets Future Amortization Expense", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r74" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less amounts representing interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r494" ] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermAxis", "presentation": [ "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r755" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://oncocyte.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://oncocyte.com/role/BalanceSheets", "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r136", "r139", "r140", "r165", "r605", "r622", "r646", "r647", "r714", "r727", "r777", "r785", "r832", "r855" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r112", "r440", "r845" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" ], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermDomain", "presentation": [ "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r755" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r733" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r737" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of loan payable", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r771" ] }, "us-gaap_DividendsPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPreferredStock", "crdr": "debit", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividends, preferred stock", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r13", "r181" ] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposal of discontinued operations", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": [ "r339", "r773", "r789" ] }, "us-gaap_ConversionOfStockDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockDescription", "presentation": [ "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of stock, description", "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r50", "r51", "r52" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative", "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r717", "r718", "r721", "r722", "r723", "r724" ] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest income (expense), net", "documentation": "The net amount of operating interest income (expense)." } } }, "auth_ref": [ "r197" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 }, "http://oncocyte.com/role/StatementsOfComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows", "http://oncocyte.com/role/StatementsOfComprehensiveLoss", "http://oncocyte.com/role/StatementsOfOperations", "http://oncocyte.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "verboseLabel": "Net Loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r146", "r163", "r196", "r213", "r230", "r232", "r236", "r247", "r253", "r255", "r256", "r257", "r258", "r261", "r262", "r273", "r284", "r297", "r303", "r305", "r316", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r470", "r474", "r537", "r624", "r643", "r644", "r696", "r725", "r795" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails", "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to common stockholders", "label": "Net loss attributable to common stockholders - Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r239", "r255", "r256", "r257", "r258", "r264", "r265", "r274", "r277", "r284", "r297", "r303", "r305", "r696" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails", "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r360", "r392", "r393", "r394", "r395", "r396", "r397", "r472", "r506", "r507", "r508", "r699", "r700", "r705", "r706", "r707" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://oncocyte.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r155", "r627" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockConvertibleConversionPrice", "presentation": [ "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion price", "documentation": "Per share conversion price of preferred stock." } } }, "auth_ref": [ "r365" ] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductInformationLineItems", "presentation": [ "http://oncocyte.com/role/ScheduleOfConcentrationOfRiskDetails", "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails", "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" ], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://oncocyte.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r731" ] }, "us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock", "crdr": "credit", "calculation": { "http://oncocyte.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://oncocyte.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Redemption of redeemable convertible Series A preferred shares", "label": "Payments for Repurchase of Redeemable Convertible Preferred Stock", "documentation": "The cash outflow to reacquire callable preferred stock which is identified as being convertible to another type of financial security." } } }, "auth_ref": [ "r46" ] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": [ "http://oncocyte.com/role/IntangibleAssetsNetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill and Intangible Assets", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": [ "r68" ] }, "us-gaap_CommonStockNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockNoParValue", "presentation": [ "http://oncocyte.com/role/BalanceSheetsParenthetical", "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, no par value", "verboseLabel": "Common stock no par value", "documentation": "Face amount per share of no-par value common stock." } } }, "auth_ref": [ "r136" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "b", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1D" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(27)", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480781/205-20-S99-3" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "25", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-11" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b),(f(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4J" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4K" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4L", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4L" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.18)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482309/360-10-15-4" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 5.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479836/810-10-S99-5" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481440/840-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-7" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-4" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479741/842-40-50-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r748": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r749": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r750": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org//705/tableOfContent" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 77 0001493152-23-040121-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-040121-xbrl.zip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̩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